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Abstract 
 
Thrombopoietin (TPO), by activating its cognate receptor, the thrombopoietin receptor (TPOR, also 
known as MPL), supports haematopoietic stem cell survival and expansion, megakaryocyte 
differentiation, as well as platelet and megakaryocyte production. LNK is an SH2-B adaptor protein 
that negatively regulates lymphohaematopoiesis by modulating various signalling pathways such as 
those mediated by TPOR. LNK can regulate downstream signalling by direct binding to the receptor 
and/or JAK2, a tyrosine kinase that is associated with the receptor and responsible for downstream 
signal transduction. In myeloproliferative neoplasms (MPNs) and leukaemia, various activating 
(oncogenic) mutations in TPOR and JAK2, as well as inactivating LNK mutations are frequently 
found. However, the mechanisms by which mutations in TPOR and LNK lead to these diseases is 
poorly understood. Further elucidation of the mechanism of JAK-STAT signal regulation by TPOR 
and LNK in normal haematopoiesis and blood cancers such as MPNs and leukaemia will be essential 
for understanding their role in disease and for developing novel targeted therapeutics. Particularly, 
the functional changes that occur in TPOR and the structural mechanisms that are used by LNK to 
regulate JAK-STAT signalling are key to this understanding.  
This thesis employed a multi-disciplinary approach to gain a greater understanding of the mechanisms 
of activation and regulation of JAK-STAT and mitogen-activated protein kinases (MAPK) signalling 
by TPOR and LNK. Novel mutations in the transmembrane domain (TMD) of TPOR that result in 
constitutive signalling were characterised. Further, a peptide antagonist against the crucial signal-
modulating domain (the extracellular domain-juxtamembrane (ECD-JM)/TMD) of TPOR was 
discovered using phage display and its functionality analysed in cell-based assays. By using single-
particle tracking photoactivated localisation microscopy (sptPALM), the spatiotemporal dynamics of 
TPOR in live cell membranes was determined. The current study also determined the regions of LNK 
that may be important in contributing to inhibition of STAT and MAPK signalling, and revealed a 
novel role in regulating receptor levels. In addition, expression and purification of LNK for structural 
and biochemical assays were performed.  
By employing sptPALM, the effect of cytokine stimulation on wild type TPOR and TPOR mutations 
(W515K and Box1Δ) on the lateral diffusion of TPOR were investigated. In the basal and stimulated 
states, TPOR exhibited bimodal mobility (fast and slow-moving receptor subpopulations). Upon 
ligand stimulation of TPOR or the TPOR mutant W515K that results in constitutive receptor 
activation, the mobility of the fast-moving subpopulation was significantly reduced and a fraction of 
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these receptors transitioned into the slow-moving subpopulation. This reduction in mobility may be 
related to the initiation or attenuation of signalling and this finding may elucidate the relationship 
between the mobility patterns of TPOR and different phases of cell signalling.  
As part of a collaborative effort, every amino acid residue in the TPOR TMD was evaluated for their 
ability to result in constitutive proliferation in Ba/F3 cells in the absence of cytokine by using the 
deep mutational scanning approach. Four novel mutants were found to result in constitutive signalling 
(L498W, V501A, V501S, and L502S) indicating that these mutations may potentially drive myeloid 
malignancies. Indeed, some of these mutations were identified for the first time in patient samples by 
collaborators. In order to develop antagonists targeting constitutive active oncogenic TPOR mutants, 
peptides against the ECD-JM/TMD were discovered via phage display screening. The functionality 
of the peptides was assessed via cell-based assays using Ba/F3 TPOR WT and W515K mutant cell 
lines. Results suggest that peptide V may be acting as a peptide antagonist against the TPO/TPOR-
mediated signalling pathway. Confirmation of peptide specificity to this pathway will allow for the 
peptide to be developed into a useful therapeutic agent by itself or to be used as a scaffold for the 
development of small molecules. This discovery may facilitate the development of improved targeted 
drugs to treat patients suffering from myeloid malignancies as a result of activating TPOR mutations. 
In order to investigate the role of individual domains of LNK in regulating JAK2, various LNK 
domain deletions and point mutations were generated. All LNK expression constructs retained the 
SH2 domain required for JAK2 phosphorylated tyrosine binding. A novel function of the LNK proline 
dimerisation domain (Pro/DD) was found in mediating constitutive binding to TPOR with the LNK 
SH2 acting as the main anchor to bind to JAK2. These interactions prevent downstream signalling 
through a mechanism that has yet to be fully elucidated. The findings of the current study act as an 
important foundation for future work to increase the understanding regarding the structure-function 
of this important negative regulator of JAK2 signalling.   
As the crystal structure of LNK is not currently available, there is still a lack of understanding towards 
its role as a negative regulator, in particular, for JAK signalling. Therefore, expression and 
purification of LNK for structural and biophysical studies were performed. Although LNK was able 
to be purified to a high level, sufficient quantities of soluble human LNK fractions that could be used 
for crystallisation studies were not able to be obtained. In the absence of LNK crystals, the purified 
protein could also be used for protein interaction studies and kinase activity assays. These 
investigations will allow better understanding regarding how LNK mutations may contribute to the 
different diseases. 
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1.1 Haematopoiesis 
 
Haematopoiesis is the process of formation, development, and differentiation of blood cellular 
components (Figure 1). All blood cells arise from haematopoietic stem cells (HSCs) (pluripotent 
cells) that are usually maintained in a quiescent state but can self-renew and differentiate. These 
processes must be maintained in equilibrium to maintain the stem cell pool. The induction of 
proliferation and differentiation of cells of the haematopoietic system occurs with the direction of 
cytokines and their cognate receptors whereby different cell types express unique combinations of 
receptors and can respond to myriads of cytokines. Deregulation of haematopoiesis can occur due to 
mutations in the receptors and their signalling partners which may lead to enhanced cell growth, 
proliferation, and survival of HSC derived cells. As a result, myeloid malignancies such as leukaemia 
and MPNs can develop. 
 
 
Figure 1: Haematopoiesis. 
The process of differentiation of HSCs into various haematopoietic progenitor cells (HPCs) and 
mature blood cells. Image reproduced from Wikipedia [1]. 
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1.2 Myeloproliferative neoplasms 
 
MPNs are myeloid neoplasms that arise due to elevated levels of mature erythrocytes, leukocytes, 
and/or megakaryocytes as a result of clonal expansion. Progression of the disease can lead to acute 
myeloid leukaemia (AML). Although the majority of MPNs occur in adults, this disease has also been 
reported in children. MPNs can be divided into two major categories depending on whether the 
patients harbour the BCR-ABL1 fusion gene. Chronic myeloid leukaemia (CML) is classified as 
Philadelphia (Ph)-positive MPN whereas Ph-negative MPN includes polycythaemia vera (PV), 
essential thrombocythaemia (ET), myelofibrosis (MF), chronic eosinophilic leukaemia (CEL), 
chronic neutrophilic leukaemia (CNL), and MPN-unclassifiable (MPN-U) [2]. PV, ET, and MF are 
classed as classic MPNs as they are the most common. PV is distinguished by erythrocytosis, ET is 
characterised by thrombocytosis, whereas MF patients exhibit thrombocytosis and bone marrow 
fibrosis. BCR-ABL1-negative MPNs occur as a result of mutations in three main driver genes that 
encode proteins such as Janus Kinase 2 (JAK2) [3-17], TPOR/MPL, and calreticulin (CALR) [18]. 
All these proteins are involved in the TPOR signalling pathway and hence can influence 
thrombopoiesis and megakaryopoiesis. Driver mutations in MPNs can co-operate with mutations in 
other genes such as those involved in epigenetic regulation, splicing, and signalling. About 10-15% 
of ET/MF patients are diagnosed as triple-negative where they do not possess mutations in any of the 
three main driver genes of MPN [18]. These patients have mutations in the genes encoding the LNK, 
CBL, and other proteins [19-21]. Mutations in LNK and CBL comprise approximately 5-7% of MPN 
patients [22, 23]. These mutations may also occur with JAK2 mutation [24-28]. Most MPNs are 
sporadic but familial MPNs which contribute to approximately 7-8% of MPN cases have also been 
reported [29, 30]. Driver mutations in these familial MPNs arise from somatic mutations [29, 31, 32]. 
 
1.2.1 JAK2 mutations 
 
In MPNs, JAK2 is highly mutated and this mutation is most prevalent in PV (95%) and to a lesser 
extent in ET and MF patients (50-60%) [3-5, 33]. JAK2 mutations have also been reported in 
leukaemic patients [14, 33]. Most mutations of this gene are clustered in or are adjacent to the 
proposed interface formed between the pseudokinase domain and the kinase domain [34], for example 
the commonly known JAK2V617F (located in the pseudokinase domain) [3-5] as well as JAK2 exon 
12 mutations (located at the start of the pseudokinase domain, residues 536 to 547) such as the 
JAK2K539L mutation [35, 36]. JAK2 exon 12 mutations can co-occur with JAK2V617F [35, 37]. 
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Intriguingly, the same JAK2V617F mutation can result in three different diseases (PV, ET, and MF). 
This is hypothesised to be due to the amount of mutant allele burden present in the patients [19]. In 
mice, the homozygous mutation can result in PV from an ET-like phenotype [38]. A previous study 
found that constitutively active JAK2 mutants can preferentially associate with certain cytokine 
receptors with different binding affinities, and may also differently affect their tyrosine 
phosphorylation [39]. As a consequence, downstream signalling pathways are varyingly affected 
which results in the different phenotypic variations of MPN [39]. 
 
1.2.2 TPOR mutations 
 
Activating TPOR mutations have been reported in 1-4% of ET (4, 6, 8-11) and 5-11% of MF patients 
[40-42]. The most common gain-of-function TPOR mutations are the W515K/L mutations [40, 43] 
with W515L being the most frequently reported (60-80%), and less common activating mutations 
include the S505N, and W515A/R mutations [40, 41, 44]. TPOR mutations such as W515K/L can 
co-occur with JAK2V617F [40, 43]. When bone marrow cells that harbour oncogenic TPOR mutations 
were transplanted into mice, these mice developed a MPN-like phenotype [43]. 
The expression level of TPOR is downregulated in the platelets and megakaryocytes of PV and MF 
patients [45] regardless of driver mutations [45-48]. Besides the downregulation of receptor 
expression, in these patients, TPOR is vulnerable to digestion by the endoglycosidase H enzyme 
leading to under-glycosylation and reduced cell surface localisation [45, 49, 50]. The low levels of 
TPOR expression induce megakaryocyte production by the HPCs [51] which results in the 
thrombocytic phenotype of patients with MPNs [52, 53]. 
 
1.2.3 CALR mutations 
 
CALR is a calcium buffering chaperone protein that contains a negatively charged C-terminal tail 
that can bind to calcium ions. It retains newly glycosylated proteins in the endoplasmic reticulum 
(ER) until these proteins have achieved a proper folding conformation [54]. CALR mutations have 
been described in ~25% of ET patients and 35% MF patients [18, 55]; which includes insertions and 
deletions. Mutated CALR proteins acquire a novel C-terminal tail as a result of the frameshift 
mutation [18, 55]. This truncated C-terminal tail destroys the ER retention signal (KDEL) which 
results in the protein localising to another area in the cell. However, only two CALR mutations are 
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tightly associated with MPNs, the CALRdel52 and CALRins5. These mutations confer an ET-like 
disease in mice [56]. Mutation in CALR may influence the progression of an ET to MF [47, 56-59]. 
However, the pathogenesis of CALR requires binding to TPOR [18, 47, 60]. Mutant CALR is 
speculated to exert its effects by locking the receptor in an active conformation [61]. Amongst all the 
type I and II cytokine receptors, only TPOR is able to confer constitutive activation by CALR 
mutants. It was shown that the mutated CALR protein only associates with TPOR and not EPOR [47] 
as the introduction of mutant CALR into mice only results in thrombocytosis and not erythrocytosis 
[47].  
 
1.3 Type I cytokine/haematopoietin receptors 
 
Type I cytokine receptors also known as haematopoietin receptors play important roles in 
haematopoiesis and immunity. They are the largest family of all cytokine receptors [62, 63] and 
include the growth hormone receptor (GHR), prolactin receptor (PRLR), erythropoietin receptor 
(EPOR), and the thrombopoietin receptor (TPOR/ c-MPL). The sequence homology amongst the 
members is, however, low [64]. Nevertheless, they share structural similarities (Figure 2). Type I 
cytokine receptors are single-pass transmembrane (TM) spanning receptors and are composed by 
three main structures: the ECD where the amino terminus of the receptor resides, the intracellular 
domain (ICD) where the carboxy terminus of the receptor resides, and the TM domain that is anchored 
in the hydrophobic cell membrane, separating the ECD and ICD.   
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Figure 2: Haematopoietin receptors domain structure. 
The figure shows the domain structures for both homomeric and heteromeric receptors (with their 
corresponding shared receptor unit i.e. gp130, βC, γC, and leukaemia inhibitory factor receptor 
(LIFR)). Figure reproduced from [65]. 
 
The ECD of type I cytokine receptors possesses at least one cytokine receptor homology domain 
(CRHD) which is responsible for ligand-receptor interaction. The CRHD is approximately 200 amino 
acids long [64, 66, 67] and consists of two fibronectin type III folds (FBN III). Similar to the 
immunoglobulin (Ig) domain fold, these folds are made up of β-sheets stacked together. The first 
FBN III fold is where four conserved cysteine residues reside, linked by disulphide bonds. These 
cysteine residues are important for maintaining receptor structure-function. The second FBN III fold 
has the conserved, consensus WSXWS motif (except for GHR where the motif is YGEFS) [64, 68] 
that is located at the C-terminus of the CRHD. The WSXWS is a consensus motif for C-
mannosylation which is a post-translational modification where a mannose is added to a tryptophan 
residue via a C-C bond. This consensus sequence is important for maintaining receptor structure and 
expression [69] but is not involved in cytokine binding. For simple receptors such as GHR [70] and 
EPOR [71], one CRHD is sufficient for cytokine-binding but TPOR possesses two CRHD. Other 
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receptors may be equipped with additional features such as the Ig-like domain and extra FBN domains 
to facilitate cytokine-induced signalling [72, 73]. 
The CRHD also possesses a binding site (consisting mainly of loops) for the cytokine. Cytokines that 
bind type I receptors share a common protein structure, known as the ‘four-helix bundle’ consisting 
of four amphipathic α-helixes. The hydrophobic part of the helixes makes up the core of the bundle 
whereas the hydrophilic part of the helixes surrounds the core and is in contact with the aqueous 
environment. These helixes are arranged in an up-up-down-down topology and are connected by three 
loops (long-short-long) [62, 64]. Class I haematopoietic cytokines can be classified based on their 
helix length: short or long-chain cytokines. Short-chain cytokines are approximately 10-20 amino 
acids long and include interleukin (IL)-2 and IL-4, whereas long-chain cytokines are approximately 
20-30 amino acids long and include the thrombopoietin (TPO), erythropoietin (EPO), growth 
hormone (GH), and IL-6-like cytokines [74].  
The intracytoplasmic domain of type I cytokine receptors is where the Box1 and Box2 conserved 
motifs are located. The Box1 motif usually resides within 30 amino acid residues from the TM domain 
[75] and its consensus sequence is identified by proline residues that are spaced by two ‘X’ amino 
acids whereas Box2 is comprised mostly of serine and glutamic acid residues and lies approximately 
35 to 60 residues downstream of the TM domain [75]. The ICD of cytokine receptors has low 
sequence homology apart from the Box 1 and Box 2 motifs although these motifs are also not well 
conserved between members of the type I cytokine receptor family. However, they are important for 
mediating Janus kinase (JAK) - signal transducer and activator of transcription (STAT) signalling 
[75, 76].  
Type I cytokine receptors are either homomeric or heteromeric (Figure 2). Homomeric receptors 
include the GHR, PRLR, EPOR, and TPOR which have a single ligand-binding, signal-transducing 
subunit but require receptor homodimerisation to activate signal transduction. Heteromeric receptors, 
on the other hand, are comprised of at least two receptor subunits. Examples of heteromeric receptors 
are the granulocyte macrophage-colony stimulating factor (GM-CSF), IL-3, and IL-5 receptors that 
form heterodimers with the common β subunit, the IL-6, IL-11, IL-12, IL-27, oncostatin M (OSM), 
and LIFR that form heterodimers with the common gp130 subunit; and the IL-4, IL-7, IL-9, IL-13, 
and IL-15 receptors that form heterodimers with the common γ subunit. These common subunits are 
responsible for transducing the signal received as a result of cytokine binding. 
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1.4   JAK family of tyrosine kinases 
 
Unlike many other receptor families, type I cytokine receptors do not possess intrinsic kinase activity. 
Hence, they require association with tyrosine kinases such as JAKs. JAKs are non-receptor tyrosine 
kinases that are located intracellularly. They act as signal mediators of cytokine and hormone 
signalling using by activating the STAT pathway that is important for modulating haematopoiesis, 
cell growth, cell metabolism, as well as adaptive immunity. The JAK family consists of JAK1, JAK2, 
JAK3, and tyrosine kinase 2 (TYK2) and its members are approximately 1150 amino acids long. 
JAK1, JAK2, and TYK2 are ubiquitously expressed [77, 78], whereas JAK3 is mostly expressed in 
haematopoietic cells and tissues [79, 80]. JAK family members possess seven homologous domains 
(JAK homology domain (JH) 1 to JH7) (Figure 3).  
JH1 is a kinase domain that is located near the C-terminus, spanning residues 849-1124. The kinase 
domain crystal structures have been solved for all JAK members [81-84]. It consists of three loops, 
namely the activation, catalytic and nucleotide-binding loop. The Y1007 and Y1008 residues of JAK2 
that are located in the activation loop and are phosphorylated upon activation. However, only the 
phosphorylation of Y1007 appears important for kinase activation as the mutation of Y1007 but not 
Y1008 to phenylalanine negatively affects kinase activity [85]. Phosphorylation of Y1007 may trigger 
kinase activation by the elimination of steric constraints in the inactive JAK [86]. Phosphorylated 
Y1007 has also been reported to bind other proteins such as suppressor of cytokine signalling 1 
(SOCS1; negative regulator) [87] and acts as a substrate for protein tyrosine phosphatase, non-
receptor type 1 (PTPN1) [88]. Competitive adenosine triphosphate (ATP) binding pocket inhibitors 
that are used clinically, target this JH1 domain.  
Adjacent to JH1 is the JH2 pseudokinase domain that spans residues 545 to 808 (Figure 3). So far, 
the pseudokinase domain crystal structures have been solved for JAK1, JAK2, and TYK2 [34, 89, 
90]. JH2 has two lobes, the N- and C-lobe [90]. The C-lobe is made up of α-helices whereas the N-
lobe has five strands of β-sheets and an α-helix (αC) [90]. Interestingly, Y1007 of the constitutively 
active JAK2V617F (that resides in the pseudokinase domain) undergoes continuous phosphorylation. 
Unlike its name, previous findings suggested that JH2 does exhibit some level of kinase activity [91]. 
JH2 was found to acquire both serine and tyrosine kinase activity and it phosphorylates residues S523 
(located in the Src homology 2 (SH2)-JH2 linker) and Y570 (located in the β2-β3 loop of JH2) (Figure 
3), both of which are negative regulatory sites, to maintain JAK2 in a basal state in the absence of 
cytokine binding [92-96]. However, JH2 kinase activity is limited and this can be attributed to its 
structure. Although JH2 adopts a prototypical kinase fold, it binds magnesium (Mg)-ATP in an 
atypical manner [90]. Compared to JH1, JH2 has a shorter activation loop ending with an α-helix that 
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is not able to be phosphorylated, and a longer loop between the β7 and β8 strands [90]. JH2 is also 
deficient of certain residues in JH1 that are important for catalysis [90]. 
The SH2-like and band 4.1, ezrin/radixin/moesin (FERM) domains of JAK2 corresponds to JH3 to 
JH7 domains located at the N-terminus of each JAK [97, 98] (Figure 3). Thus far, the FERM-SH2 
domain crystal structures of TYK2, JAK2, and JAK1 have been determined. The structures revealed 
that these domains are tightly associated with each other [99-101]. Using these domains, JAK binds 
to their associated receptor cytoplasmic domains (at the Box 1 and Box 2 motifs) to form the JAK-
receptor complex. The FERM domain is pivotal for regulating JAK activity [102, 103]. JAK2 
mutations that impair its ability to bind to the receptor have been mapped to residues in the 
hydrophobic core of the FERM domain and are proposed to cause a disturbance in the tightly 
associated FERM-SH2 structure leading to a decrease in stability of these domains.  
The SH2 domains of JAKs are unusual in that they are unable to recognise phosphotyrosine residues 
[76, 104, 105] unlike typical SH2 domains and may act as scaffolds instead [106, 107]. It was 
discovered that the canonical phosphotyrosine-binding pocket in the JAK SH2 domain is inhibited 
by the presence of a bulky hydrophobic residue (for example, phenylalanine in JAK2) in place of a 
less bulky polar or hydrophobic residue [99]. An earlier study has shown that the manner in which 
the SH2 domain of TYK2 binds to its cognate interferon (IFN)-α and -β receptor subunit 1 (IFNAR1), 
is similar to how canonical SH2 domain binds to phosphotyrosine residues [108-110]. However, 
instead of a phosphotyrosine, TYK2 SH2 domain binds to i) a glutamate residue of the IFNAR1 and 
the ii) hydrophobic C-terminal region, both of which are located in the Box2 motif. A new model was 
proposed for the binding between JAK2 and EPOR/LEPR where a switch motif that is located N-
terminal to the Box1 motif, is responsible for positioning the JAK2 FERM/SH2 as an active dimer 
[107]. The switch motif is not essential for JAK2 binding but is important for kinase activation, 
leading to downstream STAT phosphorylation [111-113]. It remains an interesting question as to how 
the same JAK molecule can bind to and be activated by different receptor types even though their 
Box1 and Box2 regions are not very well conserved. It has been demonstrated that the FERM-SH2 
domains of JAK2 are structurally similar to TYK2, however, the putative receptor binding site of 
these two JAKs are slightly different [99]. This is probably how JAKs can confer binding specificity 
to their receptors. 
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Figure 3: Domains of human JAK2. 
 
In the JAK-receptor complex, JAKs exist as dimers. JAK2 can either form homodimers or 
heterodimers depending on the type of receptor that they associate with. Receptors such as TPOR, 
EPOR, GHR, and PRLR form homodimers. Therefore, JAK2 associates with these receptors as 
homodimers. On the other hand, when the receptors associate as heterodimers, for example, the IL-3 
receptor, IL-5 receptor and IFN-γ receptor, JAK2 can form heterodimers with TYK2 or JAK1. The 
association of JAKs with their cognate receptors not only modulates signal transduction but it also 
aids in the membrane localisation of receptors such as EPOR and TPOR [112, 114, 115]. Besides 
JAKs, members of the type I cytokine receptor family can signal via Src family kinases (SFKs) using 
the MAPK pathway. The ability of different intracellular kinases to activate and modulate different 
signalling pathways via the same receptor can be explained by previous studies showing that the 
JAK2 and Src kinase activation can be induced by different GHR TM orientations [116]. Also, it was 
suggested that the levels of expression of JAK2 and Src kinase may be a determinant in whether the 
JAK-STAT or MAPK pathway is activated. 
 
1.4.1 JAK2  
 
JAK2 has been extensively studied for its role in haematopoiesis. The importance of JAK2 in 
haematopoiesis is demonstrated when JAK2-/- mice die during early embryogenesis due to the loss of 
definitive erythropoiesis [78, 117]. Mutations in JAK2 have been reported in MPNs where the most 
common mutation causing this disease is the JAK2V617F. To investigate the pathogenic ability of 
JAK2V617F, Ba/F3 cells were transduced with this mutant and they exhibited constitutive JAK-STAT 
signalling, excessive cell growth in the absence of cytokine and cytokine hypersensitivity in the 
presence of low ligand levels [5, 118]. However, JAK2V617F needs to associate with homodimeric 
class I cytokine receptors for pathogenic signalling to occur [118, 119]. In cell lines expressing EPOR, 
JAK2V617F was not able to cause cytokine-independent cell signalling and growth when its FERM 
domain (the domain that is responsible to bind to the receptor) was mutated [119]. Another study 
showed that when TPOR is reduced or diminished, neoplastic HSCs were markedly reduced [120]. 
Mice that harbour JAK2V617F but lack TPOR do not display MPN symptoms [120]. Using antisense 
oligonucleotides to diminish TPOR expression, a decrease in the spontaneous colony forming unit 
(CFU)-MK (megakaryocytes) development in PV and ET mice was observed [121]. Nevertheless, 
overexpression of this JAK2 mutant can confer cytokine-independent proliferation of Ba/F3 parental 
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cells [4, 5]. In JAK2V617F, it was found that there are aromatic stacking interactions formed between 
V617F and the αC helix residues, F595 and F594 [90]. This interaction results in the stabilisation of 
the helix [90]. JAK2V617F induces a reduction in the cell surface expression of TPOR so that 
megakaryocytes can evade cell death [122]. It also diminishes TPOR recycling capabilities and 
disrupts TPOR maturation via the cytoplasmic Y626 of TPOR [122]. 
 
1.4.2 Mechanism of JAK2 activation by GHR 
 
It was simply thought that binding of the cytokine to their cognate receptors induces receptor 
dimerisation due to bringing the bound JAK2 close together, resulting in their autophosphorylation. 
Activated JAK2 will then phosphorylate the tyrosine residues of the receptor, which act as docking 
sites for downstream signalling molecules such as the STATs. STATs exist as pre-formed dimers 
[123-125] that when activated, undergo a conformational change. This change allows them to be 
localised to the nucleus to activate gene transcription [126-128]. However, it appears that the 
mechanism of JAK2 activation is more complicated than initially thought. Cytokine receptors such 
as GHR are pre-dimerised in the absence of cytokine-binding [129, 130]. Therefore, rather than 
receptor dimerisation–induced JAK2 activation, conformational changes in the receptor that trigger 
JAK2 activation must be the case, rather than a simple cytokine-receptor dimerisation mechanism. 
A new paradigm on the mechanism of JAK2 kinase activation has been proposed [131] (Figure 4). 
Using GHR as a model, it was shown that cytokine-binding can trigger subunit realignment in the 
receptor which leads to activation of JAK2 kinase [131]. In the basal state, GHR is pre-dimerised 
[129], bound together via their TM helix [131]. GH binds asymmetrically and sequentially to two 
sites of the GHR ECD, firstly to site 1 and then to site 2 [132]. Upon binding of GH, the ECD of GHR 
undergoes a conformational change that causes the receptor dimer to be ‘locked’ together at its 
extracellular dimerisation domain (site 3), via hydrogen and electrostatic bonds [133]. Consequently, 
the electrostatic repulsion of the EED sequences at the ECD-JM domain of the receptor pair is 
overcome and the parallel TM helix undergoes a left-handed crossover [131] whereby its N-termini 
move closer together, but its C-termini separate. This results in an increase in distance between the 
intracellular Box1 motifs where JAK2 is bound [131] causing the pseudokinase domain of one JAK2 
to ‘slide’ away from the kinase domain of its associated JAK2 [131] (Figure 4). The kinase domains 
of each JAK2 become positioned near each other, allowing trans-phosphorylation [131] and 
activation of the JAK-STAT signalling cascade to occur. A similar mechanism of JAK2 activation 
may be utilised by other type I cytokine receptors [131], however this has not yet been determined. 
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Figure 4: Model of GH-induced JAK2 activation via GHR. 
GH binds asymmetrically to the GHR thereby causing a left-handed subunit rotation of the ECD. 
Consequently, the receptors are locked together at site 3, inducing the dimerisation of the TM N-
terminus and separation of the TM C-terminus. This conformational change in the GHR induces the 
separation of the JAK2 JH1 from the JH2 of the corresponding JAK2. Subsequently, trans-
phosphorylation occurs, resulting in JAK2 activation. Figure reproduced from [131]. 
 
1.4.3 JAK2 Regulation 
 
As JAK2 plays a crucial role in transmitting cytokine-induced signals to other downstream molecules, 
its tight regulation is crucial. JAK2 can be modulated by various regulatory mechanisms such as i) 
post-translational modification, ii) its pseudokinase domain, as well as iii) extrinsic regulators such 
as protein phosphatases (PTPs) and SH2 domain-containing regulatory molecules (see Section 1.6.2). 
Human JAK2 possesses 49 tyrosine residues [134, 135] whereby the autophosphorylation of residues 
523, 570, 1007, and 1008 acts to regulate its kinase activity. Phosphorylation of S523 and Y570 of 
JAK2 maintains its activity at a basal level in the absence of stimulation [92-96]. S523 is 
phosphorylated in-cis as the residue is closer to the activation site of JH2 whereas Y570 is further 
from this site and is phosphorylated in-trans by the JH2 domain of another JAK2 molecule [90]. In 
the absence of cytokine-binding, only S523 is constitutively phosphorylated to maintain JAK2 
activity at a basal level [94] whereas Y570 is phosphorylated following cytokine binding to inhibit 
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JAK2 activity [93, 95]. Both S523 and Y570 residues in JAK2 are not conserved in other JAK family 
members and hence may represent an extra negative regulatory component of JAK2 [90]. 
The JH2 domain also associates and represses the kinase activity of JH1 to maintain JAK in an 
inactive state in the absence of stimulation [136]. There are two proposed models by which this 
inhibition can occur in JAKs: i) cis- model and ii) trans-model. Crystal structure studies based on 
TYK2 suggested the cis mechanism of inhibition [34]. Initially, there were three proposed 
hypothetical ways by which the JH1-JH2 interaction can occur within a TYK2 tyrosine kinase. Based 
on the distance (JH1-JH2 linker length) between the C-terminus of JH2 and N-terminus of JH1, 
interaction faces A, B, and C predict a distance of 67Å, 26Å, and 54Å respectively. An inhibition 
mechanism based on interaction face B was supported as it requires the shortest linker length that can 
be accomplished by the putative 14 amino acid JH1-JH2 linker.  However, these findings were only 
based on studies of one TYK2 molecule. If the interaction between two TYK2 molecules was to be 
studied, it may be possible that a model similar to interaction face A may exist between these 
molecules. It is important to note that interaction A is the largest interaction face (1608Å2, while 
interact B is 1463Å2), however, this interaction places the C-termini of the JH2 domain and N-termini 
of the JH1 domain too far apart to be linked by the JH1-JH2 linker, thus could only represent a trans-
interaction. However, trans-inhibition of TYK2 by an opposing TYK2 would not be expected to 
occur as TYK2 is not known to be activated by an opposing TYK2, rather it is activated by a different 
JAK family member bound to the opposing receptor subunit [137]. The interaction surface A 
observed in the TYK2 crystal structure may still be representative of what may occur in trans-
inhibition with a different JAK family member. If so, this will be reminiscent of the trans-inhibition 
model of JAK2 [131]. This model proposed that the mechanism of inhibition of JAK2 occurs as a 
result of an interaction between the JH1 activation loop residues of one JAK2 molecule and the JH2 
N-terminal lobe of another JAK2 molecule [131]. Furthermore, when a synthetic JAK2 mutant (with 
pseudokinase and kinase domain positions switched) was co-expressed with wild-type JAK2, it 
resulted in constitutive JAK2 activation [131]. However, a cis-inhibition model of JAK2 was also 
proposed [138]. Through molecular dynamics simulation, they found that the SH2-JH2 linker 
mediates JH1-JH2 interaction, allowing JH2 to bind to the back of JH1 kinase [138]. By doing this, 
JH1 is stabilised in an inactive state [138]. However, this inactive state is in conformational 
equilibrium with the partially active state where the JH1-JH2 domains of JAK2 are not in contact 
with each other [138]. In the presence of cytokine binding, conformational changes in the receptor 
bring the JH1 of both JAK2 close together thereby allowing phosphorylation to occur; the equilibrium 
subsequently shifts towards the active JAK2 conformation [138]. Nevertheless, the authors did not 
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consider the possibility of a trans-inhibition model (i.e. the pseudokinase domain of one JAK2 
inhibiting another JAK2 kinase domain).  
Another level of JAK2 regulation occurs after cytokine stimulation which may result in either 
negative or positive regulation depending on which tyrosine residues are involved. Phosphorylation 
of the main residues in the JH1 activation loop, Y1007 and Y1008, induces JAK2 catalytic activity. 
Positive regulation of JAK2 kinase activity can also occur through phosphorylation of residues Y637, 
Y813, Y868, Y966, and Y972. On the other hand, phosphorylation of residues Y119, Y221, Y317, 
Y570, and Y913 negatively regulates JAK2 [93, 95, 96, 139-141]. Extrinsic JAK2 negative regulation 
after cytokine-binding also occurs through the action of PTPs such as SH2 domain-containing 
phosphatase (SHP) 1, SHP2, and tyrosine-protein phosphatase non-receptor type 1 (PTP1B) which 
dephosphorylate JAK2 stimulatory sites, as well as by the action of SOCS, protein inhibitor of 
activated STATs (PIAS), and SH2B adaptor protein 3 (LNK/SH2B3) proteins (see Section 1.8) [136, 
142-144]. Interestingly, JAK2 may also be regulated by oxidation and reduction whereby its oxidation 
leads to its inactivity and its reduction leads to its activity [145]. 
 
1.5 TPO and its receptor, TPOR  
 
TPO (Figure 5), also known as megakaryocyte growth and differentiation factor (MGDF), is an acidic 
and strongly glycosylated cytokine. It is mostly produced in the liver [146] and to a lesser extent in 
the kidney, bone marrow, and spleen [146-148] whereas constitutive production of the cytokine is 
performed by the liver and kidney [149]. TPO binds to its cognate receptor, TPOR (Figure 5) via its 
N-terminus (1-153 amino acids). TPOR (635 amino acids) is encoded by the 11 exon MPL gene and 
this gene resides on chromosome 1 (p34). It is the human homologue of the v-Mpl that is derived 
from murine c-MPL that was discovered first. The murine myeloproliferative leukaemia virus 
(MPLV) infection results in acute myeloproliferative neoplasms in mice [150]. TPOR is expressed in 
haematopoietic cells such as HSCs [151], progenitor cells of the megakaryocyte lineage, 
megakaryocytes, platelets [152], as well as in haematopoietic tissues. Approximately 70% of HSCs 
express TPOR and this value decreases during differentiation [151, 153].  
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Figure 5: TPO and its cognate receptor, TPOR. 
A) Crystal structure of the receptor-binding domain of human TPO (hTPO) co-crystallised with the 
neutralising antibody Fab. hTPO is made up of four α-helices and contains two receptor-binding sites 
that allow for sequential binding to the ECD of TPOR [154]. The first receptor binding in the dimer 
is mediated by its A and D helices whereas the second receptor binding in the dimer is conferred by 
its A and C helices [155]. Image reproduced from NCBI molecular graphic [156]. B) Modelled 
structure of TPOR ECD [157]. C) Cartoon image of TPOR showing two CRHD at the ECD and 
several motifs (RWQFP, Box1, Box2) at the ICD.  
 
Compared to other receptors, TPOR is not highly expressed on the surface with approximately 25-
100 receptors on a platelet [158, 159]. Circulating TPO is removed from circulation by platelets and 
megakaryocytes that express TPOR. The binding of TPO to the receptor results in internalisation of 
the TPO-TPOR complex. After TPOR is internalised, it can either be recycled back to the cell surface 
or degraded. However, in platelets, TPOR is not recycled but is degraded instead. Due to the negative 
feedback mechanism, an inverse relationship between circulating TPO and platelet levels has been 
observed [160]. Therefore, TPO plasma concentration depends on the level of TPOR present on 
thrombocytes and megakaryocytes [160]. This inversely proportional relationship helps to regulate 
thrombopoiesis and HSC quiescence. In the case of thrombocytosis, high levels of TPOR cause more 
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internalisation of the cytokine leading to reduced TPO concentration in the plasma. On the other hand, 
in thrombocytopaenic patients, low TPOR levels lead to reduced TPO internalisation and 
subsequently increase in the production of megakaryocytes and platelets.  
 
1.5.1 TPOR isoforms 
 
Isoforms for several cytokine receptors that arise from alternative splicing have been described 
whether they can positively (IL-6) [161, 162] or negatively (IL-5 or GM-CSF) [163-166] regulate 
signalling. Several alternative splicing isoforms of TPOR exist that vary in their biological activity. 
These include those with deletion of the ECD [167], a different ICD (K-isoform) [150], and those 
that lack the entire TMD and ICD (Mpl-tr) [168]. The K-isoform has no impact on TPO-mediated 
signalling as it does not bind the wild-type receptor [169]. The truncated soluble TPOR isoform, Mpl-
tr, is conserved between humans and mice. This isoform retains the signal peptide but is deficient in 
the TM domain (and ECD-JM) [170, 171]. Regardless of the presence of signal peptide, it remains in 
the intracellular compartment of the cell. Interestingly, this truncated receptor can act as a dominant-
negative mutant to inhibit TPOR-mediated cell proliferation by downregulating the full-length TPOR 
via cathepsin-like cysteine protease activity through its unique short peptide at its C-terminus tail 
[168].  
 
1.5.2 Megakaryopoiesis and thrombopoiesis 
 
Haematopoietic cells undergo lineage commitment and give rise to bipotent megakaryocyte-erythroid 
progenitors which in turn become megakaryocytic progenitors. These will terminally differentiate 
into megakaryocytes which undergo endomitosis and cytoplasmic maturation. These processes are 
termed megakaryopoiesis. TPO/TPOR plays an important role in the megakaryopoiesis that occurs 
in the bone marrow. Mice that are deficient in TPO or TPOR have markedly reduced (~85% 
reduction) megakaryocyte and thrombocyte numbers with no effects observed on other cell lineages 
[172-174]. Besides regulating megakaryocyte lineage commitment, TPO/TPOR also regulates HSC 
survival and proliferation [175]. However, they are not essential to regulate megakaryocyte 
maturation or thrombocyte generation [51, 176]. As megakaryocyte progenitors differentiate into 
mature megakaryocytes, they have reduced proliferative capacity. Megakaryocytes generate platelets 
(via a process known as thrombopoiesis) which arise from the disintegration of the pseudopial 
projections of mature megakaryocytes, termed as proplatelet fragmentation. The amount of 
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circulating platelets in the body needs to be maintained as uncontrolled or decreased production can 
result in thrombosis or excessive bleeding. Mice lacking the TPOR or TPO gene are 
thrombocytopaenic [151] as a result of markedly reduced TPO signalling leading to the reduction in 
mature megakaryocytes and megakaryocytic progenitors. Besides being stimulatory, TPO can exhibit 
inhibitory effects to maintain stem cell quiescence and cell cycle arrest in late megakaryocytes. TPO-
deficient mice had markedly reduced HSCs as they age but when stimulated with TPO, there is an 
increase in the number of these quiescent HSCs [177, 178]. TPO can work together with other 
cytokines such as EPO, IL-11, and stem cell factor (SCF) to stimulate the growth of progenitor cells 
[179].  
 
1.5.3 Mechanisms regulating TPOR 
 
Unlike other cytokine receptors, TPOR has a long half-live (surface and intracellular) where surface 
TPOR has higher stability than that in the intracellular stores [115]. The life cycle of TPOR involves: 
i) the post-translational modification of immature TPOR, ii) cell surface localisation of mature TPOR, 
and iii) its internalisation from the cell surface. TPOR can exist in two forms, the fully glycosylated 
mature form (~85kDa) and the immature form with much-reduced glycosylation (~80kDa) [49, 180]. 
TPOR maturation and full glycosylation are essential for its cell surface expression [181]. Studies 
have shown that impaired glycosylation of TPOR negatively affects its function [180], leads to 
reduced platelet production, and reduced TPOR membrane localisation [181, 182].  
Upon ligand binding, TPOR is endocytosed (internalised) and the receptor can either undergo 
recycling or degradation. TPOR internalisation is mediated via clathrin-mediated endocytosis [183] 
which is facilitated by adaptor protein 2 (AP2) complexes. AP2 facilitates TPOR endocytosis by 
recognising the Y591RRL (Y78RRL cytoplasmic numbering of mouse TPOR) motif in the receptor 
[183]. Mutation of Tyr to Phe in the Y78RRL motif results in increased and extended signalling [184]. 
This motif is also important in lysosomal-mediated degradation of TPOR [183] besides the Y521RRL 
(Y7RRL cytoplasmic numbering of mouse TPOR) motif [183]. Mutation of Y78 causes an increase 
in cell proliferation and signalling (and duration of signalling) via JAK2, STAT5, Akt, and 
extracellular-signal-regulated kinase (ERK) 1/2. Interestingly, the putative AP2-recognition motif 
can also be found in EPOR and granulocyte colony-stimulating factor receptor (G-CSFR) [183]. The 
importance of the dileucine/leucine repeats (in the Box 2 motif) and Y112 (mouse TPOR cytoplasmic 
numbering; equivalent to human TPOR Y626) for receptor internalisation following TPO stimulation 
was also previously reported [185]. 
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The ability to be recycled is unique to TPOR  [185] as other type I cytokine receptors do not possess 
this capability. As a result of ligand binding, the mature receptor is internalised with a turnover rate 
of approximately 6 hours [186]. Each cycle internalises a maximum of 65-75% of mature TPOR [159, 
185]. Interestingly, JAK2 and TYK2 can induce mature TPOR recycling and maintain its ability to 
retain TPOR cell surface localisation [187]. If recycling does not occur, the receptor will be targeted 
for degradation. One of the ways in which proteins are degraded is through a process known as 
ubiquitination although ubiquitination of target proteins may mediate different functions. Mono-
ubiquitination regulates protein localisation and signalling [188] whereas poly-ubiquitination 
mediates proteasomal degradation. It is known that TPOR is promptly ubiquitinated after TPO 
induction and is then degraded by lysosomes and/or proteasomes [186]. Ubiquitination of TPOR 
occurs via c-CBL, an E3 ubiquitin ligase, on K553 and K573 (located in the intracytoplasmic 
domain). Mutation of these residues to arginine prevents receptor degradation and results in 
constitutive cell proliferation [186]. Upon cytokine stimulation, c-CBL is recruited and activated by 
phosphorylation [189, 190] which allows it to mediate the conjugation of poly-ubiquitin to TPOR. 
 
1.5.4 Mechanism of JAK2 activation by TPOR         
                                                                                                       
Previous efforts by other groups have been predominantly focussed on explaining how TPO binding 
leads to TPOR activation, however it is not clear as to how ligand-induced conformational change in 
TPOR can activate its associated JAK2 or how JAK2 JH2-JH1 interaction is relieved following 
activation. It is not clear as to whether JAK2 activation occurs as a result of TPOR dimerisation or 
that conformational change occurs in preformed TPOR dimers which leads to JAK2 activation. 
Currently, it is known that GHR [129], PRLR [191], IL-6R [192], and EPOR [193, 194] can exist as 
pre-formed dimers on the cell surface. Also, homodimeric gp130 was found to be pre-dimerised 
without cytokine binding but this is a transient interaction that can be stabilised by the ligand, IL-6 
[195]. On the other hand, heterodimerisation between gp130 and LIFR is mediated by ligand binding 
[195]. For other type I cytokine receptors, their pre-dimerisation status has not yet been determined. 
Most importantly, there is currently no strong evidence supporting the pre-dimerisation status of 
TPOR. Nevertheless, as TPOR is structurally and functionally similar to EPOR, TPOR may also exist 
as pre-formed dimers similar to EPOR. 
A recent study using split luciferase assay showed that TPOR exists in monomer-dimer equilibrium 
and that this equilibrium is shifted towards the formation of monomers in the inactive state [196]. 
This technique, however, measures the total fluorescence that is emitted from the cell and includes 
the fluorescence signal generated by receptors on the cell surface as well as from receptor aggregates. 
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Therefore, this may have masked the ratio of dimers and monomers that are present on the cell 
membrane. Furthermore, the receptor was C-terminal tagged with Gluc1 and Gluc2. The ICD of 
TPOR, like other cytokine receptor cytoplasmic domains, lacks secondary structure. Hence, tagging 
these molecules at the C-terminus may not allow for a clear evaluation of the occurrence of receptor 
dimerisation. Another study also suggests that TPOR exists as monomers in their inactive state. In 
this study, the authors found that the incorporation of cysteine instead of serine at position 368 
(located in the putative dimerisation interface of TPOR) forced the dimerisation of TPOR via 
disulphide bonds and this led to constitutive signalling [197]. On the contrary, studies using 
complementation assay between WT and mutant TPOR have suggested that TPOR exists as pre-
formed dimers prior to receptor activation [182] as WT TPOR can rescue the TPOR R102P mutant 
to the Golgi (R102P mutant alone can only localise in the rough ER) although it is not able to rescue 
this mutant to the cell membrane. The cysteine dimerisation may have locked the receptor in an 
induced dimeric active structure, rather than an inactive dimer. 
 
1.5.5 TPOR-mediated signalling pathways 
 
TPOR activation mediates the JAK-STAT, phosphoinositide 3-kinases (PI3K)/AKT, and MAPK 
pathways (Figure 6). In the JAK-STAT pathway, it can activate JAK2, TYK2, STAT1, STAT3, and 
STAT5 [184, 198-202] while the STATs induce genes involved in proliferation and survival. TPO 
stimulation results in phosphorylation of the receptor on residues Y112 and Y117 where they act as 
docking sites for STAT3 and STAT5 which subsequently undergo phosphorylation by JAK2 [184]. 
SHC also binds to phosphorylated Tyr112 and subsequently recruits GRB2 and SOS, leading to RAS 
activation. Downstream RAF, ERK1/2, p38 MAPK are recruited and activated. Stimulation of RAF 
also results in PI3K activation. The GAB/IRS, SHP2, p85, p110 complex is recruited N-terminal of 
Tyr112 following Akt phosphorylation.  
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Figure 6: Figure showing a simplified diagram of the TPOR signalling pathway. 
TPO binds to inactive TPOR and activates the receptor. This will initiate signal transduction through 
various pathways.  
 
TPO signalling can be mediated by both JAK2 and TYK2 but only JAK2 can confer persistent JAK-
STAT signalling [201]. This finding was supported by another study that showed that in the absence 
of JAK2, TPO-mediated signalling cannot occur, whereas in the absence of TYK2, signal 
transduction still occurs [203]. Furthermore, in the presence of TPO stimulation, mature 
megakaryocytes displayed obvious phosphorylation of JAK2 but not TYK2 [204]. JAK2 deficient 
foetal liver cells are defective in megakaryocyte production despite the presence of TPO [78]. 
Downstream signalling via the PI3K/AKT pathway regulates the cell cycle in megakaryocyte 
progenitors [205, 206] whereas TPOR-mediated ERK signalling is important for primary 
megakaryocyte endomitosis [207] and maturation [201]. In UT7 cells expressing TPOR, sustained 
ERK1/2 stimulation can influence megakaryocyte differentiation [201]. Activation of the MAPK 
pathway induced by TPO can be Shc-independent or dependent [184, 208]. When the Shc-dependent 
pathway is impeded, PI3K-mediated ERK activation occurs. Activation of the ERK signalling 
pathway can also be mediated via protein kinase c (PKC)-γ which does not require the distal 
phosphotyrosine of TPOR [209]. 
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1.5.6 TPOR extracellular domain  
 
The ECD maintains TPOR in an inactive state in the absence of stimulation. It has been suggested 
that the distal CRHD (CRHD-1) is particularly important for this function as deletion of CRHD-1 
causes constitutive cell proliferation [210]. Furthermore, the substitution of CRHD-1 by CRHD-2 
showed similar results [210]. Indeed, a mutation in CRHD-1, P106L, can stimulate cell growth in the 
absence of cytokine [182]. This mechanism is in place to prevent spontaneous signalling via the 
CRHD-2 and TMD [210]. The inhibition conferred by CRHD-1 is alleviated upon TPO binding [210]. 
Residues 102 to 251 of CRHD-1 are suggested to be the ligand-binding region where residues 206-
251 are core residues for this binding [211]. In support of this finding, alanine-scanning mutagenesis 
showed that D235 and L239 residues were the most important for ligand binding as alanine 
substitution of these residues disrupts TPOR affinity for ligand binding [211]. In particular, residues 
in the F’-G’ domain of CRHD-1 are suggested to potentially bind TPO [211]. This domain has been 
shown to play a role in ligand binding in granulocyte-colony stimulating factor (G-CSF) [212], GM-
CSF [213], and IL-6 [69] receptors. Another study showed that F104 of TPOR is important for TPO 
association with the receptor as F104S disrupts TPOR ability to bind TPO [214]. However, unlike 
D235 and L239, F104 is not located in the putative F’-G’ domain. Instead, it is located at the G-A’ 
domain of TPOR ECD. This suggests that ligand binding sites can occur in regions outside of the 
conserved F’-G’ domain and that these three residues or even other amino acid residues may play a 
role in forming the ligand-binding site of the receptor. 
The ECD of human TPOR possesses several potential N-linked glycosylation sites such as residues 
117, 178, 298, and 358 that can modulate the localisation of TPOR to the cell surface [215]. 
Furthermore, studies using EPOR showed that the c-mannosylation consensus motif, WSXWS, plays 
a role in receptor internalisation, cytokine binding, proper receptor folding as well as signal 
transduction [216, 217]. In TPOR, the C-mannosylation sites include tryptophan residues at positions 
269 and 272 (located in the first WSXWS motif), 474, 477 (located in the second WSXWS motif), 
as well as 416 [218]. Consistent with EPOR data, the previous study showed that the TPOR C-
mannosylated sites (except W416) are important for JAK-STAT signalling [218].  
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1.5.7 TPOR transmembrane domain  
 
The N-terminal TPOR TM domain is predicted to comprise amino acid residues I492 to V495 that 
are connected to the hydrophobic TM region (T496-L513) by non-helical residues [219]. Mutations 
in the TPOR TM domain can result in spontaneous TPOR activation. A TM domain mutation, S505N, 
was discovered as an inherited form in familial ET [220] and then as an acquired form in ET patients 
[41]. It was recently discovered that the TM amino acid sequence before 499 is non-helical and that 
S505N can induce helix formation and strong TM helix dimerisation [196, 221]. Site-directed 
mutagenesis on the wild-type S505 amino residue to generate synthetic E/D/Q505 showed that these 
synthetic and the clinical mutation, N505 induce spontaneous receptor dimerisation [222]. The 
spontaneous receptor dimerisation was thought to occur via hydrogen bonding induced by strong 
amino acid polarity [222, 223].  
However, studies by another group suggested that the N505 mutation causes spontaneous receptor 
activation via a different mechanism [221]. They have shown that this mutation causes TPOR TM to 
adopt a different conformation from the wild-type receptor via subunit rotation [221]. N505 
conformation is achieved by rotating the putative inactive TPOR state by approximately 100° which 
results in stronger dimerisation of the TM helix with consequent spontaneous receptor activation 
[221]. This is reminiscent of what was proposed for the GHR in response to GH binding [131] (see 
Section 1.4.2). The different rotations also allow the N505 TM domain to utilise a different interface 
(residues L502, N505, G509, and L512) from the inactive and ligand-bound active states [221]. 
Nevertheless, this mutant may only induce partial receptor activation in the absence of ligand 
stimulation and because TPO-binding to TPOR is required for complete receptor activation [222]. 
This suggests that N505 can induce an intermediate TM conformation between the inactive and 
ligand-bound fully active states of the receptor [221]. Two types of interface clusters based on H499 
(an important residue that prevents spontaneous TPOR activation) position reflect these inactive and 
active states, known as cluster 1 (histidine-in) and cluster 2 (histidine-out), respectively [221]. For 
cluster 1, TM dimer interface is formed by residues H499, L502, A506, L510, and L513 [221]. Cluster 
2, on the other hand, is formed by rotating the putative inactive state by 150° which results in H499 
being out of the dimeric interface [221]. In the basal state, the TM domain of TPOR is structured in 
a dimerised manner in a parallel left-handed fashion [221]. In contrast, another study suggested that 
the tryptophan in the RWQFP motif, prevents the dimerisation of the TM helix in the absence of TPO 
and that the TM of the wild-type TPOR is a monomer and the dimerised form exists for the mutant 
TPOR [224].  
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1.5.8 TPOR intracellular domain  
 
Human TPOR possesses five tyrosine residues (Y521, Y542, Y591, Y626, Y631) in its intracellular 
domain. The TPOR TM helix extends towards the cytoplasm up to the F517 residue of the JM-ICD 
domain. This domain contains a unique RWQFP (human) or KWQFP (murine) amphipathic motif. 
The first and second residues of this motif are suggested to form a cation-π interaction, a noncovalent 
interaction [224] that affects protein folding, stability, and specificity. Deletion of this motif has been 
shown to result in constitutive activation of the receptor [225]. In particular, the tryptophan residue 
at position 515 plays a crucial role in regulating receptor activation. This residue maintains TPOR in 
an inactive state in the absence of TPO, and plays a role in TPOR activation in the presence of 
stimulation [224]. In the epidermal growth factor receptor (EGFR), its JM-ICD contains a 
phosphatidylinositol 4,5-bisphosphate (PIP2)-interacting motif (R645–R647) (located at a similar 
position as the RWQFP motif in TPOR) that is important for positioning its kinase domains [226]. 
This finding suggests that the TPOR RWQFP motif may use similar mechanisms as the EGFR PIP2-
interacting motif. 
The importance of conserving the tryptophan residue at position 515 is demonstrated when 
replacement of this residue with other aromatic amino acids (tyrosine or phenylalanine) was not able 
to retain the receptor in its inactive conformation [224]. A mutation in the W515 residue can drive 
myeloid malignancy. Although only six activating clinical TPOR W515 mutations have been 
currently discovered, another publication has shown that the alteration of W515 to another eleven 
amino acid residues (hydrophobic, charged or polar residues) was able to result in similar spontaneous 
activation of the JAK-STAT pathway [227]. Only the alterations of W515 to proline (W515P) or 
cysteine (W515C) was able to maintain the receptor in its inactive state without TPO [227]. TPOR 
W515P may have lost its ability to localise and anchor itself to the cell membrane for activation to 
occur [227]. C515 on the other hand is part of a conserved motif in birds and turtles and hence is 
thought not to be able to confer spontaneous receptor activation [227]. Interestingly, when amino acid 
residues beside W515K/L mutants were mutated to tryptophan, this was able to restore normal 
receptor activity [224]. This finding suggests that the five amino-acid motifs are crucial for regulating 
the active and inactive states of the TPOR.  
Studies using K515 demonstrated that the TM of K515, but not the inactive wild-type TM, can induce 
TM dimerisation, with a helix tilt angle relative to the membrane normal of ~23° for the former and 
~30° for the latter [224]. In support of the ability of W515 mutants to confer a different helix tilt angle 
from wild-type, another study found that TPOR can adopt seven different orientations [61], unlike 
EPOR which signals through only one dimeric orientation [228]. To investigate this, they replaced 
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the ECD domain of TPOR with coiled-coil dimers to orientate TPOR into various orientations with 
the assumption that the TM and ICD domains of TPOR are rigid [61]. It was identified that out of the 
seven possible orientations, one orientation does not activate TPOR and is thought to correspond to 
the non-ligand binding state [61]. The other six orientations were able to result in TPOR activation 
and may correspond to the ligand-bound state of the receptor or mutant receptor active state [61]. In 
agreement with these findings, another study discovered three different TM dimeric orientations of 
TPOR that correspond with the inactive, partially active, and fully active state of TPOR [221]. The 
several possible dimeric orientations that can be adopted by TPOR may explain how TPOR can 
exhibit a pleiotropic role in haematopoiesis (such as megakaryocytic differentiation) and how TPOR 
mutations can cause corresponding disease phenotypes [61].  
Similar to human TPOR, the murine TPOR Box1 (cytoplasmic residues 17-20) and Box2 motifs 
(cytoplasmic residues 46-64) are important for JAK2 binding and activation. The intracytoplasmic 
TPOR residues can either be involved in JAK-STAT pathway activation or inhibition. The region 
between residues 69-83 after the Box2 motif, is thought to be involved in partial inhibition of cellular 
proliferation [184]. Mutation or truncation in this region results in augmented proliferation [184]. On 
the contrary, engineered truncation of 53 amino acid residues from the C-terminus of murine TPOR, 
designated as T53 was found to down-regulate ligand-stimulated cell proliferation [184]. This 
truncation resulted in the loss of the positive regulatory sites, Y616 and Y621 (equivalent to human 
TPOR Y626 and Y631, respectively), as well as the negative regulatory region, but may negatively 
impact the positive regulatory sites more than the negative regulatory sites [184]. The mouse TPOR 
Y616 and human TPOR Y626 residues are pivotal for SHIP protein phosphorylation, Shc activation 
(for MAPK signalling) [229], and the spontaneous activation of human TPOR W515A in MPN 
patients [230]. Human TPOR W515A-positive cell lines and mouse models harbouring Y616F, have 
significantly reduced pathologic signalling and dampened MPN-like phenotype [230]. Although the 
mouse TPOR Y616 residue mediates cell proliferation, its role is dispensable in wild-type TPOR 
[208]. It is, however, important for mutant TPOR pathogenesis [230]. The mouse TPOR Y621 is 
associated with the phosphorylation of TPOR and STAT3 [184]. 
It has been shown that in the case of human PRLR and GHR, their ICDs are structurally disordered 
but they can mediate the interaction with the inner cell membrane lipid via their ITAM (immune 
receptor tyrosine-based activation motifs)-like motifs [231]. This suggests another level of signal 
regulation and a similar mechanism may be utilised by other members of the type I cytokine receptor 
family such as TPOR. 
In summary, the ECD, TM (H499 and S505), and ICD (514RWQFP518 motif) co-operate to regulate 
TPOR activation but further studies are required to understand how conformational changes in these 
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domains can lead to JAK2 activation. In the case of GHR, it was discovered that in the presence of 
GH, the ECD and TM N-terminus come together in a receptor dimer but the TM C-terminus and ICD 
are pulled apart as a result of ligand-binding [131]. This relieves the inhibition of JAK2 JH2 on the 
JH1 domain. Elucidating the mechanism of JAK2 activation by TPOR is important to facilitate the 
development of improved targeted drugs to treat patients suffering from myeloid malignancies as a 
result of activating TPOR mutations. Furthermore, this knowledge will help to understand how TPOR 
mutations can cause MPNs and leukaemia. 
 
1.5.9 TPOR activating and inactivating mutations 
 
Mutations in TPOR can be activating or inactivating. Inactivating mutations (nonsense or missense) 
such as R102P and F104S can lead to congenital amegakaryocytic thrombocytopaenia (CAMT) [232-
234]. In these patients, the resulting receptor may be non-functional [232, 233] or have markedly 
reduced function [232]. The R102P mutation results in the receptor being underglycosylated with 
dampened ability to bind TPO [180]. In contrast, TPOR activating mutations such as the P106L 
mutation cause familial essential thrombocythaemia (FET) [235]. Although R102P and P106L result 
in contrasting diseases, both mutations cause reduced receptor cell surface expression, unusual 
subcellular localisation, under-glycosylation, and an increase in circulating TPO [182]. This suggests 
that activating mutations such as P106L do not require proper cellular localisation, glycosylation, or 
surface expression to confer constitutive cell signalling and proliferation [182].  
Mutations that result in constitutive TPOR activation (Figure 7) are frequently found to reside in the 
RWQFP motif (this motif is located at the JM-ICD and is unique to TPOR), for example, the 
W515L/K/A mutations. These mutations result in MPNs as they can confer cytokine-independent cell 
proliferation and activation of JAK-STAT, RAS/MAPK, and PI3K signal pathways which play a role 
in cell survival and proliferation [43, 225, 236]. TPO stimulation can, however, increase the signalling 
effect of the W515L mutant. Furthermore, W515L/K mutations of TPOR enhanced cell proliferation 
by inducing spontaneous G1 to S phase transition [237] in the cell cycle. The cytoplasmic 
phosphorylated tyrosine residue 626 (putative STAT5 binding site when phosphorylated) of TPOR 
is crucial for the pathogenesis of W515 mutations [230]. It was previously shown that W515L with 
an KDEL is retained in the ER/ Golgi and is unable to cause spontaneous FDCP-1 cell proliferation 
and tumour growth in nude mice [238]. The W515L-KDEL mutant can bind JAK2 but is unable to 
induce JAK2 phosphorylation [238]. Forced dimerisation of W515L-KDEL (by substituting the S402 
residue to cysteine for the formation of a disulphide-bond) allowed the mutant to localise to the cell 
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surface and cause constitutive activation [238]. This suggests that the binding between TPOR W515L 
and JAK2 occurs in the ER/ Golgi in an inactive form (either monomer or inactive dimer) and that 
translocation to the membrane is required for JAK2 activation and constitutive signalling to occur 
[238]. Other mutations that can cause constitutive receptor activation, that are located outside of the 
TMD include the S505N (TM domain) and T487A (JM-ECD) mutations [239]. S505N has also been 
reported in FET whereas the TPOR T487A mutation has only been reported in a childhood acute 
megakaryoblastic leukaemia (AMKL) case (without Down-syndrome) [239]. In a bone marrow 
transplantation experiment, the T487A mutation was sufficient to confer MPN-like symptoms in mice 
[239].  
 
Figure 7: Clinical TPOR activating mutations and polymorphisms. 
Most activating mutations reside in and around the TMD. 
 
The W515K and T487A JM mutations are predicted to increase the tendency of TPOR to form dimers 
as well as to induce TPOR conformational change to the active form [40, 43, 224, 225, 240]. On the 
other hand, the TM S505N mutation acts by stabilising TPOR in the active dimer form [222, 241]. 
Interestingly, it was reported that the TPOR T487A mutation results in slower MPN development 
compared to the JM-ICD mutation, W515L [239]. This may suggest that the JM-ICD may play a 
bigger role than the JM-ECD in terms of modulating cytokine signalling, although the significance 
of both domains in inhibiting spontaneous signalling cannot be denied. Other MPL mutations such as 
P106L, S204P, Y591N, S505C, A506T, and L510P have also been reported.  
 
1.5.10 Modulation of TPOR activity using agonists or antagonists 
 
Patients that potentially require TPO agonist treatment include those with bone marrow failure, liver 
cirrhosis, autoimmune diseases, myelodysplastic syndrome (MDS), and those undergoing 
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chemotherapy/radiation. However, TPO agonists need to be used with caution particularly for MDS 
and chemotherapy/radiation-induced thrombocytopaenia patients as there have been reports of 
disease transformation to leukaemia due to the use of these agonists. Various TPO agonists have been 
developed and improved over the years which include mimetics (small molecules or peptides) that 
activate TPOR such as Eltrombopag (Promacta) and Romiplostim (Nplate), both of which have been 
approved by the US Food and Drug Administration (FDA). Eltrombopag (small molecule) and 
Romiplostim (peptide mimetic) have been developed to treat immune thrombocytopenic purpura 
(ITP) [242, 243]. These mimetics can induce normal thrombopoiesis in thrombocytopaenic patients. 
Romiplostim binds to the ECD of TPOR and induces receptor dimerisation. In contrast, Eltrombopag 
is structurally different from endogenous TPO and interacts with the TMD of TPOR. Therefore, 
Eltrombopag could potentially activate TPOR with inactivating ECD mutations. The interaction 
between Romiplostim or Eltrombopag with TPOR induces JAK-STAT and MAPK activation 
resulting in elevated platelet levels [244-246]. 
Treatments for MPN patients harbouring activating TPOR mutations include administration of 
hydroxyurea, IFN-α or JAK2 inhibitors. Ruxolitinib or also known as Jakafi works by inhibiting 
JAK1/JAK2 [247] and is used for the treatment of MF (de novo MF or post-ET/PV MF). AMKL 
patients with MPL mutation are not treated differently from other leukaemic patients and are 
administered chemotherapy drugs. As these treatments are not specific, patients develop various side 
effects. This highlights the need to develop more specific, targeted treatments against this receptor. 
However, it has to be taken into account that the absolute elimination of TPOR is unlikely to be 
beneficial as shown by patients with CAMT who can progress from thrombocytopaenia to 
pancytopaenia.  
 
1.6 Negative regulators of JAK-STAT signalling  
 
JAK-STAT signalling can be regulated by i) dephosphorylation of signalling molecules or receptors 
that mediate signalling, ii) transcriptional inhibition, iii), membrane receptor internalisation, and/or 
iv) degradation of signalling intermediates or receptors. These are carried out by various negative 
regulators that act in different stages of the pathway (discussed below). Particularly, the ones that are 
involved in downregulating TPO-mediated signalling include SOCS, LNK, Lyn, and phosphatases 
[248-251]. 
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1.6.1 SOCS 
 
The SOCS family of proteins is comprised of of SOCS1-SOCS7 and cytokine-induced STAT 
inhibitor (CIS). This family of proteins participates in the negative feedback loop of JAK-STAT 
signalling [252-254]. Initiation of signal transduction results in SOCS expression that is induced by 
STATs [253]. The SOCS family members generally possess an N-terminal domain (NTD), an SH2 
domain, as well as a SOCS box domain that is located in the C-terminus. An extra region known as 
the kinase inhibitory region (KIR) is only present in SOCS1 and SOCS3 [84]. SOCS can work by i) 
blocking JAK activity directly using the KIR, ii) binding to their cognate JAKs to mediate the 
proteasomal degradation of the JAK-associated receptors, and/or iii) competing with STATs for 
binding to the receptor. Interestingly, it was discovered that when SOCS3 is not bound to JAK, its 
KIR is structurally disordered [255]. However, its association with JAK allows the KIR to be inserted 
into the substrate-binding site of JAK [81]. In turn, JAK is prevented from catalysing its substrate 
and this consequently results in inhibition of JAK-STAT signalling. This mechanism of inhibition is 
distinct from the one used by small molecule inhibitors that are used clinically. Activation of the TPO 
signalling pathway results in upregulation of SOCS3 whereas SOCS1 is upregulated by IFN-α, both 
of which functions to downregulate TPOR-mediated signalling [256]. 
 
1.6.2 PTPs 
 
Protein phosphatases include SHP1, SHP2, PTP1B, and CD45 and they can terminate signalling by 
dephosphorylating receptors, JAKs, and/or STATs. The crystal structure of SHP1 and SHP2 in their 
closed conformation revealed that the catalytic domain is obstructed by their N-SH2 domain [257, 
258]. In response to ligand binding to its SH2 domain, the crystal structure revealed a conformational 
change in SHP1 [259]. This change involves the dissociation of the N-SH2 domain from the catalytic 
domain thereby allowing phosphatase activity [259]. 
 
1.6.3 PIASs 
 
These proteins are ubiquitously expressed and play a role in the negative feedback loop of JAK-STAT 
signalling. They are able to regulate signalling via their ability to small ubiquitin-like modifier 
59 
 
(SUMO)lyate their substrates, attracting additional co-repressors, and blocking STATs from 
associating with their target DNA.  
 
1.6.4 CBL 
 
CBL proteins are E3 ubiquitin ligases that target proteins for degradation via the proteasome or 
lysosome [260]. However, in some cases, CBL can positively regulate signalling [261-265]. CBL is 
recruited to the K553 and K573 residues in the intracytoplasmic domain of TPOR to mediate 
degradation [266].  
 
1.6.5 Src family kinases 
 
SFKs are comprised of Blk, Lck, Yes, Hck, Fgr, Src, Fyn, and Lyn that play a role in cellular 
migration, proliferation, and differentiation [267, 268]. In megakaryocytes, only Lyn and Fyn are 
activated after TPO induction [269]. Lyn can play dual functions (activating or inhibitory) but in the 
TPO signalling pathway, Lyn has an inhibitory function [269]. Cell proliferation was reported to be 
enhanced in the presence of Src kinase inhibitors (pyrolopyrimidine 1 and 2 (PP1 and PP2)) [270]. It 
was shown that the use of SFK inhibitors did not have an effect on the activation of JAK2 and STATs 
(STAT3 and STAT5) but it appeared to result in enhanced ERK activation thus showing that the 
TPO/TPOR signalling is limited by Lyn via ERK activation [270]. Activated Lyn can either accelerate 
inactivation or impede activation of ERK1/2 [270]. Auto-inhibition of SFKs occurs when its 
conserved C-terminal Tyr residue is phosphorylated by the C-Src kinase (CSK). When this residue is 
dephosphorylated or repositioned from the SH2 domain, it is activated. Residue Y112 in the 
intracytoplasmic domain of TPOR is indispensable for Lyn activation [270]. Lyn could be directly 
bound to this residue or via another phosphoprotein that relieves the binding of Lyn SH2 domain 
from its regulatory C-terminal Tyr residue [270]. 
 
1.7 Adaptor proteins  
 
Most adaptor proteins do not contain intrinsic enzymatic activity but they are able to co-ordinate and 
regulate various signalling pathways by recruiting necessary proteins/substrates together. They can 
also aid in the localisation of various signalling proteins to their respective location in the cells. 
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Adaptor proteins themselves can be localised to the membrane (TM adaptor proteins), cell 
compartments such as the cytosol and ER, as well as to the cytosol (where they can be localised to 
the membrane when necessary). They may be ubiquitously expressed or can be expressed in specific 
cell types. 
The ability of adaptor proteins to interact with various proteins/substrates owes to their various 
protein-binding modules. Generally, adaptor proteins possess an SH2 or phosphotyrosine-binding 
(PTB) domain that functions to bind to phosphotyrosine residues of their cognate proteins [271, 272]. 
They may also contain the WW and PDZ motifs that allow for protein-protein interaction to occur 
[273]. Moreover, adaptor proteins that contain SH3 domains are able to interact with other proteins 
via their proline-rich domains [274]. Still, others possess a pleckstrin homology (PH) domain that is 
responsible for their ability to interact with phosphatidylinositol lipids that are present in the plasma 
membrane or on other proteins [275]. LNK is an adaptor protein that negatively regulates TPOR-
mediated signalling and will be further discussed below.  
 
1.7.1 SH2 domain-containing adaptor proteins 
 
LNK (~68kDa), encoded by the SH2B3 gene located on chromosome 12, is a member of a family of 
SH2-containing adaptor proteins that includes SH2B1 (SH2B or PSM (proline-rich, PH and SH2 
domain-containing signalling mediator)) and APS (adaptor protein with PH and SH2 domain) (or 
SH2B2). The SH2-adaptor protein family is conserved from Drosophila melanogaster to humans. 
LNK is predominantly expressed in haematopoietic cells such as HSC, HPCs of the myeloid and 
lymphoid lineage [276], pre-B and pro-B cells, as well as in mature cells such as megakaryocytes and 
mast cells. LNK maintains megakaryopoiesis, erythropoiesis, and HSC quiescence and self-renewal 
[175, 249, 276-281]. Only LNK has been found to modulate both megakaryopoiesis and 
erythropoiesis whereas its family members regulate only erythropoiesis [282, 283]. Enhanced LNK 
expression in mice bone marrow HPCs diminished megakaryocyte proliferation and endomitosis 
which are induced by TPO [249]. In contrast, mice with LNK deficiency have a higher ploidy number 
in their megakaryocytes [249, 284] and develop MPN-like phenotype such as enlarged spleen, 
expansion of the HSC compartment, and increase in megakaryocyte, platelet, and leukocyte counts 
[276]. Interestingly, TPO and LNK play paradoxical roles in order to maintain HSC homeostasis and 
myeloid progenitor expansion [175]. LNK has been reported to be localised in the cytoplasm, 
perinuclear region, and cell membrane [285, 286]. 
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LNK has one characterised isoform whereas SH2B1 has four isoforms denoted as α, β, γ, and δ [287-
290]. SH2B1 isoforms have different C-terminus regions due to alternative mRNA splicing [289-
291]. On the other hand, APS has two isoforms denoted as α and β [292]. SH2B1 and APS can act as 
positive or negative regulators depending on the type of cells they are expressed in and the signalling 
pathway that they control. Both APS and SH2B1-β upregulate the nerve growth factor (NGF)-
mediated PC12 cell differentiation [293, 294]. SH2B1 is a positive regulator of insulin, insulin growth 
factor (IGF)-1 [295-297], and JAK-STAT signalling induced by GH [298] and leptin. APS is also a 
positive regulator [291, 299] of GH-induced signalling [298]. LNK is more often associated as a 
negative regulator (see section 1.8). This is particularly true in haematopoiesis but it plays a 
paradoxical role in ovarian cancer [300]. High levels of LNK has been detected in ovarian cancer and 
when it is overexpressed, cell death is markedly reduced [300]. Furthermore, LNK was also shown 
to be able to prevent endothelial cells from cell death [301]. All three family members of SH2 domain-
containing adaptor proteins are able to negatively regulate EPO-mediated signalling [277, 282, 283]. 
 
1.7.2 Structure 
 
LNK, SH2B1, and APS possess four structurally similar domains: i) N-terminal region with a) a 
dimerisation domain where a phenylalanine zipper can be found and b) proline-rich motifs (with a 
minimal consensus sequence of Pro-X-X-Pro); ii) PH domain that is important for co-localisation at 
cell membrane [285]; iii) SH2 domain that functions to bind phosphotyrosine residues of their target 
proteins; iv) C-terminal region (Figure 8). This protein family also possesses several putative serine 
and tyrosine phosphorylation sites. The last tyrosine residue at the C-terminal region (Y572 in human 
LNK protein) is conserved amongst all the family members.  
 
Figure 8: Domains of human LNK. 
Pro/DD: Proline dimerisation domain. Red star denotes the conserved C-terminal residue at position 
572.  
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The sequence homology amongst the family members is relatively high, approximately 72-80% [291, 
302, 303]. Amongst the three main domains, the N-terminal Pro/DD domain is the most variable 
region among LNK family members. The phenylalanine zipper, unlike those found in SH2B1 and 
APS is slightly different in LNK. The zipper found in LNK has a tyrosine and a leucine residue that 
replace two of the phenylalanine residues present in the SH2B1/APS zipper. This difference probably 
contributed to the inability of LNK to heterodimerise with APS or SH2B1, as shown using a yeast 
model [291]. On the contrary, LNK was shown to be able to heterodimerise with SH2B1 in PC12 
cells [304]. LNK homodimerisation has also been reported [281], however, this has only been 
demonstrated in an overexpressed system and, hence, may mask the inability/low affinity of LNK to 
homodimerise.  
The PH and SH2 domains are partly conserved amongst the members of this family. It was discovered 
that the amino acid sequence of hLNK (human LNK) PH domain is 29% identical to rSH2B1 (rat 
SH2B1) and 35% identical to hAPS (human APS) whereas the hLNK SH2 domain is 68% identical 
to rSH2B1 and 65% identical to hAPS [286]. Although SH2B1, APS, and LNK may play different 
regulatory roles in JAK-STAT signalling, a significant percentage of sequence similarity suggests 
that there may be some conserved structure-function relationships between the members of this family 
of adaptor proteins, in particular, referring to the SH2 domain. Nevertheless, each individual member 
is still able to confer specificity in their own function. The SH2 domains may be monomers or form 
dimers. The SH2 domain of APS associates as a dimer where one SH2 domain binds to pTyr 1158 
and another to pTyr 1162 of the insulin receptor, and both residues are located in the kinase activation 
loop [305]. Residue W475 of APS is important for this dimerisation as substitution of this residue to 
histidine causes disruption of the SH2 dimer [305]. It is speculated that LNK may be monomeric as 
it harbours a histidine residue at a similar location [305]. However, although SH2B1 possesses a 
tryptophan residue at a similar location to APS, its SH2 domain exists as a monomer [305].  
It has been shown that SH2B1 and APS are able to undergo homo- [291, 306] and heterodimerisation 
[307]. The ability of these adaptor proteins to undergo dimerisation is due to the presence of a 
phenylalanine zipper located approximately in the middle of the dimerisation domain. The aromatic 
side chains of the phenylalanine residues reside in the hydrophobic core of the zipper and are bonded 
by stacking interactions. Modelling studies showed that the mechanism of SH2B1 homodimerisation 
is almost identical to APS [291]. The ability of these adaptor proteins to homodimerise suggests the 
creation of a heterotetrameric complex formed by two SH2B1 or APS molecules bound to their two 
cognate JAK2s [291]. Interestingly, it has been proposed that the heterotetrameric complexes formed 
by two SH2B1s/APSs with two JAK2s are able to induce JAK2 activation in the absence of 
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stimulation [291] whereas, in the presence of stimulation, this complex is able to enhance JAK2 
signalling in the presence of receptor [291].  
 
1.8 LNK  
 
LNK has been suggested to act as a tumour suppressor protein [308] and this is consistent with its 
role as a negative regulator of lymphohaematopoiesis. LNK is expressed as a result of a negative 
feedback mechanism and inhibits signalling mediated by c-Kit [280, 311], c-Fms [312], and tumour 
necrosis factor receptor (TNFR) [313], as well as those receptors involved in the JAK-STAT pathway 
such as TPOR [314], EPOR [277], IL7-receptor [276, 315], and platelet-derived growth factor 
receptor (PDGFR) [316]. 
LNK affects different downstream signalling pathways. In primary erythroblasts, LNK is able to 
inhibit the STAT5, MAPK, and Akt pathways that are stimulated by EPO in order to downregulate 
the production of erythrocytes [277]. In megakaryocytes, LNK inhibits ERK1/2 signalling which is 
induced by TPO and subsequently reduces the responsiveness of megakaryocytes to the cytokine 
[284, 317]. Downregulation of ERK activation was also reported in stimulated cells expressing IL-3 
or c-Kit receptor [276, 311]. LNK effects on activated ERK and Akt differ for different receptors. 
LNK prevented ERK activation in NIH3T3 cells (expressing endogenous PDGFRA and PDGFRB) 
that were stimulated with PDGF but without Akt activation [316]. In contrast, LNK reduced the 
activation of Akt but not ERK in c-Fms mediated signalling [312]. Interestingly, LNK was able to 
diminish the activation of both ERK and AKT in TPOR [249] or EPOR [277] mediated signalling 
pathway. For TNF, LNK intensified Akt activation but attenuated ERK activation [313]. These 
differences suggest that there are other LNK domains that may be involved in mediating the varying 
effects on different signalling pathways depending on which receptor is concerned. 
Lack of LNK expression in HPCs results in increased cell growth and differentiation [280, 318] 
whereas megakaryocytes that are deficient in LNK expression exhibit TPO-hypersensitivity [249]. 
Loss-of-function of LNK can enhance the oncogenic properties caused by JAK2V617F in an MPN-
mouse model [319]. When overexpressed, LNK is able to block constitutive cell proliferation induced 
by JAK2V617F [309, 310], mutated c-Kit [311, 320], and W515L [285]. LNK was able to down-
regulate spontaneous cell proliferation in BaF/3 EPOR cells lines with JAK2 mutations such as the 
classic V617F and K539L [321]. Overexpression of LNK in Ba/F3 TPOR W515L cell lines was able 
to prevent spontaneous cell proliferation [321]. This inhibition of cell proliferation occurred via 
suppression of the JAK-STAT, MAPK, and PI3K pathway [321]. LNK overexpression also hampers 
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the growth of Ba/F3 cells expressing the PDGFR [316]. On the other hand, the R392E (SH2 domain 
mutation) LNK mutant was unable to do so [316]. LNK also inhibited the growth of 32D cells 
expressing fusion oncogenic proteins such as TEL-PDGFRB (associated with chronic 
myelomonocytic leukaemia) or FIP1L1-PDGRFA (associated with systemic mast cell disease and 
hypereosinophilic syndrome) [322, 323] when expressed [316].  
 
Mice devoid of LNK exhibit elevated B cell levels, enlarged HSC compartment, and increased 
erythropoiesis and megakaryocytopoiesis due to lack of inhibition which subsequently leads to hyper-
responsiveness to several cytokines such as EPO, SCF, and TPO [175, 249, 276, 277, 280, 284, 315]. 
Particularly, MAPK activation but not STATs and Akt was enhanced and lengthened in the 
megakaryocytes of these mice [284]. When JAK2 mutation is present in these mice lacking LNK, it 
was observed that the pool of myeloid progenitor cells was enlarged [324]. The degree of LNK 
expression was also shown to affect patient prognosis such as in B-ALL [325]. It was found that adult 
B-ALL that expressed the IL7RhighSH2B3low phenotype (overexpression of IL7R but the suppressed 
expression of LNK) is linked to high-risk ALL, resulting in a decrease of the number disease-free 
survival patients and increased tendency of relapse [326]. Another subtype of B-ALL, iAMP21 
(Intrachromosomal amplification of chromosome 21), is associated with the loss of LNK [327]. This 
loss may be linked to leukaemia progression due to uncontrolled signalling [327]. Patients harbouring 
this subtype of B-ALL are associated with poor prognosis and susceptibility to relapse [327]. In 
contrast, increased expression of LNK has been described in the HSCs and platelets of MPN patients, 
particularly in patients harbouring the JAK2V617F mutation that may be due to the sustained negative 
feedback mechanism . 
 
1.8.1 Negative regulation of c-Kit signalling 
 
LNK plays a role in regulating B-cell production [315, 328] as LNK-deficient mice demonstrated 
hypersensitivity to SCF and consequently displayed elevated levels of pre- and pro-B cells [315]. The 
ICD-JM of c-Kit plays an important role to prevent receptor activation. When c-Kit binds to its ligand, 
SCF, two residues are transphosphorylated in human c-Kit, Y568 and Y570. Phosphorylation of these 
residues relieves the autoinhibition of the JM domain of the receptor [329]. These phosphorylated 
residues can also act as docking sites for various positive and negative regulators. The pY568 residue, 
in particular, has been shown to bind to PTPs such as SHP1 and SHP2 [330] as well as LNK (via its 
SH2 domain) [276, 281, 311, 318, 320, 331]. APS also binds to Y568 and Y935 of c-Kit [331]. The 
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binding of either of these regulators leads to attenuation of SCF-mediated c-Kit signalling [311] [330] 
in primary mast and progenitor cells.  
 
1.8.2 Negative regulation of PDGFR signalling 
 
The binding of the PDGF ligand to its receptor, PDGFR induces autophosphorylation of the tyrosine 
residues in the JM-ICD kinase domain where LNK binds to one of the phosphorylated residues. LNK 
can also bind to inactive PDGFRs although ligand stimulation increased LNK binding to the receptor 
[331]. This result suggests that LNK can constitutively bind to PDGFR [316]. On the other hand, 
LNK R392E mutant (SH2 function disruption) maintained the receptor binding property but this was 
significantly reduced [316]. LNK SH2 domain is however more important for binding to oncogenic 
FIP1L1-PDGFRA fusion protein than to WT PDGFRA or PDGFRB [316]. 
 
1.8.3 Negative regulation of fms-like tyrosine kinase 3(FLT3) signalling 
 
Binding of ligand to FLT3 results in the phosphorylation of the ICD tyrosine residues 572, 591, and 
919 (conserved residue) which serve as binding sites for LNK [332]. The binding of LNK to these 
residues via its SH2 domain results in its activation [332]. Both the WT FLT3 receptor and 
constitutively activated ITD-mutated FLT3 receptor can phosphorylate LNK [332]. LNK activation 
results in subsequent inhibition of the STAT5, ERK1/2, and PI3K/Akt signalling, as well as reduced 
cell proliferation of cells expressing WT or FLT3 mutants [332].  
 
1.8.4 Negative regulation of JAK-STAT signalling 
 
In the JAK-STAT signalling pathway, LNK negatively inhibits downstream signalling of TPOR, 
EPOR [249, 277, 324], IL7R [333], and others. Hence, disruption of LNK function can result in 
cytokine hypersensitivity to EPO and TPO [277, 284] with subsequent erythrocytosis and 
thrombocytosis, respectively. It has been suggested that LNK associates with JAK2 in haematopoietic 
stem/progenitor cells whereas it associates with JAK3 in B cell lineage cells [333]. By associating 
with JAK3/IL7R, LNK regulates pro-B and pre-B progenitor cell homeostasis [333]. Besides normal 
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signalling through the JAK2 pathway [278, 314], LNK can also dampen aberrant signalling by 
inhibiting JAK2V617F [278]. 
 
1.8.5 Proposed mechanism of inhibition for LNK 
 
Although the role of LNK as a negative regulator of cytokine signalling has been well-documented, 
it is still unclear as to how it is able to modulate JAK-STAT signalling, although, a few mechanisms 
have been proposed.  
 
1.8.5.1 LNK as a competitive inhibitor 
 
When overexpressed or in the presence of cytokine stimulation, JAK2 is autophosphorylated 
particularly at Y813 which is located in the consensus YXXL motif in the pseudokinase-kinase linker 
[278, 334]. Interestingly, it was demonstrated that Y813 of JAK2 can also be phosphorylated in the 
absence of stimulation albeit at a slower rate [291]. This phosphorylated residue has been shown to 
be a docking site for SH2B1, APS, and LNK where they bind via their SH2 domains [291, 299, 334]. 
The corresponding phosphorylated tyrosine residue in JAK3, Y785, is also a binding site for the 
SH2B1-β adaptor protein. After docking to the pY813 on JAK2, the SH2 domain-containing adaptor 
protein family member is in turn phosphorylated by JAK2 [278, 282, 286-288, 293, 335-340]. 
Phosphorylation activates the adaptor proteins thereby allowing them to either enhance or inhibit 
downstream signalling. It has been shown that docking to pY813 allows SH2B1-β to amplify JAK2 
and STAT5B activity. Due to the ability of all members to bind to pY813, they may compete against 
LNK for binding. It is currently unknown as to what factors determine which adaptor protein binds 
to JAK2 at a particular time and how binding to the same residue can trigger different responses i.e. 
signal activation or inhibition. It was proposed that LNK can compete for binding to the c-Kit receptor 
where it binds to the JM-ICD region to prevent positive regulators from binding [280, 311]. 
 
1.8.5.2 LNK binds via other domains besides the SH2  
 
Although pY813 acts as an important binding site for these adaptor proteins, there may be other 
JAK2-binding sites unique to the particular adaptor protein that may facilitate positive or negative 
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regulation of signal transduction. SH2B1, APS, and LNK have also been reported to bind inactive 
JAK2. SH2B1-β can bind to unstimulated JAK2 via one or more sites located in its N-terminal region 
(amino acids 269-555 that includes the PH domain, PH-SH2 linker and a small part of the SH2 
domain) albeit with a lower affinity [341]. The ability of SH2B1-β to bind to these lower affinity sites 
makes it able to recruit more SH2B1-β that surrounds JAK2 as proposed [341]. The recruitment of 
SH2B1-β may prevent abnormal JAK2 activation [341]. On the other hand, when JAK2 is activated, 
the presence of a high concentration of SH2B1-β surrounding JAK2 will allow its rapid binding to 
JAK2 phosphotyrosine residues and consequent enhanced JAK2 signalling [341].  
LNK has been shown to bind to another JAK2 site, the pY613 residue (minor binding site) that is 
located in the pseudokinase domain [278]. Other low-affinity interaction(s) with inactive JAK2 not 
mediated by LNK SH2 domain may probably serve to stop abnormal JAK2 signalling [299, 309, 
341]. Studies suggest that the LNK NTD may facilitate weak interactions with inactive JAK2 [309]. 
However, it is not clear as to which residues are involved in this interaction. LNK can also bind to 
mutant proteins such as JAK2V617F [278, 285, 309] and TPOR W515L via its SH2 domain and NTD 
where LNK NTD binds stronger to JAK2V617F than wild-type JAK2 [309]. The LNK PH domain was 
also suggested to be able to bind to inactive JAK2 through a weak interaction [310] but the residues 
that are involved in this interaction remain to be elucidated. In EPOR-mediated signalling, only SH2 
appears essential for LNK function and not PH or the conserved C-terminal tyrosine residue [277]. 
 
1.8.5.3 LNK expression levels  
 
JAK2 may have a differential binding affinity for SH2B1, APS, and LNK, or a preferential binding 
of a particular adaptor protein may be influenced by its respective expression levels. Interestingly, 
low levels of SH2B1/APS have been reported to cause an increase in JAK2 activation [291]. This has 
been proposed to be caused by the ability of SH2B1/APS to bring its associated JAK2s in closer 
proximity to each other. In contrast, high-level expression of these adaptor molecules resulted in a 
paradoxical effect where JAK2 activity is abrogated [291]. Thus, this suggests that depending on the 
relative levels of SH2B1 or APS, they are able to either positively or negatively regulate JAK2 kinase 
activity [291]. This effect may also be translatable to LNK.  
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1.8.5.4 LNK possesses a novel structure  
 
There are limited studies on the structural changes that occur as LNK binds JAK2. This is due in part 
because of the lack of any LNK domains or full-length crystal structures. Nevertheless, LNK binding 
may induce a conformational change in activated JAK2, thereby resulting in inhibition of JAK2 
kinase activity. Binding of LNK SH2 domain to regions around the pseudokinase domain of activated 
JAK2 may induce the pseudokinase domain to return to its original position where autoinhibition of 
JAK2 is restored. Other novel mechanisms of structural changes in JAK2 that are induced by LNK 
may also occur. It was recently discovered that SOCS3, a JAK2 inhibitor, inhibits JAK2 via its KIR. 
The KIR obstructs the substrate-binding site of JAK2 to prevent JAK2 from interacting with and 
phosphorylating its substrate [81]. It remains a possibility that LNK may contain an undiscovered 
mechanism that is similar to the KIR of SOCS3. A higher binding affinity was observed between 
LNK and JAK2V617F compared to wild-type JAK, which may be due to high levels of phosphorylation 
[6, 309, 310, 342].  
 
1.8.5.5 LNK regulates its inhibition via other proteins 
 
LNK can bind to ubiquitin ligases such as CBL [309, 343] which may facilitate degradation of its 
associated receptor/JAK [344]. Activation of the insulin receptor recruits APS, where its 
phosphorylated C-terminal tyrosine residue binds CBL [344]. The tyrosine kinase binding (TKB) 
domain of CBL binds to the (RA(V/I)XNQpY(S/T)) sequence in APS (pTyr613) [345-347] which is 
also highly conserved in LNK and SH2B1 [348]. This binding allows APS to inhibit signalling [282, 
349].  
 
1.8.6 LNK mutations in myeloid malignancies 
 
Germline and somatic LNK mutations have been reported in patients affected by familial and sporadic 
MPNs [23, 350] (5-7%) [23], MDS (3-5%) [25, 351-353], early T-cell acute lymphoblastic leukaemia 
(T-ALL) (5%) [354], B-cell acute lymphoblastic leukaemia/lymphoma (B-ALL), and post-AML 
MPNs (10%). The frequency of the occurrence of LNK mutations is typically low, particularly in 
chronic-phase MPN patients. In T- and B-cell ALL, LNK mutations are usually frameshift or deletion 
mutations whereas, in MPNs, missense mutations are usually found [350]. This suggests that a more 
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severe loss of LNK function is needed to cause lymphoid malignancies [350]. LNK mutations can 
also occur during transformation to leukaemia [350].  
The role of LNK mutations as a driver or co-operating mutation is debatable. It has been previously 
reported that LNK loss-of-function occurs in ET and MF patients but is not able to confer MPN 
pathogenesis alone [353, 355]. LNK mutations can be present concomitantly with driver mutations 
such as those in JAK2, TPOR, and CALR as well as with other genes such as CBL and TET2. 
However, the frequency of occurrence of LNK mutations in patients with or without the JAK2V617F 
mutation is similar [24]. It is not known whether these mutations occurred in the same or different 
clonal population, which might have different effects on the phenotype of the disease [24]. Mice 
lacking both TP53 and LNK gene develop B-ALL suggesting that TP53 can also work hand in hand 
with LNK in this disease [333]. The co-existence of LNK mutations with other driver mutations 
suggests its possible role as a co-operating mutation to cause MPN. On the other hand, a germline 
LNK mutation was reported in a triple-negative PV patient which may suggest LNK mutations can 
act as driver mutations, however, the association of this germline mutation with the disease was not 
clear [356]. A study has reported the presence of a LNK mutation in two JAK2V617F-negative MPN 
patients [353]. Furthermore, mice harbouring a homologous LNK mutation were susceptible to 
myeloproliferative diseases [276]. These studies suggest that a more severe homozygous LNK 
mutation can drive MPN pathogenesis although other findings suggest that the heterozygous C613G 
loss-of-function mutation alone was able to induce MPN [353]. Moreover, the frequent occurrence 
of LNK heterozygous PH mutations in MPN patients suggests that the loss of one allele is sufficient 
to lead to haematologic malignancies. This evidence suggests that LNK mutants may not only be 
secondary mutations as previously thought but that they can drive MPN pathogenesis in these 
patients. Indeed, LNK knockout mice exhibit excessive HSC proliferation with enhanced self-
renewal property [276, 278].  
Currently, LNK mutations that have been associated with myeloid malignancies are primarily point 
mutations affecting the PH domain. Because of this, the PH domain was regarded as a ‘hot spot’ [25]. 
Clinical PH domain point mutations include E208Q [353], A215V [25], G220V, G220R, A223V, 
D234N, and G229S [24] and those reported in MPN patients were mostly heterozygous [24, 353]. 
This suggests that loss-of-function of one LNK allele may be sufficient to drive MPN pathogenesis. 
Further evidence to support this haploinsufficiency model was demonstrated using murine models. 
LNK-/+ mouse models exhibit an intermediate, less severe MPN-like feature compared to LNK-/- 
mouse models. A ‘dosage effect’ is apparent where the loss of both alleles results in a more severe 
phenotype compared to the loss of one allele [276]. PH domain point mutants resulted in partial 
disruption of LNK function. It was observed that PH domain LNK mutants, compared to wild-type, 
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have reduced inhibition on STAT5 phosphorylation and cell growth [277, 353, 355, 357]. The partial 
disruption of LNK activity could be due to the reduced ability of the mutant proteins to localise to the 
cell surface and bind JAK2, with a consequent reduction in inhibition of JAK-STAT signalling [353]. 
In contrast, another study showed that PH domain mutants, similar to wild-types, were able to localise 
to both the cytoplasm and cell surface [355]. These mutants also retained their JAK2 binding ability 
[355]. However, a LNK mutant with synthetic deletion of the PH domain has abolished cell surface 
localisation ability [285]. It may be possible that the degree of retained LNK inhibitory function 
depends on the severity of the mutation type (i.e. missense mutations might have a lesser impact on 
LNK function compared to whole PH domain deletion).  
Clinical LNK SH2 mutations such as Q423X, have also been reported in MPNs [352]. Unlike PH 
domain point mutants, SH2 mutations cause a more severe disruption of LNK function [249, 277, 
278, 285, 353, 355]. This may be due to the decreased ability of LNK to associate with JAK2. The 
effect of SH2 domain mutation has been studied using a synthetic R392E mutant and it was found 
that this mutant abolished SH2 domain function. Ba/F3-TPOR cells harbouring this mutant exhibit 
increased cell proliferation [285] and loss of inhibition on JAK-STAT signalling [353] which may be 
attributed to the loss of JAK2 binding [355]. LNK mutations affecting both the PH and SH2 domains 
have also been reported, the E208X [25] and DEL (603-607delGCGCT;613 C>G) [353] mutation 
which result in truncation of these domains. Studies have shown that a synthetic truncation mutant 
that lacks the PH domain is unable to localise to the cell surface [285] and will most likely result in 
abolished LNK function. 
Mutations in the LNK C-terminal domain (CTD) have also been reported. Clinical mutations found 
in the CTD region include R551W and I568T [352] but their pathogenic significance is unknown. 
Although CTD mutations have been discovered, there have not been reported any mutations of the 
conserved LNK C-terminus residue at position 572. To investigate the possible effects of Y572 
mutation on LNK inhibitory function, the murine equivalent Y536 was mutated to phenylalanine 
[249]. This mutation did not affect murine LNK inhibitory function [277] on cell proliferation [249] 
nor JAK2 binding [278]. This Y536 residue has also shown to play no significant role in TPO-
mediated signalling, although the function of its human counterpart, Y572, has not been investigated 
[249, 311]. In the EPOR-mediated pathway, this tyrosine residue is essential but not necessary for 
EPO-induced erythroblast survival and cell growth [277]. However, deletion of the C-terminal tail of 
the murine LNK only affected its function partially [281]. Overall, SH2 mutations appear to cause a 
more severe phenotype compared to PH or CTD mutations. Although various LNK mutations have 
been reported, it is currently unknown as to how these mutations affect LNK function and drive 
myeloid malignancies.  
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LNK polymorphisms have also been reported and these may play a role in contributing to the different 
clinical phenotypes observed in patients and may confer a predisposition to MPN development [356]. 
The position 262W (c.784T>C) nonsynonymous polymorphism (located in the PH domain) has a 
strong relation with the occurrence of JAK2V617F in MPN patients [358]. This suggests that LNK 
mutations can predispose patients to progress to MPNs or leukaemia [358]. The p.262W 
polymorphism is often related to MPN patients whereas the p.262R polymorphism is more related to 
CML [356]. This observation suggests that polymorphisms in LNK can play a role in causing clinical 
phenotypic variations by affecting the differentiation of malignant cells in the bone marrow [356]. 
The R262W polymorphism is also linked to increased risk of autoimmune diseases [359], myocardial 
infarction, and hypertension. 
It was proposed that mutant LNK can exhibit a dominant-negative effect. This may be possible 
because most LNK mutations affect either the PH and/or SH2 domain. Therefore, functional NTD is 
retained. Mutant proteins that are not able to translocate to the cell surface may form a complex with 
wild-type LNK via homophilic interactions between the NTD [281], sequestering the complex in the 
cytoplasm and preventing LNK interaction with its target kinases and downstream signalling proteins 
[281]. A previous mouse study showed that co-expression of LNK R364E mutant (R392E in humans) 
with endogenous LNK facilitates the engraftment of HSCs and progenitor cells [281] suggesting that 
mutant LNK is able to confer a dominant-negative phenotype. Furthermore, NTD deletion of 
R364E/C-terminal tail deletion mutant abolished its dominant-negative effect [281] demonstrating 
the importance of NTD for this effect. On the contrary, another study showed that there was no 
observed growth advantage (in terms of colony formation) when PH domain point mutants expressed 
in murine bone marrow cells that also express endogenous wild-type LNK [355]. Moreover, these 
mutants retained the ability to suppress the growth of LNK-/- bone marrow cells although this 
suppression was slightly lower compared to the one observed in wild-type LNK [355]. However, it 
is unclear as to why this difference exists. These findings may in part explain why LNK R392E 
mutants cause a more severe disruption of LNK function than PH domain point mutants. In addition, 
LNK R364E has been observed to still be able to bind JAK2, phospho-JAK2, EPOR, and phospho-
EPOR when stimulated by EPO although the phosphorylation of LNK and its ability to inhibit EPOR 
signalling were abolished [277]. On the other hand, LNK R364E was not able to bind phospho-JAK2 
in the context of TPOR signalling [278]. In support of this finding, the R364E mutation was found to 
completely abolish the ability of LNK to interact with phosphorylated c-Kit [281].  
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1.8.7 LNK mutations in non-haematopoietic diseases/disorders 
 
Besides myeloid malignancies, LNK mutations have also been associated with non-haematopoietic 
diseases and disorders. LNK is an important modulator of inflammation [312, 313, 316, 360] where 
polymorphisms in the LNK gene have been shown to be linked to autoimmune disorders such as 
celiac disease and type I diabetes. LNK has also been implicated in vascular disease [359] as it 
negatively regulates the TNF signalling pathway via downregulation of the ERK and PI3K [313]. 
Reduced LNK regulation in dendritic cells contributes to increased inflammatory response via IFN-
γ that is produced by T cells [361]. LNK is also an important player in post-myocardial infarction 
inflammation and fibrosis [362], as well as hypertension [363]. Furthermore, LNK can regulate 
integrin signalling in platelets and endothelial cells that are involved in regulating cell adhesion and 
migration for the formation of blood clots. 
 
1.8.8 LNK as a therapeutic agent 
 
Interestingly, delivery of WT LNK with octa-arginine (cell-penetrating peptide) modification (WT 
Lnk R8) resulted in inhibition of leukaemic cell proliferation [364]. WT Lnk R8 can suppress the 
growth of M-MOK leukaemic cells but not of non-haematopoietic cells, by inducing cell death via 
apoptosis [364]. WT Lnk R8 binds to JAK2 and suppresses the activation of the JAK-STAT and ERK 
pathway that is induced by TPO in M-MOK cells [364]. WT Lnk R8 also inhibits megakaryopoieisis 
which is stimulated by TPO [364]. This peptide is also capable of inhibiting cell growth in signalling 
pathways regulated by JAK2 such as IL-3 and GM-CSF [364]. However, as the effect of the peptide 
is quite broad, this may lead to side effects such as thrombocytopaenia [364]. 
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Research Aims 
 
The overarching aim of this project is to deepen our understanding on how JAK-STAT signalling is 
regulated by the TPOR (encoded by MPL) and its negative regulator, LNK in normal haematopoiesis 
and blood cancers (myeloproliferative neoplasms and leukaemia). The aims that have been set out 
below seek to define the functional changes that occur in the receptor in order to mediate JAK-STAT 
activation and to shed light on the structural mechanisms that are used by LNK to downregulate this 
signalling. Improved understanding of these mechanisms will reveal novel avenues for drug 
development (to inhibit TPOR or specifically JAK2) and improve current treatment strategies for 
haematological malignancies such as MPNs and certain types of leukaemia caused by various TPOR 
and LNK mutations (e.g. W515K, T487A, and S505N in TPOR, and E395K and R425P in LNK). 
 
Aim 1. (A): To analyse the effects of various TPOR TMD activating mutants on receptor 
function. For the purpose of the cell-based assays set out in aim 1 (B), stably-transduced Ba/F3 cells 
harbouring the clinical mutations (W515K, T487A, S505N) that lie in the TMD and surrounding 
(juxtamembrane) regions will be generated. The functionality of these mutants will be confirmed by 
analysis of their signalling and proliferative capabilities. Furthermore, stably-transduced Ba/F3 cells 
that harbour various engineered mutations at the important TMD domain of TPOR will be generated 
to investigate the specific parts of the domain that are important in regulating TPOR structure-
function. 
 
Aim 1. (B): To identify peptide antagonists against the ECD-JM/ TMD of TPOR using phage 
display. Clinically available treatments for MPN patients harbouring activating TPOR mutants still 
rely on JAK2 inhibitors that are not specific i.e. they do not target TPOR and in addition, they also 
inhibit other JAKs and resulting downstream signalling, which are vital for physiological functions. 
This fact clearly represents a gap in current treatment modalities for these patients and encourages 
the need for the development of better targeted treatments. This study will seek to discover suitable 
peptide antagonists against the crucial signal-modulating TPOR domain, the ECD linker/TMD. This 
aim will involve the search for candidate peptides via phage display and these peptides will be 
screened for functionality using cell-based assays. 
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Aim 2: To investigate the effect of cytokine stimulation and mutations on the molecular 
dynamics of the transmembrane receptor, TPOR in the plasma membrane using sptPALM. 
The majority of TPOR understanding is based on biochemical works with little or no relation to the 
spatiotemporal patterns of TPOR and its activity. Specifically, the lateral diffusion/mobility of the 
W515K and Box1 mutation in comparison to WT TPOR will be examined on the surface of live cells. 
This aim seeks to investigate if the constitutively active TPOR W515K and Box1 mutants mediate 
their effect on signalling via modulating their rates of lateral diffusion by tracking single molecules. 
Cytokine stimulation with thrombopoietin (TPO) will further provide critical information to better 
understand this effect.  
 
Aim 3. (A): To fully characterise the region of LNK that interacts with and regulates JAK2 
and/or TPOR activity in co-operation with its SH2 domain. It has been well established that LNK 
associates with phosphorylated JAK2 (pY613 and 813) via its SH2 domain [278] and that other LNK 
domains may associate with JAK2 in its inactive state [309, 310]. Nevertheless, there is a lack of 
information to explain the detailed mechanisms on how LNK inhibits JAK2/TPOR. This aim seeks 
to elucidate whether other LNK domain interactions with JAK2/TPOR are crucial for their inhibitory 
effect, i.e. the ability of other LNK domains to affect SH2 domain binding to JAK2/TPOR, and their 
effects on downstream signalling. By elucidating these domain interactions, novel mechanisms for 
JAK2/TPOR inhibition will be revealed. 
 
Aim 3. (B): Expression and purification of LNK for structural and biochemical assays. Hitherto, 
the crystal structure of LNK has not been solved and this remains one of the main reasons contributing 
to the lack of understanding of LNK inhibitory function. The crystal structure will reveal functional 
sites of LNK and also predict exactly which sites of LNK are associated with JAK2. Therefore, 
solving the crystal structure of full-length LNK is one of my important aims, although if obtaining 
LNK crystals becomes difficult, the soluble protein will be used for interaction studies and kinase 
activity assays. The goal of this aim is also to facilitate understanding regarding the role of the 
important domains identified in Aim 2(A), although this will be better addressed by obtaining 
interacting LNK-JAK2 crystals. Furthermore, the outcome of this aim will allow us to predict possible 
conformational changes that can occur due to alterations of certain amino acid residues that lead to 
the inability of mutant LNK to inhibit its associated proteins. Addressing this aim will facilitate the 
development of novel treatments.  
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Chapter 2 
 
Materials and General Methods 
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Cell Culture 
Ba/F3 murine pro-B cells (RRID:CVCL_0161) are dependent on the cytokine IL-3 for growth. Ba/F3 
parental and stably-transduced cells were maintained in RPMI (Roswell Park Memorial Institute)-
1640 (Sigma) supplemented with 10% (vol/vol) foetal bovine serum (FBS) (Gibco, Thermo Fisher 
Scientific), 1× IL-3 (mouse recombinant 100× IL-3 produced in SF9 baculovirus cells), 1× 
GlutaMAX™ (Gibco, Thermo Fisher Scientific), and 1× sodium pyruvate (Gibco, Thermo Fisher 
Scientific). Adherent cell lines such as Lenti-X 293T, human embryonic kidney 293 (HEK293), 
HEK293T, and HeLa cells were maintained in DMEM (Dulbecco's Modified Eagle Medium) (Sigma) 
supplemented with 10% (vol/vol) FBS and 1× GlutaMAX™ (Gibco, Thermo Fisher Scientific). HeLa 
cells were generously provided by Dr Eloïse Dray (UT Health San Antonio). All cell culture flasks 
were supplied by Corning® Costar® (Sigma-Aldrich). Puromycin and Hygromycin B were 
purchased from Gibco (Thermo Fisher Scientific) and AG Scientific, respectively. 
 
Circular Polymerase Extension Cloning (CPEC) 
Polymerase chain reaction (PCR) was performed to generate fragments of DNA with overlapping 
complementary ends suitable for CPEC based on the method previously described [131]. For each 
CPEC assembly, 200 ng of the largest DNA fragment and equimolar ratio of other fragments were 
added to the Phusion HF reaction according to the manufacturer’s instructions (New England Biolabs, 
NEB). CPEC was performed using a thermo cycler (Eppendorf) with cycling conditions at 98°C for 
30 seconds (one cycle), 20 cycles of {98°C for 10 seconds, 70°C for 30 seconds, and 72°C for 23 
seconds/kilobase pair final construct size}, and 4°C for 5 minutes (one cycle). CPEC products were 
transformed into either DH5α or Stbl3 E. coli cells.  
 
Gateway (GW) Cloning  
Gateway reaction (BP and LR reaction) was performed according to the manufacturer’s instructions 
(Thermo Fisher Scientific). For each BP reaction, 70 ng/kilobase pair of purified PCR product, 75 ng 
of donor vector (pDONR221), and 1 l of BP Clonase II enzyme mix was added to the reaction. The 
reaction was incubated at room temperature for at least 3 hours. For each LR reaction, 4 l of BP 
reaction, 140 ng of destination vector of choice, 1 l 112mM NaCl and 1 l of LR Clonase II enzyme 
mix was added to the reaction. The reaction was incubated at room temperature for 1-3 hours. DH5 
or Stbl3 cells was transformed with 1 µl of either the BP or LR reaction on kanamycin (30 g/ml) or 
carbenicillin (100 µg/ml)-containing LB agar plates. 
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Preparation of Chemically Competent Escherichia coli (E. coli) Cells  
DH5α or Stbl3 E. coli cells were allowed to grow for 16 hours at 37°C with shaking at 200 RPM in 
LB media without antibiotics. The culture was diluted 30-40 times in LB media (no antibiotics) and 
allowed to grow at 37°C with shaking at 200 RPM until the culture reaches an OD540 of approximately 
0.4-0.6. Cells were centrifuged at 4500 RPM (rotor radius: 8.4 cm) at 4°C for 5 minutes. Supernatant 
was removed and cells were resuspended in ice-cold 50 mM calcium chloride and left to incubate on 
ice for 30 minutes to an hour. The cells were centrifuged at 4500 RPM (rotor radius: 8.4 cm) at 4°C 
for 5 minutes and resuspended in a tenth volume of 50 mM calcium chloride containing 15% (vol/vol) 
glycerol. Cells were aliquoted into tubes and snap-frozen in dry ice/ethanol baths immediately. 
Competent cells were stored at -80°C. 
 
Bacterial Transformation  
Plasmid DNA or ligation mixture was added to chemically competent E. coli cells and left to incubate 
on ice for 30 minutes. Heat shock was performed at 42°C for 40 seconds and the cells immediately 
placed on ice for 2 minutes. Following, 1 ml LB medium was added to the cells and incubated at 200 
RPM at 37°C for 1-2 hours to allow for expression of antibiotic resistance gene. The culture was 
plated on LB agar plates containing appropriate antibiotics (100 µg/ml carbenicillin or 30 g/ml 
kanamycin) and allowed to incubate overnight at 37°C. 
 
Plasmid DNA Isolation using Alkaline Lysis 
Bacterial cultures were centrifuged at 14 000 RPM (rotor radius: 8.4 cm) for 1 minute and the 
supernatant discarded. Cells were re-suspended in resuspension buffer containing RNase A and 
alkaline lysis was carried out according to manufacturer’s protocol (Favorgen). Plasmid concentration 
was determined using NanoDrop™ Lite Spectrophotometer (Thermo Fisher Scientific). 
 
Agarose Gel Electrophoresis  
SeaKem® LE Agarose (Lonza) was melted in 1x tris-acetate ethylenediaminetetraacetic acid (TAE) 
buffer in an appropriate amount depending on the desired final percentage of the gels. After the 
molten agarose was allowed to cool for 20-30 minutes, Sybr Safe DNA gel stain (Invitrogen) was 
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added at a 1:30 ratio. The mixture was poured into a gel cast and allowed to solidify. Before loading 
into gel, appropriate amounts of plasmid DNA or PCR products was added with 10x DNA loading 
buffer (50% dye, 50% glycerol). A 1kb DNA ladder was also loaded as a marker for size and 
quantification (NEB). Electrophoresis was performed at 100V in 1X TAE buffer.  
 
DNA Sequencing  
DNA sequencing was performed by the Australian Genome Research Facility (AGRF, University of 
Queensland, QLD, Australia). Plasmids to be sequenced was prepared as following: plasmid (600 – 
1500 ng) and primer (10 pmol final concentration) in a total volume of 12 µl made up to final volume 
with milliQ. The primers used for sequencing are listed in Appendix Section D. 
 
Cytokines  
Recombinant human TPO were purchased from R&D Systems. Mouse recombinant IL-3 was 
produced using SF9 Baculovirus expression by the Protein Expression Facility at University of 
Queensland.  
 
Preparation of Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gels 
Laemmli resolving gel was prepared by adding 40% (vol/vol) acrylamide/bis Solution, 29:1 (final 
concentration 8% (vol/vol)) (Bio-Rad), N,N,N’-tetra-methylethylenediamine (TEMED) (final 
concentration 0.05% (vol/vol)) (Sigma-Aldrich), and 10% (wt/vol) ammonium persulphate (final 
concentration 0.05% (vol/vol)) to the Laemmli resolving gel buffer. The mixture was transferred to 
the Mini-PROTEAN® casting apparatus (Bio-Rad). A layer of water was added to the unpolymerised 
gel to ensure a smooth interface. After polymerisation, the water was removed and the stacking gel 
was added (Laemmli stacking gel buffer with 40% acrylamide/bis solution (final concentration 4.5% 
(vol/vol)), TEMED (final concentration 0.1% (vol/vol)), and 10% ammonium persulphate (final 
concentration 0.06% (vol/vol)) on top of the resolving gel followed by a spacer comb.  
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Western Blotting 
Supernatant was mixed with 3× SDS sample buffer (containing 0.1 M dithiothreitol (DTT)) and 
heated to 98°C for 5 minutes before the samples were run on SDS-PAGE gel at 100 V in gel tanks 
filled with 1x SDS running buffer. Precision Plus Protein™ Kaleidoscope™ Prestained Protein 
Standards (BioRad) was used as a molecular weight marker. After electrophoresis, semi-dry transfer 
of proteins onto PVDF membranes was performed using Trans-Blot® Turbo™ Transfer System 
(BioRad). After transfer to PVDF membranes and blocking in 5% (wt/vol) bovine serum albumin 
(BSA) (Gibco)/ tris-buffered saline–Tween (TBST), immunoblotting was performed overnight at 4°C 
with corresponding primary antibodies in a solution of 5% (wt/vol) BSA/TBST. Secondary mouse or 
rabbit antibodies conjugated to horseradish peroxidase were used to detect the corresponding primary 
antibodies (see Appendix Section E). Visualisation of antibody was performed by using enhanced 
chemiluminescent (Clarity™ Western ECL Substrate (Bio-Rad) or Immobilon Western 
Chemiluminescent horseradish peroxidase (HRP) Substrate (Merck Millipore)) coupled with the 
ChemiDoc™ Touch Gel Imaging System. Densitometric analysis of immunoblot was performed 
using Fiji software. 
 
Antibodies and Enzymes  
Primary antibodies were purchased from Cell Signaling Technology®, BioLegend, and Merck 
(Millipore) (see Appendix Section E). HRP-conjugated secondary antibodies were supplied by Cell 
Signaling Technology® (MA, USA). Restriction enzymes used for molecular cloning were purchased 
from NEB (Genesearch Ltd.).   
  
Stripping and Re-probing of PVDF Membranes  
PVDF membranes were incubated with mild stripping buffer with agitation for 10 minutes, twice. 
Membranes were rinsed and incubated with phosphate buffered saline (PBS) with agitation for 10 
minutes, twice. Finally, the membranes were washed in TBST with agitation for 5 minutes, twice. 
Blots were blocked for at least 30 minutes before re-probing.  
 
Coomassie Staining and Destaining 
SDS-PAGE gels containing protein samples were incubated with coomassie stain (R-250 (final 
concentration 0.1% (wt/vol)), acetic acid (final concentration 10% (vol/vol)), methanol (final 
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concentration 40% (vol/vol)) for 30 minutes followed by de-staining solution (methanol (final 
concentration 20% (vol/vol)), acetic acid (final concentration 10% (vol/vol)) for 30 minutes, twice. 
Gel was destained overnight. 
 
Statistical analysis 
One-way and two-way analysis of variance (ANOVA) testing were used. All statistical analyses were 
performed using GraphPad Prism® version 7.03 software. 
 
Buffers and Solutions 
 
Chemicals  
All chemicals and reagents used were of analytical grade and purchased from Sigma-Aldrich unless 
otherwise specified.  
 
Lysogeny Broth (LB) and Agar Plates  
LB medium was prepared by dissolving 10 g of bacto-tryptone, 5 g of yeast extract, and 5 g of NaCl, 
in 1 L final volume of milliQ water, and sterilised by autoclaving. LB agar was prepared by dissolving 
15g of agar in LB medium to a 1L final volume of water, sterilising by autoclaving and cooling to 
50°C before the respective antibiotics were added. The liquefied agar was poured into Petri dishes 
and left at room temperature to solidify and finally, stored at 4°C.  
 
Phosphate Buffered Saline 
A 1× working PBS solution was prepared by dissolving one tablet of PBS (10 mM phosphate, 2.68 
mM KCl, 140 mM NaCl ) (Thermo Fisher Scientific) in 500 ml of water. 
 
20% Sodium Dodecyl Sulfate (SDS) Solution  
A 20% (wt/vol) SDS solution was made by dissolving 10 g SDS in 50 ml of water.  
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50× TAE Buffer  
A 50× concentrated stock was made by dissolving Trizma® base (final concentration 2 M), EDTA 
(final concentration 50 mM, pH 8), and glacial acetic acid (final concentration 1 M) to a final volume 
of 1 L of water. A 1× TAE buffer was prepared by diluting 50-fold of the 50× TAE buffer with water. 
 
Laemmli resolving gel buffer  
Laemmli resolving gel buffer was prepared by mixing 1:4 of 1.5 M Tris pH 8.8 and a final 
concentration of 0.1% (vol/vol) of 20% SDS. 
 
Laemmli stacking gel buffer  
Laemmli stacking gel buffer was prepared by mixing 1:7 of 1 M Tris pH 6.8 and a final concentration 
of 0.1% (vol/vol) of 20% SDS. 
  
10× SDS running buffer  
A 10× SDS running buffer was prepared by dissolving Trizma® Base (final concentration 250 mM), 
glycine (final concentration 1.92 M), and 40% (wt/vol) SDS (final concentration 1%) to a final 
volume of 1 L of water.  
 
1× SDS running buffer  
A 1× SDS running buffer was prepared by diluting 10-fold of the 10× SDS running buffer with water. 
 
3× SDS sample buffer  
A 3× SDS sample buffer was prepared by mixing Tris-HCl (final concentration 150 mM, pH 6.8), 
SDS (final concentration 6%), bromophenol blue (0.3% final concentration), and glycerol (final 
concentration 30%) to a final volume of 50 ml milliQ water. 
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10× DNA loading dye 
A 10× DNA loading dye was prepared by mixing dye and glycerol (final concentration 50%) to a 
final volume of 10 ml milliQ water. 
 
10× TBS 
A 10× TBS was prepared by dissolving Tris (final concentration 200 mM) and NaCl (final 
concentration 1.5 M) in milliQ water, pH adjusted to 7.6, and made up to a final volume of 1 L with 
milliQ water.  
 
1× TBST 
A 1× TBS-Tween solution was prepared by diluting 10-fold of the 10× TBS with milliQ water and 
Tween-20 was added to a final concentration of 0.1%. 
 
Mild stripping buffer 
A 1x mild stripping buffer was prepared by dissolving 15 g glycine, 1 g SDS, 10 ml Tween-20 in 
milliQ and pH adjusted to 2.2. 
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Chapter 3 
 
Analysis of TPOR TMD Activating Mutants and Development of Novel 
Peptides Targeting TPOR 
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Introduction 
 
Oncogenic TPOR mutations that result in constitutive receptor activation and downstream signalling 
are frequently located in the TMD and JM regions. In MPNs, mutation in the ICD-JM at the W515 
residues such as W515L/K are most commonly reported. These findings are consistent with the role 
of the TMD and JM regions in regulating receptor activation. On the other side of the spectrum, 
inactivating mutations can result in CAMT where patients present with severe thrombocytopaenia. 
TPOR agonists have been developed to treat thrombocytopaenic patients such as those afflicted with 
CAMT, ITP, MDS, bone marrow failure, liver cirrhosis, autoimmune diseases, and those undergoing 
chemotherapy/radiation. Several TPO agonists have been developed and of interest is Eltrombopag 
(Promacta), a small molecule that binds to the TMD of TPOR. The ability of Eltrombopag to bind to 
the TMD to exert its effects provides the rationale for developing TPOR antagonists against this 
region. In this chapter, the phage display screen was utilised to discover peptide antagonists targeting 
constitutively active TPOR mutants.  
The phage display screening method was first described in 1985 which can be used to identify protein-
DNA, protein-peptide, and protein-protein interactions [365]. The versatility of this method has 
enabled it to be utilised for many important applications such as vaccine development [366], 
discovery of bioactive peptides (agonists and antagonists) [367-373], drug target validation [374, 
375], discovery of drug delivery agents [376, 377], and antibody epitope mapping [378]. In 
comparison to cDNA library screening, phage display is a high-throughput technology that is time 
and cost effective that enables a vast number of various oligonucleotides or peptides, ~1010 to be 
screened at any one time against a target of interest [379, 380]. The ability to screen large pools of 
unique oligonucleotide/peptide sequences increases the probability of discovering high affinity 
oligonucleotides or peptides that can bind to the target of interest. Phage display technology takes 
advantage of the properties of bacteriophages that have been used as a platform include T4 [381], T7 
[382], and λ [383] but filamentous phages (such as fd, f1, and M13) are more commonly used [383]. 
Filamentous phages are small, long, and have filament-like shape. They have a basic genome 
arrangement [384] with genes that encode capsid proteins (pIII, pVI, pVII, pVIII, pIX), proteins that 
facilitate DNA replication (pII, pV, PX), and proteins for phage assembly (pI, pIV, pXI) [385]. To 
utilise bacteriophages for phage display, foreign DNA will be cloned into the phage gene that encodes 
capsid proteins. Capsid protein gene pIII and pVIII are more commonly used. When the recombinant 
DNA is expressed, foreign peptides will be displayed on the surface of viral particles. These 
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recombinant virions can then be used for in vitro (using purified protein fragments, receptors or whole 
cells as bait) or in vivo (murine) screening. 
 
 
Figure 9: General flow of phage display. 
Phage particles displaying the foreign peptide is allowed to bind to the target (bait) of interest. 
Unbound phage is washed away. Bound phage is eluted from the target and amplified via E. coli. 
Steps 1 to 5 is repeated for 2-3 times. The amplified phage is sequenced to identify high affinity 
displayed peptides.  
 
The phage display general workflow (Figure 9) is as follows: i) the prey (recombinant virions) is 
allowed to bind to the bait (target of interest), ii) unbound phages are washed away, iii) affinity 
enrichment/biopanning is performed (steps i and ii are repeated several times), iv) phages bound to 
the bait are eluted using acidic solution, v) phage capsid gene is sequenced. The sequence of interest 
can then be used to synthesise lead peptides that can potentially be developed into clinical drugs.  
A bioactive peptide targeting TPOR, Romiplostim (TPO agonist), has been discovered using phage 
display. Initially, filamentous phages were made to display random foreign peptides on the pVIII 
capsid protein. Then, monoclonal antibodies that bind to the ECD carboxyl-terminus of TPOR were 
used to immobilise the receptor [367, 386]. Biopanning was performed and the consensus sequence 
of the peptide (AF13948) identified from bound phage was found to not share sequence homology 
with TPO [368], but was able to compete with TPO for binding to TPOR. Dimerisation of the peptide 
by covalent linkage was able to increase its efficacy with potency similar to TPO [368]. AF13948 
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was then used to develop Romiplostim which has subsequently been approved clinically for the 
treatment of ITP [387].  
Antagonists such as those against IL-6 have also been discovered by phage display [388]. Excessive 
production of IL-6 leads to inflammation that has been associated with diseases including 
Castleman’s disease and rheumatoid arthritis [388]. To discover peptides that bind to IL-6, a vector 
containing a region of the IL-6 receptor that binds to the cytokine, was used to discover a scaffold 
protein using computational methods [388]. Following, certain residues at determined positions were 
randomised [388]. The sequences were then incorporated into the M13 phage [388]. A solution-based 
biopanning was performed for four to five rounds using different biotin-conjugated IL-6 as a bait 
[388]. Bound phage particles were eluted and the sequences were used to make synthetic peptides 
[388] which led to the development of PN-2921 (pegylated peptide) that has shown to be a potent 
antagonist and is currently in clinical trials [388]. 
Current treatments for MPN patients harbouring activating TPOR mutations include administration 
of hydroxyurea, IFN-α, or JAK2 inhibitors. Ruxolitinib or also known as Jakafi, works by inhibiting 
JAK1/JAK2 [247] and is used for the treatment of MF (de novo MF or post-ET/polycythaemia vera 
MF). As these treatments are not specific, patients developed various side effects. In particular for 
JAK inhibitors, these inhibit JAK activation induced by many receptors, hence, lack specificity for 
TPOR signalling and for specifically targeting TPOR activating mutants. This provides the rationale 
for specific targeting of the TPOR rather than targeting JAK activation.  
Currently, two TPOR antagonists have been developed whereby one of them is known as LCP4, that 
inhibits myelofibrotic HSCs which expresses TPOR [389]. LCP4 is a 20-amino acid cyclic peptide 
that targets TPOR and acts by competitive binding to the TPOR ECD at the site where TPO binds 
[389]. LCP4 has been shown to deplete myelofibrotic HSCs and HPCs but does not fully eliminate 
these cells [389]. This peptide also results in inhibition of normal cells although it more effectively 
affects malignant cells [389]. The other TPOR antagonist that has been developed is a small molecule 
inhibitor, an analogue of 3-(4-piperidinyl) indole [390]. However, this antagonist is not specific to 
TPOR and can also target other monoamine receptors such as EPOR [390]. This inhibitor shows no 
difference in inhibition between TPOR WT and W515L [390]. This highlights the need and rationale 
to develop more specific, targeted treatments against TPOR (i.e. by targeting the ECD linker/ TM). 
Oncogenic mutations in the TMD-JM of several receptors besides TPOR have been reported which 
includes the IL7RA and thymic stromal lymphopoietin receptor (TSLPR). In TPOR, these activating 
mutations include the T487A, L498W, S505N, and W515L/K/A/R/S whereas in TSLPR the TMD 
F232 residue was mutated to cysteine. Oncogenic mutations in IL7 receptor-α (IL7RA) are caused by 
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in-frame insertions or deletions in the TMD [391, 392], or insertion of a cysteine residue in the ECD-
JM [392, 393]. Poor sequence conservation of the TMD and JM regions between these receptors 
(Figure 10) demonstrates the suitability of targeting this region as more specific targets to a single 
receptor can be found. The aim of this chapter is to quantify the signalling strength of activating 
mutations in the TMD region of TPOR and develop peptides targeting WT TPOR and constitutive 
active oncogenic mutants.  
 
Figure 10: Poor sequence conservation of the ECD-JM and TMD regions of IL7RA, TPOR, 
and TSLPR. 
Conserved residues are indicated by * and highlighted in yellow. Purple, red, and blue fonts indicate 
the TMD regions of the IL7RA, TPOR, and TSLPR, respectively.  
 
Materials and Methods 
DNA Constructs  
WT hTPOR in pLV411 lentiviral vector (generously provided by ARVEC) was shuttled into 
pDONR221 donor vector and a HA-tag was added to the N-terminus of hTPOR after the signal 
peptide via CPEC. Various primers (see Appendix Section C) were designed to generate hTPOR with 
point mutations (W515K, S505N, T487A) via PCR mediated site-directed mutagenesis (Table 1) 
using the pDONR221 HA-tagged WT hTPOR as a template. attB sites were added to the N-terminal 
HA-tagged hTPOR constructs via PCR. Constructs were subsequently shuttled into the pMX-GW-
mPGKpro-puroR/green fluorescent protein (GFP) destination vector by Gateway cloning (Figure 11). 
Primers were used to generate a Box1 mutant (this motif was mutated from PxxP to AAAA) of 
hTPOR via PCR mediated site-directed mutagenesis and CPEC (see Chapter 2) using pDONR221 
HA-tagged WT hTPOR, and subsequently shuttled into pMX-GW-mPGKpro-puroR/GFP destination 
vector via Gateway cloning. All constructs were verified by DNA sequencing performed by AGRF 
Brisbane. 
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Table 1: PCR cycling conditions used. 
Double-stranded DNA was denatured to single-stranded DNA and primers were allowed to anneal. 
PCR was performed with KOD DNA polymerase (Merck Millipore). 
 
 
Figure 11: Representative vector map of the pMX-GW-mPGKpro-puroR/GFP HA-hTPOR 
vector constructs. 
An HA-tag was present at the N-terminus of the hMPL gene. 
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Retroviral Transduction and Generation of Stably-Transduced Ba/F3 Cell Lines   
PLAT-E cells were seeded (1.7 × 105 cells/well) into 6-well cell culture plates and cultured overnight 
in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Cells were 
transiently transfected with 3 µg plasmid DNA (pMX-GW-mPGKpro-puroR/GFP HA-tagged TPOR 
constructs) using Lipofectamine 2000 according to manufacturer’s instructions (Invitrogen, Thermo 
Fisher Scientific). After 24 hours incubation at 37°C, media was replaced with fresh DMEM 
supplemented with 10% FBS for 48 hours. Parental Ba/F3 cells (2 × 105 cells per infection) were 
infected with ecotropic retroviral supernatants generated in PLAT-E cells and incubated at 37C for 
1-2 hours before an equal volume of RPMI-1640 (supplemented with 10% FBS and 2× IL-3) was 
added. After 3 days, puromycin selection was performed by re-suspending cells in a final 
concentration of 1 µg/ml puromycin (Gibco, Life Technologies, Thermo Fisher Scientific) in RPMI-
1640 (supplemented with 10% FBS) and left for 3-5 days before cells were expanded to T25 cell 
culture flasks.  
 
TPOR Signalling Assay using Ba/F3 TPOR Retroviral Transduced Cells 
Retroviral transduced Ba/F3 TPOR WT and mutants were cultured to near end of log-phase growth 
(~1-3 × 106 cells/ml) in RPMI-1640 supplemented with 10% FBS and 1 × IL-3 at 37°C in a 
humidified 5% CO2 incubator. Cells were starved in RPMI-1640 supplemented with 0.5% FBS (no 
IL-3) for 12-16 hours. Cells were then stimulated with 50 ng/ml recombinant human (rhTPO) (R & 
D Systems) or PBS for 30 minutes at 37°C. Cells were subsequently washed with cold-PBS and lysed 
in 50-100 μl ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris pH7.5, 150 mM 
NaCl, 5 mM EDTA, 0.5% Triton X-100) containing 2 mM sodium orthovanadate (Sigma), 30 mM 
sodium fluoride (Sigma), 10 mM sodium pyrophosphate (Sigma), and 1x complete protease inhibitor 
cocktail (Roche Applied Science). Protein concentration was determined using the Pierce 
Bicinchoninic (BCA) Protein Assay Kit (Thermo Fisher Scientific). Supernatant was mixed with 3x 
SDS sample buffer (containing 0.1 M DTT) and heated to 98°C for 5 minutes before the samples 
were run on SDS-PAGE gel and subjected to western analysis using the appropriate antibodies (see 
Appendix Section E). 
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Lentiviral Transduction and Generation of Stably-Transduced HEK293 Cell Lines   
Lentiviral transduction and generation of stably-transduced HEK293 cell lines were performed by Dr 
Yash Chhabra. Lenti-X 293T cells were seeded (1.9 × 105 cells/well) into 6-well cell culture plates 
and cultured overnight in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 
incubator. Cells were transiently transfected with 1 µg pCMV (cytomegalovirus)-VSV-G, 2.5 µg 
pVPac-Gag-Pol, and 3 µg pQCXIP HA-tagged hTPOR constructs using Lipofectamine 2000 
according to manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific). After 15 hours 
incubation at 37°C, media was replaced with fresh DMEM supplemented with 10% FBS for 48 hours. 
Parental HEK293 cells (3.5 × 105 cells per infection) were infected with lentiviral supernatants 
filtered with a 0.2 µm PVDF Millex-GV filter unit (Millipore) that was generated in Lenti-X 293T 
cells. After 2-3 days, puromycin selection was performed by adding to the cells to a final 
concentration of 1 µg/ml puromycin (Gibco, Life Technologies, Thermo Fisher Scientific) in DMEM 
(supplemented with 10% FBS) and left for 3-5 days before cells were expanded to T25 cell culture 
flasks.  
 
TPOR Signalling Assay using HEK293 TPOR Stably-Transduced Cells 
Stably-transduced TPOR HEK293 cells were seeded (0.7 × 106 cells/well) into T25 cell culture flasks 
and cultured overnight in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 
incubator. Cells were starved in DMEM supplemented with 0.5% FBS for 12-16 hours. Cells were 
then stimulated with 50 ng/ml rhTPO (R & D Systems) or PBS for 10 minutes at 37°C. Cells were 
subsequently washed with cold-PBS and lysed in 100 μl ice-cold RIPA buffer. Protein concentration 
was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Supernatant was 
mixed with 3x SDS sample buffer (containing 0.1 M DTT) and heated to 98°C for 5 minutes before 
the samples were run on SDS-PAGE gel and subjected to western analysis using the appropriate 
antibodies (see Appendix Section E). 
 
TPO Dose Response Assays 
Retroviral transduced Ba/F3 TPOR WT and mutants were seeded (3 × 103 cells/ well) into 384-well 
plates in IL-3-free and phenol red-free RPMI-1640 medium (with 10% FBS, 1× Glutamax, 1× sodium 
pyruvate, 1:200 penicillin-streptomycin). Increasing concentrations of rhTPO (R & D Systems) (0, 
1.25, 3.7, 11.1, 33.3, 100, and 300 ng/ml) were added to the respective wells and live cells were 
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evaluated from day 0 to day 6 after seeding using the IN Cell Analyser (GE Healthcare Life Sciences) 
determined by GFP-positivity using the FITC channel (GFP expression of cells).  
 
Flow Cytometry Analysis 
Retroviral transduced Ba/F3 TPOR WT and mutant cells were tested for cell surface expression of 
TPOR by flow cytometry. Approximately 1 × 106 cells were washed twice to remove excess culture 
media, resuspended in 80 μl PBS (2% FBS) containing anti-HA primary antibody (BioLegend) (1:100 
dilution) raised against the HA-tag that was engineered to the N-terminus of the receptor, and 
incubated for 2 hours at 4°C. Cells were washed twice, resuspended in 80 μl PBS (2% FBS) 
containing Alexa Fluor 647 secondary antibody, goat anti-mouse (Thermo Fisher Scientific) (1:500 
dilution), and incubated for 40 minutes (in the dark) at 4°C. Cells were washed twice to remove 
unbound antibody, resuspended in 500 μl PBS (2% FBS), and analysed by flow cytometry (BD 
LSRFortessa X20, Becton Dickinson). Ten thousand gated events were collected for each sample and 
analysed using FlowJo software.  
 
Phage Display Screening Assay 
A peptide encoding the ECD linker of the human TPOR (480PTRVETATETAW491) was synthesized 
by Peptide2.0 company. This oligonucleotide was biotinylated at its N-terminal domain. Peptide 
targets were also obtained from LifeTein representing part of the ECD and TM region 
(480PTRVETATETAWISLVTALH499). Underlined amino acid sequences indicate the predicted 
transmembrane region of TPOR. Phage display was used to select TPOR extracellular linker/ TM 
binding phage particles from a 7-mer or 12-mer library (Ph.D.-7 or 12 Peptide Library Kit; NEB) 
comprising up to 1011 theoretical sequences. Before panning, various negative selections were 
performed for library selection using the solution-phase panning method. Negative selection of plate 
plastic adherent was performed by diluting 10 µl phage library in 0.1% TBST and this mixture was 
added to a well of a 96-well tissue culture plate. This was incubated with agitation for 30 minutes at 
room temperature. For tube plastic adherent negative selection, the supernatant library from previous 
selection was transferred to a microcentrifuge tube and a plastic tip added into the tube. This was 
incubated with rotation for 30 minutes at room temperature. For negative selection of BSA/plastic 
adherents, a microcentrifuge tube was added with BSA blocking solution and left rotating for 60 
minutes at room temperature. The tube was rinsed 3 times with 0.1% TBST and the supernatant 
library from the previous step was added into the tube. This was incubated for 30 minutes at room 
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temperature with rotation. For biotin negative selection, 50 µl of washed, blocked streptavidin-coated 
paramagnetic beads (NEB) was mixed with 0.1 mM biotin in TBS and incubated for 15 minutes at 
room temperature with gentle agitation. Supernatant was removed and supernatant library from 
previous step was added to the biotin-beads and incubated for 15 minutes at room temperature with 
gentle agitation. Finally, negative selection of the beads were performed by mixing the supernatant 
library from the previous step to 50 µl of washed, blocked beads and incubated for 15 minutes at 
room temperature with gentle agitation. The first round of panning was performed by incubating the 
supernatant library from previous selection step with biotinylated target in 0.1% TBST for 20 minutes 
at room temperature with agitation. Target-bound phage was captured using beads by incubation for 
15 minutes at room temperature with agitation. Beads were extensively washed with TBS containing 
0.1% Tween-20 to remove non-binding phage. The remaining phage particles were eluted by 
incubation with 100 µM target, 0.1 mM biotin, glycine elution buffer, or 1x trypsin for 10-30 minutes 
with gentle agitation, and amplified by infecting log phase ER2738 E. coli cells at 250 RPM for 4.5 
hours. Polyethylene glycol (PEG) precipitation was carried out using 20% PEG/2.5 M NaCl to 
capture the amplified phage particles. Panning was repeated as above for a total of three rounds using 
increasing volume of Tween-20 in each subsequent rounds (0.3% TBST for second panning; 0.5% 
for third panning). Target concentration was also decreased in each subsequent rounds (1 µM for first 
panning, 100 nM for second panning; 10 nM for third panning). Selected phage clones (from the last 
round of panning) were DNA sequenced. 
 
Phage Amplification and Tittering 
Eluted phage suspension (180 µl) was added to 20 ml ER2738 cell culture in early-log phase (OD600 
0.01–0.05). After incubation with vigorous shaking for 4.5–5 hours at 37°C, the culture was 
centrifuged at 12,000g for 10 minutes at 4°C. The supernatant was precipitated with 1/6 volume 20% 
PEG/2.5 M NaCl overnight at 4°C. The next day, precipitated phage was collected by centrifugation 
at 15,000g for 15 minutes at 4°C and resuspended in 200 µl TBS for tittering and the next round of 
panning. For tittering, 10 µl serial dilutions of phage solutions were added to 200 µl mid-log phase, 
OD600 ~0.5 ER2738 cell cultures. After incubation for 1-5 minutes, the culture was mixed with 5 ml 
50°C top agar containing isopropyl β-d-1-thiogalactopyranoside (IPTG)/ X-gal and poured onto the 
LB agar plates immediately. After incubation of the plates overnight at 37°C, blue plaques were 
counted and phage titter as plaque forming units (pfu)/10 µl was calculated. 
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Hit Validation in Cell-based Assays  
Stably-transduced Ba/F3 TPOR WT, TPOR W515K, or GHR WT were seeded (3 × 103 cells/ well) 
into 384-well plates in IL-3-free and phenol red-free RPMI-1640 medium (with 10% FBS, 1x 
Glutamax, 1x sodium pyruvate, 1:200 penicillin-streptomycin). Peptides (final concentration of 1 
mM) were added to the respective wells containing cells and incubated for 30 minutes. rhTPO (R & 
D Systems) was added to the respective wells and live cells were evaluated from day 0 to day 6 after 
seeding using the IN Cell Analyser (GE Healthcare Life Sciences) determined by GFP-positivity 
using the FITC channel (GFP expression of cells).  
 
Results 
 
TPOR mutants show different constitutive signalling strengths in the absence of cytokine treatment 
using Ba/F3 cells 
 
The functionality of the Ba/F3 TPOR WT and mutant (W515K, T487A, and S505N) cell lines was 
investigated for their ability to activate downstream signalling pathways such as JAK-STAT and 
ERK1/2. W515K and S505N but not T487A, showed constitutive activation of STAT3 in the absence 
of cytokine treatment with the W515K mutant showing a stronger constitutive signalling (Figure 12). 
In contrast, all mutants showed constitutive activation of ERK1/2 in the absence of cytokine treatment 
with the S505N mutant showing the strongest constitutive signalling, followed by W515K and T487A 
(Figure 12). However, W515K showed similar pERK1/2 levels in the presence and absence of TPO. 
In the presence of cytokine, WT and mutants were all able to respond to rhTPO stimulation as shown 
by the increase in STAT3 and ERK1/2 activation (Figure 12). Comparison between mutants suggest 
that W515K and T487A were hypersensitive to rhTPO as shown by the increase in STAT3 activation 
that was stronger than in WT in the presence of TPO (Figure 12). Receptor levels of the mutants were 
slightly increased compared to WT which may be due to the increase in expression levels or stability 
of the mutant receptors on the cell surface (Figure 12). Interestingly, there was a stark decrease in the 
mature receptor expression level of the S505N mutant compared to WT and other mutants suggesting 
that this mutation may impair glycosylation, trafficking, or degradation of mature receptor (Figure 
12). 
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Figure 12: TPOR mutants conferred constitutive STAT3 or ERK1/2 activation in Ba/F3 cells. 
Retroviral transduced Ba/F3 TPOR WT and mutant cells (W515K, T487A, S505N) were starved for 
12-16 hours in RPMI-1640 media containing 0.5% FBS and no IL-3. Prior to cell harvesting, cells 
were stimulated accordingly with 50 ng/ml rhTPO for 30 minutes. Total protein was subjected to 
SDS-PAGE and immunoblotted with indicated antibodies. GAPDH was used as a loading control. 
A) and B) Two separate transductions. C) Graph of relative pSTAT3 and pERK levels of 4 
independent experiments generated using densitometry data. For a complete list of densitometry data 
for replicates, see Appendix Section B. Image representative of n=4 experiments.  
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TPOR WT and mutants (except Box1Δ) express similar surface levels of mature receptors in BaF3 
cells 
 
The receptor surface expression of Ba/F3 TPOR WT and mutant (W515K, T487A, S505N, and 
Box1Δ) cell lines were compared in order to investigate if the increase in cell signalling was due to 
the increase in receptor expression levels on the cell surface. Immunoblot analysis (Figure 13 B) 
showed that there was slight variation between the mature receptor levels amongst the mutant 
receptors, except for Box1Δ which showed a dramatic loss of the mature receptor form. As the mature 
receptor levels observed on Western analysis only suggests glycosylation status and does not fully 
reflect the presence of receptors at the cell surface, FACS performed on non-permeabilised cells was 
utilised for this investigation. A two-step staining procedure was used where the primary antibody, 
anti-HA was used against the HA-tag present at the receptor N-terminus (after signal peptide) which 
was detected using the Alexa Fluor 647 secondary antibody (far-red dye). Similar surface expression 
was observed for WT and mutant receptors, except for Box1Δ which showed a reduced signal for 
surface receptors (Figure 13 A). As the Box1 motif is essential for the binding of JAK2 which acts as 
a chaperone to transport the receptor to the cell surface [115], mutation of this motif resulted in 
markedly reduced receptor expression at the cell membrane. This result was supported by the inability 
of the Box1Δ to signal via STAT3 and ERK1/2 even in the presence of TPO stimulation due to the 
absence of JAK2 binding (Figure 14). 
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Figure 13: TPOR WT and mutants (except Box1Δ) express similar amounts of mature surface 
receptors. 
(A) Flow cytometric analysis of surface HA-TPOR expression levels of stably transduced Ba/F3 
TPOR WT and mutant cells. Cell surface expression of receptors was detected using anti-HA and 
AF647 anti–mouse IgG secondary antibody. Cells were not serum starved. (B) Western analysis of 
TPOR expression levels. Stably transduced Ba/F3 TPOR WT and mutant cells were starved for 7-8 
hours in RPMI-1640 media containing no FBS and no IL-3. No TPO stimulation was performed. 
Total protein was subjected to SDS-PAGE and immunoblotted with indicated antibodies. GAPDH 
was used as a loading control. (A & B) N=1 experiment. 
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Figure 14: Box1Δ TPOR mutant does not signal via STAT3 or ERK1/2 in Ba/F3 cells. 
Retroviral transduced Ba/F3 TPOR WT and Box1Δ were starved for 12-16 hours in RPMI-1640 
media containing 0.5% FBS and no IL-3. Prior to cell harvesting, cells were stimulated accordingly 
with 50 ng/ml rhTPO for 30 minutes. Total protein was subjected to SDS-PAGE and immunoblotted 
with indicated antibodies. β-tubulin was used as a loading control. N=1 experiment. 
 
TPOR W515K confers cytokine-independent cell proliferation whereas TPOR S505N confers partial 
cytokine-independent cell proliferation 
 
The functionality of the Ba/F3 TPOR WT and mutant (W515K, T487A, and S505N) cell lines was 
investigated for their ability to proliferate in the presence and absence of TPO as activation of JAK-
STAT signalling correlates with proliferation in Ba/F3 cells. WT and all mutants responded to 
increasing TPO concentrations used (0.0001 ng/ml to 300 ng/ml) (Figure 15). Using these polyclonal 
populations of cells, the TPO effective concentration (EC50) was determined (Figure 15 B) and this 
information was used for the cell-based screening assay of peptide antagonists identified below.  
 
A. 
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Figure 15: Ba/F3 TPOR WT and mutants respond to increasing TPO concentrations. 
Stably transduced Ba/F3 TPOR WT and mutant cells in log growth were plated at a density of 3 × 
103 cells/ well in 384-well plates in IL-3-free and phenol-red free RPMI-1640 media (no starving 
condition). Increasing rhTPO concentrations were used: 0, 1.25, 3.7, 11.1, 33.3, 100, and 300 ng/ ml. 
Viable cells were assayed based on GFP expression from day 0 to day 6 after seeding. (A) 
Proliferation assay results from day 2. Results and standard error of mean represent the mean of four 
readings of a single experiment. Image representative of n=3 experiments. (B) rhTPO EC50 data from 
day 2 of the mean of three experimental replicates were plotted as bar charts. Statistical analysis was 
performed in GraphPad Prism software using student’s 2-tailed unpaired t-test. All data were 
presented as mean ± SEM. No statistically significant difference were observed when comparing the 
rhTPO EC50 between WT and mutants. For replicates, see Appendix Section B. 
 
The ability of Ba/F3 TPOR WT and mutant (W515K, T487A, and S505N) cell lines to confer 
cytokine-independent cell proliferation was investigated. Consistent with the Western analysis results 
(Figure 12), only the W515K and S505N mutants were able to proliferate/survive in the absence of 
cytokine where W515K conferred a stronger phenotype (Figure 16).  
B. 
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Figure 16: Ba/F3 TPOR mutants W515K and S505N show significant proliferation in the 
absence of cytokine, but not T487A.  
T487A. Retroviral transduced Ba/F3 TPOR WT and mutant cells cultured in IL-3 until log growth 
were plated at a density of 3 × 103 cells/well in 384-well plates in IL-3-free, TPO free, and phenol-
red free RPMI-1640 media. Viable cells were counted by image analysis of GFP expressing cells 
from day 0 to day 6 after seeding. Results and standard deviations represent the mean of four readings 
of a single experiment. For replicates, see Appendix Section B. Image representative of n=3 
experiments. 
 
Novel TPOR TMD mutations (L498W, V501A, V501S, and L502S) confer constitutive signalling 
 
As part of a collaborative effort with group led by Melissa and Matthew Call at the WEHI (Walter 
and Eliza Hall Institute), this work investigated every amino acid residue in the TPOR TMD in order 
to evaluate their ability to result in constitutive proliferation in Ba/F3 cells in the absence of cytokine 
by using the deep mutational scanning (DMS) approach (Figure 17) [394].  
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Figure 17: Deep Mutational Scanning (DMS) overview and workflow. 
The DMS library was calcium phosphate transfected into HEK293T cells in order to generate virus 
that was used to transduced parental Ba/F3 cells. Puromycin selection (5 µg/ml) was performed for 
48 hours in order to select for successfully transduced cells followed by cytokine withdrawal for 48 
hours to allow for selection of constitutively active mutants. Cell lines that survived cytokine 
withdrawal were subjected to sequencing. Figure reproduced from [394].  
 
Using the mutants identified to cause cytokine-independent cell proliferation, analysis of signalling 
was performed. Four novel mutants were found to result in constitutive STAT5 and ERK1/2 
activation (L498W, V501A, V501S, and L502S) (Figure 18 A) which complemented the proliferation 
assays performed by the WEHI group (Figure 18 B). V501S resulted in a stronger constitutive 
receptor signalling compared to V501A (Figure 18 A). 
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Figure 18: Four novel mutations of TPOR TMD (L498W, V501A, V501S, and L502S) conferred 
constitutive STAT5 and/or ERK signalling, and cell proliferation. 
(A) Stably transduced Ba/F3 TPOR WT and mutant cells were starved for 6-8 hours in RPMI-1640 
media containing no FBS and no IL-3. Prior to cell harvesting, cells were stimulated accordingly with 
50 ng/ml rhTPO for 30 minutes. Total protein was subjected to SDS-PAGE and immunoblotted with 
indicated antibodies. β-tubulin was used as a loading control. Image representative of n=3 
experiments. For a complete list of replicates, see Appendix Section B. (B) Figure reproduced from 
[394].  
 
TPOR W515K and S505N conferred constitutive signalling in the absence of cytokine treatment in 
HEK293 cells 
 
As the TPOR constructs were all based on human constructs and Ba/F3 cells are from mice, the 
signalling of each TPOR construct was further investigated in the human cell line HEK293. In order 
to confirm that the different patterns of STAT3 and ERK1/2 activation by the TPOR variants were 
not due to species-specific differences, a similar analysis as above was performed on retroviral-
transduced HEK293 cells to express each TPOR construct. Some differences were observed when 
A. B. 
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compared with the Ba/F3 results in that while W515K was able to confer constitutive activation of 
STAT3, S505N and T487A do not (Figure 19). The low total STAT3 levels may have masked the 
weak constitutive activity of the S505N (Figure 19). Similar to the Ba/F3 results, W515K and S505N 
showed constitutive ERK1/2 activation but the T487A showed no or only very weak activation 
(Figure 19). In the presence of cytokine, WT and mutants were able to respond to rhTPO as shown 
by the increase in STAT5, STAT3, and ERK1/2 activation signals (Figure 19). However, the mutants 
did not appear to be cytokine-hypersensitive in this cell line (Figure 19) as shown by the similar levels 
of activation compared to WT in the presence of stimulation. A stark difference was observed upon 
ligand stimulation where ERK1/2 was similarly activated across all mutants but in BaF/3, a strong 
activation was observed for T487A (Figure 12 and Figure 19).  
 
Figure 19: W515K and S505N conferred constitutive STAT3 or ERK1/2 activation in HEK293 
cells. 
Retroviral-transduced HEK293 TPOR WT and mutant cells (W515K, T487A, S505N) were starved 
for 12-16 hours in DMEM media containing 0.5% FBS. Prior to cell harvesting, cells were stimulated 
accordingly with 50 ng/ml rhTPO for 10 minutes. Total protein was subjected to SDS-PAGE and 
immunoblotted with indicated antibodies. GAPDH was used as a loading control. Image 
representative of n=3 experiments. 
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12-mer phage display peptide library yield 3 consensus peptide motifs 
 
Peptide antagonists against the crucial-signal modulating domain (ECD linker/TMD) of TPOR were 
discovered using the commercial 12-mer phage display peptide library kit (NEB). Panning procedures 
were carried out using solution-phase panning. Three panning procedures were performed for each 
target and target-bound phage DNA was subsequently sequenced. Three consensus peptide motifs 
were discovered using this library in a screen of ~100 sequences: peptide T (2 hits), peptide S (11 
hits), and peptide V (7 hits), using the ECD linker as the target (biotin-DPTRVETATETAW) and 
competitive bait elution method. These sequences were sent for peptide synthesis (Biomatik) with its 
C-terminal amidated in order to block the negative charge resulting from the free carboxy terminus.  
 
Peptide V may be specifically inhibiting TPOR-mediated cell proliferation in the presence of TPO  
 
The synthesised peptides with sequences obtained from the phage display screen were tested in cell-
based assays for their ability to inhibit or enhance cell proliferation of Ba/F3 TPOR WT and mutant 
cells. Amongst the three peptides, only peptide V appeared to confer an effect. Peptide V was able to 
inhibit TPOR WT (at high dose TPO) and W515K (at low and high dose TPO) but not W515K 
cultured in the absence of cytokine or presence of IL-3 (Figure 20). Furthermore, this peptide did not 
affect the growth of Ba/F3 GHR WT cells (Figure 20). 
 
104 
 
 
 
 
 
 
 
 
 
105 
 
Cell lines 
(Ba/F3) 
Cytokine Final concentration/well 
GFP IL-3 None or 0.5% 
TPOR WT TPO None, 5.4 ng/ml (low), or 16.1 ng/ml (high) 
TPOR W515K TPO None, 2.9 ng/ml (low), or 8.7 ng/ml (high) 
GHR WT GH None, 1 ng/ml (low), or 3 ng/ml (high) 
 
Figure 20: Peptide V specifically inhibits TPOR-mediated signalling in the presence of TPO. 
Retroviral transduced Ba/F3 cell lines in log growth were plated at a density of 3 × 103 cells/well in 
384-well plates in IL-3-free and phenol-red free RPMI-1640 media (no starving condition). Peptide 
V was added (final concentration of 1mM) to respective wells and incubated with the cells for 30 
minutes. Cells were treated with plain media (phenol-red free RPMI-1640 media supplemented with 
1x L-glutamine, 10% FBS, 1:200 penicillin-streptomycin, 1x sodium pyruvate) or cytokine (see 
Table). Viable cells were assayed based on GFP expression from day 0 to day 6 after seeding. Results 
and standard deviations represent the mean of four readings of a single experiment. Image 
representative of n=2 experiments. 
 
Discussion 
 
TPOR is an important regulator of megakaryocyte differentiation, platelet formation, and HSC 
maintenance. Clinical TPOR mutations and polymorphisms have been reported where activating 
mutations were documented in MPN (ET and MF) and AMKL patients. Most TPOR mutations cluster 
in and around the TMD which is an important region that regulates receptor activation. The current 
study focusses on three clinically activating point mutations found in the ECD-JM, TMD, and ICD-
JM: W515K, T487A, and S505N. These mutations have been reported to result in spontaneous 
receptor activation leading to cytokine-independent signalling and cell proliferation [222, 239, 395]. 
W515K and T487A mutations have been speculated to increase the receptor tendency to form 
activating dimers [40, 43, 224, 225, 240] whereas the S505N is proposed to act by stabilising TPOR 
in the active dimer form [396, 397]. Prior to cell-based assay screening of peptide antagonists 
discovered using phage display, the Ba/F3 TPOR WT and mutant (W515K, T487A, S505N) cell lines 
were tested to confirm for their functionality. TPOR signalling in Ba/F3 and HEK293 cells was shown 
to produce different signalling outcomes particularly via the ERK1/2 pathway that may be attributed 
to used species and cell lines’ differences, where Ba/F3 is a haematopoietic mouse cell line whereas 
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HEK293 is a non-haematopoieitic tumorigenic human cell line that may possibly arise from the 
adrenal gland [398]. Discussion of results will be based on Ba/F3 signalling experimental results as 
their growth is dependent on JAK-STAT signalling by stimulation with IL-3 or an introduced 
alternative activation of JAK-STAT signalling. Based on the Ba/F3 results, only the W515K and 
S505N mutants conferred significant cytokine-independent cell signalling and proliferation, whereas 
T487A conferred very weak activation. The ability of W515K to cause constitutive activation was 
consistent with previous studies [239, 395] confirming the inhibitory role of the JM-ICD amphipathic 
motif in maintaining receptor inactivity in the absence of cytokine stimulation [224, 225]. This 
mutation resulted in a stronger signalling than the S505N which confirmed that the S505N mutant is 
a partially constitutive activating mutation that does not allow the cells to proliferate but only survive 
in the absence of cytokine [222]. However, published comparison of viability assays for the W515K 
and S505N have shown that the latter conferred stronger or similar cytokine-independent proliferative 
activity as the W515K mutant [227, 394]. In the current study, the addition of puromycin did not 
continue after selection. Hence, GFP expression of the cells may be low after several passages and 
this may account for the lower number of GFP-expressing cells that were detected by the In Cell 
Analyser (INCA). Nevertheless, the S505N mutation did not confer cytokine-hypersensitivity 
consistent with previous studies [222, 396]. The characteristics of the S505N may explain the milder 
phenotype of patients with hereditary thrombocytosis [220, 399, 400] harbouring this mutation [220] 
and the much lower prevalence of this mutation in ET patients [399, 401]. The T487A mutation has 
only been found in one de novo acute myeloid leukaemia case [239]. This mutation has not been 
reported in any MPN patients to date although mouse bone marrow transplantation assays showed 
that the T487A mutation was able to cause a serious myeloproliferative phenotype that is comparable 
to W515L [239]. However, the latter mutant was able to confer an MPN phenotype with a shorter 
latency [43]. The current study was not able to replicate the strong constitutive activation of the 
T487A mutant receptor that was previously documented [239] even after four separate transductions. 
The different vector backbone utilising a different promoter may account for the difference in 
observation. The previous study utilises the vector backbone with the MSCV promoter which gives 
higher expression than the vector backbone with the MMLV promoter that was used in this study 
[402]. The inability of the T487A mutation to confer strong constitutive signalling and proliferation 
demonstrates that the ECD linker of the TPOR may facilitate but is not crucial for receptor activation.  
FACS analysis confirmed that the increase in signalling of TPOR mutants (W515K and T487A) 
compared to WT in the presence of TPO was not due to the increase in mature receptor expression 
levels but that this may be attributed to the higher inherent stability of the mutant receptors. Receptor 
stability could be further investigated by utilising a cycloheximide chase assay where cells are treated 
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with cycloheximide to inhibit protein synthesis and analysed for changes in receptor expression levels 
over time. In the collaborative work, a few novel constitutively active mutants were discovered: 
L498W, V501A, V501S, and L502S [394]. These oncogenic substitutions are dependent on the 
position and amino acid residues that are mutated [394]. Consistent with these results, the V501A 
mutation was found in MPN patients and recently reported to confer constitutive receptor activation 
[403]. All these mutations lie on the same face of an α-helix which may suggest that they may form 
structurally similar TMD dimer interfaces [61, 221] and may potentially drive myeloid malignancies.  
Currently, available treatments for MPN and leukaemia patients harbouring TPOR mutations include 
the use of JAK inhibitors, hydroxyurea, interferon-α, and chemotherapy which are not target specific 
and can cause various significant side effects. Therefore, TPOR presents as an important clinical 
target for therapeutic inhibition. In particular, peptide antagonists against the crucial signal-
modulating TPOR domain, ECD/linker TMD, were discovered via phage display and their 
functionality assessed using BaF3 TPOR WT and mutant cells. This discovery may facilitate the 
development of improved targeted drugs to treat patients suffering from myeloid malignancies such 
as MPNs and AMKL as a result of activating TPOR mutations. The initial trials using the commercial 
7-mer peptide library kit (NEB) yielded phages that were not specific to the target of interest or were 
binding non-specifically to materials used in panning (such as textile, BSA, and plastic phage 
binders). Indeed, comparison of peptide sequences has shown that these sequences were actually 
binding to fabric baits [404]. Furthermore, non-specific phage binders may be amplified over specific 
phage binders due to their growth advantage resulting in a library that is highly over-represented in 
certain clones. As the same 7-mer library as the ones used for isolating phage-binding fabric baits 
was used in this study, the library may have a large over-representation of certain clones making it 
difficult to eliminate them. Hence, several negative selections were performed before the first panning 
procedure. These negative selections were carried out by exposing the naïve unpanned phage library 
to materials used in panning such as plastic tubes, plastic plates, BSA, plastic tips, biotin, and 
streptavidin-coated magnetic beads, in order to remove non-specific phage binders. Additionally, 
specific competitive elution methods were employed such as using biotin (for N-terminally tagged 
target) or bait elution instead of the general elution methods using glycine elution buffer or trypsin 
which may elute nonspecific binding phages. However, these efforts did not significantly improve 
the discovery of true consensus peptide motifs. An alternative 12-mer peptide library kit was utilised 
where the phage displays 12 amino acid long random peptide sequences which may increase binding 
affinity and specificity. A peptide antagonist, peptide V, was discovered via phage display using the 
TPOR ECD linker as bait, and it was found that this may be a potential peptide that requires further 
investigation. Interestingly, the peptide only inhibited the proliferation of Ba/F3 TPOR cell lines 
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cultured in the presence of TPO. As TPOR has been documented to be able to adopt various 
conformations [61, 221], TPO stimulation may induce a unique conformation which can only be 
affected by the peptide. However, although this peptide inhibited TPOR W515K, it also exhibited a 
negative effect on TPOR WT proliferation which suggests that this peptide may not be specifically 
inhibiting the W515K mutant receptor. Furthermore, as this mutation is located at the JM-ICD, the 
peptide should not specifically bind to this region. Analysis on a range of peptide concentrations on 
Ba/F3 TPOR WT and W515K cells may be required in order to determine if there is a therapeutic 
window for the peptide that results in inhibition of the W515K receptor and not WT. As the cell-
based assays were not informative as to whether the peptide can specifically bind to the respective 
target, an enzyme-linked immunosorbent assay (ELISA) assay may be useful to confirm target 
specificity. Furthermore, a scrambled peptide with the same amino acid composition may be used to 
determine if the small effect seen by peptide V was real and specific. An unpublished parallel study 
on GHR using phage display has shown two peptides that have high specificity for inhibiting GHR-
mediated signalling while having a minimal effect on IL-3 signalling (Figure 21). This result 
strengthens the rationale for using phage display in discovering useful peptide therapeutics.  
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Figure 21: Peptide 3 and 4 specifically inhibit GHR-mediated signalling and not IL-3-mediated 
signalling in the presence of GH. 
Retroviral transduced Ba/F3 cell lines in log growth were plated at a density of 3 × 103 cells/well in 
384-well plates in IL-3-free and phenol-red free RPMI-1640 media (no starving condition). Peptides 
were added (final concentration 250 µM) to respective wells and incubated with the cells for 30 
minutes. Cells were treated with plain media (phenol-red free RPMI-1640 media supplemented with 
1x L-glutamine, 10% FBS, 1:200 penicillin-streptomycin) or cytokine. Viable cells were assayed 
based on GFP expression from day 0 to day 6 after seeding. Results and standard deviations represent 
the mean of four readings of a single experiment. These results were obtained by Rob Luetterforst.  
 
Unlike small molecules and antibody therapies, peptide-based drugs are rarely found in the market as 
these have low bioavailability, solubility, and stability. However, for the purpose of the current study 
to discover antagonists that target the ECD linker/TM region, peptides are the more suitable option 
to be used as a therapeutic target compared to monoclonal antibodies as they can more easily target 
a smaller area of the protein of interest. Peptides also bind to their targets with high specificities and 
affinities, and have low immunogenicity and toxicity. Various modifications of peptides have been 
developed to enhance their efficacy which includes conjugation with PEG, termed as pegylation. The 
addition of PEG will prolong the half-life of peptides (by preventing proteolytic cleavage), enabling 
a longer pharmacological effect in the body. Pegylation also improves peptide solubility and reduces 
immunogenic response. Peptides may also be conjugated with phosphate ester at the amino-terminus 
end to improve half-life. Addition of non-natural amino acids, glycosylation, and lipidation can also 
improve peptide stability and/or solubility. As peptides lack avidity, covalent linkage to form peptide 
dimers is a possible solution in order for the peptides to bind to several targets. Generation of cyclic 
peptides is also of interest as these exhibit reduced toxicity, increased target specificity, and strong 
binding affinities to target [405, 406]. Compared to linear peptides, they are also more membrane-
permeable, have increased biological activity, and are more resistant to exopeptidases and 
endopeptidases [407-409]. Alternatively, the peptide sequence can be used as a scaffold for the 
development of organic small molecules that are more stable and soluble (owing to their size and 
composition).  
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Conclusions 
 
In summary, results from both the signalling and Ba/F3 cell proliferation assays, showed that the 
W515K mutant conferred constitutive signalling and was able to sustain cell proliferation even when 
cells were deprived of cytokine. On the other hand, the T487A mutant was either not or was weakly 
constitutively active, and cells expressing it may weakly survive in the absence of cytokine. Finally, 
the S505N mutant conferred constitutive signalling and promoted cell survival in the absence of 
cytokine, but may have weaker effects compared to W515K. Novel activating mutations (L498W, 
V501A, V501S, and L502S) were discovered where collaborators at WEHI identified for the first 
time some of the same mutations in patient samples. Cell-based assays using Ba/F3 TPOR WT and 
W515K mutant suggest that peptide V, identified by phage display screening, can be further 
investigated as a potential peptide antagonist against the TPO/TPOR-mediated signalling pathway. 
Confirmation of peptide specificity to this pathway will allow for the peptide to be developed into a 
useful therapeutic agent by itself or to be used as a scaffold for the development of small molecules.  
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Chapter 4 
Investigation of the Effect of TPOR Activation upon Cell Membrane 
Mobility 
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Introduction 
 
The majority of TPOR understanding is based on biochemical studies with little or no relation to the 
spatiotemporal patterns of TPOR in cell membranes and its activity. The lateral diffusion of the 
receptor allows interaction with other proteins/molecules in the membrane, in the cells, or outside the 
cells to transmit signals that are important to regulate cell proliferation, survival, and growth. These 
movements can be influenced by various factors including the fluidity of the phospholipid bilayer 
(due to variation in the composition of cholesterol in different parts of the membrane), dimerisation 
states of the receptor, and association with actin filaments or clathrin. The differential mobility pattern 
of the receptors on the plasma membrane has been shown to influence the different phases of cell 
signalling [410].  
A cutting edge technique known as single-particle tracking photoactivated localisation microscopy 
(sptPALM) allows detection and tracking of particles down to a single molecule level by tagging 
molecules with photoconvertible or photoactivatable fluorescent tags. This technique allows for finer 
observation of structures such as cytoskeletal components, cellular adhesion complexes, cellular 
organelles, and visualisation of the plasma membrane organisation. sptPALM has also been utilised 
for a variety of different studies. Through this technique, it has been shown that ligand binding leads 
to dimerisation of IFNAR1 and IFNAR2 [411]. sptPALM also revealed different mobilities of VSVG 
and Gag where VSVG are free diffusing in comparison to Gag proteins that are immobile [412]. This 
technique also demonstrated that conformational change of p2x purinoceptor 7 (P2X7R) is 
responsible for influencing their mobility and confinement on the cell surface [413]. In this chapter, 
sptPALM was performed in conjunction with total internal reflection fluorescence (TIRF) 
microscopy to analyse the lateral diffusion and clustering of TPOR at the cell surface. TIRF 
microscopy allows for illumination of a thin portion of the sample (~ <200 nm), such as the plasma 
membrane, which is adjoining the glass-aqueous medium interface at a TIRF angle (Figure 22). 
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Figure 22: TIRF illumination. 
The plasma membrane of a cell adjoining the glass-aqueous medium interface can be imaged at a 
TIRF angle. Figure reproduced from [414]. 
 
Specifically for this project, receptor constructs were tagged with a photoconvertible fluorophore, 
mEos2. This fluorescent protein is green in its native form and it converts to red when it is illuminated 
with UV light. In its green form it can be excited with 488 nm laser, while the red form can be excited 
using the 561 nm laser (Figure 23). In order to ensure that only a few molecules will be in their red 
state at any one time, a very low 405 nm laser power is used for the conversion of the fluorophore. 
This allows detection of isolated mEos2 molecules. The position of each mEos2 molecule can then 
be determined with high localisation precision (~20 nm in x and y and ~50 nm in z dimension) by 
fitting its image to a two-dimensional Gaussian function. This technique is superior to diffraction-
limited conventional light microscopy techniques where the resolving power is very low i.e. objects 
smaller then ~300 nm cannot be resolved.  In this study, images were first taken in green channel to 
find the cells that are expressing mEos2-labeled TPOR and to visualise the outline of the cells. In this 
channel all mEos2 molecules are fluorescent. By exposing the cells to very dim 405 nm light, we 
were able to convert a small subset of mEos2 molecules from green to red colour. In the red channel, 
these molecules were visible as well separated fluorescent puncta approximately 500 nm in size and 
were often moving from one frame to the other until they were bleached. These spots were imaged 
over thousands of frames until all molecules were converted from green to red and bleached in the 
red channel. The images were subsequently analysed using the Fiji TrackMate application which 
locates individual molecules and creates trajectories (molecule tracks) from the image series as shown 
in Figure 2. TPOR can exhibit various track lengths i.e. short or long trajectories (Figure 24) that 
could relate to receptor turnover or photobleaching [415]. Different modes of receptor diffusion can 
also be determined using sptPALM which includes confined/immobile, free (Brownian), and directed 
movements. The simplest form of the mode of diffusion in a homogenous plasma membrane is the 
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free Brownian motion. Confined/immobile motions can arise due to restriction of diffusion in a small 
area which may be due to cytoskeletal proteins residing juxtamembrane to the plasma membrane 
[416, 417], binding to immobile particles, or sequestering in lipid rafts. The directed motion of 
receptors has been thought to occur after free diffusion into the cell membrane and subsequent 
transport into the cell via transport vesicles that are mediated by the cytoskeleton leading to the 
observed directed movement. It was, however, shown that receptor directed movement can also occur 
on the cell membrane for example for the ephrin type-B receptor 2 (EphB2R) which in this case is 
cholesterol and not cytoskeleton-dependent [418].  
 
This chapter seeks to investigate the effect of cytokine stimulation and mutations, on the molecular 
dynamics of the transmembrane receptor TPOR in the plasma membrane using sptPALM. This 
understanding may elucidate the relationship between the downstream signalling of TPOR and their 
mobility/clustering by tracking single molecules. sptPALM can provide invaluable information into 
the characteristics of TPOR in cell membranes. 
            
                           
    
Figure 23: Properties of mEos2 fluorescent proteins. 
A) Cartoon image showing photoconversion. The mEos2 photoconvertible fluorophore can be 
visualized using 488 nm laser in green channel (left) and with 561 nm laser in the red channel (right). 
The 405 nm laser is used to convert mEos2 from the green to the red-state. B) Snapshot of the mEos2 
A. 
B. 
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TPOR construct expressed in live HEK293 cells. Right: Same cell in the red channel (in Grays) with 
single mEos2 molecules in their red form. Circles around spots are showing receptor molecules 
detected using TrackMate (Fiji).  
 
 
 
Figure 24: TPOR exhibits a variety of trajectories. 
TrackMate locates receptor spots and connects the spots that reside within 0.5 microns to create 
trajectories. Tracks were coloured based on the number of spots (localisations). Tracks that lasts less 
than 10 frames were not analysed. 
 
 
 
 
 
 
116 
 
Materials and methods 
 
DNA Constructs  
The mEos2 gene was added to the N- or C-terminus of the full-length HA-tagged TPOR (WT, 
W515K, or Box1Δ) via CPEC essentially as described in Chapter 2, with a short linker separating the 
receptor and fluorescent gene to provide flexibility. TPOR construct with N-terminus mEos2 was 
denoted mEos2-TPOR whereas those with C-terminus tag was denoted TPOR-mEos2. The plasmid 
backbone containing the mEos2 gene was generated and kindly provided by Farhad Dehkhoda. 
 
Transfection 
HEK293 cells were seeded (0.6 × 105 cells/dish) into 29 mm glass-bottom dishes (#1 coverslip) 
(Cellvis) and cultured overnight in phenol-red free DMEM supplemented with 10% FBS at 37°C in 
a humidified 5% CO2 incubator. Cells were transiently transfected with 50 ng receptor (TPOR WT-
mEos2, TPOR W515K-mEos2, or TPOR Box1Δ-mEos2) using 1.5 µl Attractene according to 
manufacturer’s instructions (Qiagen). After 19-21 hours incubation at 37°C, sptPALM was 
performed. 
 
Visualisation of TPOR constructs expression  
HEK293 cells were seeded (0.6 × 105 cells/well) into 6-well cell culture plates and cultured overnight 
in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Cells were 
transiently transfected with 100 ng receptor (mEos2-TPOR WT, TPOR WT-mEos2, or C-terminal 
citrine TPOR WT) using Lipofectamine 2000 according to manufacturer’s instructions (Invitrogen, 
Thermo Fisher Scientific). After 25 hours incubation at 37°C, receptor expression was visualised and 
captured using the inverted epifluorescence Olympus IX73 microscope.  
 
sptPALM  
Imaging was performed at The University of Queensland, Queensland Brain Institute's Advanced 
Microscopy Facility using the Elyra SIM/PALM/STORM microscope, generously supported by the 
Australian Government through the ARC LIEF LE130100078. sptPALM was performed using the 
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100× objective α Plan-Apochromat 100× 1.46 NA oil immersion lens and an EMCCD camera Andor 
iXon Ultra 897 (Andor Technologies). The mEos2-tagged receptors were excited using the 561 nm 
laser and converted with a 405 nm laser with gradually increased laser power accordingly. GFP 
fluorescence was detected using the 488 nm laser. Cells were imaged in TIRF angle (~66-68⁰) at room 
temperature. For each cell expressing the mEos2-tagged receptors, images were acquired at 30 ms 
exposures every 32 ms for 4 000 to 16 000 frames.  
 
Data and Statistical Analysis  
Data were first analysed with TrackMate, a FIJI plugin for single particle tracking [419]. We used 
LoG detector and Simple LAP tracker. The spot diameter was estimated to be 0.5 µm and the temporal 
resolution was adjusted experimentally so that molecules can move at most 0.5 µm between frames. 
Together with low density of single mEos2 molecules in the red channel, these analysis parameters 
ensured that fluorescent spots linked into a trace belong to the same molecule. The list of traces were 
then imported into a custom-written MatLab routine (kindly provided by Dr Nela Durisic, QBI, UQ). 
Instantaneous diffusion coefficient for each trace was calculated from the fit to the first four point to 
the mean-squared displacement (MSD) curves. Only trajectories that last for ten or more frames were 
used for analysis. Modes of receptor diffusion were determined using the ‘divide-and-conquer 
moment scaling spectrum’ (DC-MSS) method [420]. Only trajectories that last for 20 or more frames 
were analysed using moment scaling spectrum (MSS) analysis [421, 422]. Analysis of density-based 
receptor clustering was conducted via the SR-Tesseler software [423] using single molecule 
localisation list from TrackMate (Fiji) as an input file. A density factor δ of 1 and a minimum area of 
0.5 was used. Within individual objects, clusters were identified with δ =1 and a minimum area of 
0.02. All data were presented as mean ± SEM. Statistical analysis was performed in SigmaPlot or 
GraphPad Prism software using a One-way ANOVA with posthoc Tukey HSD (Honestly Significant 
Difference), Holm-Sidak method, Dunn's Method or student’s 2-tailed unpaired t-test. All data were 
presented as mean ± SEM. Significance (unpaired t-test): * P ≤0.05; ** P ≤0.01; *** P ≤0.001; **** 
P ≤0.0001. 
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Results 
 
In order to determine the role of receptor mobility/clustering in regulating downstream signalling 
various TPOR constructs (WT, W515K, Box1Δ) that were tagged with mEos2 were generated. It was 
previously shown that the TPOR W515K mutant was able to confer constitutive signalling in the 
absence of TPO. This observation was also confirmed in Chapter 6. This chapter investigated if there 
are differences in the mobility/clustering of TPOR W515K compared to WT that was able to aid its 
constitutive signalling. The effect of cytokine addition and their effects on the lateral 
diffusion/clustering of TPOR was also studied. Furthermore, JAK2 was shown to be important in 
associating with the receptor at its Box1 motif and plays a role in aiding the localisation of TPOR to 
the cell membrane. The Box1Δ TPOR mutant (with disrupted JAK2 binding) was used in the current 
study to determine if JAK2 plays a role in receptor mobility/clustering.  
Initially, fluorescence resonance energy transfer (FRET) was planned to be utilised to gain a greater 
understanding of the conformational change that occurs specifically between the Box1-Box2 motifs 
of TPOR monomers to determine the structural rearrangements of these motifs for signal 
transmission. Several issues were encountered including difficulty in expressing the receptors at the 
cell surface, the high background of FRET images, and variability in the results obtained (see 
Appendix Section A for a description of the technique and more in-depth explanation regarding the 
issues encountered). Due to the different technical difficulties and time limitation, sptPALM was 
pursed to gain novel insights into the TPOR by investigating the relationship between the mobility 
(lateral diffusion) and clustering of TPOR, and its effect on downstream signalling.  
 
TPOR-mEos2 constructs respond to TPO and signals downstream   
 
The various TPOR constructs were tagged with an mEos2 photoconvertible fluorophore at its N- or 
C-terminus (Figure 25). Their expression was visualised using an inverted epifluorescence 
microscope. Results showed that constructs with an N-terminal mEos2 tag was not visualised as easily 
as the C-terminally tagged constructs indicating a less efficient expression of the N-terminal tagged 
constructs (Figure 26). As the presence of the mEos2 at the N-terminal might interfere with the 
localisation or insertion of the receptor into the plasma membrane, full-length TPOR that was tagged 
with mEos2 at its C-terminus were utilised for sptPALM analysis.  
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Figure 25: mEos2 was tagged at the N- or C-terminus of the full-length hTPOR. 
 
 
Figure 26: TPOR tagged with mEos2 at the C-terminus expressed more efficiently than N-
terminally tagged receptors. 
Full-length TPOR was tagged with the mEos2 fluorophore at the N- (middle) or C-terminus (right). 
The constructs were transfected (100 ng) and expressed in HEK293 cells. After 25 hours of 
transfection, receptor expression was visualised using the epifluorescence microscope. TPOR WT-
Citrine acts as a positive control. 
 
The constructs were subsequently confirmed for their functionality via their ability to confer 
downstream signalling to ensure that the fusion of the fluorescent gene does not interfere with the 
function of the receptor. TPOR WT and W515K tagged with mEos2 were able to signal upon cytokine 
stimulation as observed by the increase in ERK activation (Figure 27). TPOR W515K-mEos2 was 
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also able to signal in the absence of cytokine treatment. However, the lower constitutive activation 
seen in W515K tagged versus untagged may be due to the lower receptor expression. These reduced 
expression levels may be attributed to the different vector backbone used. 
 
 
Figure 27: TPOR-mEos2 constructs respond to TPO stimulation. 
HEK293 cells were transiently transfected with pQCXIP HA-hTPOR WT, pQCXIP HA-hTPOR 
W515K, HA-hTPOR WT-mEos2, or HA-hTPOR W515KmEos2. Cells were starved overnight and 
TPO (final concentration of 50 ng/ml) was added (+) for 10 minutes. Samples in the absence of TPO 
(-) were used for comparison. Total protein was subjected to SDS-PAGE and immunoblotted with 
indicated antibodies. GAPDH was used as a loading control.    
 
TPOR exhibits bimodal mobility in the plasma membrane of HEK293 cells 
 
Trajectories of single particle tracking TPOR diffusing on the cell surface were obtained from time-
lapse series of 4 000 to 16 000 fluorescent images recorded at 32 milliseconds/frame using an Elyra 
PS1 PALM/STORM microscope. The recording of 4 000 frames was performed for non-stimulated 
cells whereas a longer recording of 16 000 frames was performed on cells stimulated with TPO to 
capture any difference in receptor mobility patterns upon addition of cytokine. The movement of 
TPOR in the plasma membrane was bimodal; many receptors were highly mobile and freely diffusing 
but there was also a population of slowly moving molecules. Consequently, a histogram of diffusion 
coefficients (Figure 28) showed two populations which were well resolved when the X-axis was 
shown on a Logarithmic scale. The distribution of diffusion coefficients to two Gaussians was fitted. 
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Fast moving population peaked at Log (D) = -0.8 and the slow moving one was centred at Log (D) = 
-1.5. For simplification, receptors were classified into two categories: type I (peak 1) comprised the 
slower diffusing receptors and type II (peak 2) comprised the highly mobile receptors with the cut-
off Log (D) = -1.2. 
 
Figure 28: TPOR exhibits two mobile receptor populations, slow-diffusing (type I) and highly 
mobile (type II). 
The diffusion coefficient D (µm2/s) was calculated from a linear fit to the first four points of the MSD 
curve.  Highly mobile receptors displayed an average diffusion coefficient of 10-0.8 µm2/s and slow-
diffusing receptor populations exhibited an average diffusion coefficient of 10-1.5 µm2/s.  
 
Activated TPOR WT and activating W515K mutation caused a decrease in receptor mobility  
 
In order to determine the effect of an activating ligand on TPOR mobility, the cells were stimulated 
with rhTPO and after 30 seconds, recording began for 16 000 frames (approximately 9 minutes of 
stimulation). The centre and width of the two Gaussian distributions were used to compare receptor 
mobility between different experiments. After addition of TPO, type II receptor population (fast-
moving) of TPOR WT decreased in mobility and occurrence, in favour of the type I receptors in 
which the slow-moving subpopulation increased substantially (Figure 29). This is reflected in the 
shift of the ‘centre’ of peak 2 from -0.7 to -0.8, and the change in the ‘width’ of peak 1 from 1.4 to 
1.3 and peak 2 from 0.5 to 0.6 (Figure 29). However, TPO binding did not result in the increase in 
occurrence of type I populations over type II. This suggests that only a small fraction of the type II 
subpopulations respond to TPO. Unlike TPOR WT, the W515K receptor was not affected by the 
addition of cytokine as the type I and type II receptor populations, in this case, did not exhibit 
significantly different receptor mobility (Figure 29).  
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In order to determine the effect of a constitutively active receptor on mobility, TPOR WT and W515K 
were compared. In the absence of TPO, the type II receptor population (fast-moving) of TPOR 
W515K decreased in mobility and occurrence compared to WT whereas the portion of type I receptors 
(slow-diffusing) did not differ (Figure 29). This was observed by the increase in ‘centre’ log (D) 
values and ‘width’ (Figure 29) of type II W515K compared to WT. In the presence of cytokine 
stimulation, the effect of the W515K mutant on type I and II receptor populations was not observed 
to be significantly different compared to WT (Figure 29).  
 
 
 
Figure 29: WT Type II receptors (in the presence of TPO) and W515K Type II receptors (in 
the basal state) exhibit decreased diffusivity.  
A) Data were plotted as bar charts to highlight the difference in the diffusivity of TPOR WT and 
W515K in the basal, inactive state and the stimulated, active state. B) Diffusivity was calculated from 
a linear fit to the MSD of the first four recorded values (D1–4) (red lines). Bar charts were obtained 
from histogram fits that assume the presence of two Gaussian distributions (C). Data representative 
of N=5 independent experiments.  
 
 
 
A. 
B. C. 
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JAK2 does not play a role in TPOR mobility 
 
In order to determine the involvement of JAK2 on receptor mobility, TPOR WT and Box1Δ were 
compared. However, in the basal state, the effect of the Box1Δ on type I and II receptor populations 
was not observed to be significantly different compared to WT (Figure 30).  
 
 
Figure 30: In the basal state, the diffusivity of WT Box1Δ TPOR did not differ. 
Data were plotted as bar charts to highlight the difference in the diffusivity of TPOR WT and Box1Δ 
in the basal, inactive state. Data representative of N=3 independent experiments.  
 
TPOR exhibits various modes of diffusion 
 
The mode of diffusion of TPOR was investigated. The analysis framework used for analysing 
mobility patterns were determined based on the DC-MSS method from [420]. TPOR showed three 
distinguishable mobility regimes in the phospholipid bilayer: i) immobile/confined, ii) free Brownian 
diffusion, iii) and directed motion (or ‘super-diffusive’) (Figure 31). Receptors in the basal state, 
activated, or with mutation of the Box1 motif displayed all three distinct diffusion modes. Immobile 
and confined receptors were considered the same category as it is difficult to define the distinction 
between these two states. A small subset of receptors also changed their mode of diffusion (Figure 
32), termed multiple diffusion states.  
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Figure 31: TPOR exhibit various modes of diffusion on the surface of HEK293 cells. 
A) A representative image of TPOR trajectories in a cell. The different modes of receptor diffusion 
are shown in different colors: red-immobile, orange-confined, blue-free diffusion, black-directed 
motion). B) A representative image based on one cell of the tracks by time of appearance (0 time 
(dark blue) to 120 seconds (dark brown). C) Representative confined and free tracks from B) and 
their corresponding time of appearance. As it is difficult to accurately assign the type of motion to 
tracks that lasts for less than 20 frames, these tracks were not shown.  
 
A. 
B. 
C. 
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Figure 32: Track movements of TPOR can change between different diffusive states. 
A) A representative image of a track that changed between freely diffusive (blue) and directed (black) 
states. B) A representative image of a trajectory (boxed in yellow) that changed between immobile 
(red) and freely diffusive (blue) states that were superimposed on a frame of a red green blue (RGB) 
image of receptor molecules (white blobs). 
 
TPOR activation increased receptor confinement 
 
The role of receptor activation on the mobility patterns of TPOR WT and W515K was investigated. 
TPOR is mostly present as immobile/confined followed by free-diffusing and a very low population 
of TPOR exhibited directed motion (Figure 33). For single-diffusive state receptors, activation of the 
receptor resulted in increased receptor confinement where the addition of cytokine more significantly 
enhanced the confinement (Figure 33). However, the comparison between the unstimulated and 
stimulated receptor states showed no significant difference between the numbers of free or confined 
molecules (Figure 33). In all cases, with or without receptor activation, the number of receptors 
exhibiting directed movement was less than 3.1% and hence were not included for further analysis. 
Receptor trajectories can exhibit multiple diffusion states with one or more changes to a different 
diffusion state and this contributed to less than 13% of the whole receptor population (Figure 34). 
However, for the ease of analysis, these are not grouped into different categories based on the number 
A. B. 
126 
 
of state changes. Ligand stimulation or the W515K mutation does not affect tracks with multiple 
diffusion states (Figure 34).  
  
Figure 33: TPO stimulation or constitutively active receptor increases receptor confinement. 
Only single-state diffusions were included in the analysis. 7782 trajectories analysed for WT-, 37580 
trajectories analysed for WT+, 12090 trajectories analysed for W515K-, and 45063 trajectories 
analysed for W515K+. N=6 or 7 cells per condition. Data representative of N=2 independent 
experiments. Student’s 2-tailed unpaired t-test was used for statistical analysis. Only comparisons 
that were statistically significant were denoted on the bar chart. WT+ C vs WT- C = ns (p = 0.3133), 
W515K+ C vs W515K- C = ns (p = 0.7189), W515K- C vs WT-C = ns (p = 0.5687), W515K+ C vs 
WT+ C = ns (p = 0.7901), WT- F vs WT- C = ns (p = 0.0964), WT+ F vs WT+ C = **** (p <0.0001), 
W515K- F vs W515K- C = * (p = 0.0215), W515K+ F vs W515K+ C = *** (p = 0.0004), WT+ F vs 
WT- F = ns (p = 0.3012), W515K+ F vs W515K- F = ns (p = 0.7274), W515K- F vs WT- F = ns (p 
= 0.5526), W515K+ F vs WT+ F = ns (p = 0.8138), WT+ D vs WT- D = ns (p = 0.7589), W515K+ 
D vs W515K- D = ns (p = 0.6449), W515K- D vs WT- D = ns (p = 0.8971), W515K+ D vs WT+ D 
= ns (p = 0.4225). 
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Figure 34: TPO stimulation or constitutively active receptor does not affect trajectories with 
multiple diffusive states. 
Only multi-state diffusions were included in the analysis. Percentage of multiple-diffusive state 
receptors was calculated by dividing the number of receptors with multiple diffusion states with the 
total number of receptors (including single-state diffusions) and normalised. “-” represents no 
stimulation, “+” represents with 50 ng/ml TPO stimulation. 310 trajectories analysed for WT-, 2661 
trajectories analysed for WT+, 578 trajectories analysed for W515K-, and 3370 trajectories analysed 
for W515K+. N=6 or 7 cells per condition. Student’s 2-tailed unpaired t-test was used for statistical 
analysis. All comparisons were not statistically significant. WT+ vs WT- = ns (p = 0.2022), W515K+ 
vs W515K- = ns (p = 0.1997), W515K- vs WT- = ns (p = 0.6837), W515K+ vs WT+ = ns (p = 
0.9604). 
 
The effect of different receptor activation states on the diffusion coefficient of trapped 
(confined/immobile) and free-diffusing molecules were investigated. Receptors exhibiting Brownian 
free-motion have a significantly higher diffusion coefficient (faster diffusing) than trapped receptors 
(Figure 35). However, the diffusion coefficient of freely-diffusing or trapped receptor molecules 
between different receptor activation states does not significantly differ (Figure 35 B and Figure 36). 
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Figure 35: Free-diffusing TPOR WT and W515K molecules have a higher diffusion coefficient 
than trapped (confined/immobile) molecules with or without cytokine stimulation. 
A) Histogram showing trapped versus free molecules for TPOR WT and W515K in the presence or 
absence of cytokine stimulation. B) Dot plot showing the median for trajectories. Data from each dot 
was obtained from a single video. Horizontal lines are means for 6-7 videos; 7782 trajectories 
A. 
v 
B. 
v 
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analysed for WT-, 37580 trajectories analysed for WT+, 12090 trajectories analysed for W515K-, 
and 45063 trajectories analysed for W515K+.. Only single-state diffusions were included in the 
analysis. “-” represents no stimulation, “+” represents with 50 ng/ml TPO stimulation. “C” denotes 
confined/immobile receptors and “F” represents free diffusing (Brownian) receptors. N=6 or 7 cells 
per condition. Data representative of N=2 independent experiments. Student’s 2-tailed unpaired t-test 
was used for statistical analysis in B). Only comparisons that were statistically significant were 
denoted on the bar chart. WT- F vs WT- C = **** (p <0.0001), WT+ F vs WT+ C = **** (p <0.0001), 
W515K- F vs W515K- C = **** (p <0.0001), W515K+ F vs W515K+ C = *** (p = 0.0003), WT+ 
C vs WT- C = ns (p = 0.3042), WT+ F vs WT- F = ns (p = 0.2636), W515K+ C vs W515K- C = ns 
(p = 0.5895), W515K+ F vs W515K- F = ns (p = 0.2355), W515K- C vs WT-C = ns (p = 0.2344), 
W515K- F vs WT- F = ns (p = 0.3521), W515K+ C vs WT+ C = ns (p = 0.8130), W515K+ F vs WT+ 
F = ns (p = 0.3018). Log [D] units = µm2/s. 
 
 
 
A. 
B. 
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Figure 36: Cytokine stimulation or constitutive receptor activation does not affect the diffusion 
of the trapped (confined/immobile) or free-diffusing molecules. 
A) Comparison of trapped molecules for TPOR WT or W515K in the presence and absence of 
cytokine stimulation. B) Comparison of free molecules for TPOR WT or W515K in the presence and 
absence of cytokine stimulation. C) Comparison of trapped molecules between TPOR WT and 
W515K in the presence (right) and absence (left) of cytokine stimulation. D) Comparison of free 
molecules between TPOR WT and W515K in the presence (right) and absence (left) of cytokine 
stimulation. Only single-state diffusions were included in the analysis. “-” represents no stimulation, 
“+” represents with 50 ng/ml TPO stimulation. 7782 trajectories analysed for WT-, 37580 trajectories 
analysed for WT+, 12090 trajectories analysed for W515K-, and 45063 trajectories analysed for 
W515K+. N=6 or 7 cells per condition. Data representative of N=2 independent experiments. Log 
[D] units = µm2/s. 
 
JAK2 does not play a role in TPOR mobility patterns 
 
The role of JAK2 on the mobility patterns of TPOR WT and Box1Δ was investigated. For single-
diffusion state receptors, the percentage of free-diffusing receptors is significantly lower than 
confined receptors for both TPOR WT and Box1Δ (Figure 37). However, the comparison between 
TPOR WT and Box1Δ in the basal state showed no significant difference between the amount of free 
or confined molecules (Figure 37). The number of receptors exhibiting directed movement was less 
than 2% and hence were not included in further analysis. Receptors with multiple diffusion states 
C. 
D. 
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contributed to less than 8% of the whole receptor population (Figure 37). Box1Δ mutation did not 
affect tracks with multiple diffusion states (Figure 38).  
 
 
Figure 37: TPOR Box1 mutation does not affect the receptor mode of diffusion. 
Only single-state diffusions were included in the analysis. Receptor populations that have directed 
movement are less than 2% and hence excluded from statistical analysis. 1682 trajectories were 
analysed for WT and 5984 trajectories were analysed for Box1Δ-. N=4 cells per condition. Data 
representative of N=1 experiment. Student’s 2-tailed unpaired t-test was used for statistical analysis. 
Only comparisons that were statistically significant were denoted on the bar chart. WT- F vs WT- C 
= *** (p = 0.0001), Box1- F vs Box1- C = **** (<0.0001), Box1- C vs WT- C = ns (p = 0.2121), 
Box1- F vs WT- F = ns (p = 0.1787). 
 
Figure 38: TPOR Box1 mutation does not affect track changes to multiple diffusive states. 
Only multi-state diffusions (one or more segmentations) were included in the analysis. Percentage of 
multiple-diffusive state receptors was calculated by dividing by the total number of receptors 
(including single-state diffusions) and normalising. “-” represents no stimulation. 64 trajectories were 
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analysed for WT and 335 trajectories were analysed for Box1Δ-. N=4 cells per condition. Data 
representative of N=1 experiment. Student’s 2-tailed unpaired t-test was used for statistical analysis.  
 
The effect of the lack of JAK2 binding to TPOR using the Box1Δ on the diffusion coefficient of 
trapped (confined/immobile) and free-diffusing molecules was investigated. Receptors exhibiting 
Brownian free-motion have a significantly higher diffusion coefficient (faster diffusing) than trapped 
receptors (Figure 39). However, the diffusion coefficient of freely-diffusing or trapped receptor 
molecules in TPOR WT and Box1Δ does not significantly differ although a trend did appear apparent 
(Figure 39 C and Figure 40). 
 
Figure 39: Free-diffusing TPOR WT and Box1Δ molecules have a higher diffusion coefficient 
than trapped (confined/immobile) molecules in the absence of cytokine stimulation. 
A & B) Histogram showing trapped versus free molecules of TPOR WT and Box1Δ. C) Dot plots 
showing the median for trajectories. Data for each dot was obtained from a single video. Horizontal 
lines are means of 4 videos; 1682 trajectories were analysed for WT and 5984 trajectories were 
analysed for Box1Δ-. Only single-state diffusions were included in the analysis. “-” represents no 
stimulation. “C” denotes confined/immobile receptors and “F” represents free diffusing (Brownian) 
receptors. N=4 cells per condition. Data representative of N=1 experiment. Student’s 2-tailed 
unpaired t-test was used for statistical analysis in C). Only comparisons that were statistically 
significant were denoted on the bar chart. WT- F vs WT- C = *** (p = 0.0003), Box1- F vs Box1- C 
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= **** (<0.0001), Box1- C vs WT- C = ns (p = 0.0636), Box1- F vs WT- F = ns (p = 0.1089). Log 
[D] units = µm2/s. 
 
 
Figure 40: TPOR Box1 mutation does not affect the diffusion of the trapped 
(confined/immobile) or free-diffusing molecules. 
Only single-state diffusions were included in the analysis. “-” represents no stimulation. Left: 
comparison of the diffusion coefficient of trapped TPOR WT and Box1Δ. Right: comparison of the 
diffusion coefficient of free TPOR WT and Box1Δ.  1682 trajectories were analysed for WT and 5984 
trajectories were analysed for Box1Δ-. N=4 cells per condition. Data representative of N=1 
experiment. Log [D] units = µm2/s. 
 
TPOR forms clusters, but clustering may not play a role in regulating signalling 
 
As changes in receptor clustering have been shown to fine-tune signalling in some receptors, this was 
investigated for TPOR. TPOR can form clusters of different sizes (based on area and diameter) 
(Figure 41, Figure 43, and Figure 44) and it is organised in nanometer-scale small clusters in HEK293 
cells (Figure 43 and Figure 44). The majority of TPOR clusters have diameters between 10 and 100 
nm for both control and TPO-stimulated cells or TPOR variants (Figure 43). The number of receptors 
in each cluster varies between as little as 18 and as much as ~140 000 (data not shown). 
Confined/immobile receptors were usually located in receptor clusters whereas freely-diffusing 
molecules were usually situated outside of receptor clusters (Figure 42). Addition of TPO, using 
constitutively active W515K mutant, or mutation of the Box1 motif of TPOR did not affect the cluster 
diameters or areas (Figure 43 and Figure 44). However, the observation of clusters may be affected 
by the transient expression in HEK293 cells and may not clearly represent what occurs in 
haematopoietic cells with endogenous TPOR expression levels.   
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Figure 41: TPOR cluster into different cluster sizes and shapes. 
A representative image of a single cell showing TPOR clusters analysed using Zen software. 
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Figure 42: TPOR are clusters usually comprised of immobile/confined receptors whereas 
freely-diffusing receptors are usually located outside of clusters. 
A representative image of trajectories (with different modes of diffusion) of a single cell that is 
superimposed on an RGB image of receptor clusters (white blobs) analysed using Fiji software. Track 
colour codes: red (immobile), orange (confined), blue (free), black (directed). 
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Figure 43: Receptor cluster area and diameter do not change with receptor activation due to 
TPO stimulation or constitutively active W515K mutant. 
A) Cluster area. B) Cluster diameter. “-” represents no stimulation, “+” represents with 50 ng/ml TPO 
stimulation. Receptor cluster analysis based on N=6 WT TPOR cells and N=7 W515K TPOR cells. 
Clusters with an area of more than 7500 nm2 were excluded as the percentage of these clusters was 
too insignificant and can span up to an area of 60 000 nm2.  
A. 
B. 
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Figure 44: In the basal state, receptor cluster area and diameter do not change with the 
mutation of the Box1 motif. 
Left: cluster area; right: cluster diameter. “-” represents no stimulation. Receptor cluster analysis 
based on N=8 WT TPOR cells and N=8 Box1Δ TPOR cells. Data representative of N=2 independent 
experiments. Clusters with area more than 10 000 nm2 were excluded as the percentage of clusters 
was insignificant.  
 
Discussion 
 
Receptor activation can affect clustering and mobility which subsequently alters cell signalling [410, 
424-427]. Currently, the understanding of the spatiotemporal patterns of TPOR and its relation to 
their receptor activity (i.e. downstream signalling) has been lacking. To fill this gap, the lateral 
diffusion and clustering of TPOR were investigated using sptPALM. For this purpose, full-length 
TPOR (WT, W515K, and Box1Δ) constructs tagged with the photoconvertible mEos2 fluorophore at 
the C-terminus were utilised. These constructs were examined for their effect in influencing TPOR 
spatiotemporal patterns due to constitutive receptor activation or involvement of JAK2. The effect of 
activation of the WT TPOR by addition of the TPO ligand on the lateral diffusion and clustering of 
the receptor was also determined. 
The two-state model of receptor mobility pattern has been observed regarding different receptors in 
the plasma membrane [410, 428-431]. This model shows the existence of receptors in the highly 
mobile and slow diffusing states although receptors can also exist in immobile and other diffusive 
states. It was previously shown that the molecular weight of the receptor plays a role in influencing 
the diffusion coefficient of the receptor where increased weight results in a lower diffusivity and vice 
versa [432]. TPOR exhibited bimodal mobility: type I as the slow-diffusing receptor subpopulation 
and type II as the more mobile receptor subpopulation. A high fraction of TPOR exhibited the type 
II subpopulation. The two different receptor subpopulations may be explained by the interactions 
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with other proteins, recruitment to lipid rafts in the bilayer, receptor dimerisation states, as well as 
association with the cytoskeleton or clathrin-coated pits. Highly-mobile receptors may exist as 
receptor monomers [430] but there is a possibility that the presence of the highly mobile receptors 
may also be an artefact due to overexpression. On the other hand, the presence of slow-diffusing 
receptors may be due to sequestration of the receptor in lipid rafts or receptor clusters [433], 
undergoing pre-internalisation [434-437], interaction with cytoskeleton components [422, 438, 439], 
and association with other proteins.  
Ligand binding has been shown to cause reduction in the lateral mobility of receptors such as 
tropomyosin receptor kinase A (TrkA) [430], EGFR [440], G protein-coupled receptor (GPCR) [441, 
442], and insulin receptor [443]. Similarly, upon TPO stimulation or constitutive activating mutation 
in the absence of cytokine, the mobility of type II receptors was strongly shifted towards significantly 
reduced mobility upon receptor activation. In the presence of TPO, this shift resulted in two distinct 
effects: i) the diffusion coefficient of type II subpopulation significantly increased, and ii) a fraction 
of type II subpopulation shifted to type I (although this was significant only for TPO stimulation on 
WT and not for W515K in the absence of cytokine). These data suggest that receptor activation results 
in only a fraction of fast-moving subpopulation becoming slow-moving, but that the majority 
remained still in the fast-moving subpopulation that diffuses slightly slower. The addition of higher 
TPO concentration may elucidate if this partial transition from Type II to Type I was due to ligand 
concentration effect. It was speculated that the decrease in receptor mobility may be due to various 
reasons including formation of protein complexes, altered receptor conformation [444], recruitment 
of receptors to proteins that are involved in receptor recycling (thereby restricting movement) [185], 
and induction of receptor clustering [430]. Receptor clusters have been shown to allow less ligand to 
bind [445], although upon cytokine binding, signalling responses are enhanced in receptor clusters 
due to rebinding [445, 446]. In Ba/F3 cells, TPO stimulation resulted in clathrin-dependent 
endocytosis of TPOR [183]. AP2 facilitates TPOR endocytosis by recognising the Y78RRL 
(cytoplasmic numbering of TPOR) motif in TPOR and leading to the formation of clathrin-coated 
pits (CCP) [183]. Therefore, TPO stimulation may result in the association of the receptor with CCP 
which subsequently contributes to the reduced receptor mobility. It has also been shown that upon 
ligand binding, TPOR binds to the actin cytoskeleton via Filamin A which protects the receptor from 
proteasomal and lysosomal-mediated degradation [447] and can also lead to decreased receptor 
movements. The association of TPOR with clathrin or filamin A can result in decreased receptor 
mobility. Lipid rafts have also been shown to restrict receptor movements [410]. The association of 
TPOR with lipid rafts in the cell membrane can be investigated using β-methyl cyclodextrin to deplete 
cholesterol. Overall, reduced receptor diffusion due to cytokine binding or constitutive receptor 
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activation may act to either mediate or attenuate signalling although further clarification is required 
to elucidate this fact. In contrast to TPOR WT, the addition of TPO did not affect the mobility of 
W515K. In the Western blot analysis, however, the addition of TPO increased signalling of both WT 
and W515K. Similarly, in the presence of TPO, the diffusion of WT and W515K did not significantly 
differ. This suggests that the variation in receptor mobility plays a role in regulating signalling but 
these movements do not appear to play a significant role in fine-tuning the extent of signalling.  
Several modes of molecule diffusion have been reported which include immobile, free/Brownian, or 
directed movements. For mobility analysis, tracks with less than 20 frames were not included in the 
analysis as the DC-MSS could not define them as a distinct state [420]. All states of diffusion were 
present in the receptors in their basal and stimulated conditions, including those with the Box1Δ. It 
was observed that TPOR in its stimulated or constitutively activate state shows a statistically 
significant difference between free-diffusing and confined molecules with a lower percentage of the 
former and a higher percentage of the latter. These results suggest that the reduced mobility of the 
fast-diffusing receptors due to cytokine stimulation may be attributed to the increase in receptor 
confinement. It was also observed that there is a higher occurrence of fast-diffusing receptors 
compared to slow-moving receptors in the presence or absence of cytokine. As confined receptors 
can be fast or slow-diffusing, the increase in confinement and reduction in mobility due to cytokine 
stimulation may be attributed to the increase in the confined slow-diffusing TPOR population. 
However, the comparison between basal and activated receptors did not reveal a significant difference 
in the amount of free or confined receptor states. As a small sample size was analysed, this may have 
contributed to the non-significance observed. It was also observed that a small percentage of TPOR 
changed to a different diffusion state although this amount was not altered in the basal and stimulated 
states. The multiple-states of TPOR diffusion may be due to interaction with other proteins or due to 
conformational changes in the receptor [448, 449]. Larger data analysis may be needed to confirm 
these findings.  
Receptor clusters have been shown to aid in the initiation of signal transmission and receptor 
internalisation for example, the ones related to the EGF receptor [426, 450-455]. On the other hand, 
modification in receptor clusters may regulate sensitivity to signalling. Published studies have shown 
that high cytokine concentrations can influence the formation of clusters but not low concentrations 
[456]. The results of the current study showed that receptor activation (by TPO induction or by using 
the W515K mutant) did not affect receptor cluster size (area and diameter) and that in the basal state, 
receptor clusters have already been formed. Since pre-formed TPOR dimers are present in the absence 
of cytokine stimulation, this suggests that TPOR clusters do not form as a result of receptor activation 
but that they may play a role in the activation itself. Indeed, it has been suggested that EGF receptor 
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clusters can be present on the membrane in the basal state [457, 458]. Similarly, T-cell receptors 
(TCRs) have also been shown to form preformed clusters prior to antigen binding [459-462]. It is also 
plausible that the pre-formed receptor clusters allow for more efficient signal regulation upon receptor 
activation. It was previously shown that TCR nanoclusters are more sensitive to reduced antigen 
levels compared to TCR monomers [461, 463, 464]. It has been shown that the binding of cytokine 
to receptors in clusters enhanced signalling due to rebinding [445, 446]. The findings of the current 
study suggest that instead of changes in cluster size, changes in receptor mobility are the driving force 
for regulating signalling in TPOR. However, it cannot be discarded that there is also a possibility that 
other factors that have yet to be determined may play a role modulating TPOR signalling. Indeed, 
receptor concentration and meshwork density can influence the extent of receptor clustering [465, 
466]. As the current study utilises transient transfection of TPOR in HEK293 cells, receptor clustering 
observed in the basal state may be due to enhanced expression of the receptor. Furthermore, the 
addition of higher TPO concentration may significantly increase cluster size and may reflect a 
difference compared to what happens in the absence of cytokine stimulation. On the contrary, it has 
been shown that stimulation of EGFR can result in smaller receptor clusters due to recycling [467]. 
Despite these speculations, the small sample size that has been analysed may be insufficient to reveal 
any significant changes. 
It was previously shown that the diffusion coefficient of EGFR increased outside of the clusters [456]. 
Indeed, the results of the current investigation showed that these TPOR clusters were mainly consisted 
of immobile/confined receptors whereas receptors exhibiting Brownian or directed movements were 
usually diffusing outside of these clusters. As the presence of cytokine results in increased receptor 
confinement and confined receptors are mostly found in clusters, it is of interest to define whether 
the clustering of receptors occurs as a result of the confinement or that the confinement occurred as 
a result of receptor clustering. Nevertheless, although cytokine stimulation resulted in increased 
receptor confinement, receptor cluster size was not affected. It was speculated that instead of forming 
bigger clusters, TPOR may form more clusters of similar size. It was previously shown that signal 
initiation is mediated by an increase in cluster density of the TCR-CD3 clusters [427]. Analysis of 
cluster density and the number of receptors that are present in each cluster might aid in understanding 
the role of TPOR clusters. Overall, the current study showed that immobile/confined receptors that 
make up the majority of receptor clusters may be the main players in regulating the signal transduction 
of TPOR.  
JAK2 has been previously shown to stabilise TPOR at the cell surface by stabilising the glycosylated 
form of the receptor or by preventing proteasomal degradation of the receptor which subsequently 
enhances receptor recycling [115]. Currently, studies on the role of JAK2 in the spatiotemporal 
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patterns of type I cytokine receptors have not been published. As the Box1 motif of this family of 
cytokine receptors is known to be important to bind to JAK2, mutation/disruption of this motif results 
in markedly reduced/diminished JAK2 binding. Hence, this mutant was used to investigate the role 
of JAK2 in TPOR mobility and clustering. As JAK2 binds TPOR constitutively and this binding 
occurs even before receptor localisation to the membrane [238], it is speculated that the lack of JAK2 
binding may relieve the movements of the receptor and therefore, may result in increased mobility. 
Hence, it was interesting to observe that in the basal state, the loss of JAK2 binding did not affect the 
mobility (diffusivity and mobility patterns) or clustering of TPOR. Future work including TPO 
stimulation may elucidate if receptor conformational changes may be involved in the role of JAK2 in 
TPOR mobility and clustering. A difference was observed in Figures 13 and 17 where the former 
showed that the percentages of confined and free molecules of TPOR WT in the basal state were not 
statistically different, but in the latter they showed a statistical difference. The small sample size in 
the latter may have contributed to the difference observed. Furthermore, results for the latter were 
obtained from only one experimental day whereas, for the former, results were obtained from two 
experimental days which may have led to a greater variation in the results. Larger sample sizes may 
be beneficial to investigate the reasons behind these differences. 
 
Conclusions 
 
In the basal and stimulated states, TPOR exhibited bimodal mobility: fast and slow-moving receptor 
subpopulations. Upon ligand stimulation or mutation such as W515K that causes constitutive receptor 
activation, the diffusivity of the fast-moving subpopulation was significantly reduced and a fraction 
of these receptors transitioned into the slow-moving subpopulation. This reduction in mobility may 
be associated with the increase in receptor confinement due to formation of protein complexes, altered 
receptor conformation, receptor recycling, as well as increased association with clathrin, actin 
cytoskeleton, or lipid rafts. Further work is required to elucidate if the reduction in receptor movement 
is a consequence of signal induction or attenuation. In addition, TPOR cluster size did not appear to 
be important in regulating signalling although the pre-formed clusters themselves may be important 
in mediating more efficient signal transduction due to receptor activation. Finally, JAK2 did not 
appear to be important in mediating TPOR mobility or clustering. The findings of the current study 
act as an important foundation for future work to elucidate how TPOR mobility and clustering can 
influence cell signalling.  
 
142 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Specific Domains of LNK (SH2B3) Bind to TPOR and Regulate its Stability 
and Signalling on the Cell Surface 
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Introduction  
 
LNK, also known as SH2B3, is one of the members of the SH2-domain containing adaptor proteins, 
which also includes SH2B1 and APS (SH2B2), that plays an important role in regulating various 
cytokine receptors such as c-Kit [280, 311], c-Fms [312], TNFR [313], TPOR [314]), EPOR [277], 
IL7-receptor [276, 315], and platelet-derived growth factor receptor (PDGFR) [316], as well as 
integrin receptors [284, 468]. While LNK is ubiquitously expressed, it is highly expressed in 
haematopoietic cells. As a result, several somatic and germline mutations in LNK have been 
associated with various myeloid and lymphoid malignancies. The SH2B3 gene that encodes for LNK 
resides on Chromosome 12q24 and the translated human LNK protein consists of 575 amino acids. 
Structurally, LNK comprises of three domains: i) a 70 amino acid long Pro/DD speculated to mediate 
homo- or hetero- dimerisation [281, 291, 306, 307], ii) a 114 amino acid long PH domain that is 
shown to bind to phosphoinositides in the plasma membrane [278, 285], and iii) a 99 amino acid long 
SH2 domain that acts as a canonical phosphotyrosine binding site.  
 
The LNK Pro/DD domain is the least conserved amongst its family members, encoding a zipper motif 
that is different from its other family members. Instead of two phenylalanine residues, it comprises 
the tyrosine and leucine residues. These differences in the LNK Pro/DD domain may subject this 
domain to an alternative role whereby instead of homo- or heterodimerisation, may facilitate binding 
to other molecules/receptors. This proline rich region of LNK also has a consensus sequence of PXXP 
that acts as a potential binding site for SH3 containing proteins. A number of different, clinically 
relevant LNK mutations have been reported in the different LNK domains with most mutations 
residing in the PH domain, resulting in this region being known as a ‘hotspot’ for mutations. It was 
shown that mutations in this region disrupts the localisation of LNK to the membrane [285] and may 
therefore impair interaction with transmembrane receptors and subsequent downregulation.  
The mechanism by which LNK mediates receptor downregulation is still not fully understood. It was 
previously shown that LNK is able to bind to active JAK2 at phosphorylated tyrosine 813 (pY813) 
(in the pseudokinase-kinase linker domain of JAK2) and pY613 (in the pseudokinase domain of 
JAK2) via its SH2 domain [278] which may suggest the formation of LNK homodimers to bind to 
both phosphotyrosine residues. It was proposed that upon JAK2 activation, the SH2 domain of LNK 
binds to phosphorylated residues of activated JAK2 in order to be phosphorylated [278]. 
Subsequently, LNK inhibits signalling [278]. Interestingly, other family members of LNK such as 
SH2B1 and APS also bind to pY813 of JAK2 although they exert different effects depending on the 
associated receptor (they typically enhance receptor signalling). Hence, other LNK domains may 
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govern specificity for its negative regulatory function on JAK2 and its interaction with the different 
receptors as LNK is also able to inhibit various other receptors via its SH2 domain [276, 277, 280, 
311-316]. This chapter investigated if the other domains of LNK (besides SH2) are involved in 
inhibiting/regulating signalling of JAK2 that is associated with TPOR. By understanding this, the 
mechanism of LNK-mediated negative regulation may be deciphered.  
 
Materials and Methods 
 
DNA Constructs  
Various primers (see Appendix Section C) were designed to generate hLNK with point mutations 
(E395K, Y572A, R392E, or R425P) via PCR mediated site-directed mutagenesis (Table 2), and 
domain deletions (deletion of Pro/DD, PH, CTD, or PH-SH2 linker region) via CPEC, using the N-
terminal FLAG-tag WT hLNK in pcDNA3.1+ mammalian expression vector (containing the 
SV40ori) (Figure 45). ‘AttB’ sites were added to the N-terminal FLAG-tagged hLNK constructs via 
PCR and subsequently shuttled into the pMX-IRES-Hygro destination vector by Gateway cloning to 
generate FLAG-tagged hLNK constructs in pMX-IRES-Hygro vector. 
 
Table 2: PCR cycling conditions used. 
Double-stranded DNA was denatured to single-stranded DNA and primers were allowed to anneal. 
PCR was performed with KOD DNA polymerase (Merck Millipore). 
 
The coding sequences (CDS) of N-terminal HA-tagged hMPL WT or mutants (W515K, S505N, and 
T487A) in pMX-GW-mPGKpro-puroR/GFP vector (see Chapter 4) were shuttled into pDONR221 
vector and subsequently into the pQCXP CMV/TO DEST vector (Addgene (Plasmid #17386)) [469] 
(Figure 46) by Gateway cloning.  
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The different lengths (T7, T28, T53, T69, T83, T98, T111, T116) and substitution of tyrosine (Y) to 
phenylalanine (F) residues (Y8F, Y29F, Y78F, Y113F, Y118F, Y113F/Y118F) (numbering is from 
the start of the intracellular domain) of the ICD of TPOR were made by PCR mediated site-directed 
mutagenesis using the HA-tagged hMPL Box1 mutant in pDONR221 plasmid (see Appendix Section 
C for primers used), which were subsequently shuttled into the pQCXP CMV/TO DEST vector by 
Gateway cloning. The number followed by ‘T’ represents the number of amino acids remaining in 
the ICD after truncation. All constructs were verified by DNA sequencing performed by the AGRF 
Brisbane. 
 
 
Figure 45: Representative vector map of the pcDNA3.1+ FLAG-hLNK vector constructs. 
A FLAG-tag was present at the N-terminus of the SH2B3 gene. The CMV promoter allows for high-
level gene expression following transient transfection.  
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Figure 46: Representative vector map of the pQCXIP-HA-hTPOR vector constructs. 
A HA-tag was present at the N-terminus of the MPL gene. The CMV promoter allows for high-level 
gene expression following transient transfection. 
 
Murine JAK2 and kinase dead mutant (KE; K882E) in pBluescriptSK was generously provided by J. 
N. Ihle, St. Jude Children's Research Hospital, TN, USA [86]. Each JAK2 clone was re-cloned by Dr 
Andrew Brooks in pEGFP-N1 (with EGFP replaced by JAK2). 
 
Retroviral Transduction and Generation of Stably-Transduced Cell Lines   
PLAT-E cells were seeded (1.7 × 105 cells/well) into 6-well cell culture plates and cultured overnight 
in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Cells were 
transiently transfected with 3 µg plasmid DNA (pMX-GW-mPGKpro-puroR/GFP HA-tagged TPOR 
constructs (see Chapter 4) using Lipofectamine 2000 according to manufacturer’s instructions 
(Invitrogen, Thermo Fisher Scientific). After 24 hours incubation at 37°C, media was replaced with 
fresh DMEM supplemented with 10% FBS for 48 hours. Parental Ba/F3 cells (2 × 105 cells per 
infection) were infected with ecotropic retroviral supernatants generated in PLAT-E cells and 
incubated at 37°C for 1-2 hours before an equal volume of RPMI (supplemented with 10% FBS and 
2× IL-3) was added. After 3 days, puromycin selection was performed by resuspending cells in a final 
concentration of 1 µg/ml puromycin (Gibco, Life Technologies, Thermo Fisher Scientific) in RPMI 
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(supplemented with 10% FBS) and left for 3-5 days before cells were expanded to T25 cell culture 
flasks. For cotransduction of pMX-IRES-Hygro FLAG-tagged hLNK constructs into Ba/F3 TPOR 
WT, W515K, or S505N cells, ecotropic retroviral supernatants were generated in PLAT-E cells and 
retroviral transduction was performed as before. After 3 days of transduction, hygromycin 
(Invitrogen, Thermo Fisher Scientific) selection was performed by resuspending cells in a final 
concentration of 1 mg/ml for co-transduced Ba/F3 TPOR WT or 1.5 mg/ ml for co-transduced Ba/F3 
TPOR W515K or S505N in RPMI (supplemented with 10% FBS) and left for 7-10 days before cells 
were expanded to T25 cell culture flasks. 
 
TPOR/LNK Signalling Assay  
Lenti-X 293T cells  were seeded (3 × 105 cells/well) into 6-well cell culture plates and cultured 
overnight in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Cells 
were then transiently transfected with 500 ng receptor (pQCXIP HA-tagged hTPOR WT, pQCXIP 
HA-tagged hGHR WT, or pQCXIP EV), 700 ng STAT3 (pBABE-STAT3 or pBABE-EV), and/or 
300 ng LNK constructs (pcDNA3.1+ FLAG-tagged hLNK WT or mutants) using Lipofectamine 
2000 according to manufacturer’s instructions (Invitrogen, Thermo Fisher Scientific). After 24 hours 
incubation at 37°C, cells were starved in DMEM supplemented with 0.5% FBS for 12-16 hours. Cells 
were then stimulated with 50 ng/ml rhTPO (R & D Systems) or PBS for 10 minutes at 37°C. Cells 
were subsequently washed with cold-PBS and lysed in 40-60 μl ice-cold RIPA buffer (50 mM Tris 
pH7.5, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100) containing 2 mM sodium orthovanadate 
(Sigma), 30 mM sodium fluoride (Sigma), 10 mM sodium pyrophosphate (Sigma), and 1x complete 
protease inhibitor cocktail (Roche Applied Science). Protein concentration was determined using the 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Supernatant was mixed with 3x SDS 
sample buffer (containing 0.1 M DTT) and heated to 98°C for 5 minutes before the samples were run 
on SDS-PAGE gel and subjected to western blotting analysis using the appropriate antibodies (see 
Appendix Section E). 
 
Co-immunoprecipitation Assay  
Lenti-X 293T cells were seeded at a density of 3.8 x 106 cells/T75 cell culture flask  and cultured 
overnight in DMEM supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Cells 
were then transiently transfected with 5 µg receptor (pQCXIP HA-tagged hTPOR WT, pQCXIP HA-
tagged hGHR WT, or pQCXIP EV), 3 µg LNK constructs (pcDNA3.1+ FLAG-tagged hLNK WT or 
mutants), and/or 100 ng JAK2 (WT JAK2 or kinase-dead (KE) JAK2 mutant (KE mutation; dominant 
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negative) using Lipofectamine 2000 according to manufacturer’s instructions (Invitrogen, Thermo 
Fisher Scientific). After 24 hours incubation at 37°C, cells were starved in DMEM supplemented 
with 0.5% FBS for 12-16 hours. Following, cells were stimulated with 50 ng/ml recombinant human 
TPO (rhTPO) (R & D Systems), recombinant human pituitary GH (100 ng/ml), or PBS for 10 minutes 
at 37°C. After stimulation, cells were washed once in ice-cold PBS (containing 100 µM sodium 
orthovanadate (Sigma)), lysed in 400 μl ice-cold extraction buffer (50 mM Tris pH7.5, 150 mM NaCl, 
5 mM EDTA, 0.5% Triton X-100) containing 2 mM sodium orthovanadate (Sigma), 30 mM sodium 
fluoride (Sigma), 10 mM sodium pyrophosphate (Sigma), and 1x complete protease inhibitor cocktail 
(Roche Applied Science). Protein concentration was determined using the Pierce BCA Protein Assay 
Kit (Thermo Fisher Scientific). Cell lysates (3-5 mg) were pre-cleared with 40 µl of washed, blocked, 
50% resuspended Protein G SepharoseTM 4 Fast Flow (GE Healthcare) before incubating with their 
corresponding antibody for 2 hours at 4°C. After incubation, 60 µl of 50% resuspended Protein G 
Sepharose were added and incubated for another 1.5 hours at 4°C. The bound beads were washed 
twice with wash buffer (50 mM Tris pH7.5, 150 mM NaCl, 5 mM EDTA) containing 2 mM sodium 
orthovanadate, 30 mM sodium fluoride, 10 mM sodium pyrophosphate, and 1x complete protease 
inhibitor cocktail. Supernatant was removed and bound beads were mixed with 3x SDS sample buffer 
(containing 0.1 M DTT) and heated to 98°C for 5 minutes. Sepharose was pelleted by centrifugation 
at 17, 900g for 5 minutes before the supernatants were run on SDS-PAGE gel and subjected to western 
analysis using the appropriate antibodies (see Appendix Section E). 
 
Results 
 
Various LNK domain deletions and point mutations were generated in order to determine if the other 
domains of LNK (besides SH2) are involved in inhibiting/regulating signalling of JAK2 associated 
with TPOR. All LNK expression constructs retained the SH2 domain required for JAK2 
phosphorylated tyrosine binding. Several point mutations in LNK were created in the SH2 domain 
(R425P, R392E, and E395K), and a single point mutation of the conserved C-terminal tyrosine 
residue (Y572A) was introduced (Table 3 and Figure 47). The Y572 residue was mutated to an alanine 
to determine if there are any phenotypic consequences that accompany the loss of this conserved 
tyrosine residue. Alanine is a non-bulky, hydrophobic residue and would not be expected to affect 
the function of the protein except for the loss of the tyrosine and its potential phosphorylation. Domain 
truncations of Pro/DD, PH, PH-SH2 linker, and CTD were also created (Figure 47).  
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Table 3: Point mutations in pcDNA3.1+ FLAG-LNK constructs generated. 
Mutations Type Details 
R425P Clinical; 
uncharacterised 
Causes clinical phenotype between ET and atypical CML 
(personal communication from Professor Andrew Perkins, 
Monash University) 
R392E  
 
Synthetic Destroys the ability of the SH2 domain to bind to 
phosphorylated JAK2 in TPOR-mediated signalling [278]. 
R364E is the murine homologue 
E395K Clinical; 
characterised 
Reported in ET patients [470] 
Y572A Synthetic Y572 is well-conserved between the members of the SH2- 
domain containing adaptor proteins. Murine counterpart, 
Y536F, showed that this mutation does not appear to affect 
LNK function [249, 277] 
 
 
Figure 47: Illustration of pcDNA3.1+ FLAG-LNK constructs generated for this study. 
Four deletion constructs were made: ΔPro/DD, ΔPH, ΔPH-SH2 linker, and ΔCTD, and four point 
mutations were introduced: R392E (SH2 domain), E395K (SH2 domain), R425P (SH2 domain), and 
Y572A (CTD domain). The Pro/DD domain spans from amino acid residue 1 to 193, the PH domain 
spans from amino acid residue 206 to 307, the SH2 domain spans from amino acid residue 364 to 
462, and the CTD spans from amino acid residue 463 to 575. 
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Although it is known that the SH2 domain acts as a mediator to dock LNK to phosphorylated JAK2 
at Y813, this binding provides little explanation regarding how LNK can negatively regulate this 
kinase. Therefore, it was hypothesised that other LNK domains may be involved in facilitating kinase 
inhibition by a currently unknown mechanism. In order to address this gap in knowledge, the above 
LNK constructs were used in signalling and co-IP assays. The outcome of these experiments showed 
that LNK Pro/DD domain potentially binds to TPOR and suppress TPOR-mediated signalling.  
 
LNK Pro/DD Domain Downregulates TPOR Signalling in Co-operation with its SH2 Domain 
 
Ba/F3-stably transduced cell lines that express TPOR-WT or clinical TPOR mutants W515K or 
S505N were subjected to viral transduction to introduce the various LNK constructs. However, due 
to various issues (outlined in Discussion section), these constructs were utilised in a transient, over 
expression system using Lenti-X 293T cells as these cells do not rely on cytokine receptor activation 
for proliferation or growth. In the current study, repeated transductions of LNK into Ba/F3 cells were 
performed but western analysis of LNK WT and some mutants showed little to no expression which 
was speculated to be due to the inhibitor effects on JAK-STAT signalling by LNK whereby cells 
expressing LNK are rapidly selected against during cytokine-stimulated cell proliferation. A previous 
study was able to observe the effects in Ba/F3 cells with LNK expression [344]. However, this was 
performed by transfection of these cells, therefore all data may be from transient transfection and 
short term analysis. In order to observe the effect of LNK on JAK-STAT signalling from TPOR in 
Lenti-X 293T cells, STAT3 was transfected as these cells have low endogenous STAT3 levels. 
STAT3 rather than STAT5 or STAT1 was utilised as STAT3 requires binding to TPOR in order to 
mediate signalling whereas STAT5 binding to TPOR is not essential for signalling [184]. 
Transfection of moderate to high amounts of STAT3 have not been shown to cause constitutive 
activation in a transient system, unlike JAK2 [119, 471]. This is likely due to STAT3 not possessing 
a kinase activity, and requiring tyrosine phosphorylation for activation. Overexpression of STAT3 
was confirmed to not cause constitutive activation nor affect receptor levels (Figure 48). However, 
STAT3 over expression does increase sensitivity to JAK activation signals. No cell growth retardation 
by LNK on Lenti-X 293T cells was evident as these are non-haematopoietic cells that do not rely on 
JAK signalling for their growth. LNK also had no change on STAT3 protein levels (Figure 48). 
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Figure 48: TPOR protein levels are increased by co-expression of LNK WT. 
Lenti-X 293T cells were transiently transfected with the respective constructs: pQCXIP HA-hTPOR 
WT, pcDNA3.1+ FLAG-hLNK WT, pBABE-STAT3 or pBABE-empty vector (EV), and pEGFP-
N1. No TPO stimulation on cells was performed. Total protein was subjected to SDS-PAGE and 
immunoblotted with indicated antibodies. GAPDH was used as a loading control. Image 
representative of n=3 experiments. 
 
Depending on the type of mutation, LNK constructs were either able to abrogate or downregulate 
STAT3 and ERK activation following TPO stimulation. As expected, LNK WT reduced STAT3 and 
ERK signalling compared to GFP control (Figure 49). Several constructs, in a similar manner to LNK 
WT, were able to reduce signalling such as LNK ΔCTD (pSTAT3 and pERK), ΔPH (pERK), and 
Y572A (pERK) (Figure 49). On the other hand, LNK ΔPro/DD, LNK Δlinker, and SH2 domain point 
mutants such as R392E, E395K, and R425P showed reduced inhibition on both STAT3 and ERK 
signalling compared to LNK WT (Figure 49). Expression levels of the various LNK constructs were 
also found to differ (Figure 49). This was not unexpected as modifications in the protein sequence 
can alter their expression levels. Co-transfection of expression constructs for LNK WT and TPOR 
resulted in a higher level of the receptor detected by western analysis as opposed to GFP co-
transfection with TPOR (Figure 49 and Figure 50A). However, the corresponding TPOR level with 
co-transfection of different LNK constructs together with TPO treatment was difficult to evaluate due 
to LNK-dependent ligand-mediated degradation. Therefore, a separate experiment to compare 
differences between the receptor levels in the absence of TPO was performed (Figure 50 A). Co-
expression of TPOR with LNK WT was observed to increase receptor levels compared to GFP control 
(Figure 50 A). In order to determine if the increase in TPOR levels when co-expressed with LNK WT 
was specific to TPOR, the effect of the expression of LNK on GHR was investigated and a similar 
striking increase in GHR was observed when LNK WT was co-transfected with GHR (Figure 50 B). 
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Although a stark increase in receptor stability was observed when either TPOR or GHR was co-
transfected with LNK WT, unlike GHR, all LNK constructs were able to increase TPOR levels (at 
different levels) (Figure 50). However, a similar trend of markedly increased receptor levels was 
observed when TPOR or GHR was co-expressed with LNK constructs that retained their signalling 
inhibition such as LNK ΔPH and LNK ΔCTD (except for E395K) (Figure 50). STAT3 transfection 
did not affect receptor expression, nor LNK expression, indicating no role of elevated STAT3 levels 
in regulating TPOR levels (Figure 48). This was not unexpected as there are no reports of STAT3 
directly regulating TPOR protein levels. 
 
  
 
A. 
B. 
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Figure 49: The ΔPro/DD and Δlinker domain deletions of LNK, and SH2 domain point mutants 
increased both STAT3 and ERK signalling. 
Lenti-X 293T cells were transiently transfected with pQCXIP HA-hTPOR WT and pBABE-STAT3, 
as well as different pcDNA3.1-FLAG-hLNK constructs or pEGFP-N1. Cells were starved overnight 
and TPO (final concentration of 50 ng/ml) was added (+) for 10 minutes. Samples in the absence of 
TPO (-) were used for comparison. Total protein was subjected to SDS-PAGE and immunoblotted 
with indicated antibodies. GAPDH was used as a loading control. A) A representative immunoblot 
was shown. B & C) Graph of relative pSTAT3 and pERK levels of 3 independent experiments 
generated using densitometry data. For a complete list of densitometry data for replicates, see 
Appendix Section B. Image representative of n=3 experiments.  
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Figure 50: Co-expression of TPOR or GHR with LNK WT or non-disruptive mutations such 
as ΔPH and ΔCTD (except for E395K) resulted in markedly increased receptor levels in the 
absence of cytokine. 
Lenti-X 293T cells were transiently transfected with the respective constructs: pQCXIP HA-hTPOR 
WT (A) or pQCXIP HA-hGHR (B) and pBABE-STAT3, as well as different pcDNA3.1-FLAG-
hLNK constructs or pEGFP-N1. All transfections included STAT3. No TPO stimulation on cells was 
performed. Total protein was subjected to SDS-PAGE and immunoblotted with indicated antibodies. 
GAPDH was used as a loading control. Image representative of n=1 experiment for A and n=3 for B. 
 
 
 
 
A. 
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LNK associates with active JAK2 strongly, only in the presence of TPOR  
 
The role of active JAK2 and TPOR in association with LNK was investigated by Co-IP. Initially, 
anti-HA antibody was used for TPOR (HA-tagged) co-immunoprecipitation during attempted 
optimisation of the co-IP procedure. However, the use of this antibody repeatedly showed binding to 
non-specific proteins. Alternatively, the anti-FLAG antibody was used to co-precipitate LNK 
(FLAG-tagged) and its interacting proteins, which was successful. As endogenous JAK2 is expressed 
at a low levels in Lenti-X 293T cells, it was necessary to transfect JAK2 as endogenous levels would 
be expected to be very low compared to the transfected TPOR and LNK levels, and therefore may 
have not allowed for full interpretation of results. For transfection, the use of 100 ng of the JAK2 WT 
plasmid was maintained although this amount causes overexpression of JAK2 which is known to 
result in constitutive activation of JAK2 [119, 471]. This JAK2 expression plasmid has a SV40ori 
which leads to further elevated expression in HEK293T cells. LNK WT was shown to be able to 
associate with the active form of JAK2 only when TPOR is present (Figure 51 and Figure 52). 
Receptor protein level in cells was significantly lower when only TPOR was transfected compared to 
when LNK was co-transfected (Figure 51) further supporting that LNK interacts with TPOR and 
stabilises the protein. Interestingly, little to no interaction between LNK and JAK2 WT or KE mutant 
was observed in the absence of TPOR (Figure 51 and Figure 52), supporting the requirement for 
TPOR for strong association of LNK with JAK2. LNK was still shown to associate with TPOR in the 
presence of exogenous JAK2 KE, however, this interaction was much less efficient compared to when 
JAK2 WT was transfected (Figure 51). In addition, LNK was shown to associate with TPOR in the 
absence of exogenous JAK2 (Figure 51 and Figure 52) although it is possible that low level 
endogenous JAK2 expression may be aiding the co-precipitation of TPOR by LNK. It was also 
evident that LNK interacted with JAK2 WT to a similar extent irrespective of TPO stimulation 
(Figure 52). However the lack of effect of TPO stimulation is likely due to the constitutive activation 
of the overexpressed JAK2.  
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Figure 51: LNK preferentially associates with active JAK2 rather than inactive JAK2, but only 
in the presence of TPOR. 
Lenti-X 293T cells were co-transfected with either HA-tagged hTPOR WT, FLAG-tagged hLNK 
WT, and/or JAK2 WT or KE. Immunoblot showing (Top) Co-IP analysis; (Bottom) Whole cell lysate 
(WCL). All conditions were performed without TPO stimulation. For Co-IP, protein lysates were 
immunoprecipitated with FLAG antibodies and blotted with antibodies specific for JAK2, HA (to 
detect FL-TPOR), and FLAG (to detect LNK). For WCL, total protein was subjected to SDS-PAGE 
and immunoblotted with indicated antibodies. Image representative of n=2 experiments.  
157 
 
 
Figure 52: LNK strongly associates with JAK2 only in the presence of TPOR. 
Immunoblot showing (Top) Co-IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected 
with either HA-tagged hTPOR WT, FLAG-tagged hLNK WT, and/or JAK2 WT or KE. For co-IP, 
protein lysates were immunoprecipitated with FLAG antibodies and blotted with antibodies specific 
for pJAK2 (detects phosphorylation on Tyr1007/1008), JAK2, HA (to detect FL-TPOR), and FLAG 
(to detect LNK). (B) For WCL, total protein was subjected to SDS-PAGE and immunoblotted with 
indicated antibodies. GAPDH was used as a loading control. Image representative of n=2 
experiments.  
 
LNK constitutively binds GHR and TPOR  
 
The ability of LNK to constitutively associate with a homodimeric class I cytokine receptor (TPOR 
and a related family member, GHR) or require JAK2 for this interaction, was investigated. LNK was 
found to bind directly to GHR and not require JAK2 (Figure 53 A). This was clearly shown as GHR 
was co-precipitated to similar levels by LNK irrespective of JAK2 transfection (Figure 53 A). This 
was in stark contrast to TPOR (Figure 53 B) which showed a requirement of JAK2 overexpression 
for detectable TPOR co-precipitated by LNK. Interestingly, LNK preferentially interacts with the 
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immature rather than the mature GHR (Figure 53 A) although both precursor and glycosylated mature 
TPOR were detected to be precipitated by LNK (Figure 53). Overall, these results suggest that LNK 
binds directly to homodimeric class I cytokine receptors and that this interaction does not require 
JAK2.  
 
      
Figure 53: LNK constitutively binds to GHR and TPOR but TPOR binding requires JAK2 for 
efficient association. 
Immunoblot showing (Top) Co-IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected 
with either HA-tagged hTPOR WT, HA-tagged hGHR WT, FLAG-tagged hLNK WT, and/or JAK2 
WT. For co-IP, protein lysates were immunoprecipitated with FLAG antibodies and blotted with 
antibodies specific for JAK2, HA (to detect FL-hGHR), TPOR (to detect FL-hTPOR), and FLAG (to 
detect LNK). For WCL, total protein was subjected to SDS-PAGE and immunoblotted with indicated 
antibodies. GAPDH was used as a loading control. Image representative of n=2 experiments for A, 
n=1 experiment for B.  
 
In order to clearly determine the role of JAK2 association with TPOR in facilitating LNK interaction 
with TPOR, the Box1 motif which is essential for JAK association was mutated. As the Box1 motif 
is the major receptor binding site of JAK2, this motif was mutated from PxxP to AAAA (Proline-X-
X-Proline to Alanine-Alanine-Alanine-Alanine) in order to disrupt binding to JAK2. This disruption 
A. B. 
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of binding between receptor and JAK2 will ensure that any observed LNK binding to the receptor 
should be independent of JAK2. However, it remains a possibility that JAK2 may still weakly interact 
with the Box2 motif and interbox residues [472]. Results showed that LNK was still able to co-
precipitate similar levels of TPOR Box1 mutant and WT although JAK2 association was decreased 
when Box1 mutant was transfected (Figure 54). The lack of STAT5 activation by TPO stimulated 
Box1 mutant receptor supported that there was no significant interaction of JAK2 with the mutant 
receptor (Figure 54). These results suggest that LNK is able to bind directly to TPOR without the 
requirement for JAK2. 
 
 
Figure 54: LNK constitutively binds to both TPOR WT and Box1 mutant. 
Immunoblot showing (Top) Co-IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected 
with either HA-tagged hTPOR WT, HA-tagged hTPOR Box1 mutant, FLAG-tagged hLNK WT, 
and/or JAK2 WT. For co-IP, protein lysates were immunoprecipitated with FLAG antibodies and 
blotted with antibodies specific for JAK2, TPOR (to detect FL-hTPOR), and FLAG (to detect LNK). 
For WCL, total protein was subjected to SDS-PAGE and immunoblotted with indicated antibodies. 
GAPDH was used as a loading control. Red asterisks denote no antibody used in Co-IP. Constitutive 
binding to receptor is supported by figures 17 and 18. 
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LNK Pro/DD domain mediates association with TPOR 
 
The role of individual domains of LNK in mediating association with JAK2 and TPOR were then 
investigated. Domain deletions and point mutations of LNK were used to determine whether LNK 
has a binding site to either JAK2 or TPOR other than its SH2 domain. LNK was shown to be able to 
associate with the TPOR Box1 mutant receptor suggesting that LNK does not bind to the Box1 motif 
and can bind receptor independently of JAK2 (Figure 55). It was observed that the expression levels 
of JAK2 and TPOR WT co-expressed were increased compared to when JAK2 and Box1Δ were co-
expressed (data not shown). This suggested that the interaction of JAK2 with TPOR resulted in a 
stabilised complex. In order to overcome this issue of difference in total protein levels, an increased 
amount of JAK2 (three-fold) was transfected for all transfections with the Box1 mutant receptor in 
order to equalise the expression levels. The most striking observation was the markedly reduced 
association of receptor with LNK ΔPro/DD compared to LNK WT although JAK2 binding was still 
maintained (Figure 55). In contrast, JAK2 binding with LNK Δlinker was abolished but a strong level 
of TPOR interaction was retained. Similarly, LNK SH2 domain mutants (except for E395K) showed 
reduced binding to JAK2 but maintained a significant level of TPOR binding. The LNK Y572A 
mutation does not affect binding to both TPOR and JAK2, hence it maintained the same binding 
capabilities as WT. Following, the same experimental conditions with the inclusion of cytokine was 
performed to determine if the interaction between LNK mutants and JAK2/TPOR would change. This 
assay showed similar results as to without TPO stimulation (Figure 56), however with overexpression 
of JAK2, there was likely no significant increase in pJAK2 levels upon TPO stimulation as shown 
previously (Figure 52). 
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Figure 55: LNK domain deletions and point mutations show altered affinity to JAK2 or TPOR. 
A) Immunoblot showing (Top) Co-IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-
transfected with either HA-tagged hTPOR WT, HA-tagged hTPOR Box1 mutant, FLAG-tagged 
hLNK WT or mutants, and/or JAK2 WT. All conditions were performed without TPO stimulation. 
For co-IP, protein lysates were immunoprecipitated with FLAG antibodies and blotted with 
antibodies specific for JAK2, TPOR (to detect FL-hTPOR), and FLAG (to detect LNK). For WCL, 
total protein was subjected to SDS-PAGE and immunoblotted with indicated antibodies. β-tubulin 
was used as a loading control. Red asterisks denote 3x JAK2 concentration used. ΔP represents 
ΔPro/DD, ΔL represents Δlinker, RP represents R425P, RE represent R392E, EK represents E395K, 
A. 
B. 
162 
 
and YA represents Y572A. B) Graph of relative JAK2 and TPOR levels of 3 independent experiments 
generated using densitometry data. For a complete list of densitometry data for replicates, see 
Appendix Section B (Figure 90). Image representative of n=3 experiments.  
 
 
 
Figure 56: Addition of TPO does not alter LNK mutant binding affinities to TPOR or JAK2. 
Immunoblot showing (Top) Co-IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected 
with either HA-tagged hTPOR WT, HA-tagged hTPOR Box1 mutant, FLAG-tagged hLNK WT or 
A. 
B. 
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mutants, and/or JAK2 WT. All conditions were performed with TPO stimulation. For co-IP, protein 
lysates were immunoprecipitated with FLAG antibodies and blotted with antibodies specific for 
JAK2, TPOR (to detect FL-hTPOR), and FLAG (to detect LNK). For WCL, total protein was 
subjected to SDS-PAGE and immunoblotted with indicated antibodies. β-tubulin was used as a 
loading control. Red asterisks denote 3x JAK2 concentration used. ΔP represents ΔPro/DD, ΔL 
represents Δlinker, RP represents R425P, RE represent R392E, EK represents E395K, and YA 
represents Y572A. B) Graph of relative JAK2 and TPOR levels of 2 independent experiments 
generated using densitometry data. For a complete list of densitometry data for replicates, see 
Appendix Section B (Figure 91). Image representative of n=2 experiments. 
 
All LNK mutants exhibit similar tyrosine phosphorylation levels  
 
As LNK is known to be tyrosine phosphorylated by JAK2 [278, 473], the various LNK mutant 
constructs were investigated for differences in phosphotyrosine levels in the presence of TPO as these 
phosphorylated sites may be important for LNK function or binding to other proteins. No significant 
difference in the level of phosphotyrosine levels was observed across all the LNK mutants indicating 
that loss of tyrosine phosphorylation of LNK was not playing a role in mediating interactions with 
JAK2 or LNK for any of the LNK mutants (Figure 57). 
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Figure 57: All LNK mutants exhibit similar tyrosine phosphorylation levels when stimulated 
with TPO. 
Immunoblot showing (Top) IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected with 
either HA-tagged hTPOR WT, FLAG-tagged hLNK WT or mutants, and/or JAK2 WT. For IP, 
protein lysates were immunoprecipitated with FLAG antibodies and blotted with antibodies specific 
for pTyr (4G10) and FLAG (to detect LNK). For WCL, total protein was subjected to SDS-PAGE 
and immunoblotted with indicated antibodies. RIPA buffer was used for this assay to disrupt any 
interactions between LNK and other proteins in order to focus specifically on the tyrosine 
phosphorylation of LNK. β-tubulin was used as a loading control. ΔP represents ΔPro/DD, ΔL 
represents Δlinker, RP represents R425P, RE represent R392E, EK represents E395K, and YA 
represents Y572A. Arrow shows non-specific phospho band. Image representative of n=3 
experiments. 
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LNK binding to TPOR involves cytoplasmic residues Y113 and Y118 of the receptor  
 
Following the determination of the LNK Pro/DD domain that associates with TPOR, next the region 
of the TPOR responsible for interacting with LNK was investigated. In order to answer this question, 
various TPOR ICD truncations were generated. Each truncation was based on a previous study 
analysing the signalling function of regions of TPOR [184]. The tyrosine residues in the TPOR ICD 
were mutated to phenylalanine as this residue is structurally very similar to tyrosine, but importantly 
is not able to be phosphorylated. These phenylalanine substitutions will allow for the determination 
if any of the sites on the receptor are required to be phosphorylated for LNK binding. These constructs 
(Figure 58) were created in the pQCXP CMV/TO DEST backbone and all constructs contain the 
Box1 mutation (PxxP to AAAA). The Box1 mutation was included to ensure that any interaction 
observed was due to LNK binding and not JAK2-mediated binding. Results showed that mutation of 
any ICD tyrosine residues of TPOR to phenylalanine resulted in reduced LNK binding but double 
mutation of Tyr113/118 to phenylalanine resulted in abolished LNK binding (Figure 59). These 
results suggest that both of these tyrosine residues are particularly important for LNK association to 
the receptor. Co-precipitation assays with TPOR truncation constructs were challenging due to 
variation in expression levels and were not pursued further due to time limitation.  
 
Figure 58: Illustration of the different TPOR ICD truncations and point mutations that were 
generated. 
The number followed by ‘T’ represents the number of amino acids left in the ICD after truncation. 
All tyrosine residues ‘Y’ were individually mutated to phenylalanine. A dual point mutation was 
created for Y113/ Y118. ‘TMD’ represents receptor transmembrane domain. Figure was adapted from 
[184]. 
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Figure 59: TPOR Y113 and Y118 residues are important for LNK association to the receptor. 
Immunoblot showing (Top) IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected with 
either HA-tagged hTPOR Box1Δ and Box1Δ Tyr mutants (Y8F, Y29F, Y78F, Y113F, Y118F, 
Y113/118F), FLAG-tagged hLNK WT, and/or JAK2 WT. For IP, protein lysates were 
immunoprecipitated with antibodies specific for JAK2, TPOR (to detect FL-hTPOR), and FLAG (to 
detect LNK). For WCL, total protein was subjected to SDS-PAGE and immunoblotted with indicated 
antibodies. β-tubulin was used as a loading control. Top arrow for HA-hTPOR showing the mature 
glycosylated receptor band; bottom arrow for HA-hTPOR showing the immature receptor band. n=1 
experiment. 
 
LNK binding to TPOR is partially affected by the W515K and S505N mutations  
 
The ability of TPOR TMD and JM mutants to bind to LNK was investigated. These constitutively 
active mutations may position the receptor in a conformation that allows for continued 
phosphorylation of their associated JAK2 but may reflect different degrees of phosphorylation that 
can affect LNK binding to JAK2 and TPOR. LNK showed reduced binding to TPOR TMD and ICD-
JM mutations such as S505N and W515K (Figure 60).  
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Figure 60: TPOR TMD and ICD mutations (S505N & W515K) reduce binding to LNK. 
Immunoblot showing (Top) IP analysis; (Bottom) WCL. Lenti-X 293T cells were co-transfected with 
either HA-tagged hTPOR WT or mutants (W515K, T487A, S505N), FLAG-tagged hLNK WT, and 
JAK2 WT. For IP, protein lysates were immunoprecipitated with antibodies specific for JAK2, TPOR 
(to detect FL-hTPOR), and FLAG (to detect LNK). For WCL, total protein was subjected to SDS-
PAGE and immunoblotted with indicated antibodies. GAPDH was used as a loading control. Image 
representative of n=2 experiments. 
 
Discussion  
 
LNK is an important negative regulator of JAK2 activation and mutations in LNK that impair this 
regulatory function are found in MPNs. The mechanism of LNK regulation of JAK is currently poorly 
understood. In order to address this lack of understanding, various LNK constructs with domain 
truncations and clinical/synthetic point mutations that retained their SH2 domain were generated. 
These constructs were tested and compared to LNK WT for their ability to bind TPOR and JAK2, 
and to determine if the different mutations can negatively regulate downstream signalling. Initially, 
the various LNK domain deletions and mutations (all of which retained the SH2 domain) were co-
transduced into Ba/F3 TPOR WT or W515K cells. The purpose of co-transducing the different LNK 
constructs into both the Ba/F3 TPOR WT and W515K (or S505N initially) was to test the effects on 
constitutively active cells (those expressing TPOR W515K) and on those cells that are induced (those 
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expressing TPOR WT), using cell proliferation and signalling assays as a readout. However, several 
issues were encountered to achieve stable expression of LNK constructs in Ba/F3 cells. Certain 
constructs, in particular LNK WT, showed weak expression that was lost after culturing the cells for 
a short period of time (see Appendix Section B Figure 94 and Figure 95). Ba/F3 cells even while 
cultured in TPO or IL-3 containing media, will activate JAK (which is inhibited by LNK) which plays 
a pivotal role in providing the growth signals. Therefore, cells that were able to proliferate would 
only be those that have developed a mechanism to overcome JAK2 inhibition by LNK. This inhibition 
of cell growth has also been previously reported [249], but was highlighted in a study where it was 
found necessary to transduce the BCR-ABL oncogene in order to express LNK WT in 32D cells to 
allow growth while expressing LNK [342, 474]. LNK, however, when experimentally introduced, 
does not affect the growth of non-haematopoietic cells [249], which is consistent with its expression 
in cells of the megakaryocytic lineage (megakaryocyte progenitors to platelets). In the current study, 
constitutively active TPOR mutants did not prevent this growth inhibition (see Appendix Section B 
Figure 93). A previous study also showed that stably-transduced Ba/F3 expressing TPOR W515L 
which is a constitutively active mutant construct, were more sensitive to the growth inhibitory effects 
of transfected LNK than those cells expressing TPOR WT [285]. The difference in observation 
regarding the ability of the cells to overcome growth inhibition with the use of BCR-ABL instead of 
constitutively active TPOR is likely due to the ability of BCR-ABL to directly activate STATs 
without utilising JAKs [475]. The growth inhibitory effect of LNK was also evident in HEL cells 
which express the JAK2V617F mutant [309]. When these cells were transduced to express exogenous 
LNK, it was observed that the levels of LNK were significantly lowered after approximately four 
weeks of culture, and cell growth as well as the JAK-STAT and ERK/ MAPK signalling were no 
longer significantly repressed [309]. This observation is consistent with the findings in the current 
study but the effect occurred in a shorter time frame (less than 4 weeks) (see Appendix Section B 
Figure 92-Figure 95). The proliferation rate of Ba/F3 TPOR WT or W515K/S505N cells that were 
co-transduced with LNK WT (minimal expression on Western analysis) (Appendix Section B Figure 
94 and Figure 95) seemed to be at a comparable level or even slightly elevated compared with cells 
that were not made to express LNK WT (see Appendix Section B Figure 92 and Figure 93). The 
increase in proliferation rate of these cells may be due to the utilisation of some mechanism to 
overcome LNK inhibition of growth. Even if the different LNK constructs were able to be expressed, 
their expression levels differed (see Appendix Section B Figure 94 and Figure 95). Due to the 
difficulties in generating stable Ba/F3 cell lines expressing different LNK constructs at comparable 
levels, an alternative was sought utilising transient transfection of Lenti-X 293T cells (non-
haematopoietic) [249] to investigate signalling mediated by LNK.  
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Various LNK domain deletions (ΔPro/DD, ΔPH, ΔPH-SH2 linker, ΔCTD) and point mutations in the 
SH2 domain (R425P, R392E, E395K) as well as C-terminal domain, Y572A, were generated in order 
to determine if the other domains of LNK (besides SH2) are involved in inhibiting/regulating 
signalling of JAK2 associated with TPOR. All LNK expression constructs retained the SH2 domain 
required for JAK2 phosphorylated tyrosine binding. Domain truncations such as LNK ΔPro/DD and 
LNK Δlinker, and SH2 domain point mutants reduced or abolished LNK capability to inhibit 
downstream signalling as observed by the increase in STAT3 and ERK1/2 activation. As the Pro/DD 
domain is thought to mediate dimerisation via the zipper region, it is plausible that the deletion of this 
domain (LNK ΔPro/DD) may have abolished the ability of LNK to form homo-dimers. As a result, 
this prevented the formation of the complex that is required to bind and inhibit JAK2 signalling. This 
may occur concurrently with its SH2 domain acting as a main anchor to bind to JAK2. It has been 
shown that the LNK family members, SH2B1 and APS, can hetero-dimerise and associate with their 
two cognate JAKs [291]. Accordingly, LNK homo-dimerisation has also been reported in an 
overexpressed system [281]. Alternatively, it is also possible that this domain is involved in 
interacting with the receptor and plays a role in impeding further activation of downstream pathways. 
The current study has revealed a novel function of the LNK Pro/DD domain. This domain appears to 
play an important role in binding to TPOR whilst maintaining JAK2 interaction via the SH2 domain. 
Supporting this notion, it was previously shown that the related family member, APS is able to bind 
to a related receptor, EPOR, at its ICD [282].  On the contrary, another study showed that a similar 
region in LNK transiently associates with inactive JAK2 instead of TPOR [278, 309, 310, 355]. In 
this study, a Co-IP of glutathione-S-transferase (GST)-tagged Pro/DD-PH construct containing no 
SH2 domain was performed in UT7 cells expressing TPOR. It is plausible that TPOR-mediated JAK2 
binding might have occurred. Based on the current results, it is likely that the LNK Pro/DD domain 
is another site that works in close association with the SH2 domain to bind the receptor and JAK2, 
respectively, and regulate TPOR-mediated signalling. Alternatively, LNK SH2 binds both TPOR and 
LNK independently, and forms dimers via the Pro/DD which strengthens the binding as a complex. 
The importance of the LNK SH2 domain in binding and inhibiting JAK2 has been well established. 
This finding is well supported by the results of this study that showed all three point mutations in this 
domain (clinical mutants E395K and R425P, and synthetic R392E mutant) resulted in enhanced 
signalling and disrupted JAK2 binding capability (except for E395K). These results characterise and 
confirm the novel R425P mutation as oncogenic due to its role in increased signalling, and therefore, 
enhanced cell growth and proliferation. This explains the MPN/leukaemic clinical phenotype 
observed in patients harbouring the R425P mutation. The enhanced ERK1/2 activation in a transient 
transfection system caused by the E395K mutant was previously reported [476]. However, unlike the 
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other two mutations, the E395K mutant retained binding capabilities to both JAK2 and TPOR, 
although binding to JAK2 capability was slightly reduced compared to LNK WT. It is possible that 
this residue may not be directly binding JAK2 but that this amino acid or negative charge at this 
position may be important for regulating LNK function. The ability of this mutant to bind strongly to 
JAK2 may explain why TPOR expression was stabilised at the cell surface compared to the R392E 
and R425P mutant. A functional assay using a stably-transduced haematopoietic cell line of this 
mutation may be required to confirm the reduced inhibition on signalling and ensure that this was the 
consequence of the mutation and not of the cell type. The R392E synthetic mutation in SH2 domain 
has been reported to cause disruption of LNK function that is more severe than the one observed in 
the missense mutations in the PH domain [249, 277]. This is in complete agreement with the current 
data showing that SH2 domain point mutations resulted in severe functional disruption of LNK 
compared to ΔPH, further supporting the notion that the SH2 domain is the main regulatory site. 
Deletion of the PH-SH2 linker region (LNK Δlinker) also showed some effect on LNK inhibitory 
function. Due to the proximity to the SH2 domain, the Δlinker may have affected the conformation 
of the SH2 domain thereby causing ineffective LNK binding to JAK2 (with maintained TPOR 
binding) as observed in this study, resulting in elevated pSTAT3 and pERK1/2 levels. This 
observation confirms the notion that LNK can indeed bind directly to TPOR and that this binding 
occurs between the Pro/DD and PH domain.  
LNK contains a PH domain that is responsible for lipid interaction with the inner cell membrane 
containing phosphoinositides [278, 285]. Deletion of the PH from LNK did not show any strong 
change in LNK function. A similar effect was observed for the deletion of the LNK C-terminal 
domain. Previous studies have suggested that the PH domain of LNK is involved in a weak interaction 
with inactive JAK2 and constitutively active JAK2V617F [310], and that this domain is crucial for LNK 
localisation to the cell membrane [285]. LNK PH domain missense mutations have also been shown 
to impair its cell surface localisation leading to reduced interaction with JAK2 and reduced inhibition 
of signalling [353]. The findings of the current study give support to this observation as LNK ΔPH 
was observed to increase STAT3 but not ERK1/2 signalling compared to LNK WT.  It is plausible 
that in a transient high expression system, LNK does not require the PH domain to anchor to the 
membrane to enhance interaction with JAK2. However, in a low expression system (endogenous 
LNK), the PH domain may be important for membrane anchorage in order to bring LNK in close 
proximity to JAK2. This is in concordance with previous reports that found that the PH domain 
contributes to inhibition but is not required to hinder TPOR- or EPOR-mediated cell growth or 
haematopoiesis [249, 277]. The Y572 residue in the C-terminal domain of LNK was also not crucial 
in maintaining the interaction between LNK, JAK2, and TPOR. In support of this finding, previous 
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studies have shown that the Y572 residue that lies in the aforementioned domain may aid, but is not 
essential for EPOR signalling [277] and; in the context of TPOR signalling, the murine counterpart 
of this residue was shown to have no functional effect [249, 311]. It was also previously described 
that in the context of c-KIT signalling, the PH and C-terminal domain of LNK play a minor role in 
contributing to the LNK inhibitory function whereas its NTD and Y536 (Y572 human equivalent) are 
not important for this function [311]. This is in contrast to the results of the current study where in 
the case of TPOR, the PH and CTD do not appear to be as important for LNK function compared to 
the NTD that may be a potential binding site for TPOR. LNK may regulate different receptors in a 
different manner, something that is yet to be fully understood.  
TPOR ICD domain contains several tyrosine phosphorylation residues that serve as sites for the 
binding of positive or negative regulatory proteins. Co-precipitation results showed that the two distal 
ICD Tyr residues of TPOR, Y113 and Y118 (Y112 and Y117 murine homologue) were important for 
LNK association. This may be one of the mechanisms whereby these constitutively activating 
mutations are able to enhance signalling. These residues are also positive regulatory sites that are able 
to be phosphorylated and are important for the recruitment and activation of various proteins such as 
Shc, STAT5, STAT3, SHIP, SHP2, and Gab2. Due to the ability of these two residues to bind various 
proteins, LNK may either be competitively binding to TPOR or its binding to TPOR may be mediated 
by other proteins. Interestingly, it has been shown for the murine homologue Tyr112 that this residue 
is important for the pathogenesis of the W515A mutation which affects the MAPK pathway and not 
JAK2 activation [230]. Based on this observation, LNK may bind to other proteins that are bound to 
Tyr112 such as Shc which mediates the activation of the MAPK pathway. Although the binding of 
LNK to Shc has not been shown, the related family member, APS, has been shown to bind to this 
protein [335].  
Although a previous study has demonstrated that LNK binds to JAK2 in the absence of receptor [285], 
the data presented here showed that the binding of LNK to JAK2 requires the presence of a cytokine 
receptor, which is consistent with another study [278]. It is plausible that the binding of JAK2 to LNK 
preferentially occurs at the cell membrane as an entire complex, with the receptor present to anchor 
JAK2 at the surface (and JAK2 present to stabilise the receptor at the surface). It is likely that LNK 
has a higher affinity for the JAK2-TPOR complex than for JAK2 alone. In support of the observation 
that LNK interacts with TPOR, it has been shown that LNK is able to co-localise with this receptor 
at the cell surface [285, 474]. The current investigation showed that LNK was able to associate with 
inactive JAK2 as previously reported [278, 309, 310, 355] but it showed higher binding affinity for 
active JAK2. The murine JAK2 KE construct harbours the K882E mutation in the ATP binding 
pocket rendering JAK2 kinase dead and unable to perform downstream signalling. However, this 
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mutant still retained the ability to be phosphorylated by other signalling molecules including 
endogenous JAK2. Therefore, it is possible that a small portion of the JAK2 KE molecules was 
phosphorylated at the Y813 and/or Y613 residue allowing LNK to bind to this residue. The anti-
pJAK2 antibody that was used only detects phosphorylation at Tyr1007/1008 and not at Tyr613/813. 
Alternatively, LNK may be able to bind to kinase inactive JAK2 but with a much lower affinity than 
to active JAK2, and this may be mediated by a site other than the SH2 domain of LNK. The SH2-
disrupted LNK mutant, R392E has been shown to bind to inactive JAK2 [310, 355] as the mutation 
may not have completely abolished SH2 binding ability although there were contradictory findings 
reported by another group [342]. The presence of a second binding site in LNK either in the N-
terminal [309] or PH domain [310], that binds inactive JAK2 WT has been reported [310], although 
the precise location of this site remains debatable.  
Previous studies have provided conflicting data on whether LNK constitutively binds to TPOR or not 
[285, 342]. The data presented above showed that LNK binds constitutively to TPOR and the related 
family member, GHR, and that JAK2 may contribute to TPOR-LNK interaction but is not required 
for TPOR binding. This was confirmed using the TPOR Box1 mutant and supported by previous 
finding that state that binding of LNK WT to both TPOR WT and Box1 mutant receptor was 
comparable [342], suggesting that JAK2 presence may not be crucial for TPOR and LNK interaction. 
However, 32D cells (murine IL-3 dependent myeloid cell line) were used in this study [477] and these 
cells may express endogenous levels of TPOR [478]. Hence, it is plausible that LNK WT may be 
bound to endogenous TPOR (that is associated with JAK2) leading to the observation of a constitutive 
interaction with TPOR. A contradictory study showed that SH2-disrupted LNK R392E mutant does 
not bind to TPOR [285] possibly due to abolished binding to JAK2, indicating that it does not bind 
directly to TPOR. This previous study also showed that the interaction between LNK WT and TPOR 
W515L (constitutive active TPOR mutant) was increased in the presence of TPO stimulation [285]. 
LNK showed preferential co-precipitation with the immature GHR rather than with the mature form 
although this was not the case for TPOR. This suggests that LNK may be binding JAK2 bound to the 
precursor GHR in the ER. Alternatively, LNK may preferentially bind to precursor GHR preventing 
the maturation (glycosylation) and inhibiting cell surface localisation which would further 
downregulate the ability of the receptor to be activated by ligand binding. In the case of TPOR, LNK 
may already be bound to the precursor before localising to the surface. Activation of GHR or TPOR 
did not show a change in the association with LNK. However, the amount of JAK2 overexpressed by 
these transfected cells may have caused significant constitutive activation and therefore, ligand 
stimulation of GHR and TPOR may not produce any significant elevation in pJAK2 levels. The 
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results of this study confirmed that LNK constitutively binds to both JAK2 and TPOR, but that a 
TPOR-JAK2 complex is not required for LNK association.   
Interestingly, TPOR levels were observed to be elevated in the presence of LNK. The reduced 
signalling due to LNK presence may have led to the reduced receptor degradation which may explain 
this observation. Alternatively, as LNK WT is overexpressed in this system, the limited amount of c-
CBL or SOCSs in the cells may have degraded the unbound LNK that is present, thereby leaving the 
remaining LNK still bound to the receptor. This results in the receptor not being degraded as much 
as expected. It was previously shown for the related family member, APS, that its C-terminal tyrosine 
residue is a binding site for the c-CBL protein and this interaction results in the attenuation of the 
signalling [282, 349] and LNK was also previously shown to bind c-CBL  [343, 344]. Interestingly, 
the co-expression of LNK WT with not just TPOR, but also GHR, resulted in increased receptor 
expression suggesting a general mechanism of receptor stability by LNK overexpression. When co-
expressed with GHR, LNK mutations that retained their signalling inhibition resulted in increased 
receptor levels suggesting that LNK may be eliminating low level basal signalling [122]. 
Interestingly, only the precursor receptor levels seemed to have increased in this regard and not the 
mature receptor levels. This may be attributed to a trafficking issue where LNK may be affecting 
JAK2 which acts as a chaperone for the receptor to localise to the surface.  
The results of this chapter showed that all LNK mutant constructs displayed similar tyrosine 
phosphorylation levels. This suggests that the potential site of LNK phosphorylation does not lie in 
the mutated regions. As only certain LNK mutant constructs (based on their ability to disrupt LNK 
function) were tested for the assay, it may be possible that other untested constructs (ΔPH and ΔCTD) 
may have a similar or different tyrosine phosphorylation pattern. LNK has ten potential tyrosine 
phosphorylation sites (Figure 61). The PH domain contains the Tyr273, the SH2 domain contains 
Tyr401 and Tyr461, whereas the CTD contains Tyr555 and Tyr572. It has been suggested that only 
the Y572 is a putative site for LNK phosphorylation, based on data obtained testing the similar murine 
tyrosine residue LNK Y536. The results of the current study showed that there are other sites in LNK 
besides the putative Y572 residue that can be phosphorylated, at least in the context of TPOR 
signalling, which may act as binding sites for other regulators.  
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Figure 61: Domain organisation of LNK showing the location of tyrosine residues. 
Position of tyrosine residues are shown in red text. 
 
The relationship between LNK and the TPOR mutants that were investigated in this thesis (W515K, 
T487A, and S505N) has not been defined. This study found that LNK binds less efficiently to the 
W515K and S505N mutants, and may consider this as an additional mechanism that contributes to 
the enhanced signalling caused by these mutations. Contrary to the current study, a previous 
publication has shown that LNK binds to the TPOR W515L mutant better than to the WT and that 
this is suggested to be mediated by the SH2 domain as the R392E (with disruption of SH2 function) 
was unable to bind to this mutant [285]. Furthermore, the W515L mutant appeared to be more 
sensitive to LNK inhibition. Another point of difference was that LNK does not constitutively bind 
to TPOR WT although it is able to bind to W515L in the absence of cytokine and that this binding is 
enhanced by the presence of cytokine [285]. This is in contrary to the results of the current study, 
where LNK was shown to constitutively bind TPOR, and that this binding is reduced in the presence 
of TPOR mutations. The presence of exogenous JAK2 in the current study may account for the 
differences in observation. Future studies investigating the effect of LNK on the signalling properties 
of W515K and S505N mutations may reveal if LNK can suppress signalling of the mutants better 
than WT.  
 
Conclusion 
 
A novel function of the Pro/DD domain was found in mediating constitutive binding to TPOR 
possibly to the Y113 and Y118 residues with the LNK SH2 acting as a main anchor to bind to JAK2 
(Figure 62 A). Alternatively, LNK may form homodimers via the Pro/DD with each unit binding to 
TPOR and JAK2 separately (Figure 62 B). These interactions may prevent downstream signalling 
through a mechanism that has yet to be fully elucidated. Several point mutations in the Pro/DD 
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domain have been reported in T-ALL (R43C and E78K) and acute myeloid leukaemia (R80C and 
I145T), and predicted to be pathogenic (based on FATHMM score) [479]. The findings of the current 
study act as an important foundation for future work aimed to increase the understanding regarding 
the structure-function of this important negative regulator of JAK2 signalling.  
 
 
Figure 62: Proposed model for LNK interaction with TPOR and JAK2. 
When receptor is present, LNK adopts a more open active conformation. A) LNK may bind to the 
receptor via its Pro/DD domain and to JAK2 via its SH2 domain with a strong affinity. B) LNK may 
form homodimers via the Pro/DD, with each unit binding to TPOR and JAK2 separately, via its SH2 
domain. For the purpose of the illustration, the receptor is shown as a monomer.  
A. 
B. 
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Chapter 6 
Protein Expression and Purification of Full-Length WT SH2B3 (LNK) 
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Introduction 
 
Protein crystallisation for X-ray crystallography is a valuable technique that is used to determine 
protein structure. These structures are important to better understand protein function in terms of how 
the different domains/ amino acids interact with each other or with other proteins. This understanding 
will also facilitate the development of targeted drugs to enhance or inhibit protein activity. The 
development of targeted drugs will be useful in clinical applications to treat myriads of diseases.  
In order to obtain protein for structural and biophysical studies, a suitable protein expression system 
needs to be employed. The bacterial expression system is one of the most common protein expression 
systems that is used as it is time-efficient, able to generate high yields of recombinant protein, and is 
relatively inexpensive compared to other expression systems [480-487]. In the case of low protein 
yield, codon optimisation for high expression in E. coli has been shown to significantly increase 
protein expression for many genes [488-493]. However, expression of protein in bacterial systems do 
not allow for many secondary structure modifications of proteins that occur in eukaryotes such as 
glycosylation, which may be important for the structure-function of the protein. Insect and 
mammalian expression systems can also be used, however these are typically much more costly and 
time consuming, and typically produce lower protein yields compared to bacterial expression 
systems, although secondary structure modifications that may be important for eukaryotic protein 
functions will be able to occur when expressed in higher eukaryotic cells [494, 495].  
In order to obtain purified protein for structural or biophysical studies, the expressed protein will 
normally require purification using methods such as affinity chromatography, size exclusion 
chromatography (SEC), and ion exchange chromatography [496, 497]. Protein aggregation and 
precipitation is one of the major issues that hinder the process of obtaining soluble proteins for further 
characterisation. Buffer contents such as pH, salt concentration, detergents, metal ions, and other 
contaminants and impurities can contribute to protein aggregation. Aggregation can exist as insoluble 
or soluble forms, and various methods can be utilised to improve protein solubility such as 
incorporation of ubiquitin sequences in the constructs and/or using tags such as maltose-binding 
protein (MBP) and GST. Although various methods have been developed to improve protein 
solubility, protein aggregation remains a challenge because different proteins have varying solubility 
conditions and there is currently no reliable method to accurately predict the conditions for optimal 
solubility for each purified protein [498, 499]. Despite this, successful attainment of purified protein 
can be invaluable for understanding protein structure-function.  
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As the crystal structure of LNK is currently not currently available, there is still lack of understanding 
towards its role as a negative regulator i.e. how its structure contributes to its function and why LNK 
functions differently from its other family members. Currently, crystal structures of LNK family 
members have been separately solved such as the dimerisation domain of APS [306], the SH2 domain 
of APS in complex with the activated tyrosine kinase domain of the insulin receptor [305], the SH2 
domain of SH2B1 in complex with JAK2 pTyr813 phosphopeptide [500], and the SH2 domain of 
SH2B1 [501]. Therefore, successful expression and purification of LNK for structural and 
biophysical studies would greatly enhance our knowledge and understanding of the mechanisms of 
how LNK regulates JAK signalling.  
 
Materials and Methods 
 
Expression Plasmid Constructs 
The hLNK constructs for E. coli protein expression and purification were made in two different vector 
backbones using CPEC (see Chapter 2), the pHUE vector [502] (containing 6x Histidine (His)-tag 
followed by an ubiquitin sequence and the hLNK gene) and the pET11a vector (Novagen) (with 6x 
His-tag followed by a Tobacco Etch Virus (TEV) protease cleavage site inserted) (see Appendix 
Section C for primers used). These constructs were made to contain truncations (deletion of 
hydrophobic rich regions in either the N- and C-terminal regions of LNK). An E. coli codon optimised 
hLNK gene for high expression was also designed and created (ATUM). Similar constructs for the 
codon optimised hLNK were created in pHUE and pET11a essentially as described above using 
primers (see Appendix Section C for primers used) specific for the codon optimised hLNK. 
Adenoviral constructs for hLNK and JAK2 JH2-JH1 mammalian protein expression and purification 
were generated. Sequence verified pDONR221 FLAG-hLNK WT (see Chapter 2) was shuttled into 
the pAD/CMV/V5-Dest adenoviral destination vector (Life Technologies) via Gateway cloning. The 
coding sequences for human JAK2 JH2-JH1 and 6xHis-TEV was amplified by PCR using 
complementary primers and joined via CPEC. The JAK2 JH2-JH1 plasmid was a gift from Associate 
Professor Jeff Babon (Walter and Eliza Hall Institute of Medical Research (WEHI)). The joined 
coding sequences of 6xHis-TEV JAK2 JH2-JH1 was amplified by PCR using primers including 
relevant attB sequences and were cloned into pAD/CMV/V5-DEST by Gateway cloning via 
pDONR221 (Life Technologies). All constructs were verified by DNA sequencing. Gateway cloning 
of pDONR221 FLAG-hLNK WT and pDORN221 6xHis-TEV JAK2 JH2-JH1 into pAD/CMV/V5-
DEST was performed by preparing an LR reaction mix based on the manufacturer’s method: 75 ng 
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pDONR221 constructs, 100 ng pAD/CMV/V5-Dest vector, 0.5 µl 112 mM NaCl, 1.6 µl TE (Tris-
EDTA) buffer, and 1 µl LR clonase II enzyme. The components were incubated for 1-3 hours before 
being used for bacterial transformation.  
 
Expression of human LNK in E. coli 
BL21-Gold (DE3) E. coli cells (Agilent Technologies) were used to express the various LNK 
constructs in pHUE and pET11. Each plasmid was transformed into BL21-Gold (DE3) competent E. 
coli cells for high-level protein expression on ampicillin plates (100 µg/ ml) and incubated overnight 
at 37°C. Single colonies for each construct were then grown in LB to log phase with vigorous shaking 
(220 RPM) at 37°C. An aliquot of the pre-induction sample was centrifuged for 1 minute at 17,900g. 
After collection of the pre-induction sample, IPTG induction was added to a final concentration of 1 
mM to induce expression for 2.5 hours with vigorous shaking (220 RPM) at 37°C. An aliquot of post-
induction sample was collected as per the pre-induction sample and cell pellets were resuspended 1:9 
with 20% SDS and heated to 95°C for 15 minutes. Samples were subsequently analysed by SDS-
PAGE and western analysis (described in Chapter 2).  
 
Adenovirus Production 
The pAD/CMV/FLAG-hLNK WT and pAD/CMV/6xHis-TEV JAK2 JH2-JH1 constructs were 
transformed into Stbl3 E. coli cells and confirmed through restriction digest. The purified plasmids 
were then digested with Pac1 enzyme (New England Biolabs, R0547S) to linearise and remove the 
bacterial backbone from the sequence in a reaction containing 10 µg plasmid, 40 U of PacI enzyme, 
2 μl of the enzyme 10× CutSmart® buffer, and H2O to a total volume of 20 μl and incubated for 3 
hours at 37°C. Digestion products were confirmed by electrophoresis of 750 µg of the digest on a 
0.9% agarose gel. The remaining product was purified by phenol/chloroform extraction and ethanol 
precipitation, and used to make adenovirus. The pAD/ CMV/GFP control plasmid (Pac1 digested, 
phenol/chloroform extracted, and ethanol precipitated) was used to create a control virus.  
HEK293 cells (see Chapter 2) were seeded at density of 1.3 × 106 cells/flask in 25cm2 cell culture 
flasks and incubated overnight until 60-70% confluence was reached. Cells were then transfected 
with 5 µg of digested and purified recombinant adenoviral plasmid (pAD/CMV/GFP control, 
pAD/CMV/FLAG-hLNK, or pAD/CMV/6xHis-TEV JAK2 JH2-JH1) using Lipofectamine 2000 
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s instructions. Transfected cells 
were monitored for cytopathic effect and collected 7–10 days after transfection until the majority of 
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cells showed morphology changes indicating significant virus production within the cells. Cell were 
collected by dislodging from the flask by agitation, and centrifuged at 300g for 5 minutes. Supernatant 
was removed so that the final volume was approximately 10-15 ml. Adenovirus was released from 
cells by three cycles of freeze/thaw and virus titer was determined.  
 
Adenovirus Titration by Expression Test 
HeLa cells were seeded with 0.5 × 106 cells/well in a 6-well culture plate and incubated overnight at 
37°C in a humidified 5% CO2 incubator until 70-80% confluence was reached. Increasing volumes 
of virus was used to infect cells in respective wells (no infection, 10 µl, 20 µl, 30 µl, 40 µl, or 50 µl). 
Cells were monitored after 48 hours for morphological changes. Subsequently, the cells were washed 
once with ice-cold PBS and detached using PBS (containing 1 mM EDTA), and centrifuged. The cell 
pellets were resuspended and lysed using lysis buffer pH 7.4 (50 mM Tris HCl, 500 mM NaCl, 1 mM 
EDTA, 15% glycerol, 1% Triton X-100, 1x protease inhibitor) and centrifuged for 20 minutes at 12, 
000g. Supernatant was transferred to a fresh tube and 10 µl of supernatant was mixed with 3x SDS 
sample buffer (containing 0.1 M DTT) and heated to 98°C for 5 minutes before the samples were run 
on SDS-PAGE gel. Western analysis was performed and a suitable amount of virus to be used for 
subsequent experiments were predicted based on the virus titer that caused the least cell death but 
achieve highest protein expression.  
 
Adenoviral Expression of human LNK and human JAK2 JH2-JH1 in Mammalian Cells  
HeLa cells were seeded with 3 × 106 cells/175 cm2 cell culture flask and incubated for 48 hours. 
Based on the ‘adenovirus titration by expression test’ section, appropriate amounts of HEK293 lysate 
from adenoviral production of LNK were used to infect a 70-80% confluent cell culture flask of HeLa 
cells. For co-infection of HEK293 lysate from adenoviral production of JAK2 JH2-JH1, this was 
performed 4-5 hours after initial infection. After 24 hours of incubation at 37°C in a humidified 5% 
CO2 incubator, the cells were washed twice with PBS and fresh DMEM (containing 10% FBS) was 
added containing 2 mM sodium butyrate to enhance protein expression and incubated again for a 
further 24 hours. Cells were washed once with ice-cold PBS and detached using PBS (containing 1 
mM EDTA), and centrifuge. The cell pellets were resuspended and lysed using lysis buffer pH 7.4 
(50 mM Tris HCl, 500 mM NaCl, 1 mM EDTA, 15% glycerol, 1% Triton X-100, 1x protease 
inhibitor) and centrifuged for 20 minutes at 12, 000g. Supernatant was transferred to a fresh tube and 
10 µl of supernatant was mixed with 3x SDS sample buffer (containing 0.1 M DTT) and heated to 
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98°C for 5 minutes before the samples were run on SDS-PAGE gel. Coomassie staining and western 
analysis were performed to analyse recombinant FLAG-hLNK and 6xHis-TEV JAK2 JH2-JH1 
protein expression. Remaining supernatant was used for affinity purification.  
 
Small-scale Affinity Purification of FLAG-tagged Recombinant human LNK (or with His-tagged 
human JAK2 JH2-JH1) 
Supernatant from cleared lysate from adenoviral expression of human LNK (or with human JAK2 
JH2-JH1) in HeLa cells was made to a final volume of 1 ml with lysis buffer (50 mM Tris HCl, pH 
7.6, 300 mM NaCl ,1 mM EDTA, 10% glycerol, 1% Triton X-100 (Sigma), 1× EDTA-free complete 
protease inhibitor ((Roche Applied Science)) and incubated with 100 µl of a 50% slurry of anti-
DYKDDDDK G1 Affinity Resin (GenScript) for 2 hours on a tube rotator at 4°C. Affinity resin was 
then pelleted by centrifugation at 6, 000g for 30 seconds. Resin was then washed three times with 
TBS (50 mM Tris-HCl, pH 7.6, 300 mM NaCl, 10% glycerol). Supernatant was removed and the 
resin was re-suspended in either 3x SDS sample buffer (containing 0.1M DTT) followed by heating 
to 98°C for 5 minutes. Centrifugation was performed at 12, 000g for 5 minutes before the eluate was 
subjected to SDS-PAGE followed by Coomassie staining or western analysis to investigate the 
efficiency of the purification. 
 
Affinity Purification of FLAG-tagged Recombinant human LNK (or with His-tagged human JAK2 
JH2-JH1) 
An increased scale of protein production was performed (8-20 times larger than small-scale). 
Supernatant from cleared lysate from adenoviral expression of human LNK (or with human JAK2 
JH2-JH1) in HeLa cells was made to a final volume of ~9 ml with lysis buffer (see Table 3) and 
incubated in a 2:1 ratio of lysates to resin (with 2× EDTA-free complete protease inhibitor ((Roche 
Applied Science) and DNase I (Roche)) added) for 2 hours on a tube rotator at 4°C. In certain assays, 
2mM activated sodium orthovanadate and JAK2 phosphopeptide (synthesised by Peptide2.0) (at a 
ratio of 3:1 peptide to protein) was added. The sample-resin mix was then transferred to a pre-wet 
column and allowed to flow by gravity at room temperature. The column was washed with 10-20 bed 
volumes of TBS wash buffer pH 7.6 (see Table 3). FLAG-tagged proteins were eluted with 1 column 
volume (CV) of elution buffer (see Table 3) which was added into the column containing 5 ml resin 
and left to incubate for 30 minutes. The eluate was collected and subjected to SDS-PAGE followed 
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by Coomassie staining and western analysis to investigate the efficiency of the purification. Protein 
concentration was estimated by running known concentrations of BSA on the SDS-PAGE. 
 
Table 4: Composition of buffers used for cell lysis, affinity column washes, and elution of 
protein from the column.  
1x Lysis Buffer (TBS pH 7.6) 
Reagents Concentration 
Detergent (OG or Triton X-100) 20 mM OG or 1% Triton X-100 
Tris 50 mM 
NaCl 300 mM, 500 mM, or 1 M 
EDTA 1 mM 
Glycerol 10% or 15% 
Protease inhibitor 1x 
Activated sodium orthovanadate None or final 2 mM 
Tris(2-carboxyethyl)phosphine 
(TCEP)/ DTT  
None or 5 mM 
 
1x Wash Buffer (TBS pH 7.6) 
Reagents Concentration 
Detergent (OG or Triton X-100) 5 mM, 10 mM, or 20 mM OG, or 1% Triton X-100 
Tris 50 mM 
NaCl 300 mM or 1 M 
Glycerol 10%  
Protease inhibitor None or 1x 
Activated sodium orthovanadate None or final 2 mM 
 
500 μg/ml FLAG (LifeTein, USA) Elution Buffer (pH 7.6 or 8.6) 
Reagents Concentration 
Detergent (OG or Triton X-100) 5 mM, 10 mM, or 20 mM OG, or 1% Triton X-100 
Tris 50 mM 
NaCl 300 mM or 500 mM 
Glycerol 10% or 15% 
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Protease inhibitor None or 1x 
JAK2 phosphopeptide None or 3:1 ratio of peptide to protein 
TCEP Final 5 mM 
 
1x Arginine-HCl Elution Buffer (pH 4) 
Reagents Concentration 
Detergent (OG) 20 mM  
Arginine 200 mM 
NaCl 1 M 
Glycerol 10%  
Protease inhibitor 1x 
TCEP Final 5 mM 
 
Size Exclusion Chromatography 
Affinity purified FLAG-tagged hLNK fractions collected following elution with FLAG peptide were 
further purified by SEC on an ÄKTA purifier using a Superdex 200 10/300 GL column (GE 
Healthcare). The column was pre-equilibrated with 2 column volumes of TBS or sodium citrate 
solution (see Table 4). After equilibration, fractions containing the protein of interest were loaded 
into the injection ring (~800µl per injection). SEC chromatogram results (UV absorbance at 280 nm 
(mAU) against elution volume (ml)) were examined and purified protein was further analysed by 
SDS-PAGE followed by Commassie staining and western analysis.  
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Table 5: Composition of buffers used for SEC. 
1x SEC Buffer (TBS pH 7.6 or 8.6) 
Reagents Concentration 
Detergent (OG or Triton X-100) 5 mM OG or 1% Triton X-100 
Tris 50 mM 
NaCl 300 mM or 500 mM 
Glycerol 10% or 15% 
TCEP Final 1 mM 
 
1x SEC Buffer (Sodium Citrate pH 4) 
Reagents Concentration 
Detergent (OG) 20 mM 
Sodium citrate 10 mM 
EDTA 1 mM 
NaCl 1 M 
Glycerol 10%  
TCEP Final 1 mM 
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Results 
 
Creation of LNK constructs for protein expression in E. coli  
 
The human SH2B3 gene was cloned into two different vector backbones, the pET11a vector (with 6x 
His-tag inserted) (Figure 63 A) and pHUE vector (containing 6x Histidine (His)-tag followed by an 
ubiquitin sequence) (Figure 63 B) in order to exploit the benefits of recombinant protein expression 
in E. coli. A 6x His-tag was present in all constructs to facilitate purification of the proteins via affinity 
chromatography. These constructs (Figure 64) were also modified in various ways in an attempt to 
improve protein expression and solubility, such as incorporating ubiquitin sequences (also increases 
protein yield) and truncating the N- and C-terminal regions of LNK that contained hydrophobic rich 
sequences. Some constructs also included a TEV protease cleavage site after the 6x His-tag, to allow 
the His-tag to be cleaved using a TEV protease that recognises the ENLYFQG sequence (enzyme 
cleaves at Q^G). Cleavage of this tag may also be able to improve the purification of the protein. 
Furthermore, presence of the His-tag may also obstruct protein crystallisation and solubility. These 
constructs were all generated using CPEC and have been confirmed by restriction digest and DNA 
sequencing.  
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Figure 63: Representative vector map of the pET11a (A) and pHUE (B) LNK vector constructs. 
A 6x His-tag is present at the N-terminus of the SH2B3 gene to facilitate protein purification. (A) The 
pET11a-6HIS-TEV-hLNK vector series contains the TEV protease cleavage site after the 6x His-tag. 
(B) The pHUE.6His.Ub.hLNK vector contains the ubiquitin gene after the 6x His-tag. Both vectors 
possess the ampicillin resistance gene for bacterial cell selection. The expression of recombinant 
protein is initiated from the T7 promoter. 
 
A 
B 
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Figure 64: Illustration of the various hLNK constructs created for protein expression and 
purification. 
All constructs possess a 6x His-tag followed by an ubiquitin or TEV protease cleavage site. The His-
tag will facilitate protein purification via affinity chromatography. Numbers denote the number of 
amino acids that have been deleted either from the N-terminus (N22, N37) or from the C-terminus 
(C2) of the LNK gene. 
 
Small scale expression of human LNK in E. coli 
 
The hLNK constructs for expression in E. coli were tested in small scale induction for protein 
expression. Initially, each of the pHUE and pET11a hLNK plasmids were transformed into BL21-
Gold (DE3) competent E. coli cells for high-level protein expression. Single colonies for each 
construct were then grown in LB to log phase (OD600 of 0.5 – 0.6) where IPTG induction was 
performed. In the absence of lactose, the lac repressor that is transcribed from the lacI gene present 
in both the DE3 lysogen (in E. coli genome) and plasmid binds to the lac operon. In the presence of 
IPTG, the lac repressors dissociate from both lac operons. This allows the E. coli RNA polymerase 
to initiate transcription of the T7 RNA polymerase from the T7 gene under the control of the lacUV5 
promoter. Subsequently, the T7 RNA polymerase transcribes the target gene in the plasmid under the 
control of the T7lac promoter. This allows for expression of the recombinant protein that can be 
detected by SDS-PAGE with Coomassie staining and/or western analysis. Analysis of induced 
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recombinant protein expression by SDS-PAGE with Coomassie staining was unable to identify 
induced protein with expected protein sizes ranging from 61-72 kDa for any of the constructs (Figure 
65 A). However recombinant protein expression for all constructs could be confirmed using western 
analysis with the anti-His antibody to detect the His-tag at the N-terminus of the LNK gene (Figure 
65 B). This result showed that there is indeed recombinant protein expression but that the level of 
expression was below detection within the E. coli lysate but was able to be detected by the more 
sensitive and specific Western analysis method (low-femtogram-level sensitivity). In order to 
improve expression of human LNK in E. coli a gene sequence was designed and created for optimised 
expression in E. coli [503].  
 
 
 
Figure 65: Protein expression of truncated LNK N-terminal domain constructs in E. coli after 
1mM IPTG induction visualised by (A) Coomassie stained SDS-PAGE and (B) Western 
analysis. 
BL21-Gold (DE3) cells were transformed with hLNK expression constructs in pHUE or pET11a 
vector on ampicillin plates and incubated overnight at 37°C. Single colonies for each construct were 
grown to log phase (OD600 of 0.5 – 0.6) at 37°C. An aliquot of the pre-induction sample was collected 
B 
A 
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followed by induction with IPTG (final concentration 1 mM) for 2.5 hours at 37°C. An aliquot of 
post-induction sample was collected and cell pellets were resuspended with 20% SDS and heated to 
95°C for 15 minutes. Samples were subsequently analysed by SDS-PAGE and western analysis. Anti-
His antibody was used to detect His-tagged proteins. ‘TEV’ denotes constructs in the pET11a vector 
and ‘Ub’ denotes constructs in the pHUE vector. Numbering followed by ‘-N’ denotes the number of 
amino acids that was truncated from the N-terminus of the protein. Arrows show expected size of 
induced protein products.  
 
Protein expression of codon optimised human LNK in E. coli  
 
Since E. coli expression of the human SH2B3 gene (which encodes LNK) was found to be not suitable 
for high level protein expression, a codon optimised sequence of the gene for high expression in E. 
coli was designed and created in an attempt to achieve suitable expression of the human LNK protein. 
The same modifications were made to the codon optimised gene as were previously described for the 
original LNK coding sequence (Figure 66) in order to increase the solubility and expression of the 
translated protein. Analysis of induced expression of the optimised hLNK constructs showed that 
they were still not able to achieve a suitable protein expression level as Coomassie staining of SDS-
PAGE did not indicate any protein expression was induced (data not shown) while western analysis 
showed weakly detected bands at the expected sizes for each protein (Figure 67).  
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Figure 66: E. coli codon optimised LNK constructs for protein expression and purification. 
All constructs possess a 6x His-tag followed by an ubiquitin or TEV protease cleavage site. His-tag 
was included for the purpose of protein purification via affinity chromatography. Numbers denote the 
number of amino acids that have been deleted either from the N-terminus (N22, N37) or from the C-
terminus (C2) of the SH2B3 gene. 
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Figure 67: Protein expression of codon optimised LNK constructs in E. coli. 
BL21-Gold (DE3) cells were transformed with codon optimised hLNK expression constructs in 
pHUE or pET11a vector on ampicillin plates and incubated overnight at 37°C. Single colonies for 
each construct were grown to log phase (OD600 of 0.5 – 0.6) at 37°C. An aliquot of the pre-induction 
sample was collected followed by induction with IPTG (final concentration 1 mM) for 2.5 hours at 
37°C. An aliquot of post-induction sample was collected and cell pellets were resuspended with 20% 
SDS and heated to 95°C for 15 minutes. Samples were subsequently analysed by SDS-PAGE and 
western analysis. Anti-His antibody was used to detect His-tagged proteins. ‘TEV’ denotes constructs 
in the pET11a vector and ‘UB’ denotes constructs in the pHUE vector. Numbering followed by ‘-C’ 
denotes the number of amino acids that was truncated from the C-terminus of the protein. (A, C, E) 
Coomassie-stained SDS-PAGE (B & D) Whole cell lysate western analysis using anti-His antibody. 
Arrows show the expected size of the constructs: TEV WT (CO) (64.8 kDa), TEV (-N22) (CO) (62.91 
kDa), TEV (-N37) (CO) (61.28 kDa), TEV (-C2) (CO) (64.5 kDa), Ub WT (CO) (74 kDa), Ub (-
N22) (CO) (71.87 kDa), Ub (-N37) (CO) (70.24 kDa), and Ub (-C2) (CO) (73.6 kDa).  
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Protein expression of human LNK in mammalian cells  
 
As expression of various human LNK constructs in E. coli were found to all give very low expression 
levels, protein expression of hLNK was tested in a mammalian system. The hLNK gene (with an N-
terminal FLAG-tag) was cloned into an adenovirus vector (pAD/CMV/V5) whereby hLNK is under 
the control CMV promoter to give constitutive high expression [504]. This plasmid was used to make 
adenovirus type 5 by transfecting HEK293 cells and the resulting adenovirus was harvested from 
these cells and was used to infect HeLa cells for two days. Analysis of proteins from virus infected 
HeLa cells compared to uninfected HeLa cells by Coomassie stained SDS-PAGE showed a 
significant induction of protein expression at the expected size of LNK (Figure 68 A). This band was 
confirmed to be LNK by western analysis (Figure 68 B). One of the advantages of using the 
mammalian system to express a mammalian protein over the E. coli system for protein expression is 
that the proteins can attain their in situ modifications and correct folding due to the presence of 
chaperones [505-508]. However, the negatives to mammalian expression systems include that they 
are typically costlier and commonly difficult to obtain high levels of expression in mammalian cells 
compared to using bacterial protein production systems. 
 
 
Figure 68: Adenovirus expression of FLAG-hLNK protein in HeLa cells. 
HeLa cells (8 × 106 cells) were infected with adenovirus carrying the FLAG-hLNK gene and 
harvested 2 days after infection. (A) Coomassie stained SDS-PAGE of whole cell lysate. Arrow 
shows expected size of of FLAG-hLNK WT (64 kDa); (B) Whole cell lysate western analysis using 
anti-FLAG antibody.  
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Purification of FLAG-tagged human LNK by affinity chromatography 
 
A protein expression and purification workflow using a mammalian system was developed to express 
and purify human LNK (Figure 69). After confirming the expression of the LNK protein, a small-
scale purification using FLAG resin (anti-DYKDDDDK monoclonal antibodies coupled to agarose 
matrix resin) was performed. This small-scale purification was initially performed using an 
immunoprecipitation-based method to determine whether the expressed FLAG-tagged LNK can bind 
the FLAG resin effectively. 
 
 
Figure 69: Workflow of LNK protein expression and purification. 
Protein purification via immunoprecipitation showed that LNK was able to be purified to a high level 
(Figure 70). Two non-specific bands of smaller molecular weight than LNK were also observed on 
SDS-PAGE for proteins specifically bound to the anti-FLAG resin (Figure 70 A). The same size non-
specific bands were also observed in the control sample (Figure 70 A). It was speculated that the 
lowest band (~50 kDa) is likely from the denatured heavy chain of the antibody that was released 
from the resin when the slurry was mixed with SDS sample buffer containing DTT prior to SDS-
PAGE. This was expected to occur when eluting protein via this method. The other significant non-
specific band was possibly a non-specific protein produced by HeLa cells that has some affinity to 
the monoclonal antibody on the resin. Increasing the number and stringency of washes could 
potentially reduce or eliminate binding of this non-specific protein from the FLAG resin. Size 
exclusion and/or ion exchange chromatography may also help in removing the non-specific protein. 
Degradation of LNK also appeared minimal, which should allow for efficient protein purification. 
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Figure 70: Purification of FLAG-hLNK protein using an immunoprecipitation-based method. 
(A) Coomassie stained SDS-PAGE; (B) Western analysis. HeLa cells (8 × 106 cells) were infected 
with FLAG-hLNK adenovirus and harvested 2 days after infection. FLAG-hLNK was purified 
according to the manufacturer’s protocol (GenScript). Whole cell lysate was added to the washed 
resin and mixed using a rotator for 2 hours at 4°C. The resin-sample was centrifuged at 6,000g for 30 
seconds and washed thrice. Bound proteins were eluted using 6x SDS sample buffer (containing 0.1M 
DTT). Arrows show the expected size of FLAG-hLNK WT (64 kDa). (A) Lane 1 shows purification 
of control samples (total cell lysate from HeLa cells with no infection) (1 µl loaded on the gel); lane 
3 shows purification of control samples (15 µl loaded on the gel); lane 5 shows purification of FLAG-
hLNK samples (total cell lysate from HeLa cells infected with FLAG-hLNK adenovirus) (1 µl loaded 
on the gel); lane 7 shows purification of FLAG-hLNK samples (15 µl loaded on the gel); lane 9 shows 
the flow-through from control samples; lane 10 shows FLAG-hLNK flow-through; lane 11 shows 
first wash of FLAG-hLNK samples after flow-through; lane 12 shows second wash of FLAG-hLNK 
samples after flow-through; lane 13 shows third wash of FLAG-hLNK samples after flow-through. 
(B) Lane 1 shows purification of control samples; lane 3 shows purification of FLAG-hLNK samples; 
lane 5 shows the flow-through from control samples; lane 7 shows FLAG-hLNK flow-through; lane 
9 shows first wash of FLAG-hLNK samples after flow-through; lane 10 shows second wash of 
FLAG-hLNK samples after flow-through; lane 11 shows third wash of FLAG-hLNK samples after 
flow-through. Denatured heavy chain of antibody is marked by asterisks (*). 
 
Subsequent protein purification was performed using column chromatography in order to improve 
resin washes. A caveat of using the immunoprecipitation method is that non-specific proteins are 
more difficult to be removed due to lack of a continuous washing. Using the column method will also 
help in removing precipitated proteins. For this column chromatography, concentrated FLAG peptide 
was used for elution to competitively elute the FLAG tagged LNK in order to achieve high 
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purification efficiency rather than other methods such as alkaline buffer, acidic buffer, neutral elution 
buffer (~pH 7), elution with SDS and DTT buffer). However, the initial small scale test did not reveal 
LNK detection by Coomassie stained SDS-PAGE (Figure 71 A), although western analysis showed 
the presence of the FLAG-hLNK protein in the eluate (Figure 71 B) and also in the flow-through and 
washes (Figure 71 B). This suggested that there may be insufficient time for the protein to bind to the 
resin using this column method. More LNK protein was observed in the first elution (without 
incubation with resin) than in the elution after 60 minutes incubation with resin (Figure 71 B). This 
result suggests that the FLAG peptide was efficient in eluting the FLAG-tagged protein in such a 
short time. As a much higher volume of elution buffer was used compared to the initial purification 
test with elution using SDS sample buffer with DTT, this likely contributed to the undetectable 
protein band in Coomassie due to the purified protein being too dilute. 
 
     
Figure 71: Small scale test of FLAG-hLNK protein purification by affinity column 
chromatography. 
(A) Coomassie stained SDS-PAGE; (B) Western analysis.  HeLa cells (8 × 106 cells) were infected 
with FLAG-hLNK adenovirus and harvested 2 days after infection. FLAG-hLNK was purified 
according to the manufacturer’s protocol. Regenerated FLAG resin was first added to the column. 
Samples were then loaded and the column was washed several times. 500 μg/ml of the FLAG peptide 
elution buffer was then added into the column (competitive elution) and the eluate was immediately 
collected together with the second wash step (first elution). Another 500 μg/ml of the FLAG peptide 
elution buffer was added into the column and left to incubate for an hour at room temperature. After 
incubation, the eluate was collected (second elution). (A) Lane 1 shows second elution of FLAG-
hLNK samples (8 µl loaded on the gel); lane 2 shows second elution of FLAG-hLNK samples (30 µl 
loaded on the gel); lane 4 shows FLAG-hLNK flow-through; lane 5 shows first wash of FLAG-hLNK 
samples after flow-through; lane 6 shows second wash of FLAG-hLNK samples after flow-through 
and first elution. (B) Lane 1 shows second elution of FLAG-hLNK samples; lane 2 showsFLAG-
hLNK flow-through; lane 3 shows first wash of FLAG-hLNK samples after flow-through; lane 4 
shows second wash of FLAG-hLNK samples after flow-through and first elution.  
A. B. 
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In order to enhance protein purification efficiency, a combination of batch binding and column 
purification was tested. The batch binding method was utilised for protein capture by the resin to 
allow the FLAG tagged LNK to have a longer contact time with the resin (2 hours at 4°C on a tube 
rotator). The lower temperature used may also increase binding efficiency. After the binding step, the 
bound resin was then loaded into the column and washes were performed in the column. FLAG 
peptides were then used to elute the bound protein, however purified LNK was still not able to be 
detected on Coomassie stained SDS-PAGE (Figure 72 A). Following this purification procedure, 
some of the beads were subsequently denatured in SDS sample buffer (containing DTT) to determine 
if LNK had been successfully eluted or if a large amount of the protein was still bound to the resin. 
A very weak band was visible by Coomassie stained SDS-PAGE at the molecular weight for LNK 
(Figure 72 A), however this result was not unexpected as this elution method is much harsher than 
using the FLAG peptide with a much more concentrated amount of protein run on the gel. In this 
purification test, non-regenerated resin was used. Therefore, some of FLAG peptide used for previous 
elution may still have been bound to the resin resulting in reduced capture of FLAG-tagged LNK.  
 
  
Figure 72: Small-scale batch binding and column affinity chromatography of FLAG-hLNK 
protein. 
(A) Coomassie stained SDS-PAGE; (B) Western analysis. HeLa cells (8 × 106 cells) were infected 
with FLAG-hLNK adenovirus and harvested 2 days after infection. FLAG-hLNK was purified 
according to the manufacturer’s protocol. Samples were added to the washed non-regenerated resin 
and mixed using a rotator for 2 hours at 4°C. The resin-sample were then loaded into the column and 
the column was washed several times. One column volume of 500 μg/ml FLAG peptide elution buffer 
was added into the column and left to incubate for an hour at room temperature. After incubation, the 
eluate was collected (first elution). Another 500 μg/ml of the FLAG peptide elution buffer was added 
into the column and the eluate collected immediately (second elution). (A) Lane 1 shows whole cell 
lysate; lane 2 shows first elution of FLAG-hLNK samples (4 µl loaded on the gel); lane 3 shows first 
A. B. 
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elution of FLAG-hLNK samples (30 µl loaded on the gel); lane 4 shows second elution of FLAG-
hLNK samples; lane 5 shows FLAG-hLNK flow-through; lane 7 shows first wash of FLAG-hLNK 
samples after flow-through; lane 8 shows second wash of FLAG-hLNK samples after flow-through; 
lane 9 shows elution using SDS sample buffer added to beads after the purification procedure. (B) 
Lane 1 shows whole cell lysate; lane 2 shows first elution of FLAG-hLNK samples; lane 3 shows 
second elution of FLAG-hLNK samples; lane 5 shows first wash of FLAG-hLNK samples after flow-
through; lane 6 shows second wash of FLAG-hLNK samples after flow-through; lane 7 shows third 
wash of FLAG-hLNK samples after flow-through; lane 8 shows FLAG-hLNK sample flow-through; 
lane 9 shows elution using SDS sample buffer added to beads after the purification procedure.  
 
Larger scale protein purification methods of LNK focused on using batch binding (with regenerated 
resin) followed by column chromatography. This method was able to successfully purify LNK (data 
not shown). Furthermore, after several optimisations of the purification method and by performing 
large-scale protein expression, high protein yield and purity of LNK was achieved (Figure 73). The 
fraction eluted purified LNK were subsequently subjected to SEC for further purification and to 
determine how the FLAG-hLNK protein behaves in an aqueous environment.  
 
Figure 73: Purification of FLAG-hLNK protein using batch binding followed by large-scale 
column chromatography. 
Twenty 175 cm2 cell culture flasks of HeLa cells (8 × 106 cells/flask) were infected with FLAG-
hLNK adenovirus and harvested 2 days after infection. FLAG-hLNK protein was purified according 
to the manufacturer’s protocol. Samples were added to the washed regenerated resin and mixed using 
a rotator for 2 hours at 4°C. The resin-samples were then loaded unto the column and the column was 
washed several times. One column volume of 500 μg/ml of the FLAG peptide elution buffer was 
added into the column and one column volume of eluate was collected (first elution).The FLAG 
peptides were left to incubate for 30 minutes at room temperature. After incubation, another column 
volume of eluate was collected (second elution). For each elution, ten fractions of 500 µl/ fraction 
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were collected. Coomassie stained SDS-PAGE above shows first (lanes 1-7) and second elution 
fractions (lanes 8 & 9).  
Size-exclusion chromatography (SEC) of purified human LNK 
 
The scale of protein expression was increased in order to obtain more protein for downstream 
purification and crystallisation trials of LNK. Although  purity of LNK via affinity chromatography 
was shown to be at a high level, the protein was subjected to further purification with SEC using 
Superdex 200 increase 10/ 300 GL column in conjunction with the ÄKTApurifier (GE Healthcare 
Life Sciences)) to remove any remaining impurities and FLAG peptide from the elution. The SEC 
was also performed to determine how the protein behaves in the aqueous environment. However, 
protein dilution will occur due to diffusion as it goes through the column although subsequent protein 
concentration can be performed by collecting elution peaks. Through SEC, we will be able to 
distinguish between soluble protein aggregates and their different oligomeric forms. By using a 
calibration plot with protein standards of known molecular weights against elution fraction volume 
(Figure 74), an estimation of the purified protein size can be determined and the degree of 
oligomerisation and aggregation can be identified. In addition, the purified protein can be separated 
from FLAG peptides, contaminating proteins of different sizes, and protein aggregates.  
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Figure 74: SEC calibration curve for protein standards. 
Two different chromatograms are shown, a) based on product manual (Gel Filtration Calibration 
product manual (GE Healthcare)) and b) based on standard proteins in our buffer of interest. 
Calibration curve chromatogram is plotted using absorbance (mAU) against the elution volume (ml). 
 
Prior to analysing the purified protein using SEC, the fractions from affinity chromatography that 
contained higher amounts of LNK protein (based on SDS-PAGE) were pooled and concentrated using 
Amicon® Ultra-15 Centrifugal Filter Units (Merck Millipore). However, protein precipitation was 
observed upon concentration. As contaminants remaining in the FLAG peptide eluted fractions may 
contribute to precipitation of the purified LNK, protein concentration prior to SEC was not performed 
in subsequent purifications. SEC was conducted in Tris buffer pH 8.6 (50 mM Tris, 500 mM NaCl, 
15% glycerol, 1 mM TCEP) with a flow rate of 0.3 ml/min. Desired fractions were collected and 
analysed on SDS-PAGE. These fractions were confirmed to contain LNK by western analysis (Figure 
75 A and B). LNK was also observed to exist as several oligomeric states including monomers, 
dimers, and oligomers based on the chromatogram (Figure 75 A). These fractions were confirmed to 
A. 
B. 
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be the different oligomeric states via native-PAGE western analysis (Figure 75 C) and confirmed to 
be LNK via SDS-PAGE and western analysis showing a single band of the expected size. The protein 
amount in peak 3 may be too low to be detected by western analysis or this peak may have represented 
a contaminating protein (Figure 75 B). Based on the calibration curve (Figure 74 B), we would expect 
monomeric LNK to be eluted at ~14.2 ml, dimers to be eluted at ~13 ml, and larger oligomeric forms 
to be eluted at a later elution.  
 
 
             
Figure 75: Purified LNK exists as different oligomeric states; 
A) SEC chromatogram, B) Western analysis SDS-PAGE of peaks, C) Western analysis native-PAGE 
of peaks. Peak 1 is the size of oligomer (~11.8 ml), peak 2 is the size of dimer (~12.8 ml), peak 3 is 
the size of monomer (~14.3 ml). Soluble aggregates elute in the void volume. D) Western analysis 
SDS-PAGE of soluble aggregates from a separate experiment. 
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Although soluble LNK protein was observed in different oligomeric states via SEC, the amount of 
protein was insufficient for further analysis and a significant portion of protein eluted in the void 
volume indicating they are existing as soluble aggregates (Figure 75 A and D). Adaptation of HeLa 
cells to suspension culture was attempted in order to increase the scale of cell culture and hence 
protein production, but this was unsuccessful. Larger scale protein expression using adherent HeLa 
cells was subsequently performed in order to obtain more protein for further characterisation. 
However, the increased amount of protein led to more protein aggregation after FLAG elution (data 
not shown). As protein precipitation was also an issue, a range of low to high pH was used to 
determine if the precipitated protein was able to be re-solubilised. Precipitates appeared to solubilise 
when resuspended in high pH buffers such as pH 11.16 and pH 12.21 and LNK was confirmed to be 
present in the solubilised portion (Figure 76). Although some proteins are still able to maintain proper 
folding at high pH, typically, protein unfolding can occur at approximately pH 10 [509]. However, 
in order to prevent disruption of protein structure and function due to very high pH and due to the 
sensitivity of the FLAG affinity column to extreme pH (due to the antibodies present on the resin), a 
lower pH of 8.6 was used for the elution of the protein. Furthermore, in order to reduce aggregation, 
it was important to choose a pH that is further away from the isoelectric point (pI) (either more acidic 
or basic) as this is typically more soluble for proteins [510-512]. For LNK, the predicted pI is ~pH 
6.5 and its net charge at pH 7.4 is -7.27. Therefore, in pH 8.6, LNK protein is predicted to be soluble.  
 
Figure 76: Precipitated LNK was able to be re-solubilised using high pH solution (pH 11.16 and 
12.21) shown by Coomassie stained SDS-PAGE. 
The buffer containing precipitated protein obtained after FLAG affinity purification was centrifuged 
at 12, 000g for 5 minutes. A range of low to high pH of TBS buffer (50 mM Tris, 500 mM NaCl, 
15% glycerol) was used to solubilise each separate pellet. Solubilised protein were mixed with 3x 
SDS sample buffer (containing 0.1 M DTT) and heated to 98°C for 5 minutes before the samples 
were run on SDS-PAGE gel and Coomassie stain performed. 
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Besides using a higher pH in the FLAG elution buffer, the non-ionic detergent Triton X-100 was 
added to the wash and elution buffer to improve protein solubility and also to improve purity. 
Unfortunately, the presence of Triton X-100 poses several difficulties in purification, analysis, and 
crystallisation. Triton X-100 has a significant absorbance at 280nm which is used to monitor protein 
elution by SEC.  This causes interference with the quantification, quality assessment, and is also 
known to impair the ability of proteins to crystallise [513-515] although there have been records of 
proteins that have been crystallised with Triton [516]. Triton X-100 also has a very low critical 
micelle concentration (CMC) of 0.02% and its micelle size can range from 85 to 150 kDa depending 
on the pH and molarity of the buffer that it is in [515]. The micelle size can also be affected by 
temperature [517]. The strong absorbance of Triton at this wavelength has resulted in Triton micelles 
Figure 37 masking the area where the protein presumably elutes [515]. Hence, it was difficult to 
determine if the protein of interest is indeed present based on the SEC chromatogram or if they are 
present, estimation of the protein concentration would not be accurate. However, running the elution 
fractions on SDS-PAGE may be informative regarding the presence of the protein of interest and 
estimation of protein concentration.   
 
 
Figure 77: SEC of Triton X-100. UV trace showing Triton X-100 peak with high absorbance at 
280 nm which would overlap with elution peaks for LNK. 
 
Incubation of soluble aggregates with 1% Triton X-100 was found to resolve the aggregates into 
various soluble oligomeric states (Figure 78 A) at least in the case where these proteins were in an 
alkaline solution, sodium carbonate-bicarbonate buffer pH 9.7. This phenomenon was not observed 
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in acidic pH buffers such as sodium citrate buffer pH 5, however this may have been due to the 
amount of protein being too low to be detected by western analysis (Figure 78 B). As the SEC was 
equilibrated with buffer containing Triton X-100, the UV reading dropped to below 0 (negative 
values) as the Triton was diluted when the samples were put through the run (Figure 78). 
Nevertheless, some of the observed peaks were confirmed to be LNK through SDS-PAGE. Elution 
at ~10.8 ml (Figure 78 A, peak 1) appeared to be the size of an oligomer with six LNK subunits 
whereas elution at ~13 ml appeared to be the size of a LNK homodimer (Figure 78 A; peak 3). Peak 
2 may be the Triton peak (Figure 78 A). As Triton X-100 micelle size is known to change with 
different buffers, temperature, and pH [515, 517], this can complicate the prediction of location of 
the protein peak.  
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Figure 78: Addition of 1% Triton X-100 resolves soluble LNK aggregates into various 
oligomeric states in alkaline buffer conditions. 
A) SEC UV trace of LNK protein aggregates in sodium carbonate-bicarbonate buffer pH 9.7. B) SEC 
UV trace of LNK protein aggregates in sodium citrate buffer pH 5. Protein aggregates were incubated 
with Triton-X100 (final concentration of 1%) in either sodium carbonate-bicarbonate buffer pH 9.7 
or sodium citrate buffer pH 5 and allowed to incubate on ice for 30 minutes before subjecting to SEC. 
Peaks 1 and 3 (marked by asterisks) were confirmed by western analysis to be LNK. LNK monomer 
is expected to be ~64 kDa. 
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Protein quality assessments and crystallisation trials of human LNK 
 
Purified full length human LNK expressed in HeLa cells and purified by FLAG affinity 
chromatography followed by SEC in the presence of Triton X-100, was assessed for indications of a 
structured protein and the ability to form protein crystals. This work was performed at Bio21 
Molecular Science & Biotechnology Institute (University of Melbourne) in collaboration with the 
group led by Professor Michael Parker, by Dr Steffi Cheung Tung Shing. Quality assessments such 
as dynamic light scattering (DLS) [518-522], differential scanning fluorimetry (DSF) [523-531], and 
circular dichroism (CD) spectroscopy assays [532-536] were performed. DLS provides an indication 
of the size and size distributions of molecules and particles whereas DSF monitors protein unfolding 
events and hence determines the thermal stability of proteins. One of the applications of DSF is to 
identify a stable buffer for the target protein. CD assays can be used to determine if the protein of 
interest contains secondary structure i.e. whether the protein is folded.  
DLS analysis of purified LNK indicated a homogeneous population (a positive sign for protein 
crystallisation) with a hydrodynamic diameter of ~10-20 Angstrom [537] (Figure 79 A). Aggregates 
usually have a larger hydrodynamic diameter. However, there was no clear indication whether the 
protein was properly folded or unfolded through DSF and CD spectroscopy assays due to interference 
from the presence of Triton (Figure 79 B and C). Despite this, crystallisation trials were initiated with 
3 crystallisation screening trays for which crystals were formed after about 1 month of seeding (Figure 
80). Unfortunately, despite the growth of the crystals, these did not show suitable diffraction when 
analysed at the Australian synchrotron research facility. Therefore, no information regarding the 
structure of LNK was able to be determine. Further optimisation was not possible due to insufficient 
protein.  
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Figure 79: LNK protein quality assessment; 
a) DLS, b) CD, and c) DSF. DLS indicated a homogeneous population. DSF and CD spectroscopy 
assay results were uninformative due to noise from Triton. 
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Figure 80: Example of one of the LNK protein crystals that were formed during crystallisation 
trials. 
 
Optimisation trials to increase soluble fractions of LNK protein 
 
In order to proceed with potential crystallisation studies, different conditions were tested to attempt 
to achieve a higher yield of soluble fractions of LNK. Due to difficulties posed with the incorporation 
of Triton X-100 into LNK buffers, Triton X-100 was removed from the wash used in the last half of 
the protocol, and from the elution buffer used for FLAG affinity chromatography. However, the 
absence of detergent appeared to result in severe protein aggregation as indicated on the SEC 
chromatogram (data not shown).  
Octyl glucoside (OG) was chosen as an alternative detergent as it has a higher CMC than Triton X-
100 (therefore, usage of higher concentration of detergent is made possible without the formation of 
micelles) and micelles are smaller in size (~25kDa) compared to LNK. Furthermore, OG has a very 
weak absorbance at 280nm unlike Triton X-100. Therefore, the use of OG should not affect 
interpretation of the SEC chromatogram and allow for more accurate estimate of the protein 
concentration. In addition, OG can also be removed by dialysis. The incorporation of a peptide 
(F809TPD(phosphoY)ELLTEND820) corresponding to the sequence of JAK2 comprising the 
phosphorylated tyrosine (pTyr 813) which is known to bind LNK [278] was employed in the 
purification method in an attempt to help stabilise the structure of the LNK protein [500, 538-541]. 
This phosphor-peptide was used at an estimated molar ratio of 3:1 (peptide to protein). Protease 
inhibitors were also incorporated into several steps of subsequent protein purification as rapid 
degradation of affinity purified LNK was apparent within a few days even at 4⁰C. However, analysis 
of purified protein showed that the use of OG, incorporation of JAK2 phosphopeptide, and addition 
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of protease inhibitors into different steps of purification did not significantly improve the soluble 
fraction of LNK (data not shown).  
Since purification using Triton X-100 appeared promising due to the previous indication of formation 
of LNK protein crystals, further optimistation of protein purification with Triton X-100 was tested. 
In order to prevent the presence of Triton X-100 to cause problems in protein quality assessment and 
crystallisation studies, a gradual removal of Triton X-100 after affinity purification using the 
Amicon® Ultra-15 Centrifugal Filter Units (Merck Millipore) was performed. However, during this 
process, a significant amount of protein was lost and running the remaining LNK protein through 
SEC further diluted the protein and no further informative results based on the SEC chromatogram 
could be determined (data not shown). The use low pH elution was also investigated as using buffers 
with pH more than one unit below or above the pI of LNK (pI 6.4) is thought to change the charge 
on the protein surface and increase solubility [510-512]. However, the soluble protein fractions did 
not significantly improve following this elution method at low pH (data not shown). 
After several attempts of not being able to obtain a significant yield of soluble protein, affinity 
purified LNK fractions were investigated for optimal buffers (containing no Triton X-100) for protein 
solubility (performed by Dr Steffi Cheung Tung Shing, Bio21). However, DLS indicated that LNK 
was heterogeneous, with aggregates (data not shown). Also, there was no clear unfolding event using 
DSF which may suggest that the protein is unfolded and aggregated (data not shown). As LNK may 
be stabilised by binding to its partner, JAK2, combining these two proteins after expression and before 
carrying out affinity purification may be beneficial. This can also allow for LNK/JAK2 co-
crystallisation. Alternatively, co-expression of the JAK2 JH2-JH1 domains with LNK in HeLa cells 
followed by affinity purification was performed. Unfortunately this attempt appeared to show very 
low binding of LNK to the FLAG affinity column. However, this may simply have been due to the 
frequent regeneration of the resin and loss of anti-FLAG antibody that is able to capture the FLAG-
tagged LNK (Figure 81 A). Coomassie stained SDS-PAGE showed two bands where band 1 
correlates to the expected size of LNK whereas band 2 may just be degraded LNK protein (Figure 81 
A). Furthermore, the JAK2 JH2-JH1 domain did not appear to bind to LNK under the conditions used 
for the affinity chromatography (Figure 81 B). Due to time constraint, further optimisation of the 
protein expression and purification was not possible. 
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Figure 81: Reduced efficiency of FLAG resin binding to LNK protein and the inability of the 
co-expressed JAK2 to bind to LNK. 
Twenty flasks of HeLa cells (8 x 106 cells/flask) were infected with FLAG-hLNK adenovirus and 
incubated for 4-5 hours before infecting with JAK2 JH2-JH1 adenovirus. Cells were harvested 2 days 
after infection. FLAG-hLNK was purified according to the manufacturer’s protocol. Samples were 
added to the washed resin and mixed using a rotator for 2 hours at 4⁰C. The resin-sample were then 
loaded into the column and the column was washed several times. One column volume of 500 μg/ml 
of the FLAG peptide elution buffer was added into the column and one column volume of eluate was 
collected (first elution).The FLAG peptides were incubated for 30 minutes at room temperature. After 
incubation, another column volume of eluate was collected (second elution). For each elution, 10 
fractions of 500 µl/ fraction were collected. A) Coomassie gel shows first elution fractions (band 1: 
hLNK, band 2: degraded LNK).  Western analysis (B & C) shows lane 1: cell lysate after lysis; lane 
2: flowthrough of affinity chromatography; lane 3: cell pellet after cell lysis; lane 4: FLAG resin after 
column washes; lane 5: fraction 1 of first elution; lane 6: fraction 2 of first elution; lane 7: fraction 3 
of first elution. Expected size of FLAG-hLNK is 64 kDa and for JAK2 JH2-JH1 is 71 kDa. Anti-
JAK2 antibody was used to detect JAK2 JH2-JH1 whereas anti-FLAG was used to detect FLAG-
hLNK protein. 
 
A
. 
B. C. 
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Discussion 
Currently, the crystal structure of LNK has not been solved and this is one of the main reasons that 
has contributed to the lack of understanding of LNK as a negative regulator of receptor signalling. To 
fill this gap, protein expression and purification of LNK was performed. Limited protein yield as well 
as solubility of the protein were the main issues, demonstrating that this was a challenging goal.  
Initially, the E. coli expression system was used for expression of the human LNK protein. However, 
a suitable protein expression level was unable to be achieved even when E. coli codon optimisation 
of the LNK gene was used as it did not significantly enhance protein expression for reasons that could 
not be determined. Therefore, a mammalian system using adenovirus infection of the gene was 
attempted. The rational for using adenovirus infection is that it is more cost efficient compared to 
large transient transfections, it represents an efficient gene delivery system, amplification of 
adenoviruses is straightforward, and it provides higher protein expression compared to stable cell 
lines. For adenovirus infection, multiple copies of gene can be introduced into the cell for multiplicity 
of infection (MOI) that is greater than one whereas stable cell lines can develop promoter silencing. 
However, utilising adherent cell culture for protein expression was a limiting factor to the yield of 
protein that was able to be obtained as it was impractical to harvest very large amounts of adherent 
cells. Due to this limitation, alternatives for cell culture were surveyed. This included using adherent 
cells that have been adapted for suspension culture for high yield protein expression. However, 
commercially available transformed suspension cells such as Chinese Hamster Ovary (CHO) and 
HEK293 cells were not suitable for the adenoviral expression system although these cells are 
commonly used for high level protein expression. The use of adenovirus to infect HEK293 cells will 
generate more virus and result in a cytopathic effect that deemed this cell line unsuitable for the 
purpose adenoviral-mediated protein expression. Parental CHO cells on the other hand have low 
susceptibility for infection with adenoviruses type 5 [542]. These commercially available adapted 
suspension cells are also expensive and require special media which significantly adds to the cost of 
protein production. Hence, HeLa cells were chosen for protein expression although the infection of 
mammalian HeLa cells with adenovirus is not a common method for protein expression and 
purification. HeLa cells were used as they have efficient cell proliferation that is able to express 
foreign genes to a high level and are suitable and permissive for adenovirus type 5 infection. 
Therefore, this cell line was attempted to be adapted for suspension culture. Adaptation to suspension 
culture was performed by gradual serum depletion in the cell culture media and culturing the cells in 
flasks with gentle motion. Initially, HeLa cells were successfully adapted to culturing in 1% FBS 
instead of 10% FBS. Some changes in the morphology of the cells were observed where cells looked 
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almost spherical but still clumping to each other (data not shown). However, these cells did not 
survive for long. It was speculated that the short amount of time given for adaptation may have caused 
the death of the cells. Nevertheless, this effort was discontinued as this adaptation procedure was not 
time efficient and it was uncertain if there will be any significant change in the biology of the cells 
that might affect protein production. Therefore, adherent HeLa cells were used for the purpose of this 
study.   
Significant problems were faced with purified LNK forming insoluble as well as soluble aggregates 
which subsequently reduced the yield of soluble protein for further analysis. Various methods were 
employed in an attempt to improve protein aggregation which included using different detergents 
(OG and Triton X-100), pH buffers, and salt concentrations. Rapid degradation of affinity purified 
LNK was also identified as a significant issue, therefore protease inhibitors were added into each step 
before affinity purification and SEC was subsequently performed in a short timeframe after affinity 
purification. A JAK2 phosphopeptide was also used in different stages of the LNK purification in 
order to help with low protein expression, protein stability, and improve the likelihood of 
crystallisation. This JAK2 phosphopeptide has been successfully used in small angle X-ray scattering 
(SAXS) assay to solve the structure of recombinant purified SOCS3 SH2 domain in complex with 
the gp130 phosphopeptide [538]. However, all efforts of the various optimisation methods that were 
performed did not significantly improve purified LNK solubility.  
The most successful purification of LNK was with the incorporation of the detergent, Triton X-100. 
As LNK contains a PH domain that binds to the cell membrane containing phosphoinositides [278, 
285], this domain is suspected to have a hydrophobic surface and therefore non-ionic detergents such 
as Triton X-100 and OG may help in preventing the protein from sticking together and forming 
aggregates (thereby improving solubility). A secondary structure prediction of LNK using Phyre2 
predicted that this protein may be highly disordered (69% disordered) (Figure 82 B). A surface charge 
potential analysis also found that LNK is only moderately charged at the surface at pH 6.4 (Figure 82 
A). These properties of LNK may explain why LNK requires a detergent such as Triton X-100 to 
remain soluble and reduce the formation of large protein aggregates. The ability of Triton X-100 to 
resolve the soluble aggregates into soluble oligomeric states also supports the notion that Triton X-
100 does help to prevent or disrupt LNK protein aggregation. Other mechanisms to enhance protein 
solubility besides using detergent is to include solubility tags, deleting hydrophobic regions of the 
protein, and expressing only the important domains of the protein e.g. the Pro/DD. However, it was 
shown that the dimerisation domain from the related protein, APS by itself was found to produce 
some higher-order aggregates [306]. Some other alternatives may include optimisation of co-
expression with JAK2, using high-throughput scans to identify suitable buffer conditions for the 
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protein [543-545], and using a phosphoinositide reagent such as inositolhexakisphosphate (InsP6) to 
mimic lipid membrane for PH domain binding. As LNK contains a PH domain that may assist in co-
localisation and engage in binding to the lipid membrane of the cells, the InsP6 which is a 
phosphoinositide head-group mimic [546] can therefore be used to mimic the phosphoinositides 
present in the lipid membrane which may aid in the solubility of the LNK protein. Previously, a 
crystal structure of the C2 domain of class II PI3K-C2α has been solved with InsP6 [546]. 
Furthermore, antibody fragments (Fab, scFv, VHH, and Fv) can be added to proteins to help stability 
and solubility, as well as greatly enhancing protein crystallisation by expanding the hydrophilic 
surface area [547], and structure solving  [548-551]. To improve protein yield, utilising another 
expression system such as the insect expression system may be beneficial [494] or alternatively using 
large scale bioreactors for mammalian cell culture [552]. 
              
Figure 82: Secondary structure prediction of LNK using PHYRE2. 
A) Electrostatic surface potential map. LNK is moderately charged at the surface. The surface 
potential is designated in red (−82.385) or blue (+82.385) (red for negative-charge, white for neutral, 
blue for positive-charge). B) Secondary structure prediction. LNK is predicted to be highly disordered 
(69% disordered) with limited structured regions containing α-helices and β-sheets. PHYRE2 
analysis was performed by Dr Steffi Cheung Tung Shing. 
 
Various detergents have been used for the purification and crystallisation of membrane proteins. This 
includes three different groups of conventional detergents: ionic, zwitterion, and non-ionic. Non-ionic 
detergents such as Triton X-100 and OG (alkyl glucopyranosides) were used in this study as they are 
non-denaturing (only disrupts lipid-lipid or lipid-protein interactions whilst maintaining protein-
protein interactions) although their short alkyl chain can potentially cause protein denaturation due to 
the lack of hydrophobicity. Other commonly used non-ionic detergents include the n-dodecyl-β-D-
maltopyranoside (DDM) (alkyl maltopyranosides) and n-decyl-β-D-maltopyranoside (DM) (alkyl 
A. B. 
213 
 
maltopyranosides), as well as the zwitterion n-lauryl dimethylamine n-oxide (LDAO) (amine oxide). 
Triton X-100 has a very low CMC concentration (~0.2 mM) and a variable temperature- and pH-
dependent micelle size of 60 – 90 kDa [515, 517]. The presence of the aromatic ring in Triton X-100 
poses difficulties in protein quantitation due to its absorbance in the UV wavelength. Triton X-100 is 
also heterogenous and this characteristic can compromise the need for homogeneity and purity that 
is needed for protein crystallisation [553]. On the other hand, OG has a much higher CMC (~20mM) 
and produce smaller micelles (~25 kDa) [554]. DDM has a low CMC concentration (~0.17 mM 
[555]) similar to Triton X-100 which allows the use of less detergent for purification, however, 
detergent removal would pose difficulties. Furthermore, the DDM micelles are relatively large 
(~65–70 kDa [556, 557]). DM has a shorter alkyl hydrophobic chain than DDM and hence results 
in lower protein stability and smaller micelle size (~40 kDa [556]). The CMC of DM is also much 
higher than DDM (~1.8 mM [555]), therefore requiring more detergent for solubilisation. The 
zwitterionic LDAO detergent has been shown to produce well-diffracting protein crystals [558-560] 
probably due to its compact micelle size (~21.5 kDa) that allows enhanced packing within crystals 
[557]. Also, LDAO forms elongated rather than spherical micelles [561, 562]. Advanced detergents 
with improved characteristics for solubility, stabilisation, and crystallisation of proteins have also 
been used in other studies. These include detergents with a more rigid hydrophobic alkyl chain by 
various modifications [563], membrane-mimicking properties (such as maltoside-neopentyl glycols 
(MNGs) for the human agonist β2 adrenoreceptor complex [564], addition of short alkyl chains to 
improve hydrophobicity (such as glucose neo-pentyl glucoside [565], steroid-based facial 
amphiphiles to improve crystallisation [566], and anionic calix[4]arene-based detergents to 
improve protein stability [567]. However, as one protein behaves differently from the other, 
empirical determination of suitable detergents for purification and crystallisation is required.  
As with most other proteins, LNK has a combination of structured and disordered regions. LNK 
however, is speculated to have a propensity towards being more disordered due to the prediction of a 
higher proportion of regions that lack structure. This lack of structure may allow LNK to possess 
exceptional flexibility and plasticity in its conformation. LNK binding to other proteins may help to 
bring about folding that leads to a more ordered structure. It has been found that another class of 
proteins, which are called intrinsically disordered proteins (IDPs), are able to adopt different 
structures according to their binding partners [568]. This may in part explain how the flexibility of 
LNK allows it to bind to different receptors and JAK2 to regulate their activity. However, due to the 
possible flexibility of LNK, it may be difficult to be structurally analysed using X-ray 
crystallography. In this case, analysis of structures using nuclear magnetic resonance (NMR) with the 
protein in solution would be more feasible [569-574]. Furthermore, it is predicted that the lack of 
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structure may explain why LNK seemed to be susceptible to proteolytic cleavage. LNK also appeared 
to have a propensity to form dimers and tetramers which may contribute to its stability rather than 
monomers. The formation of these homomer may suggest some protein structure being present. It 
was previously shown that APS forms a heterotetrameric complex with JAK2 (APS and JAK2 dimers 
in complex) via its dimerisation and SH2 domain [306]. Therefore, this family of SH2-containing 
adaptor proteins may preferably exist as dimers or oligomers in order to retain stability and perform 
their function. Discovery of buffer conditions that promote the formation of the more stable dimeric 
form of LNK may be optimal for crystallography and other structure-function related investigations. 
It has been suggested that one of the alternative options to reduce proteolytic cleavage of IDPs is to 
perform a heat inactivation step (by boiling the lysate) after cell lysis that is able to deactivate 
proteases. IDPs are able to be subjected to this step as they lack tertiary structures. However, caution 
is needed for proteins like LNK as subjecting it to heat may distort the structured region of the protein. 
In this case, CD assays can be used to monitor if the protein still retained its native conformation 
[535].  
In the absence of human LNK protein crystals, the purified protein could be subjected to structure 
solving using SAXS and electron cryo-microscopy (cryoEM). SAXS has been used to gain structural 
information on a wide range of molecule sizes (few kilodaltons to gigadaltons) and is applicable for 
characterisation of structurally ordered or disordered proteins, although with low resolution compared 
to X-ray crystallography or NMR spectroscopy. Nevertheless, SAXS provide details that 
complements information obtained from X-ray crystallography. Through this technique, various 
information regarding the protein could be gained including its oligomeric state, three-dimensional 
conformation, domain flexibility, as well as complex formation [575, 576]. A previously published 
paper have structurally characterise the expressed and purified JAK2-JH2-JH1 via SAXS [538] and 
this can be extended to the human LNK protein. The use of CryoEM has been limited to larger 
proteins above ~50 kDa for better resolution. However, it has recently been used with proteins as 
small as ~64 kDa (which is approximately the size of LNK monomer) [577-579] with high resolution. 
Nevertheless, as the purified LNK protein seemed to adopt a higher order state of dimers and 
tetramers, this technique may be feasible [580-584] although heterogeneity of the sample might be 
an issue. 
Furthermore, binding interactions can be performed using the purified protein. Information regarding 
the binding kinetics between LNK and JAK2-JH2-JH1 can provide details regarding how rapid this 
interaction occurs (binding and dissociation). Subsequently, this information can be extended to 
screen for competitive inhibitors of this interaction. This could potentially lead to the discovery of 
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LNK mimetics that decreases JAK activation. The binding kinetics assay can be performed through 
different platforms such as Biacore [585, 586], isothermal titration calorimetry (ITC) [587-589], and 
homogeneous time resolved fluorescence (HTRF) [590-592]. These purified proteins could also 
potentially be used in kinase assays. This assay is used to measure kinase activity and hence can be 
exploited to determine if full-length LNK or its domains is able to inhibit JAK2 kinase activity. LNK 
protein harbouring important mutations can be compared to WT (under the same expression and 
purification conditions) to characterise impaired binding to JAK2 and to confirm which 
domains/residues are important for this binding.  
 
Conclusion 
 
Overall, sufficient quantities of soluble human LNK fractions that could be used for further quality 
assessments and crystallisation trials were not obtained. Due to time restraint, further optimisation 
was not made possible. In spite of all the challenges, defining the structure of the full-length LNK is 
still something worth pursuing as it will elucidate important mechanisms of regulation of JAK-STAT 
signalling. Solving the structure of LNK will also allow us to better understand how the function of 
LNK is disrupted in mutations that may contribute to the different diseases. In the absence of LNK 
crystals, the purified protein could also be used for protein interaction studies with other purified 
protein partners such as JAK2 and receptor intracellular domains. Structure analysis by NMR and 
Cryo-EM could also be performed as well as analysis of kinase activity with purified JAK2 JH2-JH1 
domains. This analysis of expression and purification of full length human LNK in this chapter will 
provide a framework for future studies to build upon the understanding of how this protein should be 
dealt with. 
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Final Discussion 
 
TPOR is expressed predominantly in haematopoietic stem and progenitor cells, megakaryocytes, and 
thrombocytes. Together with its ligand, TPO, the receptor regulates haematopoietic stem cell survival 
and expansion, megakaryocyte differentiation, as well as platelet and megakaryocyte production. 
TPOR is a homodimeric class I cytokine receptor and is important to regulate cell growth, 
differentiation, and survival via various pathways such as the JAK-STAT, MAPK, and PI3K/Akt. 
Clinical activating mutations of TPOR have been reported where most mutations lie in the 
transmembrane domain and its juxtamembrane regions. The TMD is important to regulate receptor 
activation and hence plays a role in modulating signalling downstream. The most common gain-of-
function TPOR mutations include the W515K/L that resides in the RWQFP amphipathic motif (that 
is important to maintain TPOR in its basal state) which is juxtamembrane to the C-terminus of the 
TMD [40, 43]. Oncogenic TPOR mutations have been reported to drive the pathogenesis of myeloid 
malignancies such as MPNs and to a lesser extent, AMKL. These mutations are found in ~5-10% of 
MF patients and 1–4% of ET patients [40, 43, 593]. Predominantly, these activating mutations are 
due to substitutions of the W515 residue such as W515K/L/A/R. The associated non-receptor tyrosine 
kinase, JAK2 is constitutively bound to TPOR and mediates downstream signalling. Activating JAK2 
mutations are also found in MPNs and contribute largely to the pathogenesis of this disease. 
Predominantly, these are the V617F substitution present in more than 95% of PV patients and 60% 
in ET or MF patients [4-6, 594]. JAK2 exon 12 mutations have also been reported in 2-3% of PV 
patients [35, 36]. Tight regulation of signalling downstream via TPOR/JAK2 is therefore clearly 
important in these diseases. Various extrinsic regulators of TPOR signalling pathway include the 
SOCS, PTPs, PIASs, and LNK. In this project, the main focus was on LNK where its mechanism of 
negative regulation has not yet been fully understood, although its role as a negative regulator of 
haematopoiesis has been well documented. Dysregulation of TPOR, JAK2, and LNK due to various 
activating and inactivating mutations can lead to constitutive JAK-STAT signalling and cell 
proliferation. Treatment options that are currently available for MPN patients have significant non-
specificity to the disease-causing mutation. In the case of JAK inhibitors, these specifically inhibits 
JAK signalling but is not specific to the mutation. These inhibitors also target JAK signalling in a 
range of important cells that would be activated by a range of different cytokines. Therefore, there is 
a need for the development of novel therapies for these patients such as antagonists targeting 
oncogenic TPOR or LNK mimetics (to target JAK2). In order for these targeted therapies to be 
developed, further insights regarding the relationship between pathogenic signalling and the 
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structure-function of TPOR and LNK needs to be gained. Various aims were set out to address this 
in the current investigation (Figure 83). 
• To discover novel mutations and compare signalling strengths of TPOR TMD-JM mutations 
• To identify potential peptide antagonists against TPOR 
• To understand the spatiotemporal pattern of the TPOR JM-ICD W515K mutation in 
comparison to TPOR WT  
• To elucidate the mechanism of LNK inhibition in TPOR-mediated signalling 
• To express and purify full-length LNK WT 
  
Figure 83: Diagrammatic representation of thesis aims. Figure made with BioRender. 
 
The current investigation discovered that clinical and novel JM-TMD TPOR missense mutations 
confer different constitutive signalling strengths which may result in varying clinical phenotypes of 
MPNs. Using the clinically prevalent constitutively active W515K TPOR mutant or cytokine 
stimulation, sptPALM analysis showed that TPOR activation results in reduced receptor lateral 
diffusion that may play a role in regulating signalling. By targeting the important ECD-JM of TPOR, 
a peptide that antagonises TPOR-mediated signalling pathway was discovered via phage display. This 
peptide may act as a potential lead compound to antagonise this pathway. Investigation of the negative 
regulator of TPOR signalling, LNK, showed that inhibition of downstream signalling is regulated not 
just by the SH2 domain of LNK, but also by the proline-rich dimerisation domain. This domain was 
shown to be important for TPOR binding. Through the LNK protein expression and purification 
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analysis, it was found that LNK stability can be mediated by forming dimers or oligomers, which 
may be a result of the binding between the dimerisation domains.  
Missense mutations are most commonly reported to have occurred in TPOR with mutations in the 
TMD domain frequently resulting in constitutive receptor activation. Particularly, mutations of the 
tryptophan residue of the RWQFP motif are frequently found. The current study investigated and 
compared the signalling strengths of clinical TPOR mutations that reside in the TMD and 
juxtamembrane regions. These clinical mutations such as W515K, T487A, and S505N have been 
reported to result in constitutive receptor activation which subsequently leads to constitutive 
downstream signalling. However, the results of the current study only partly agrees with the previous 
literature regarding the ability of the T487A mutant to cause constitutive activation [239]. 
Nevertheless, these mutations demonstrate a significant difference in their signalling capacity 
(cytokine-independent and dependent) which may contribute to the varying clinical phenotypes. The 
W515K mutation has been found in MPNs (ET and MF) and leukaemic transformation from MF, 
T487A has been found in one case of acute myeloid leukaemia (AML), whereas S505N has been 
reported in familial ET, MPNs (ET and MF), MDS, AML, as well as leukaemic transformation from 
ET [479]. These clinical observations also support the notion that the TMD and RWQFP motif plays 
a major role in keeping the receptor in its inactive state in the absence of ligand. The varying clinical 
phenotypes caused by the different mutations may be explained by the ability of TPOR TMD to adopt 
several orientations that confer its pleiotropic role in haematopoiesis [61], which when dysregulated 
due to mutations, can result in the different clinical phenotypes observed in patients. Furthermore, in 
a collaborative study (with the groups headed by Dr Melissa Call and Associate Professor Matthew 
Call, The Walter and Eliza Hall Institute), several novel mutations (L498W, V501A, V501S, and 
L502S) in the TMD that result in constitutive signalling of the JAK-STAT and MAPK pathway were 
identified by utilising the deep mutational scanning approach [394]. This collaborative work also 
showed that oncogenic TPOR mutations are dependent on the position and amino acid residues that 
are mutated [394]. By discovering novel TPOR mutations, this may aid in patient diagnosis and 
treatment strategies. Using a similar DMS approach, novel oncogenic mutations of other cytokine 
receptors, such as the IL7RA can also be discovered. Oncogenic mutations in IL7 receptor-α (IL7RA) 
have been reported in ALL that are caused by in-frame insertions or deletions in the TMD [391, 392], 
or insertion/substitution of a small number of amino acids introducing a cysteine residue in the ECD-
JM  [392, 393]. These cysteine residues allow the receptors to dimerise and confer constitutive 
receptor signalling even in the absence of its associated receptor subunit, the common γ-chain (γc), 
which usually forms a functional signalling complex. Similar mutations have also been identified in 
the related TSLPR [595, 596]. Another study showed that insertion of basic amino acids in the ECD-
220 
 
JM, although does not result in constitutive activation, can induce cytokine hypersensitivity to IL-7 
ligand in the presence of the γ-chain [597]. This mutation results in a leukaemic phenotype in mice 
[597]. On the other hand, TPOR mutations usually exist as missense substitutions with a lower 
prevalence for insertion/deletion mutations. Inframe insertion TPOR mutations in the TMD have been 
discovered in MPN patients whereas inframe deletion mutations in the TMD have been found in 
melanoma patients [479]. Interestingly, deletion frameshift mutations in W515 have been reported in 
MPNs [598, 599]. Analysis of inframe and deletion mutations in the TMD or JM regions of TPOR 
using the DMS screen may reveal a potentially new mechanism that is utilised by TPOR, similar to 
IL7RA. A deep mutational scanning screen of IL7RA would be beneficial to provide a better 
structural-functional analysis of the IL7RA TMD, but may not be clinically relevant due to the short 
insertions seen in clinically activating mutations. Therefore, developing a deep mutational scanning 
screen incorporating insertions would be important to provide greater understanding of the impact of 
insertions and residues in regulating IL7RA signalling.   
 
The phage display screen to identify peptide antagonists against the important ECD/TMD region can 
be extended to screen for peptides against the similar region of other receptors such as IL7RA, 
TSLPR, and EPOR with mutations in a similar region to discover peptides that can bind to mutant 
receptors and not to WT ones. TSLPR mutations that are caused by chromosomal rearrangements are 
associated with B-ALL [595, 600, 601]. These translocations have been observed in ~60% of Down’s 
Syndrome-ALL children and result in enhanced receptor expression [600-602]. Particularly, 
oncogenic mutation of residue F232 to cysteine results in receptor dimerisation and downstream 
signalling [595, 596]. Therefore, targeting TSLPR may be beneficial for treating ALL patients 
associated with mutations in this receptor. Mutations in EPOR due to chromosomal rearrangements 
result in the deletion of the distal part of the cytoplasmic tail which is important to bind negative 
regulators [603]. However, it retains important tyrosine residues C-terminal to the TMD which enable 
effective receptor signal transduction [603]. Hence, these EPOR mutations result in receptor 
stabilisation and hypersensitivity to cytokine stimulation [603]. In mouse models, these EPOR 
truncations have been reported to induce ALL [603]. Hence, phage display can be utilised to discover 
peptides that target EPOR to reduce signalling which may aid in suppressing disease burden. 
However, a strong inhibition of WT EPOR would be expected to result in anaemia.  
Using sptPALM, comparison of the mobility of TPOR WT and W515K in the cell membrane showed 
that receptor activation results in reduced receptor mobility that may be linked to downstream 
signalling. The reason for this reduction has not yet been investigated but previous studies have shown 
that cholesterol contributes to the development of ‘lipid rafts’ that affect the mobility of membrane-
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bound receptors and also downstream signalling. However, there are contradicting reports regarding 
the effect of cholesterol depletion on receptor mobility. Cholesterol depletion in the cell membrane 
resulted in reduced mobility of the thyrotropin-releasing hormone (TRH) receptor, which 
subsequently led to reduced cell signalling [424]. The human neurokinin-1 receptor (NK1R), a G-
protein coupled receptor, also experienced reduced lateral diffusion after depletion of cholesterol with 
methyl-β-cyclodextrin leading to markedly reduced calcium signalling [410]. On the other hand, 
depletion of cholesterol has been reported to increase the mobility of GABA receptors at the 
extrasynaptic membrane [604] but the relationship to signalling was not investigated. An optimum 
amount of cholesterol is needed for the production of ‘lipid rafts’ in the cell membranes, for 
production of hormones, and cell metabolism. However, an increased amount of cholesterol can 
contribute to cardiovascular diseases and enhance cancer progression [605]. Statins have been used 
to reduce the total cholesterol level in patients with cardiovascular disease. It has been reported that 
cholesterol depletion in humans using statins improves cancer targeting and therefore may aid in 
cancer treatment [606-608]. This beneficial reduction in cholesterol levels may also be linked to the 
reduced formation of lipid rafts, with a subsequent reduction in receptor mobility and cell signalling, 
eventually preventing the progression of cancer. Furthermore, it has been reported that increased 
membrane cholesterol leads to increased TPOR signalling [609]. The role of lipid rafts in signalling 
has been shown to be contradictory depending on the type of receptor. In the case of the IL-2 receptor 
(IL-2R), in the basal state, the IL-2Rα is in a pre-formed complex with IL-2Rβ, and IL-2Rγ where 
IL-2Rα is localised to the periphery of lipid rafts whereas the IL-2Rβ and IL-2Rγ reside in the soluble 
membranes [610]. Upon activation, the IL-2Rα is able to bind more strongly to other signalling units 
of the complex and is dissociated from lipid rafts to initiate signal transduction [610]. In contrast, 
activation of the IL-7 receptor results in the formation of lipid rafts that allow the receptor to anchor 
to the cytoskeleton which subsequently stabilises the formation of a signalling complex [611]. 
Apart from receptor mobility, receptor clustering can also affect cell signalling. It was previously 
reported that ligand addition of SCF and TPO can induce receptor clustering of c-Kit and TPOR in 
lipid rafts [425]. It was speculated that this clustering involves both active and inactive receptors, 
which act in concert to enhance signalling [425]. Interestingly, this clustering is induced by opposite 
ligands i.e. SCF induced TPOR clustering whereas TPO induced c-Kit clustering [425] in lipid rafts. 
This clustering in HSCs enhances signalling downstream, particularly the PI3K–Akt–FOXO pathway 
and induces cell proliferation [425]. In contrary to the results of the current study, TPOR clustering 
has been observed even in the absence of the TPO ligand. Furthermore, cytokine stimulation did not 
change the cluster area or diameter. Unlike the utilisation of sptPALM for receptor cluster analysis 
as per current studies, previous work has used immunofluorescence for this investigation in 
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CD34+KSL cells [425]. Hence, the immunofluorescence technique is only able to detect major 
changes in clustering and accurate analysis on single clusters was not possible. For this reason, it is 
possible that the clustering that has been observed is a result of the concentration/ localisation of the 
clusters in a particular area of the cell instead. On the contrary, using sptPALM that tracks single 
molecules, allows minor clusters to be detected and this increases the accuracy in the analysis of 
clustering.  
Apart from the SH2 domain, the current study found that the LNK Pro/DD domain possesses a novel 
function in downregulating signalling via the STAT and MAPK pathway. This domain was also 
shown to be important to maintain the interaction with TPOR. Based on the results of the current 
study, two models of interaction were proposed: i) the Pro/DD domain may be binding to TPOR 
whilst the SH2 binds JAK2, or ii) the Pro/DD domain mediates the formation of a functional LNK 
homodimer where each unit is capable of binding TPOR and JAK2 separately. As the Pro/DD domain 
contains the zipper region that is responsible for dimerisation, the latter proposed model may be more 
feasible. Furthermore, purification studies of LNK suggest that this protein preferably dimerises or 
oligomerises to stabilise the protein. This is consistent with the features of the dimerisation domain 
of APS which was found to produce higher-order aggregates and it can also form a heterotetrameric 
complex with JAK2 through its SH2 and dimerisation domain [291]. However, mutations in the 
Pro/DD are not as commonly found compared to SH2 domain point mutations and those found in 
patients have not yet been characterised, although the mutations were predicted to be pathogenic. It 
is plausible that mutations in the Pro/DD are not driver mutations and hence do not result in an 
obvious clinical phenotype (which may explain the rare occurrence of mutations in this domain) but 
they may contribute as co-operating mutations. Indeed, some studies have supported the occurrence 
of LNK mutations as co-operating mutations rather than driver mutations in MPNs [26, 344]. This 
study also revealed for the first time that LNK was able to constitutively associate with the archetypal 
GHR, although JAK2 did not increase the stability of this complex, unlike what happened for TPOR. 
These differences suggest that JAK2 helps to stabilise certain receptors and by doing so, allows LNK 
to exhibit its effects on different receptors, although there is no certainty whether LNK can inhibit or 
enhance GHR-mediated signalling.  
The role of LNK serine phosphorylation has not been described in haematologic malignancies but 
has been described in ovarian cancer [300]. LNK possesses several serine phosphorylation sites where 
two serine residues have been reported to be able to be phosphorylated in humans, S103 and S150 
(murine homologues are S13 and S129, respectively) [612]. The S13 murine homologue is 
phosphorylated by glycogen synthase kinase 3 whereas the phosphorylation of S129 is performed by 
protein kinase A. These phosphorylated residues act as binding sites for the 14-3-3 adaptor protein 
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[300, 612]. These phosphorylated serine residues are not known to interact with JAK2 in ovarian 
cancer cells [300]. LNK is overexpressed in ovarian cancers and its expression has been linked to an 
increase in the downstream signalling which promotes oncogenesis [300]. The binding of 14-3-3 was 
shown to negatively regulate the effects of LNK by downregulating downstream signalling [300]. 
However, LNK and 14-3-3 play a paradoxical role in haematopoietic cells. In these cells, 14-3-3 
enhances JAK signalling by associating with LNK and preventing it from binding JAK2 to attenuate 
signalling [612]. In the LNK ProDD deletion mutant, four serine mutants are deleted, which includes 
the two serine residues that are known to play a role in binding 14-3-3. It was shown previously that 
mutation of these residues resulted in the localisation of LNK to the plasma membrane of HEK293T 
cells as the 14-3-3 was not able to sequester LNK in the cytoplasm [612]. This prevents LNK 
interaction with the receptor/JAK2 complex at the cell surface [612]. If this was true, LNK ΔProDD 
should localise to the cell surface which should result in decreased cell signalling as it can interact 
with the receptor/JAK2 complex. In the current study, however, an increase in cell signalling was 
observed with this mutant. This may be due to other important functions attributed to this domain. 
Immunofluorescence studies using LNK ΔProDD could reveal if its localisation to the membrane is 
enhanced compared to WT and this may provide further explanation regarding those differences in 
observation.  
Although crystallisation trials of LNK were not successful, the ability to obtain high purity LNK 
could be beneficial for its use in other structure-function related analysis such as protein interaction 
studies, structure analysis, and kinase assays. The purified protein may be suitable for SAXS to 
investigate its oligomeric status and for structural analysis. Previous studies showed that the 
dimerisation domain of SH2B1 and APS can interact with each other [291]. Potential interaction sites 
of LNK in a complex could be determined and may complement results from the signalling and co-
precipitation assays to allow for a deeper understanding regarding how it can regulate signalling. 
SAXS may also be performed using the Pro/DD domain and SH2 phosphopeptides of the site in 
TPOR that has shown potential binding to LNK in co-precipitation assays, to determine if there exist 
any functional interactions between them. Furthermore, the purified protein can be used to study the 
interaction between LNK and JAK3 which regulates IL7 receptor signalling. LNK can modulate IL-
7 receptor signalling via binding to phosphorylated JAK3 [333]. Similarly, the binding kinetics 
between LNK and the phosphopeptide of JAK3 (pTyr785) or JAK2 (pTyr813) could be used to 
compare the binding and dissociation of LNK to different members of the JAK family, which may 
help in understanding binding affinities to different JAKs. Kinase assays could also be performed 
between LNK and JAK2/JAK3 to determine and compare the ability of LNK to inhibit JAK2 and 
JAK3 without the presence of its Pro/DD domain. Lastly, the current study used adenovirus infection 
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of HeLa cells for protein expression which has been shown to produce a protein with high yield and 
purity. This novel combination can be extended for protein expression of those proteins that may be 
difficult to express using a bacterial system or even yeast or insect cell expression systems.  
 
Future Directions 
 
It was found that ligand binding or constitutive receptor activation resulted in reduced cell membrane 
receptor mobility. However, it is not fully understood as to what has contributed to this reduction. 
This could be affected by lipid rafts, actin cytoskeleton, and receptor endocytosis. In order to fully 
understand this, the effect of cytoskeleton on the receptor can be investigated by using cytoskeleton-
depolymerizing toxins such as Nocodazole (inhibits microtubule polymerisation) or cells can be 
treated with small interfering RNA (siRNA) against filamin A. Agents that cause cholesterol 
depletion such as methyl-β-cyclodextrin or cholesterol oxidase (COase) can be used to understand 
the role of cholesterol/lipid rafts in cell mobility. The role of endocytosis can be investigated by using 
siRNA to inhibit AP2. AP2 mediates the endocytosis of transmembrane proteins via clathrin, and the 
inhibition of this protein will aid in understanding if the reduction in receptor mobility is due to 
attenuation of signalling by internalisation. The effect of LNK on the stability of TPOR was shown 
in Chapter 4 and this can be extended to further studies on the ability of LNK to affect the mobility 
of the receptor. sptPALM using stable-transduction of LNK into HEK293 cells together with transient 
transfection of mEOS2-tagged TPOR can be performed to address this fact. Further on from 
sptPALM, step-bleaching of single molecules can also be performed to investigate the pre-
dimerisation status of TPOR. This is important to further understand the mechanism of TPOR 
activation as a result of cytokine binding or oncogenic mutations.  
In the early discovery of peptides that interact with TPOR using the 12-mer phage display library, 
three consensus peptide motifs were observed. However, only one peptide showed an effect, peptide 
V, on the proliferation of the cells. In order to discard the possibility that the other two peptides may 
have fallen out of solution and therefore, were not able to exhibit any effect on the cells, a precipitation 
condition test can be performed in order to determine if these peptides are indeed soluble and also if 
the observed effect is real.  
The effect of peptide V should also be tested on Ba/F3 cell lines expressing other type I cytokine 
receptors such as PRLR and EPOR to ensure that the inhibitory effect that was observed is indeed 
TPOR specific. This peptide can also be further evaluated on its ability to inhibit downstream 
signalling to further understand which pathway has been affected and has resulted in inhibition of cell 
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proliferation. Besides the TPOR W515K mutant, peptide V can also be used to be tested on TPOR 
T487A and S505N cell lines to determine if this peptide is still able to dampen cell proliferation. If 
the peptide is not able to, these cell lines can be utilised to obtain specificity for the W515K mutant 
using T487A/S505N for negative selection. Once specificity in cell-based assays has been confirmed, 
the mode of interaction with the receptor can be determined. This could be performed using 
simulations utilising TPOR JM-TMD constructs. Further, the efficacy of the peptide may be improved 
by covalent linkage dimerisation or other modifications.  
In the current study, the strong inhibitory effect of LNK on cell growth was observed on 
haematopoietic cells such as Ba/F3. Due to this inhibition of cell growth, it was difficult to further 
analyse the LNK mutant effect. An alternative to this, is to utilise an inducible system such as 
doxycycline-inducible gene expression where LNK can be expressed when desired. It will also be 
interesting to observe if LNK has any effects in the downstream pathway of GHR as there are 
currently no studies concerning this fact. It was observed in Chapter 4 that co-transfection of 
TPOR/GHR with LNK increased receptor expression. This effect of LNK needs to be confirmed in 
stable cell lines such as Ba/F3 expressing these receptors. It is, however, not certain that this is a 
transcriptional or a translational effect by LNK and this could be investigated by performing qPCR 
on RNA that is extracted from cells co-transfected with both TPOR/GHR and LNK. A further 
investigation could be performed to observe how TPOR levels change after LNK transfection via the 
cycloheximide chase assay. It will also be interesting to determine whether LNK mutants can inhibit 
constitutive downstream signalling of TPOR W515K and S505N or not.  
Despite several optimisation trials to obtain soluble LNK protein, this task remains challenging. More 
optimisation methods are warranted especially the one that incorporates the use of the 
phosphoinositide reagent, InsP6, which may allow the membrane-binding domain of LNK, the PH 
domain, to bind and improve the overall protein solubility. In Chapter 5, LNK co-expression with 
JAK2 JH2-JH1 did not contribute to the protein solubility of LNK. However, it was also found that 
the JAK2 protein was not fully extracted out from the cell pellet and this contributed to the low 
amount of JAK2 in the solution. Furthermore, the lack of LNK binding to JAK2 suggests that the 
buffer conditions were not optimal for maintaining the interaction between these two proteins. These 
conditions need to be optimised and may hopefully improve LNK solubility. In order to further 
evaluate the interaction between LNK and JAK2, binding interaction studies between LNK and 
JAK2-JH2-JH1 can be performed. Lastly, kinase assays can be performed to compare the ability of 
LNK mutants to inhibit JAK2 kinase activity. 
 
226 
 
References 
 
1. A. Rad, M.H. Simplified hematopoiesis. 2009  22 November 2019]; Available from: 
https://en.wikipedia.org/wiki/Haematopoiesis#/media/File:Hematopoiesis_simple.svg. 
2. Arber, D.A., et al., The 2016 revision to the World Health Organization classification of myeloid 
neoplasms and acute leukemia. Blood, 2016. 127(20): p. 2391-405. 
3. Baxter, E.J., et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative 
disorders. Lancet, 2005. 365: p. 1054-1061. 
4. James, C., et al., A unique clonal JAK2 mutation leading to constitutive signalling causes 
polycythaemia vera. Nature, 2005. 434(7037): p. 1144-8. 
5. Kralovics, R., et al., A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 
2005. 352: p. 1779-1790. 
6. Levine, R.L., et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential 
thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005. 7: p. 387-397. 
7. Zhao, R., et al., Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem, 2005. 
280(24): p. 22788-92. 
8. Kratz, C.P., et al., Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute 
lymphoblastic leukemia. Leukemia, 2006. 20(2): p. 381-3. 
9. Scott, L.M., et al., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl 
J Med, 2007. 356: p. 459-468. 
10. Lee, J.W., et al., The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene, 2006. 
25(9): p. 1434-6. 
11. Grunebach, F., et al., Detection of a new JAK2 D620E mutation in addition to V617F in a patient with 
polycythemia vera. Leukemia, 2006. 20(12): p. 2210-1. 
12. Schnittger, S., et al., Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: 
D620E and E627E. Leukemia, 2006. 20(12): p. 2195-7. 
13. Bercovich, D., et al., Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's 
syndrome. Lancet, 2008. 372(9648): p. 1484-92. 
14. Mullighan, C.G., et al., JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl 
Acad Sci U S A, 2009. 106(23): p. 9414-8. 
15. Ma, W., et al., Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative 
neoplasias. J Mol Diagn, 2009. 11: p. 49-53. 
16. Passamonti, F., et al., Molecular and clinical features of the myeloproliferative neoplasm associated 
with JAK2 exon 12 mutations. Blood, 2011. 117: p. 2813-2816. 
17. Ghoreschi, K., A. Laurence, and J.J. O'Shea, Janus kinases in immune cell signaling. Immunol Rev, 
2009. 228(1): p. 273-87. 
18. Imai, M., M. Araki, and N. Komatsu, Somatic mutations of calreticulin in myeloproliferative 
neoplasms. Int J Hematol, 2017. 105(6): p. 743-747. 
19. Milosevic, J.D. and R. Kralovics, Genetic and epigenetic alterations of myeloproliferative disorders. Int 
J Hematol, 2013. 97(2): p. 183-97. 
20. Rampal, R. and R.L. Levine, A primer on genomic and epigenomic alterations in the myeloproliferative 
neoplasms. Best Pract Res Clin Haematol, 2014. 27(2): p. 83-93. 
21. Tenedini, E., et al., Targeted cancer exome sequencing reveals recurrent mutations in 
myeloproliferative neoplasms. Leukemia, 2014. 28(5): p. 1052-9. 
22. Grand, F.H., et al., Frequent CBL mutations associated with 11q acquired uniparental disomy in 
myeloproliferative neoplasms. Blood, 2009. 113(24): p. 6182-92. 
23. McMullin, M.F. and H. Cario, LNK mutations and myeloproliferative disorders. Am J Hematol, 2016. 
91(2): p. 248-51. 
24. Pardanani, A., et al., LNK mutation studies in blast-phase myeloproliferative neoplasms, and in 
chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia, 2010. 24(10): p. 1713-8. 
227 
 
25. Lasho, T.L., A. Pardanani, and A. Tefferi, LNK mutations in JAK2 mutation-negative erythrocytosis. N 
Engl J Med, 2010. 363(12): p. 1189-90. 
26. Oh, S.T., et al., Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in 
patients with myeloproliferative neoplasms. Blood, 2010. 116(6): p. 988-92. 
27. Sanada, M., et al., Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. 
Nature, 2009. 460(7257): p. 904-8. 
28. Loh, M.L., et al., Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009. 
114(9): p. 1859-63. 
29. Bellanne-Chantelot, C., et al., Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 
families with myeloproliferative disorders. Blood, 2006. 108(1): p. 346-52. 
30. Rumi, E., et al., Familial chronic myeloproliferative disorders: clinical phenotype and evidence of 
disease anticipation. J Clin Oncol, 2007. 25(35): p. 5630-5. 
31. Rumi, E., et al., CALR exon 9 mutations are somatically acquired events in familial cases of essential 
thrombocythemia or primary myelofibrosis. Blood, 2014. 123(15): p. 2416-9. 
32. Rumi, E., et al., JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event 
associated with disease progression in familial myeloproliferative disorders. Cancer, 2006. 107(9): p. 
2206-11. 
33. Godfrey, A.L. and A.R. Green, Genotype-phenotype interactions in the myeloproliferative neoplasms. 
Hematol Oncol Clin North Am, 2012. 26(5): p. 993-1015. 
34. Lupardus, P.J., et al., Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals 
a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A, 2014. 111(22): p. 8025-
30. 
35. Scott, L.M., et al., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl 
J Med, 2007. 356(5): p. 459-68. 
36. Pietra, D., et al., Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative 
myeloproliferative disorders. Blood, 2008. 111(3): p. 1686-9. 
37. Martinez-Aviles, L., et al., JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. 
Haematologica, 2007. 92(12): p. 1717-8. 
38. Li, J., et al., JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but 
is insufficient to sustain disease. Blood, 2014. 123(20): p. 3139-51. 
39. Yao, H., et al., Activating JAK2 mutants reveal cytokine receptor coupling differences that impact 
outcomes in myeloproliferative neoplasm. Leukemia, 2017. 31(10): p. 2122-2131. 
40. Pardanani, A.D., et al., MPL515 mutations in myeloproliferative and other myeloid disorders: a study 
of 1182 patients. Blood, 2006. 108(10): p. 3472-6. 
41. Beer, P.A., et al., MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 
2008. 112: p. 141-149. 
42. Guglielmelli, P., et al., Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 
Br J Haematol, 2007. 137(3): p. 244-7. 
43. Pikman, Y., et al., MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid 
metaplasia. PLoS Med, 2006. 3(7): p. e270. 
44. Schnittger, S., et al., Characterization of 35 new cases with four different MPLW515 mutations and 
essential thrombocytosis or primary myelofibrosis. Haematologica, 2009. 94(1): p. 141-4. 
45. Moliterno, A.R., W.D. Hankins, and J.L. Spivak, Impaired expression of the thrombopoietin receptor 
by platelets from patients with polycythemia vera. N Engl J Med, 1998. 338(9): p. 572-80. 
46. Girardot, M., et al., miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of 
myeloproliferative neoplasm patient platelets. Blood, 2010. 116(3): p. 437-45. 
47. Chachoua, I., et al., Thrombopoietin receptor activation by myeloproliferative neoplasm associated 
calreticulin mutants. Blood, 2016. 127(10): p. 1325-35. 
48. Balligand, T., et al., Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by 
frameshift mutants of mouse calreticulin. Leukemia, 2016. 30(8): p. 1775-8. 
49. Moliterno, A.R. and J.L. Spivak, Posttranslational processing of the thrombopoietin receptor is 
impaired in polycythemia vera. Blood, 1999. 94(8): p. 2555-2561. 
228 
 
50. Tefferi, A., S.Y. Yoon, and C.Y. Li, Immunohistochemical staining for megakaryocyte c-mpl may 
complement morphologic distinction between polycythemia vera and secondary erythrocytosis. 
Blood, 2000. 96(2): p. 771-2. 
51. Ng, A.P., et al., Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis 
but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A, 2014. 111(16): p. 5884-9. 
52. Horikawa, Y., et al., Markedly reduced expression of platelet c-mpl receptor in essential 
thrombocythemia. Blood, 1997. 90(10): p. 4031-8. 
53. Harrison, C.N., et al., Platelet c-mpl expression is dysregulated in patients with essential 
thrombocythaemia but this is not of diagnostic value. Br J Haematol, 1999. 107(1): p. 139-47. 
54. McCaffrey, K. and I. Braakman, Protein quality control at the endoplasmic reticulum. Essays Biochem, 
2016. 60(2): p. 227-235. 
55. Nangalia, J., et al., Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. 
N Engl J Med, 2013. 369(25): p. 2391-2405. 
56. Marty, C., et al., Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent 
progression to myelofibrosis. Blood, 2016. 127(10): p. 1317-24. 
57. Elf, S., et al., Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin 
Receptor for Oncogenic Transformation. Cancer Discov, 2016. 6(4): p. 368-81. 
58. Araki, M., et al., Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant 
myeloproliferative neoplasms. Blood, 2016. 127(10): p. 1307-16. 
59. Han, L., et al., Calreticulin-mutant proteins induce megakaryocytic signaling to transform 
hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol 
Oncol, 2016. 9(1): p. 45. 
60. Rampal, R., et al., Integrated genomic analysis illustrates the central role of JAK-STAT pathway 
activation in myeloproliferative neoplasm pathogenesis. Blood, 2014. 123(22): p. e123-33. 
61. Staerk, J., et al., Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J, 2011. 
30(21): p. 4398-413. 
62. Bazan, J.F., Haemopoietic receptors and helical cytokines. Immunol Today, 1990. 11(10): p. 350-4. 
63. Cosman, D., The hematopoietin receptor superfamily. Cytokine, 1993. 5(2): p. 95-106. 
64. Bazan, J.F., Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl 
Acad Sci U S A, 1990. 87(18): p. 6934-8. 
65. Waters, M.J. and A.J. Brooks, JAK2 activation by growth hormone and other cytokines. Biochem J, 
2015. 466(1): p. 1-11. 
66. Bravo, J. and J.K. Heath, Receptor recognition by gp130 cytokines. Embo j, 2000. 19(11): p. 2399-411. 
67. Boulay, J.L., J.J. O'Shea, and W.E. Paul, Molecular phylogeny within type I cytokines and their cognate 
receptors. Immunity, 2003. 19(2): p. 159-63. 
68. Bagley, C.J., et al., The structural and functional basis of cytokine receptor activation: lessons from 
the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-
3), and IL-5 receptors. Blood, 1997. 89(5): p. 1471-82. 
69. Yawata, H., et al., Structure-function analysis of human IL-6 receptor: dissociation of amino acid 
residues required for IL-6-binding and for IL-6 signal transduction through gp130. Embo j, 1993. 12(4): 
p. 1705-12. 
70. de Vos, A.M., M. Ultsch, and A.A. Kossiakoff, Human growth hormone and extracellular domain of its 
receptor: crystal structure of the complex. Science, 1992. 255(5042): p. 306-12. 
71. Livnah, O., et al., Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor 
complex at 2.8 A. Science, 1996. 273(5274): p. 464-71. 
72. Chow, D., et al., Structure of an extracellular gp130 cytokine receptor signaling complex. Science, 
2001. 291(5511): p. 2150-5. 
73. Boulanger, M.J., et al., Hexameric structure and assembly of the interleukin-6/IL-6 alpha-
receptor/gp130 complex. Science, 2003. 300(5628): p. 2101-4. 
74. Rozwarski, D.A., et al., Structural comparisons among the short-chain helical cytokines. Structure, 
1994. 2(3): p. 159-73. 
75. Murakami, M., et al., Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is 
conserved in the cytokine receptor family. Proc Natl Acad Sci U S A, 1991. 88(24): p. 11349-53. 
229 
 
76. Haan, C., et al., Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol, 2006. 
72(11): p. 1538-46. 
77. Rodig, S.J., et al., Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the 
Jaks in cytokine-induced biologic responses. Cell, 1998. 93(3): p. 373-83. 
78. Parganas, E., et al., Jak2 is essential for signaling through a variety of cytokine receptors. Cell, 1998. 
93(3): p. 385-95. 
79. Kawamura, M., et al., Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in 
natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A, 1994. 91(14): p. 6374-8. 
80. Musso, T., et al., Regulation of JAK3 expression in human monocytes: phosphorylation in response to 
interleukins 2, 4, and 7. J Exp Med, 1995. 181(4): p. 1425-31. 
81. Kershaw, N.J., et al., SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by 
direct kinase inhibition. Nat Struct Mol Biol, 2013. 20(4): p. 469-76. 
82. Boggon, T.J., et al., Crystal structure of the Jak3 kinase domain in complex with a staurosporine 
analog. Blood, 2005. 106(3): p. 996-1002. 
83. Chrencik, J.E., et al., Structural and thermodynamic characterization of the TYK2 and JAK3 kinase 
domains in complex with CP-690550 and CMP-6. J Mol Biol, 2010. 400(3): p. 413-33. 
84. Liau, N.P.D., et al., The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun, 2018. 9(1): p. 
1558. 
85. Feng, J., et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase 
activation loop. Mol Cell Biol, 1997. 17, 2497-501 DOI: 10.1128/MCB.17.5.2497. 
86. Funakoshi-Tago, M., et al., Jak2 FERM domain interaction with the erythropoietin receptor regulates 
Jak2 kinase activity. Mol Cell Biol, 2008. 28(5): p. 1792-801. 
87. Yasukawa, H., et al., The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through 
binding in the activation loop. Embo j, 1999. 18(5): p. 1309-20. 
88. Myers, M.P., et al., TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem, 
2001. 276(51): p. 47771-4. 
89. Toms, A.V., et al., Structure of a pseudokinase-domain switch that controls oncogenic activation of 
Jak kinases. Nat Struct Mol Biol, 2013. 20(10): p. 1221-3. 
90. Bandaranayake, R.M., et al., Crystal structures of the JAK2 pseudokinase domain and the pathogenic 
mutant V617F. Nat Struct Mol Biol, 2012. 19(8): p. 754-9. 
91. Silvennoinen, O., et al., New insights into the structure and function of the pseudokinase domain in 
JAK2. Biochem Soc Trans, 2013. 41(4): p. 1002-7. 
92. Ungureanu, D., et al., The pseudokinase domain of JAK2 is a dual-specificity protein kinase that 
negatively regulates cytokine signaling. Nat Struct Mol Biol, 2011. 18(9): p. 971-6. 
93. Argetsinger, L.S., et al., Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. 
Mol Cell Biol, 2004. 24(11): p. 4955-67. 
94. Ishida-Takahashi, R., et al., Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin 
receptor signaling. Mol Cell Biol, 2006. 26(11): p. 4063-73. 
95. Feener, E.P., et al., Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. 
Mol Cell Biol, 2004. 24(11): p. 4968-78. 
96. Mazurkiewicz-Munoz, A.M., et al., Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 
that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol, 2006. 26(11): p. 
4052-62. 
97. Wilks, A.F., et al., Two novel protein-tyrosine kinases, each with a second phosphotransferase-related 
catalytic domain, define a new class of protein kinase. Mol Cell Biol, 1991. 11(4): p. 2057-65. 
98. Girault, J.A., et al., Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of 
band 4.1 domains important for cell structure and signal transduction. Mol Med, 1998. 4(12): p. 751-
69. 
99. McNally, R., A.V. Toms, and M.J. Eck, Crystal Structure of the FERM-SH2 Module of Human Jak2. PLoS 
One, 2016. 11(5): p. e0156218. 
100. Wallweber, H.J., et al., Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 
2. Nat Struct Mol Biol, 2014. 21(5): p. 443-8. 
230 
 
101. Ferrao, R., et al., The Structural Basis for Class II Cytokine Receptor Recognition by JAK1. Structure, 
2016. 24(6): p. 897-905. 
102. Zhou, Y.J., et al., Unexpected effects of FERM domain mutations on catalytic activity of Jak3: 
structural implication for Janus kinases. Mol Cell, 2001. 8(5): p. 959-69. 
103. Haan, S., et al., Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in 
stimulation-dependent Jak activation. J Immunol, 2008. 180(2): p. 998-1007. 
104. Higgins, D.G., J.D. Thompson, and T.J. Gibson, Using CLUSTAL for multiple sequence alignments. 
Methods Enzymol, 1996. 266: p. 383-402. 
105. Kampa, D. and J. Burnside, Computational and functional analysis of the putative SH2 domain in Janus 
Kinases. Biochem Biophys Res Commun, 2000. 278(1): p. 175-82. 
106. Radtke, S., et al., The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling 
but plays a structural role for receptor interaction and up-regulation of receptor surface expression. 
J Biol Chem, 2005. 280(27): p. 25760-8. 
107. Ferrao, R.D., H.J. Wallweber, and P.J. Lupardus, Receptor-mediated dimerization of JAK2 FERM 
domains is required for JAK2 activation. Elife, 2018. 7. 
108. Kuriyan, J. and D. Cowburn, Modular peptide recognition domains in eukaryotic signaling. Annu Rev 
Biophys Biomol Struct, 1997. 26: p. 259-88. 
109. Liu, B.A., et al., SRC Homology 2 Domain Binding Sites in Insulin, IGF-1 and FGF receptor mediated 
signaling networks reveal an extensive potential interactome. Cell Commun Signal, 2012. 10(1): p. 27. 
110. McNally, R. and M.J. Eck, JAK-cytokine receptor recognition, unboxed. Nat Struct Mol Biol, 2014. 
21(5): p. 431-3. 
111. Constantinescu, S.N., et al., The erythropoietin receptor cytosolic juxtamembrane domain contains 
an essential, precisely oriented, hydrophobic motif. Mol Cell, 2001. 7(2): p. 377-85. 
112. Huang, L.J., S.N. Constantinescu, and H.F. Lodish, The N-terminal domain of Janus kinase 2 is required 
for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell, 2001. 8(6): p. 
1327-38. 
113. Haan, C., P.C. Heinrich, and I. Behrmann, Structural requirements of the interleukin-6 signal 
transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. 
The Biochemical journal, 2002. 361(Pt 1): p. 105-111. 
114. Behrmann, I., et al., Janus kinase (Jak) subcellular localization revisited: the exclusive membrane 
localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor 
complex to be equivalent to a receptor tyrosine kinase. J Biol Chem, 2004. 279(34): p. 35486-93. 
115. Royer, Y., et al., Janus kinases affect thrombopoietin receptor cell surface localization and stability. J 
Biol Chem, 2005. 280(29): p. 27251-61. 
116. Rowlinson, S.W., et al., An agonist-induced conformational change in the growth hormone receptor 
determines the choice of signalling pathway. Nat Cell Biol, 2008. 10(6): p. 740-7. 
117. Neubauer, H., et al., Jak2 deficiency defines an essential developmental checkpoint in definitive 
hematopoiesis. Cell, 1998. 93(3): p. 397-409. 
118. Lu, X., L.J. Huang, and H.F. Lodish, Dimerization by a cytokine receptor is necessary for constitutive 
activation of JAK2V617F. J Biol Chem, 2008. 283: p. 5258-5266. 
119. Wernig, G., et al., The Jak2V617F oncogene associated with myeloproliferative diseases requires a 
functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. 
Blood, 2008. 111(7): p. 3751-9. 
120. Sangkhae, V., et al., The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-
induced myeloproliferative neoplasm. Blood, 2014. 124(26): p. 3956-63. 
121. Li, Y., et al., Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in 
myeloproliferative disorders. Br J Haematol, 1996. 92(1): p. 60-6. 
122. Pecquet, C., et al., Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor 
levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood, 2012. 119(20): p. 4625-
35. 
123. Braunstein, J., et al., STATs dimerize in the absence of phosphorylation. J Biol Chem, 2003. 278(36): 
p. 34133-40. 
231 
 
124. Kretzschmar, A.K., et al., Analysis of Stat3 (signal transducer and activator of transcription 3) 
dimerization by fluorescence resonance energy transfer in living cells. Biochem J, 2004. 377(Pt 2): p. 
289-97. 
125. Vogt, M., et al., The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of 
latent STAT3. J Cell Sci, 2011. 124(Pt 6): p. 900-9. 
126. Schindler, C., et al., Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-
3 proteins that are activated by interferon alpha. Proc Natl Acad Sci U S A, 1992. 89(16): p. 7836-9. 
127. Schindler, C., et al., Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic 
transcription factor. Science, 1992. 257(5071): p. 809-13. 
128. Shuai, K., et al., Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA 
binding protein. Science, 1992. 258(5089): p. 1808-12. 
129. Gent, J., et al., Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic 
reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci U S A, 2002. 
99(15): p. 9858-63. 
130. Brown, R.J., et al., Model for growth hormone receptor activation based on subunit rotation within a 
receptor dimer. Nat Struct Mol Biol, 2005. 12(9): p. 814-21. 
131. Brooks, A.J., et al., Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. 
Science, 2014. 344(6185): p. 1249783. 
132. Wells, J.A., Binding in the growth hormone receptor complex. Proceedings of the National Academy 
of Sciences of the United States of America, 1996. 93(1): p. 1-6. 
133. Chen, C., R. Brinkworth, and M.J. Waters, The role of receptor dimerization domain residues in growth 
hormone signaling. J Biol Chem, 1997. 272(8): p. 5133-40. 
134. Argetsinger, L.S., et al., Identification of JAK2 as a growth hormone receptor-associated tyrosine 
kinase. Cell, 1993. 74(2): p. 237-44. 
135. Silvennoinen, O., et al., Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 
3 signal transduction. Proc Natl Acad Sci U S A, 1993. 90(18): p. 8429-33. 
136. Saharinen, P. and O. Silvennoinen, The pseudokinase domain is required for suppression of basal 
activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. 
J Biol Chem, 2002. 277(49): p. 47954-63. 
137. Heterodimerization of JAK2 with JAK1 or TYK2 Promotes Drug Persistence. Cancer Discovery, 2012. 
2(9): p. OF10. 
138. Shan, Y., et al., Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. 
Nat Struct Mol Biol, 2014. 21(7): p. 579-84. 
139. Matsuda, T., et al., Determination of the transphosphorylation sites of Jak2 kinase. Biochem Biophys 
Res Commun, 2004. 325(2): p. 586-94. 
140. Robertson, S.A., et al., Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during 
cytokine signaling. Mol Cell Biol, 2009. 29(12): p. 3367-78. 
141. Argetsinger, L.S., et al., Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are 
autophosphorylated and required for maximal JAK2 kinase activity. Mol Endocrinol, 2010. 24(5): p. 
1062-76. 
142. Shuai, K. and B. Liu, Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol, 2003. 
3(11): p. 900-11. 
143. Saharinen, P., K. Takaluoma, and O. Silvennoinen, Regulation of the Jak2 Tyrosine Kinase by Its 
Pseudokinase Domain. Molecular and Cellular Biology, 2000. 20(10): p. 3387-3395. 
144. Saharinen, P., M. Vihinen, and O. Silvennoinen, Autoinhibition of Jak2 tyrosine kinase is dependent 
on specific regions in its pseudokinase domain. Mol Biol Cell, 2003. 14(4): p. 1448-59. 
145. Duhe, R.J., et al., Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci U 
S A, 1998. 95(1): p. 126-31. 
146. Qian, S., et al., Primary role of the liver in thrombopoietin production shown by tissue-specific 
knockout. Blood, 1998. 92(6): p. 2189-91. 
147. Sungaran, R., B. Markovic, and B.H. Chong, Localization and regulation of thrombopoietin mRNa 
expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood, 1997. 
89(1): p. 101-7. 
232 
 
148. Lok, S., et al., Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet 
production in vivo. Nature, 1994. 369(6481): p. 565-8. 
149. Stoffel, R., A. Wiestner, and R.C. Skoda, Thrombopoietin in thrombocytopenic mice: evidence against 
regulation at the mRNA level and for a direct regulatory role of platelets. Blood, 1996. 87(2): p. 567-
73. 
150. Wendling, F., et al., MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic 
disorder in adult mice. Virology, 1986. 149(2): p. 242-6. 
151. Solar, G.P., et al., Role of c-mpl in early hematopoiesis. Blood, 1998. 92(1): p. 4-10. 
152. Debili, N., et al., The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors 
to platelets. Blood, 1995. 85(2): p. 391-401. 
153. Kaushansky, K., et al., Thrombopoietin expands erythroid, granulocyte-macrophage, and 
megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol, 1996. 24(2): p. 
265-9. 
154. Pearce, K.H., Jr., et al., Mutational analysis of thrombopoietin for identification of receptor and 
neutralizing antibody sites. J Biol Chem, 1997. 272(33): p. 20595-602. 
155. Kuroki, R., et al., Crystallization of the functional domain of human thrombopoietin using an antigen-
binding fragment derived from neutralizing monoclonal antibody. Acta Crystallogr D Biol Crystallogr, 
2002. 58(Pt 5): p. 856-8. 
156. Feese, M.D., et al., Structure of the receptor-binding domain of human thrombopoietin determined 
by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A, 2004. 101(7): p. 
1816-21. 
157. Singh, V.K., et al., A Novel Peptide Thrombopoietin Mimetic Designing and Optimization Using 
Computational Approach. Front Bioeng Biotechnol, 2016. 4: p. 69. 
158. Broudy, V.C., et al., Human platelets display high-affinity receptors for thrombopoietin. Blood, 1997. 
89(6): p. 1896-904. 
159. Li, J., Y. Xia, and D.J. Kuter, Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: 
binding, internalization, stability and pharmacokinetics. Br J Haematol, 1999. 106(2): p. 345-56. 
160. Kuter, D.J. and R.D. Rosenberg, The reciprocal relationship of thrombopoietin (c-Mpl ligand) to 
changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood, 1995. 
85(10): p. 2720-30. 
161. Peters, M., et al., The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of 
human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of 
IL-6. J Exp Med, 1996. 183(4): p. 1399-406. 
162. Ogata, A., et al., IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase 
cascade. J Immunol, 1997. 159(5): p. 2212-21. 
163. Hayashida, K., et al., Molecular cloning of a second subunit of the receptor for human granulocyte-
macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. 
Proc Natl Acad Sci U S A, 1990. 87(24): p. 9655-9. 
164. Tavernier, J., et al., Molecular basis of the membrane-anchored and two soluble isoforms of the 
human interleukin 5 receptor alpha subunit. Proc Natl Acad Sci U S A, 1992. 89(15): p. 7041-5. 
165. Tsuruoka, N., K. Yamashiro, and M. Tsujimoto, Purification of soluble murine interleukin 5 (IL-5) 
receptor alpha expressed in Chinese hamster ovary cells and its action as an IL-5 antagonist. Arch 
Biochem Biophys, 1993. 307(1): p. 133-7. 
166. Brown, C.B., et al., In vitro characterization of the human recombinant soluble granulocyte-
macrophage colony-stimulating factor receptor. Blood, 1995. 85(6): p. 1488-95. 
167. Li, J., D.F. Sabath, and D.J. Kuter, Cloning and functional characterization of a novel c-mpl variant 
expressed in human CD34 cells and platelets. Cytokine, 2000. 12(7): p. 835-44. 
168. Coers, J., C. Ranft, and R.C. Skoda, A truncated isoform of c-Mpl with an essential C-terminal peptide 
targets the full-length receptor for degradation. J Biol Chem, 2004. 279(35): p. 36397-404. 
169. Millot, G.A., et al., MplK, a natural variant of the thrombopoietin receptor with a truncated 
cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell 
growth. Exp Hematol, 2002. 30(2): p. 166-75. 
233 
 
170. Skoda, R.C., et al., Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily 
that transduces a proliferative signal. Embo j, 1993. 12(7): p. 2645-53. 
171. Vigon, I., et al., Characterization of the murine Mpl proto-oncogene, a member of the hematopoietic 
cytokine receptor family: molecular cloning, chromosomal location and evidence for a function in cell 
growth. Oncogene, 1993. 8(10): p. 2607-15. 
172. Gurney, A.L., et al., Thrombocytopenia in c-mpl-deficient mice. Science, 1994. 265(5177): p. 1445-7. 
173. Alexander, W.S., et al., Deficiencies in progenitor cells of multiple hematopoietic lineages and 
defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood, 1996. 
87(6): p. 2162-70. 
174. de Sauvage, F.J., et al., Physiological regulation of early and late stages of megakaryocytopoiesis by 
thrombopoietin. J Exp Med, 1996. 183(2): p. 651-6. 
175. Buza-Vidas, N., et al., Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles 
of thrombopoietin and LNK. Genes Dev, 2006. 20(15): p. 2018-23. 
176. Nishimura, S., et al., IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response 
to acute platelet needs. J Cell Biol, 2015. 209(3): p. 453-66. 
177. Qian, H., et al., Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem 
cells. Cell Stem Cell, 2007. 1(6): p. 671-84. 
178. Yoshihara, H., et al., Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence 
and interaction with the osteoblastic niche. Cell Stem Cell, 2007. 1(6): p. 685-97. 
179. Broudy, V.C., N.L. Lin, and K. Kaushansky, Thrombopoietin (c-mpl ligand) acts synergistically with 
erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth 
and increases megakaryocyte ploidy in vitro. Blood, 1995. 85(7): p. 1719-26. 
180. Fox, N.E., et al., Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic 
thrombocytopenia: functional characterization and a review of the literature. Exp Hematol, 2009. 
37(4): p. 495-503. 
181. Moliterno, A.R., W.D. Hankins, and J.L. Spivak, Impaired expression of the thrombopoietin receptor 
by platelets from patients with polycythemia vera. New England Journal of Medicine, 1998. 338(9): 
p. 572-580. 
182. Stockklausner, C., et al., The thrombopoietin receptor P106L mutation functionally separates receptor 
signaling activity from thrombopoietin homeostasis. Blood, 2015. 125(7): p. 1159-69. 
183. Hitchcock, I.S., et al., YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate 
receptor internalization and degradation. Blood, 2008. 112(6): p. 2222-31. 
184. Drachman, J.G. and K. Kaushansky, Dissecting the thrombopoietin receptor: functional elements of 
the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A, 1997. 94(6): p. 2350-5. 
185. Dahlen, D.D., V.C. Broudy, and J.G. Drachman, Internalization of the thrombopoietin receptor is 
regulated by 2 cytoplasmic motifs. Blood, 2003. 102(1): p. 102-8. 
186. Saur, S.J., et al., Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood, 2010. 
115: p. 1254-1263. 
187. Royer, Y., et al., Janus kinases affect thrombopoietin receptor cell surface localization and stability. J 
Biol Chem, 2005. 280: p. 27251-27261. 
188. Sigismund, S., S. Polo, and P.P. Di Fiore, Signaling through monoubiquitination. Curr Top Microbiol 
Immunol, 2004. 286: p. 149-85. 
189. Levkowitz, G., et al., Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of 
growth factor signaling by c-Cbl/Sli-1. Mol Cell, 1999. 4(6): p. 1029-40. 
190. Waterman, H., et al., A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role 
for Grb2 in negative signaling. Embo j, 2002. 21(3): p. 303-13. 
191. Qazi, A.M., C.H. Tsai-Morris, and M.L. Dufau, Ligand-independent homo- and heterodimerization of 
human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol 
Endocrinol, 2006. 20(8): p. 1912-23. 
192. Schuster, B., et al., The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma 
membrane. FEBS Lett, 2003. 538(1-3): p. 113-6. 
193. Livnah, O., et al., Crystallographic evidence for preformed dimers of erythropoietin receptor before 
ligand activation. Science, 1999. 283(5404): p. 987-90. 
234 
 
194. Remy, I., I.A. Wilson, and S.W. Michnick, Erythropoietin receptor activation by a ligand-induced 
conformation change. Science, 1999. 283(5404): p. 990-3. 
195. Giese, B., et al., Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. J Cell 
Sci, 2005. 118(Pt 21): p. 5129-40. 
196. Leroy, E., et al., His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine 
Mutations of the Human Thrombopoietin Receptor. J Biol Chem, 2016. 291(6): p. 2974-87. 
197. Alexander, W.S., D. Metcalf, and A.R. Dunn, Point mutations within a dimer interface homology 
domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J, 1995. 14: p. 5569-
5578. 
198. Miyakawa, Y., et al., Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of 
Janus kinase 2 and Shc in human blood platelets. Blood, 1995. 86(1): p. 23-7. 
199. Drachman, J.G., J.D. Griffin, and K. Kaushansky, The c-Mpl ligand (thrombopoietin) stimulates tyrosine 
phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem, 1995. 270(10): p. 4979-82. 
200. Miyakawa, Y., et al., Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human 
blood platelets. Blood, 1996. 87(2): p. 439-46. 
201. Rouyez, M.C., et al., Control of thrombopoietin-induced megakaryocytic differentiation by the 
mitogen-activated protein kinase pathway. Mol Cell Biol, 1997. 17(9): p. 4991-5000. 
202. Filippi, M.D., et al., Requirement for mitogen-activated protein kinase activation in the response of 
embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro. Blood, 2002. 99(4): p. 
1174-82. 
203. Drachman, J.G., K.M. Millett, and K. Kaushansky, Thrombopoietin signal transduction requires 
functional JAK2, not TYK2. J Biol Chem, 1999. 274(19): p. 13480-4. 
204. Drachman, J.G., et al., Thrombopoietin signal transduction in purified murine megakaryocytes. Blood, 
1997. 89(2): p. 483-92. 
205. Geddis, A.E., N.E. Fox, and K. Kaushansky, Phosphatidylinositol 3-kinase is necessary but not sufficient 
for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary 
megakaryocytic progenitors. J Biol Chem, 2001. 276(37): p. 34473-9. 
206. Nakao, T., et al., PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of 
primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle, 2008. 7(2): p. 
257-66. 
207. Rojnuckarin, P., J.G. Drachman, and K. Kaushansky, Thrombopoietin-induced activation of the 
mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. 
Blood, 1999. 94(4): p. 1273-82. 
208. Luoh, S.M., et al., Role of the distal half of the c-Mpl intracellular domain in control of platelet 
production by thrombopoietin in vivo. Mol Cell Biol, 2000. 20(2): p. 507-15. 
209. Rojnuckarin, P., et al., The roles of phosphatidylinositol 3-kinase and protein kinase Czeta for 
thrombopoietin-induced mitogen-activated protein kinase activation in primary murine 
megakaryocytes. J Biol Chem, 2001. 276(44): p. 41014-22. 
210. Sabath, D.F., K. Kaushansky, and V.C. Broudy, Deletion of the extracellular membrane-distal cytokine 
receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin 
binding. Blood, 1999. 94(1): p. 365-7. 
211. Chen, W.M., et al., Identification of the residues in the extracellular domain of thrombopoietin 
receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC). 
J Biol Chem, 2010. 285(34): p. 26697-709. 
212. Layton, J.E., et al., Identification of a ligand-binding site on the granulocyte colony-stimulating factor 
receptor by molecular modeling and mutagenesis. J Biol Chem, 1997. 272(47): p. 29735-41. 
213. Rajotte, D., et al., Crucial role of the residue R280 at the F'-G' loop of the human 
granulocyte/macrophage colony-stimulating factor receptor alpha chain for ligand recognition. J Exp 
Med, 1997. 185(11): p. 1939-50. 
214. Fox, N.E., et al., F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor 
agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic 
thrombocytopenia can be stimulated with alternative thrombopoietic agents. Exp Hematol, 2010. 
38(5): p. 384-91. 
235 
 
215. Albu, R.I. and S.N. Constantinescu, Extracellular domain N-glycosylation controls human 
thrombopoietin receptor cell surface levels. Front Endocrinol (Lausanne), 2011. 2: p. 71. 
216. Yoshimura, A., et al., Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish 
processing, ligand binding, and activation of the receptor. J Biol Chem, 1992. 267(16): p. 11619-25. 
217. Quelle, D.E., F.W. Quelle, and D.M. Wojchowski, Mutations in the WSAWSE and cytosolic domains of 
the erythropoietin receptor affect signal transduction and ligand binding and internalization. Mol Cell 
Biol, 1992. 12(10): p. 4553-61. 
218. Sasazawa, Y., et al., C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-
dependent JAK-STAT signaling. Biochem Biophys Res Commun, 2015. 468(1-2): p. 262-8. 
219. Kim, M.J., et al., NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the 
thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem, 
2007. 282(19): p. 14253-61. 
220. Ding, J., et al., Familial essential thrombocythemia associated with a dominant-positive activating 
mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood, 2004. 
103(11): p. 4198-200. 
221. Matthews, E.E., et al., Thrombopoietin receptor activation: transmembrane helix dimerization, 
rotation, and allosteric modulation. Faseb j, 2011. 25(7): p. 2234-44. 
222. Ding, J.M., et al., The Asn505 mutation of the c-MPL gene, which causes familial essential 
thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino 
acid polarity. Blood, 2009. 114(15): p. 3325-3328. 
223. Choma, C., et al., Asparagine-mediated self-association of a model transmembrane helix. Nat Struct 
Biol, 2000. 7(2): p. 161-6. 
224. Defour, J.P., et al., Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin 
receptor dimerization and activation. Proc Natl Acad Sci U S A, 2013. 110(7): p. 2540-5. 
225. Staerk, J., et al., An amphipathic motif at the transmembrane-cytoplasmic junction prevents 
autonomous activation of the thrombopoietin receptor. Blood, 2006. 107(5): p. 1864-71. 
226. Abd Halim, K.B., H. Koldso, and M.S. Sansom, Interactions of the EGFR juxtamembrane domain with 
PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics simulations. Biochim 
Biophys Acta, 2015. 1850(5): p. 1017-25. 
227. Defour, J.P., et al., Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: 
implications for myeloproliferative neoplasms. Leukemia, 2016. 30(5): p. 1214-6. 
228. Seubert, N., et al., Active and inactive orientations of the transmembrane and cytosolic domains of 
the erythropoietin receptor dimer. Mol Cell, 2003. 12(5): p. 1239-50. 
229. Alexander, W.S., et al., Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the 
induction of cellular differentiation. Embo j, 1996. 15(23): p. 6531-40. 
230. Pecquet, C., et al., Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin 
receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood, 2010. 115(5): p. 
1037-48. 
231. Haxholm, G.W., et al., Intrinsically disordered cytoplasmic domains of two cytokine receptors mediate 
conserved interactions with membranes. Biochemical Journal, 2015. 468: p. 495-506. 
232. Ballmaier, M., et al., c-mpl mutations are the cause of congenital amegakaryocytic 
thrombocytopenia. Blood, 2001. 97(1): p. 139-46. 
233. Ihara, K., et al., Identification of mutations in the c-mpl gene in congenital amegakaryocytic 
thrombocytopenia. Proceedings of the National Academy of Sciences of the United States of America, 
1999. 96(6): p. 3132-3136. 
234. van den Oudenrijn, S., et al., Mutations in the thrombopoietin receptor, Mpl, in children with 
congenital amegakaryocytic thrombocytopenia. Br J Haematol, 2000. 110(2): p. 441-8. 
235. El-Harith el, H.A., et al., Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu 
in the MPL gene. Br J Haematol, 2009. 144(2): p. 185-94. 
236. Chaligne, R., et al., New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations 
promote a G1/S-phase transition. Leukemia, 2008. 22: p. 1557-1566. 
237. Chaligne, R., et al., New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations 
promote a G1/S-phase transition. Leukemia, 2008. 22(8): p. 1557-66. 
236 
 
238. Marty, C., et al., Ligand-independent thrombopoietin mutant receptor requires cell surface 
localization for endogenous activity. J Biol Chem, 2009. 284(18): p. 11781-91. 
239. Malinge, S., et al., Activating mutations in human acute megakaryoblastic leukemia. Blood, 2008. 
112(10): p. 4220-4226. 
240. Chaligne, R., et al., Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive 
myelofibrosis. Blood, 2007. 110(10): p. 3735-43. 
241. Onishi, M., et al., Identification of an oncogenic form of the thrombopoietin receptor MPL using 
retrovirus-mediated gene transfer. Blood, 1996. 88(4): p. 1399-406. 
242. Cheng, G., et al., Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-
month, randomised, phase 3 study. Lancet, 2011. 377(9763): p. 393-402. 
243. Kuter, D.J., et al., Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: 
a double-blind randomised controlled trial. Lancet, 2008. 371(9610): p. 395-403. 
244. Imbach, P. and M. Crowther, Thrombopoietin-Receptor Agonists for Primary Immune 
Thrombocytopenia. New England Journal of Medicine, 2011. 365(8): p. 734-741. 
245. Erickson-Miller, C.L., et al., Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide 
thrombopoietin receptor agonist. Stem Cells, 2009. 27(2): p. 424-30. 
246. Erickson-Miller, C.L., et al., Discovery and characterization of a selective, nonpeptidyl thrombopoietin 
receptor agonist. Exp Hematol, 2005. 33(1): p. 85-93. 
247. Quintas-Cardama, A., et al., Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: 
therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010. 115(15): p. 
3109-17. 
248. Lannutti, B.J., et al., Increased megakaryocytopoiesis in Lyn-deficient mice. Oncogene, 2006. 25(23): 
p. 3316-24. 
249. Tong, W. and H.F. Lodish, Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J 
Exp Med, 2004. 200(5): p. 569-80. 
250. Wang, Q., et al., Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-
induced signaling through induction of SOCS-1. Blood, 2000. 96: p. 2093-2099. 
251. Hitchcock, I.S., et al., Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: 
studies using a megakaryocyte lineage specific FAK knockout. Blood, 2008. 111(2): p. 596-604. 
252. Endo, T.A., et al., A new protein containing an SH2 domain that inhibits JAK kinases. Nature, 1997. 
387(6636): p. 921-4. 
253. Starr, R., et al., A family of cytokine-inducible inhibitors of signalling. Nature, 1997. 387(6636): p. 917-
21. 
254. Naka, T., et al., Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997. 387(6636): 
p. 924-9. 
255. Babon, J.J., et al., Secondary structure assignment of mouse SOCS3 by NMR defines the domain 
boundaries and identifies an unstructured insertion in the SH2 domain. Febs j, 2005. 272(23): p. 6120-
30. 
256. Wang, Q., et al., Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-
induced signaling through induction of SOCS-1. Blood, 2000. 96(6): p. 2093-9. 
257. Hof, P., et al., Crystal structure of the tyrosine phosphatase SHP-2. Cell, 1998. 92(4): p. 441-50. 
258. Yang, J., et al., Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem, 2003. 
278(8): p. 6516-20. 
259. Wang, W., et al., Crystal structure of human protein tyrosine phosphatase SHP-1 in the open 
conformation. J Cell Biochem, 2011. 112(8): p. 2062-71. 
260. Sanjay, A., W.C. Horne, and R. Baron, The Cbl family: ubiquitin ligases regulating signaling by tyrosine 
kinases. Sci STKE, 2001. 2001(110): p. pe40. 
261. Garcia-Guzman, M., E. Larsen, and K. Vuori, The proto-oncogene c-Cbl is a positive regulator of Met-
induced MAP kinase activation: a role for the adaptor protein Crk. Oncogene, 2000. 19(35): p. 4058-
65. 
262. Yasuda, T., et al., Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B 
cells. J Exp Med, 2002. 196(1): p. 51-63. 
237 
 
263. Chiang, S.H., et al., Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of 
TC10. Nature, 2001. 410(6831): p. 944-8. 
264. Ahn, M.Y., et al., Primary and essential role of the adaptor protein APS for recruitment of both c-Cbl 
and its associated protein CAP in insulin signaling. J Biol Chem, 2004. 279(20): p. 21526-32. 
265. Standaert, M.L., et al., Requirements for pYXXM motifs in Cbl for binding to the p85 subunit of 
phosphatidylinositol 3-kinase and Crk, and activation of atypical protein kinase C and glucose 
transport during insulin action in 3T3/L1 adipocytes. Biochemistry, 2004. 43(49): p. 15494-502. 
266. Saur, S.J., et al., Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood, 2010. 
115(6): p. 1254-63. 
267. Brown, M.T. and J.A. Cooper, Regulation, substrates and functions of src. Biochim Biophys Acta, 1996. 
1287(2-3): p. 121-49. 
268. Thomas, S.M. and J.S. Brugge, Cellular functions regulated by Src family kinases. Annu Rev Cell Dev 
Biol, 1997. 13: p. 513-609. 
269. Lannutti, B.J., et al., Identification and activation of Src family kinases in primary megakaryocytes. 
Exp Hematol, 2003. 31(12): p. 1268-74. 
270. Lannutti, B.J. and J.G. Drachman, Lyn tyrosine kinase regulates thrombopoietin-induced proliferation 
of hematopoietic cell lines and primary megakaryocytic progenitors. Blood, 2004. 103(10): p. 3736-
43. 
271. Wang, B., et al., SH2 domain-mediated interaction of inhibitory protein tyrosine kinase Csk with 
protein tyrosine phosphatase-HSCF. Mol Cell Biol, 2001. 21(4): p. 1077-88. 
272. Margolis, B., et al., The function of PTB domain proteins. Kidney Int, 1999. 56(4): p. 1230-7. 
273. Macias, M.J., et al., Structure of the WW domain of a kinase-associated protein complexed with a 
proline-rich peptide. Nature, 1996. 382(6592): p. 646-9. 
274. Mayer, B.J., SH3 domains: complexity in moderation. J Cell Sci, 2001. 114(Pt 7): p. 1253-63. 
275. Lemmon, M.A. and K.M. Ferguson, Signal-dependent membrane targeting by pleckstrin homology 
(PH) domains. Biochem J, 2000. 350 Pt 1: p. 1-18. 
276. Velazquez, L., et al., Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient 
mice. J Exp Med, 2002. 195(12): p. 1599-611. 
277. Tong, W., J. Zhang, and H.F. Lodish, Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation 
and downstream signaling pathways. Blood, 2005. 105(12): p. 4604-4612. 
278. Bersenev, A., et al., Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through 
direct interactions with JAK2. J Clin Invest, 2008. 118(8): p. 2832-44. 
279. Ema, H., et al., Quantification of self-renewal capacity in single hematopoietic stem cells from normal 
and Lnk-deficient mice. Dev Cell, 2005. 8(6): p. 907-14. 
280. Takaki, S., et al., Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular 
adaptor protein, Lnk. J Exp Med, 2002. 195(2): p. 151-60. 
281. Takizawa, H., et al., Enhanced engraftment of hematopoietic stem/progenitor cells by the transient 
inhibition of an adaptor protein, Lnk. Blood, 2006. 107(7): p. 2968-75. 
282. Wakioka, T., et al., APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 
(SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia, 1999. 13(5): p. 
760-7. 
283. Javadi, M., et al., The SH2B1 adaptor protein associates with a proximal region of the erythropoietin 
receptor. J Biol Chem, 2012. 287(31): p. 26223-34. 
284. Takizawa, H., et al., Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor 
protein through crosstalk between cytokine- and integrin-mediated signals. Exp Hematol, 2008. 
36(7): p. 897-906. 
285. Gery, S., et al., Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with 
myeloproliferative disorders. Blood, 2007. 110(9): p. 3360-4. 
286. Li, Y., et al., Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology 
and Src homology 2 domains that can inhibit T cell activation. J Immunol, 2000. 164(10): p. 5199-206. 
287. Osborne, M.A., S. Dalton, and J.P. Kochan, The yeast tribrid system--genetic detection of trans-
phosphorylated ITAM-SH2-interactions. Biotechnology (N Y), 1995. 13(13): p. 1474-8. 
238 
 
288. Rui, L., et al., Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth 
hormone signaling. Mol Cell Biol, 1997. 17(11): p. 6633-44. 
289. Nelms, K., et al., Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor 
kinase domain. Mamm Genome, 1999. 10(12): p. 1160-7. 
290. Yousaf, N., et al., Four PSM/SH2-B alternative splice variants and their differential roles in 
mitogenesis. Journal of Biological Chemistry, 2001. 276(44): p. 40940-40948. 
291. Nishi, M., et al., Kinase activation through dimerization by human SH2-B. Molecular and Cellular 
Biology, 2005. 25(7): p. 2607-2621. 
292. Li, M., et al., Identification of SH2B2beta as an inhibitor for SH2B1- and SH2B2alpha-promoted Janus 
kinase-2 activation and insulin signaling. Endocrinology, 2007. 148(4): p. 1615-21. 
293. Qian, X., et al., Identification and characterization of novel substrates of Trk receptors in developing 
neurons. Neuron, 1998. 21(5): p. 1017-29. 
294. Rui, L., J. Herrington, and C. Carter-Su, SH2-B is required for nerve growth factor-induced neuronal 
differentiation. J Biol Chem, 1999. 274(15): p. 10590-4. 
295. Ohtsuka, S., et al., SH2-B Is Required for Both Male and Female Reproduction. Molecular and Cellular 
Biology, 2002. 22(9): p. 3066-3077. 
296. Duan, C., et al., Disruption of the SH2-B gene causes age-dependent insulin resistance and glucose 
intolerance. Mol Cell Biol, 2004. 24(17): p. 7435-43. 
297. Ren, D., et al., Identification of SH2-B as a key regulator of leptin sensitivity, energy balance, and body 
weight in mice. Cell Metab, 2005. 2(2): p. 95-104. 
298. Rui, L.Y. and C. Carter-Su, Identification of SH2-B beta as a potent cytoplasmic activator of the tyrosine 
kinase Janus kinase 2. Proceedings of the National Academy of Sciences of the United States of 
America, 1999. 96(13): p. 7172-7177. 
299. Kurzer, J.H., et al., Binding of SH2-B family members within a potential negative regulatory region 
maintains JAK2 in an active state. Mol Cell Biol, 2006. 26(17): p. 6381-94. 
300. Ding, L.W., et al., LNK (SH2B3): paradoxical effects in ovarian cancer. Oncogene, 2015. 34(11): p. 
1463-74. 
301. Chatelais, M., et al., Gene transfer of the adaptor Lnk (SH2B3) prevents porcine endothelial cell 
activation and apoptosis: implication for xenograft's cytoprotection. Xenotransplantation, 2011. 
18(2): p. 108-20. 
302. Ahmed, Z. and T.S. Pillay, Adapter protein with a pleckstrin homology (PH) and an Src homology 2 
(SH2) domain (APS) and SH2-B enhance insulin-receptor autophosphorylation, extracellular-signal-
regulated kinase and phosphoinositide 3-kinase-dependent signalling. Biochem J, 2003. 371(Pt 2): p. 
405-12. 
303. Qian, X. and D.D. Ginty, SH2-B and APS are multimeric adapters that augment TrkA signaling. Mol 
Cell Biol, 2001. 21(5): p. 1613-20. 
304. Wang, T.C., et al., The adaptor protein SH2B3 (Lnk) negatively regulates neurite outgrowth of PC12 
cells and cortical neurons. PLoS One, 2011. 6(10): p. e26433. 
305. Hu, J., et al., Structural basis for recruitment of the adaptor protein APS to the activated insulin 
receptor. Mol Cell, 2003. 12(6): p. 1379-89. 
306. Dhe-Paganon, S., et al., A phenylalanine zipper mediates APS dimerization. Nat Struct Mol Biol, 2004. 
11(10): p. 968-74. 
307. Maures, T.J., J.H. Kurzer, and C. Carter-Su, SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein 
and kinase made for each other. Trends in Endocrinology and Metabolism, 2007. 18(1): p. 38-45. 
308. Perez-Garcia, A., et al., Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood, 2013. 122(14): 
p. 2425-32. 
309. Baran-Marszak, F., et al., Expression level and differential JAK2-V617F-binding of the adaptor protein 
Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood, 2010. 116(26): p. 5961-
71. 
310. Gery, S., et al., Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc 
Biol, 2009. 85(6): p. 957-65. 
311. Simon, C., et al., Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in 
primary mast cells. Blood, 2008. 112(10): p. 4039-47. 
239 
 
312. Gueller, S., et al., Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. J Leukoc Biol, 
2010. 88(4): p. 699-706. 
313. Fitau, J., et al., The adaptor molecule Lnk negatively regulates tumor necrosis factor-alpha-dependent 
VCAM-1 expression in endothelial cells through inhibition of the ERK1 and -2 pathways. J Biol Chem, 
2006. 281(29): p. 20148-59. 
314. Seita, J., et al., Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying 
thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A, 2007. 104(7): p. 2349-54. 
315. Takaki, S., et al., Control of B cell production by the adaptor protein lnk. Definition Of a conserved 
family of signal-modulating proteins. Immunity, 2000. 13(5): p. 599-609. 
316. Gueller, S., et al., Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling. 
Exp Hematol, 2011. 39(5): p. 591-600. 
317. Miyakawa, Y., et al., Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, 
and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol 
Chem, 2001. 276(4): p. 2494-502. 
318. Nobuhisa, I., et al., Regulation of hematopoietic development in the aorta-gonad-mesonephros 
region mediated by Lnk adaptor protein. Mol Cell Biol, 2003. 23(23): p. 8486-94. 
319. Bersenev, A., et al., Lnk constrains myeloproliferative diseases in mice. J Clin Invest, 2010. 120: p. 
2058-2069. 
320. Gueller, S., et al., Adaptor protein Lnk associates with Tyr(568) in c-Kit. Biochem J, 2008. 415(2): p. 
241-5. 
321. Gery, S., et al., Adaptor Protein Lnk Negatively Regulates Mutant MPL and JAK2 Alleles Associated 
with Myeloproliferative Disorders. Blood, 2007. 110(11): p. 1531-1531. 
322. Pardanani, A., et al., CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic 
mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 
2003. 102(9): p. 3093-6. 
323. Cools, J., et al., A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic 
target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 2003. 348(13): p. 1201-14. 
324. Bersenev, A., et al., Lnk constrains myeloproliferative diseases in mice. J Clin Invest, 2010. 120(6): p. 
2058-69. 
325. Yano, M., et al., Clinical significance of SH2B3 (LNK) expression in paediatric B-cell precursor acute 
lymphoblastic leukaemia. Br J Haematol, 2018. 183(2): p. 327-330. 
326. Ge, Z., et al., Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute 
lymphoblastic leukemia with Ikaros dysfunction. Oncotarget, 2016. 7(29): p. 46014-46027. 
327. Baughn, L.B., et al., SH2B3 aberrations enriched in iAMP21 B lymphoblastic leukemia. Cancer Genet, 
2018. 226-227: p. 30-35. 
328. Iseki, M., et al., APS, an adaptor molecule containing PH and SH2 domains, has a negative regulatory 
role in B cell proliferation. Biochem Biophys Res Commun, 2005. 330(3): p. 1005-13. 
329. Chan, P.M., et al., Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane 
region. Mol Cell Biol, 2003. 23(9): p. 3067-78. 
330. Kozlowski, M., et al., SHP-1 binds and negatively modulates the c-Kit receptor by interaction with 
tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol, 1998. 18(4): p. 2089-99. 
331. Wollberg, P., et al., The adapter protein APS associates with the multifunctional docking sites Tyr-568 
and Tyr-936 in c-Kit. Biochem J, 2003. 370(Pt 3): p. 1033-8. 
332. Lin, D.C., et al., Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood, 2012. 
120(16): p. 3310-7. 
333. Cheng, Y., et al., LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. 
J Clin Invest, 2016. 126(4): p. 1267-81. 
334. Kurzer, J.H., et al., Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by 
SH2-B beta. Mol Cell Biol, 2004. 24(10): p. 4557-70. 
335. Yokouchi, M., et al., Cloning and characterization of APS, an adaptor molecule containing PH and SH2 
domains that is tyrosine phosphorylated upon B-cell receptor stimulation. Oncogene, 1997. 15(1): p. 
7-15. 
240 
 
336. Riedel, H., et al., PSM, an insulin-dependent, pro-rich, PH, SH2 domain containing partner of the 
insulin receptor. J Biochem, 1997. 122(6): p. 1105-13. 
337. Rui, L. and C. Carter-Su, Platelet-derived growth factor (PDGF) stimulates the association of SH2-
Bbeta with PDGF receptor and phosphorylation of SH2-Bbeta. J Biol Chem, 1998. 273(33): p. 21239-
45. 
338. Kotani, K., P. Wilden, and T.S. Pillay, SH2-Balpha is an insulin-receptor adapter protein and substrate 
that interacts with the activation loop of the insulin-receptor kinase. Biochem J, 1998. 335 ( Pt 1): p. 
103-9. 
339. Moodie, S.A., J. Alleman-Sposeto, and T.A. Gustafson, Identification of the APS protein as a novel 
insulin receptor substrate. J Biol Chem, 1999. 274(16): p. 11186-93. 
340. Wang, J. and H. Riedel, Insulin-like growth factor-I receptor and insulin receptor association with a 
Src homology-2 domain-containing putative adapter. J Biol Chem, 1998. 273(6): p. 3136-9. 
341. Rui, L., et al., Differential binding to and regulation of JAK2 by the SH2 domain and N-terminal region 
of SH2-bbeta. Mol Cell Biol, 2000. 20(9): p. 3168-77. 
342. Bersenev, A., et al., Lnk Controls Hematopoietic Stem Cell Self-Renewal through Direct Interactions 
with JAK2 and Contributes to Oncogenic JAK2-Induced Myeloproliferative Diseases in Mice. Blood, 
2008. 112(11): p. 329-329. 
343. Lv, K., et al., CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic 
stem cells and myeloid malignancies. Genes Dev, 2017. 31(10): p. 1007-1023. 
344. Koren-Michowitz, M., et al., SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have 
mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol, 2013. 161(6): p. 811-20. 
345. Liu, J., et al., APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to 
insulin in 3T3-L1 adipocytes. Mol Cell Biol, 2002. 22(11): p. 3599-609. 
346. Ahmed, Z. and T.S. Pillay, Functional effects of APS and SH2-B on insulin receptor signalling. Biochem 
Soc Trans, 2001. 29(Pt 4): p. 529-34. 
347. Liu, J., et al., The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport. J Biol Chem, 2003. 
278(38): p. 36754-62. 
348. Hu, J. and S.R. Hubbard, Structural characterization of a novel Cbl phosphotyrosine recognition motif 
in the APS family of adapter proteins. J Biol Chem, 2005. 280(19): p. 18943-9. 
349. Yokouchi, M., et al., APS, an adaptor protein containing PH and SH2 domains, is associated with the 
PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis. Oncogene, 1999. 18(3): p. 759-67. 
350. Maslah, N., et al., The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and 
other hematological disorders. Leukemia, 2017. 31(8): p. 1661-1670. 
351. Hurtado, C., et al., LNK can also be mutated outside PH and SH2 domains in myeloproliferative 
neoplasms with and without V617FJAK2 mutation. Leuk Res, 2011. 35(11): p. 1537-9. 
352. Ha, J.S. and D.S. Jeon, Possible new LNK mutations in myeloproliferative neoplasms. Am J Hematol, 
2011. 86(10): p. 866-8. 
353. Oh, S.T., et al., Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in 
patients with myeloproliferative neoplasms. Blood, 2010. 116(6): p. 988-992. 
354. Zhang, J., et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 
2012. 481: p. 157-163. 
355. Koren-Michowitz, M., et al., SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have 
mild loss of function against wild type JAK2 and JAK2 V617F. British Journal of Haematology, 2013. 
161(6): p. 811-820. 
356. Chen, Y., et al., The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative 
Neoplasms. PLoS One, 2016. 11(4): p. e0154183. 
357. McMullin, M.F., et al., A nonsynonymous LNK polymorphism associated with idiopathic 
erythrocytosis. Am J Hematol, 2011. 86(11): p. 962-4. 
358. Lesteven, E., et al., Association of a single-nucleotide polymorphism in the SH2B3 gene with 
JAK2V617F-positive myeloproliferative neoplasms. Blood, 2014. 123(5): p. 794-6. 
359. Devalliere, J. and B. Charreau, The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and 
a link between immune and inflammatory signaling. Biochem Pharmacol, 2011. 82(10): p. 1391-402. 
241 
 
360. Rudd, C.E., Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE, 2001. 2001(85): 
p. pe1. 
361. Mori, T., et al., Lnk/Sh2b3 controls the production and function of dendritic cells and regulates the 
induction of IFN-gamma-producing T cells. J Immunol, 2014. 193(4): p. 1728-36. 
362. Flister, M.J., et al., SH2B3 Is a Genetic Determinant of Cardiac Inflammation and Fibrosis. Circ 
Cardiovasc Genet, 2015. 8(2): p. 294-304. 
363. Dale, B.L. and M.S. Madhur, Linking inflammation and hypertension via LNK/SH2B3. Curr Opin 
Nephrol Hypertens, 2016. 25(2): p. 87-93. 
364. Looi, C.Y., et al., Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-
MOK megakaryoblastic leukemic cell growth by promoting apoptosis. PLoS One, 2011. 6(8): p. 
e23640. 
365. Smith, G.P., Filamentous fusion phage: novel expression vectors that display cloned antigens on the 
virion surface. Science, 1985. 228(4705): p. 1315-7. 
366. De Berardinis, P. and N.L. Haigwood, New recombinant vaccines based on the use of prokaryotic 
antigen-display systems. Expert Rev Vaccines, 2004. 3(6): p. 673-9. 
367. Wrighton, N.C., et al., Small peptides as potent mimetics of the protein hormone erythropoietin. 
Science, 1996. 273(5274): p. 458-64. 
368. Cwirla, S.E., et al., Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. 
Science, 1997. 276(5319): p. 1696-9. 
369. Su, J.L., et al., A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits 
angiogenesis and tumor growth. Cancer Res, 2005. 65(11): p. 4827-35. 
370. Hetian, L., et al., A novel peptide isolated from a phage display library inhibits tumor growth and 
metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain 
receptor. J Biol Chem, 2002. 277(45): p. 43137-42. 
371. Schooltink, H. and S. Rose-John, Designing cytokine variants by phage-display. Comb Chem High 
Throughput Screen, 2005. 8(2): p. 173-9. 
372. McConnell, S.J., et al., Isolation of erythropoietin receptor agonist peptides using evolved phage 
libraries. Biol Chem, 1998. 379(10): p. 1279-86. 
373. Tipps, M.E., et al., Identification of novel specific allosteric modulators of the glycine receptor using 
phage display. J Biol Chem, 2010. 285(30): p. 22840-5. 
374. Tao, J., et al., Drug target validation: lethal infection blocked by inducible peptide. Proc Natl Acad Sci 
U S A, 2000. 97(2): p. 783-6. 
375. Hong, H.Y., et al., Phage display selection of peptides that home to atherosclerotic plaques: IL-4 
receptor as a candidate target in atherosclerosis. J Cell Mol Med, 2008. 12(5b): p. 2003-14. 
376. Sergeeva, A., et al., Display technologies: application for the discovery of drug and gene delivery 
agents. Adv Drug Deliv Rev, 2006. 58(15): p. 1622-54. 
377. Arap, W., et al., Steps toward mapping the human vasculature by phage display. Nat Med, 2002. 8(2): 
p. 121-7. 
378. Rowley, M.J., K. O'Connor, and L. Wijeyewickrema, Phage display for epitope determination: a 
paradigm for identifying receptor-ligand interactions. Biotechnol Annu Rev, 2004. 10: p. 151-88. 
379. Smith, G.P. and V.A. Petrenko, Phage Display. Chem Rev, 1997. 97(2): p. 391-410. 
380. Bratkovic, T., Progress in phage display: evolution of the technique and its application. Cell Mol Life 
Sci, 2010. 67(5): p. 749-67. 
381. Gamkrelidze, M. and K. Dabrowska, T4 bacteriophage as a phage display platform. Arch Microbiol, 
2014. 196(7): p. 473-9. 
382. Teesalu, T., K.N. Sugahara, and E. Ruoslahti, Mapping of vascular ZIP codes by phage display. Methods 
Enzymol, 2012. 503: p. 35-56. 
383. Nicastro, J., K. Sheldon, and R.A. Slavcev, Bacteriophage lambda display systems: developments and 
applications. Appl Microbiol Biotechnol, 2014. 98(7): p. 2853-66. 
384. Rakonjac, J., et al., Filamentous bacteriophage: biology, phage display and nanotechnology 
applications. Curr Issues Mol Biol, 2011. 13(2): p. 51-76. 
385. Marvin, D.A., M.F. Symmons, and S.K. Straus, Structure and assembly of filamentous bacteriophages. 
Prog Biophys Mol Biol, 2014. 114(2): p. 80-122. 
242 
 
386. Whitehorn, E.A., et al., A generic method for expression and use of "tagged" soluble versions of cell 
surface receptors. Biotechnology (N Y), 1995. 13(11): p. 1215-9. 
387. Newland, A., Romiplostim: a breakthrough treatment for the management of immune 
thrombocytopenic purpura. Eur J Haematol Suppl, 2009(71): p. 20-5. 
388. Ranganath, S., et al., Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with 
Neutralizing Activity In Vivo. PLoS One, 2015. 10(11): p. e0141330. 
389. Wang, X.L., et al., A thrombopoietin receptor antagonist is capable of depleting myelofibrosis 
hematopoietic stem and progenitor cells. Blood, 2016. 127(26): p. 3398-3409. 
390. Ngo, A., et al., A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant 
Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms. Combinatorial Chemistry & 
High Throughput Screening, 2016. 19(10): p. 824-833. 
391. Shochat, C., et al., Novel activating mutations lacking cysteine in type I cytokine receptors in acute 
lymphoblastic leukemia. Blood, 2014. 124(1): p. 106-10. 
392. Shochat, C., et al., Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood 
acute lymphoblastic leukemias. J Exp Med, 2011. 208(5): p. 901-8. 
393. Zenatti, P.P., et al., Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic 
leukemia. Nat Genet, 2011. 43(10): p. 932-9. 
394. Bridgford, J.L., et al., Novel Drivers and Modifiers of MPL-dependent Oncogenic Transformation 
Identified by Deep Mutational Scanning. Blood, 2019. 
395. Chaligne, R., et al., New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations 
promote a G(1)/S-phase transition. Leukemia, 2008. 22(8): p. 1557-1566. 
396. Onishi, M., et al., Identification of an oncogenic form of the thrombopoietin receptor MPL using 
retrovirus-mediated gene transfer. Blood, 1996. 88(4): p. 1399-1406. 
397. Ding, J., et al., The Asn505 mutation of the c-MPL gene, which causes familial essential 
thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino 
acid polarity. Blood, 2009. 114(15): p. 3325-8. 
398. Stepanenko, A.A. and V.V. Dmitrenko, HEK293 in cell biology and cancer research: phenotype, 
karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. Gene, 2015. 569(2): p. 
182-90. 
399. Teofili, L., et al., Markers of myeloproliferative diseases in childhood polycythemia vera and essential 
thrombocythemia. J Clin Oncol, 2007. 25(9): p. 1048-53. 
400. Liu, K., et al., Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with 
hereditary thrombocythemia. Haematologica, 2009. 94(10): p. 1368-74. 
401. Morrell, R., et al., Nonfamilial, MPL S505N-Mutated Essential Thrombocythaemia. Case Rep Hematol, 
2013. 2013: p. 729327. 
402. Inc., T.B. MSCV retrovirus system. 2019  22 Nov 2019]; Available from: 
https://www.takarabio.com/products/gene-function/viral-transduction/retrovirus/vector-
systems/mscv-system. 
403. Defour, J.P., et al., The S505A thrombopoietin receptor mutation in childhood hereditary 
thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. 
Leukemia, 2019. 33(2): p. 563-564. 
404. (CRI), C.f.R.a.I. Binding group: Finding novel fabric binding peptides. Available from: 
http://2016.igem.org/Team:Paris_Bettencourt/Project/Binding. 
405. Zorzi, A., K. Deyle, and C. Heinis, Cyclic peptide therapeutics: past, present and future. Curr Opin Chem 
Biol, 2017. 38: p. 24-29. 
406. Kang, H.K., et al., Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer 
Peptides. Int J Mol Sci, 2018. 19(3). 
407. C Fromageot, a. and M. Jutisz, Chemistry of Amino Acids, Peptides, and Proteins. Annual Review of 
Biochemistry, 1953. 22(1): p. 629-678. 
408. Horton, D.A., G.T. Bourne, and M.L. Smythe, Exploring privileged structures: the combinatorial 
synthesis of cyclic peptides. Mol Divers, 2002. 5(4): p. 289-304. 
409. Joo, S.H., Cyclic peptides as therapeutic agents and biochemical tools. Biomolecules & therapeutics, 
2012. 20(1): p. 19-26. 
243 
 
410. Veya, L., J. Piguet, and H. Vogel, Single Molecule Imaging Deciphers the Relation between Mobility 
and Signaling of a Prototypical G Protein-coupled Receptor in Living Cells. J Biol Chem, 2015. 290(46): 
p. 27723-35. 
411. Wilmes, S., et al., Receptor dimerization dynamics as a regulatory valve for plasticity of type I 
interferon signaling. J Cell Biol, 2015. 209(4): p. 579-93. 
412. Manley, S., et al., High-density mapping of single-molecule trajectories with photoactivated 
localization microscopy. Nat Methods, 2008. 5(2): p. 155-7. 
413. Shrivastava, A.N., et al., Dynamic micro-organization of P2X7 receptors revealed by PALM based 
single particle tracking. Front Cell Neurosci, 2013. 7: p. 232. 
414. Mattheyses, A.L., S.M. Simon, and J.Z. Rappoport, Imaging with total internal reflection fluorescence 
microscopy for the cell biologist. J Cell Sci, 2010. 123(Pt 21): p. 3621-8. 
415. Rines, D.R., et al., Live cell imaging of yeast. Cold Spring Harb Protoc, 2011. 2011(9). 
416. Kusumi, A. and Y. Sako, Cell surface organization by the membrane skeleton. Curr Opin Cell Biol, 1996. 
8(4): p. 566-74. 
417. Sheetz, M.P., Membrane skeletal dynamics: role in modulation of red cell deformability, mobility of 
transmembrane proteins, and shape. Semin Hematol, 1983. 20(3): p. 175-88. 
418. Taylor, R.D., et al., Neuronal Receptors Display Cytoskeleton-Independent Directed Motion on the 
Plasma Membrane. iScience, 2018. 10: p. 234-244. 
419. Tinevez, J.Y., et al., TrackMate: An open and extensible platform for single-particle tracking. Methods, 
2017. 115: p. 80-90. 
420. Vega, A.R., et al., Multistep Track Segmentation and Motion Classification for Transient Mobility 
Analysis. Biophys J, 2018. 114(5): p. 1018-1025. 
421. Ferrari, R., A.J. Manfroi, and W.R. Young, Strongly and weakly self-similar diffusion. Phys. D, 2001. 
154(1-2): p. 111-137. 
422. Jaqaman, K., et al., Cytoskeletal control of CD36 diffusion promotes its receptor and signaling 
function. Cell, 2011. 146(4): p. 593-606. 
423. Levet, F., et al., SR-Tesseler: a method to segment and quantify localization-based super-resolution 
microscopy data. Nat Methods, 2015. 12(11): p. 1065-71. 
424. Brejchova, J., et al., TRH-receptor mobility and function in intact and cholesterol-depleted plasma 
membrane of HEK293 cells stably expressing TRH-R-eGFP. Biochim Biophys Acta, 2015. 1848(3): p. 
781-96. 
425. Yamazaki, S., et al., Cytokine signals modulated via lipid rafts mimic niche signals and induce 
hibernation in hematopoietic stem cells. EMBO J, 2006. 25(15): p. 3515-23. 
426. Ariotti, N., et al., Epidermal growth factor receptor activation remodels the plasma membrane lipid 
environment to induce nanocluster formation. Mol Cell Biol, 2010. 30(15): p. 3795-804. 
427. Pageon, S.V., et al., Functional role of T-cell receptor nanoclusters in signal initiation and antigen 
discrimination. Proc Natl Acad Sci U S A, 2016. 113(37): p. E5454-63. 
428. Triller, A. and D. Choquet, New concepts in synaptic biology derived from single-molecule imaging. 
Neuron, 2008. 59(3): p. 359-74. 
429. Serge, A., et al., Receptor activation and homer differentially control the lateral mobility of 
metabotropic glutamate receptor 5 in the neuronal membrane. J Neurosci, 2002. 22(10): p. 3910-20. 
430. Marchetti, L., et al., Ligand signature in the membrane dynamics of single TrkA receptor molecules. J 
Cell Sci, 2013. 126(Pt 19): p. 4445-56. 
431. Barak, L.S. and W.W. Webb, Diffusion of low density lipoprotein-receptor complex on human 
fibroblasts. J Cell Biol, 1982. 95(3): p. 846-52. 
432. Thoumine, O., et al., Weak Effect of Membrane Diffusion on the Rate of Receptor Accumulation at 
Adhesive Contacts. Biophysical Journal, 2005. 89(5): p. L40-L42. 
433. Allsopp, R.C., U. Lalo, and R.J. Evans, Lipid raft association and cholesterol sensitivity of P2X1-4 
receptors for ATP: chimeras and point mutants identify intracellular amino-terminal residues involved 
in lipid regulation of P2X1 receptors. J Biol Chem, 2010. 285(43): p. 32770-7. 
434. Roosterman, D., et al., Recycling and resensitization of the neurokinin 1 receptor. Influence of agonist 
concentration and Rab GTPases. J Biol Chem, 2004. 279(29): p. 30670-9. 
244 
 
435. Cezanne, L., et al., Dynamic confinement of NK2 receptors in the plasma membrane. Improved FRAP 
analysis and biological relevance. J Biol Chem, 2004. 279(43): p. 45057-67. 
436. Ehrlich, M., et al., Endocytosis by random initiation and stabilization of clathrin-coated pits. Cell, 
2004. 118(5): p. 591-605. 
437. den Otter, W.K. and W.J. Briels, The generation of curved clathrin coats from flat plaques. Traffic, 
2011. 12(10): p. 1407-16. 
438. Andrews, N.L., et al., Actin restricts FcɛRI diffusion and facilitates antigen-induced receptor 
immobilization. Nature Cell Biology, 2008. 10(8): p. 955-963. 
439. Bouzigues, C., et al., Asymmetric redistribution of GABA receptors during GABA gradient sensing by 
nerve growth cones analyzed by single quantum dot imaging. Proceedings of the National Academy 
of Sciences, 2007. 104(27): p. 11251-11256. 
440. Chung, I., et al., Spatial control of EGF receptor activation by reversible dimerization on living cells. 
Nature, 2010. 464(7289): p. 783-7. 
441. Kasai, R.S., et al., Full characterization of GPCR monomer-dimer dynamic equilibrium by single 
molecule imaging. J Cell Biol, 2011. 192(3): p. 463-80. 
442. Lill, Y., et al., Kinetics of the initial steps of G protein-coupled receptor-mediated cellular signaling 
revealed by single-molecule imaging. Chemphyschem, 2005. 6(8): p. 1633-40. 
443. Winter, P.W., et al., Actin-dependent clustering of insulin receptors in membrane microdomains. 
Biochim Biophys Acta, 2012. 1818(3): p. 467-73. 
444. Schaaf, M.J. and J.A. Cidlowski, Molecular determinants of glucocorticoid receptor mobility in living 
cells: the importance of ligand affinity. Mol Cell Biol, 2003. 23(6): p. 1922-34. 
445. Care, B.R. and H.A. Soula, Impact of receptor clustering on ligand binding. BMC Syst Biol, 2011. 5: p. 
48. 
446. Gopalakrishnan, M., et al., Effects of receptor clustering on ligand dissociation kinetics: theory and 
simulations. Biophys J, 2005. 89(6): p. 3686-700. 
447. Jurak, A.B., et al. Filamin A stabilizes thrombopoietin receptor surface expression and inhibits its 
degradation. in 2nd European Platelet Network (EUPLAN) Conference. 2014. 
448. Hibino, K., et al., Single- and multiple-molecule dynamics of the signaling from H-Ras to cRaf-1 
visualized on the plasma membrane of living cells. Chemphyschem, 2003. 4(7): p. 748-53. 
449. Matsuoka, S., T. Shibata, and M. Ueda, Asymmetric PTEN distribution regulated by spatial 
heterogeneity in membrane-binding state transitions. PLoS Comput Biol, 2013. 9(1): p. e1002862. 
450. Clayton, A.H., M.L. Tavarnesi, and T.G. Johns, Unligated epidermal growth factor receptor forms 
higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase 
inhibitor binding. Biochemistry, 2007. 46(15): p. 4589-97. 
451. Hofman, E.G., et al., Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances 
internalization. J Biol Chem, 2010. 285(50): p. 39481-9. 
452. Boersma, Y.L., et al., Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal 
growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem, 2011. 
286(48): p. 41273-85. 
453. Friedman, L.M., et al., Synergistic down-regulation of receptor tyrosine kinases by combinations of 
mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A, 2005. 102(6): p. 1915-20. 
454. Spangler, J.B., et al., Combination antibody treatment down-regulates epidermal growth factor 
receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A, 2010. 107(30): p. 13252-7. 
455. Hackel, B.J., et al., Epidermal growth factor receptor downregulation by small heterodimeric binding 
proteins. Protein Eng Des Sel, 2012. 25(2): p. 47-57. 
456. Bag, N., S. Huang, and T. Wohland, Plasma Membrane Organization of Epidermal Growth Factor 
Receptor in Resting and Ligand-Bound States. Biophys J, 2015. 109(9): p. 1925-36. 
457. Lemmon, M.A. and J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell, 2010. 141(7): p. 
1117-34. 
458. Yang, S., et al., Mapping ErbB receptors on breast cancer cell membranes during signal transduction. 
J Cell Sci, 2007. 120(Pt 16): p. 2763-73. 
459. Lillemeier, B.F., et al., TCR and Lat are expressed on separate protein islands on T cell membranes and 
concatenate during activation. Nat Immunol, 2010. 11(1): p. 90-6. 
245 
 
460. Schamel, W.W. and B. Alarcon, Organization of the resting TCR in nanoscale oligomers. Immunol Rev, 
2013. 251(1): p. 13-20. 
461. Schamel, W.W., et al., Coexistence of multivalent and monovalent TCRs explains high sensitivity and 
wide range of response. J Exp Med, 2005. 202(4): p. 493-503. 
462. Sherman, E., et al., Functional nanoscale organization of signaling molecules downstream of the T 
cell antigen receptor. Immunity, 2011. 35(5): p. 705-20. 
463. Kumar, R., et al., Increased sensitivity of antigen-experienced T cells through the enrichment of 
oligomeric T cell receptor complexes. Immunity, 2011. 35(3): p. 375-87. 
464. Alarcon, B., et al., T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity. EMBO Rep, 
2006. 7(5): p. 490-5. 
465. Grecco, Hernán E., M. Schmick, and Philippe I.H. Bastiaens, Signaling from the Living Plasma 
Membrane. Cell, 2011. 144(6): p. 897-909. 
466. Costa, M.N., K. Radhakrishnan, and J.S. Edwards, Monte Carlo simulations of plasma membrane 
corral-induced EGFR clustering. J Biotechnol, 2011. 151(3): p. 261-70. 
467. Abulrob, A., et al., Nanoscale imaging of epidermal growth factor receptor clustering: effects of 
inhibitors. J Biol Chem, 2010. 285(5): p. 3145-56. 
468. Takizawa, H., et al., Lnk regulates integrin alphaIIbbeta3 outside-in signaling in mouse platelets, 
leading to stabilization of thrombus development in vivo. J Clin Invest, 2010. 120(1): p. 179-90. 
469. Campeau, E., et al., A versatile viral system for expression and depletion of proteins in mammalian 
cells. PLoS One, 2009. 4(8): p. e6529. 
470. Magor, G.W., et al., Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon 
Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. J Mol Diagn, 
2016. 18(5): p. 707-718. 
471. Zou, H., D. Yan, and G. Mohi, Differential biological activity of disease-associated JAK2 mutants. FEBS 
Lett, 2011. 585(7): p. 1007-13. 
472. Ferrao, R. and P.J. Lupardus, The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to 
JAK-Receptor Interactions. Front Endocrinol (Lausanne), 2017. 8: p. 71. 
473. Huang, X., et al., Cloning and characterization of Lnk, a signal transduction protein that links T-cell 
receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc 
Natl Acad Sci U S A, 1995. 92(25): p. 11618-22. 
474. Jiang, J., et al., 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor 
cells. Journal of Clinical Investigation, 2012. 122(6): p. 2079-2091. 
475. Carlesso, N., D.A. Frank, and J.D. Griffin, Tyrosyl phosphorylation and DNA binding activity of signal 
transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by 
Bcr/Abl. J Exp Med, 1996. 183(3): p. 811-20. 
476. Bastarache, L., et al., Phenotype risk scores identify patients with unrecognized Mendelian disease 
patterns. Science, 2018. 359(6381): p. 1233-1239. 
477. Migliaccio, G., et al., Isolation of pure megakaryocytic clones (32D TPO) from the murine multipotent 
IL-3-dependent 32D cell line. Experimental Hematology, 2000. 28(7): p. 77-77. 
478. Amabile, G., et al., Isolation of TPO-dependent subclones from the multipotent 32D cell line. Blood 
Cells Mol Dis, 2005. 35(2): p. 241-52. 
479. Tate, J.G., et al., COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res, 2019. 
47(D1): p. D941-D947. 
480. Demain, A.L. and P. Vaishnav, Production of recombinant proteins by microbes and higher organisms. 
Biotechnol Adv, 2009. 27(3): p. 297-306. 
481. Makino, T., G. Skretas, and G. Georgiou, Strain engineering for improved expression of recombinant 
proteins in bacteria. Microb Cell Fact, 2011. 10: p. 32. 
482. Zerbs, S., A.M. Frank, and F.R. Collart, Bacterial systems for production of heterologous proteins. 
Methods Enzymol, 2009. 463: p. 149-68. 
483. Makrides, S.C., Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol 
Rev, 1996. 60(3): p. 512-38. 
484. Hayat, S.M.G., et al., Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to 
Know. Curr Pharm Des, 2018. 24(6): p. 718-725. 
246 
 
485. Stevens, R.C., Design of high-throughput methods of protein production for structural biology. 
Structure, 2000. 8(9): p. R177-85. 
486. Jana, S. and J.K. Deb, Strategies for efficient production of heterologous proteins in Escherichia coli. 
Appl Microbiol Biotechnol, 2005. 67(3): p. 289-98. 
487. Sorensen, H.P. and K.K. Mortensen, Advanced genetic strategies for recombinant protein expression 
in Escherichia coli. J Biotechnol, 2005. 115(2): p. 113-28. 
488. Fei, D., et al., Correction: Codon Optimization, Expression in Escherichia coli, and Immunogenicity of 
Recombinant Chinese Sacbrood Virus (CSBV) Structural Proteins VP1, VP2, and VP3. PLoS One, 2015. 
10(7): p. e0134423. 
489. Burgess-Brown, N.A., et al., Codon optimization can improve expression of human genes in 
Escherichia coli: A multi-gene study. Protein Expr Purif, 2008. 59(1): p. 94-102. 
490. Maertens, B., et al., Gene optimization mechanisms: a multi-gene study reveals a high success rate 
of full-length human proteins expressed in Escherichia coli. Protein Sci, 2010. 19(7): p. 1312-26. 
491. Yadava, A. and C.F. Ockenhouse, Effect of codon optimization on expression levels of a functionally 
folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems. Infect Immun, 
2003. 71(9): p. 4961-9. 
492. Tian, J., et al., Predicting synonymous codon usage and optimizing the heterologous gene for 
expression in E. coli. Sci Rep, 2017. 7(1): p. 9926. 
493. Zhou, Z., et al., Codon usage is an important determinant of gene expression levels largely through 
its effects on transcription. Proc Natl Acad Sci U S A, 2016. 113(41): p. E6117-e6125. 
494. Contreras-Gomez, A., et al., Protein production using the baculovirus-insect cell expression system. 
Biotechnol Prog, 2014. 30(1): p. 1-18. 
495. Khan, K.H., Gene expression in Mammalian cells and its applications. Adv Pharm Bull, 2013. 3(2): p. 
257-63. 
496. Coskun, O., Separation techniques: Chromatography. North Clin Istanb, 2016. 3(2): p. 156-160. 
497. Liu, Z.Z., S.R. Wickramasinghe, and X.H. Qian, Membrane chromatography for protein purifications 
from ligand design to functionalization. Separation Science and Technology, 2017. 52(2): p. 299-319. 
498. Lebendiker, M., M. Maes, and A. Friedler, A screening methodology for purifying proteins with 
aggregation problems. Methods Mol Biol, 2015. 1258: p. 261-81. 
499. Bondos, S.E. and A. Bicknell, Detection and prevention of protein aggregation before, during, and 
after purification. Anal Biochem, 2003. 316(2): p. 223-31. 
500. Hu, J. and S.R. Hubbard, Structural basis for phosphotyrosine recognition by the Src homology-2 
domains of the adapter proteins SH2-B and APS. J Mol Biol, 2006. 361(1): p. 69-79. 
501. McKercher, M.A., et al., Diversity in peptide recognition by the SH2 domain of SH2B1. Proteins, 2018. 
86(2): p. 164-176. 
502. Catanzariti, A.M., et al., An efficient system for high-level expression and easy purification of authentic 
recombinant proteins. Protein Sci, 2004. 13(5): p. 1331-9. 
503. Gustafsson, C., et al., Engineering genes for predictable protein expression. Protein Expr Purif, 2012. 
83(1): p. 37-46. 
504. Wilkinson, G.W. and A. Akrigg, Constitutive and enhanced expression from the CMV major IE 
promoter in a defective adenovirus vector. Nucleic Acids Res, 1992. 20(9): p. 2233-9. 
505. Hartl, F.U., R. Hlodan, and T. Langer, Molecular chaperones in protein folding: the art of avoiding 
sticky situations. Trends Biochem Sci, 1994. 19(1): p. 20-5. 
506. Stuart, R.A., et al., Mitochondrial molecular chaperones: their role in protein translocation. Trends 
Biochem Sci, 1994. 19(2): p. 87-92. 
507. Hendrick, J.P. and F.U. Hartl, Molecular chaperone functions of heat-shock proteins. Annu Rev 
Biochem, 1993. 62: p. 349-84. 
508. Hendrick, J.P. and F.U. Hartl, The role of molecular chaperones in protein folding. Faseb j, 1995. 9(15): 
p. 1559-69. 
509. Monahan, F.J., J.B. German, and J.E. Kinsella, Effect of Ph and Temperature on Protein Unfolding and 
Thiol-Disulfide Interchange Reactions during Heat-Induced Gelation of Whey Proteins. Journal of 
Agricultural and Food Chemistry, 1995. 43(1): p. 46-52. 
247 
 
510. Shaw, K.L., et al., The effect of net charge on the solubility, activity, and stability of ribonuclease Sa. 
Protein Sci, 2001. 10(6): p. 1206-15. 
511. Becktel, W.J. and W.A. Baase, Thermal denaturation of bacteriophage T4 lysozyme at neutral pH. 
Biopolymers, 1987. 26(5): p. 619-23. 
512. Pace, C.N., D.V. Laurents, and R.E. Erickson, Urea denaturation of barnase: pH dependence and 
characterization of the unfolded state. Biochemistry, 1992. 31(10): p. 2728-34. 
513. Yegutkin, G.G., Effect of increasing concentrations of nonionic detergent Triton X-100 on solubilization 
and structure of rat liver and adipose plasma membranes. Membr Cell Biol, 1997. 10(5): p. 515-20. 
514. Ashani, Y. and G.N. Catravas, Highly reactive impurities in Triton X-100 and Brij 35: partial 
characterization and removal. Anal Biochem, 1980. 109(1): p. 55-62. 
515. Paradies, H.H., Shape and size of a nonionic surfactant micelle. Triton X-100 in aqueous solution. The 
Journal of Physical Chemistry, 1980. 84(6): p. 599-607. 
516. D'Angelo, I., et al., A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 
protein. EMBO Rep, 2006. 7(2): p. 174-9. 
517. Streletzky, K. and G.D.J. Phillies, Temperature Dependence of Triton X-100 Micelle Size and Hydration. 
Langmuir, 1995. 11(1): p. 42-47. 
518. Oberthuer, D., et al., Monitoring and Scoring Counter-Diffusion Protein Crystallization Experiments in 
Capillaries by in situ Dynamic Light Scattering. PLOS ONE, 2012. 7(6): p. e33545. 
519. Dierks, K., et al., Dynamic Light Scattering in Protein Crystallization Droplets: Adaptations for Analysis 
and Optimization of Crystallization Processes. Crystal Growth & Design, 2008. 8(5): p. 1628-1634. 
520. Wilson, W.W., Light scattering as a diagnostic for protein crystal growth--a practical approach. J 
Struct Biol, 2003. 142(1): p. 56-65. 
521. Ferre-D'Amare, A.R. and S.K. Burley, Use of dynamic light scattering to assess crystallizability of 
macromolecules and macromolecular assemblies. Structure, 1994. 2(5): p. 357-9. 
522. Kadima, W., et al., Characterization of precrystallization aggregation of canavalin by dynamic light 
scattering. Biophysical Journal, 1990. 57(1): p. 125-132. 
523. Vedadi, M., et al., Biophysical characterization of recombinant proteins: a key to higher structural 
genomics success. J Struct Biol, 2010. 172(1): p. 107-19. 
524. Niesen, F.H., H. Berglund, and M. Vedadi, The use of differential scanning fluorimetry to detect ligand 
interactions that promote protein stability. Nat Protoc, 2007. 2(9): p. 2212-21. 
525. Ericsson, U.B., et al., Thermofluor-based high-throughput stability optimization of proteins for 
structural studies. Anal Biochem, 2006. 357(2): p. 289-98. 
526. Vedadi, M., et al., Chemical screening methods to identify ligands that promote protein stability, 
protein crystallization, and structure determination. Proc Natl Acad Sci U S A, 2006. 103(43): p. 15835-
40. 
527. Kohlstaedt, M., et al., Development of a Thermofluor assay for stability determination of membrane 
proteins using the Na(+)/H(+) antiporter NhaA and cytochrome c oxidase. Acta Crystallogr D Biol 
Crystallogr, 2015. 71(Pt 5): p. 1112-22. 
528. Fan, J., et al., An efficient strategy for high throughput screening of recombinant integral membrane 
protein expression and stability. Protein Expr Purif, 2011. 78(1): p. 6-13. 
529. Liu, W., et al., LCP-Tm: an assay to measure and understand stability of membrane proteins in a 
membrane environment. Biophys J, 2010. 98(8): p. 1539-48. 
530. Alexandrov, A.I., et al., Microscale fluorescent thermal stability assay for membrane proteins. 
Structure, 2008. 16(3): p. 351-9. 
531. Yeh, A.P., A. McMillan, and M.H. Stowell, Rapid and simple protein-stability screens: application to 
membrane proteins. Acta Crystallogr D Biol Crystallogr, 2006. 62(Pt 4): p. 451-7. 
532. Webb, R.L., Circular Dichroism. Principles and Applications, Second Edition Edited by Nina Berova, Koji 
Nakanishi, and Robert W. Woody. Wiley-VCH Publishers, New York. 2000. xix + 877 pp. 18.5 × 26 cm. 
ISBN 0 47133003 5. $195.00. Journal of Medicinal Chemistry, 2001. 44(7): p. 1122-1122. 
533. Hussain, R., et al., CDApps: Integrated software for experimental planning and data processing at 
beamline B23, Diamond Light Source. Journal of synchrotron radiation, 2015. 22: p. 465-468. 
534. Sreerama, N. and R.W. Woody, On the analysis of membrane protein circular dichroism spectra. 
Protein Sci, 2004. 13(1): p. 100-12. 
248 
 
535. Siligardi, G. and R. Hussain, CD spectroscopy: an essential tool for quality control of protein folding. 
Methods Mol Biol, 2015. 1261: p. 255-76. 
536. Siligardi, G. and R. Hussain, Biomolecules interactions and competitions by non-immobilised ligand 
interaction assay by circular dichroism. Enantiomer, 1998. 3(2): p. 77-87. 
537. Lorber, B., et al., Protein analysis by dynamic light scattering: methods and techniques for students. 
Biochem Mol Biol Educ, 2012. 40(6): p. 372-82. 
538. Varghese, L.N., et al., Mechanistic insights into activation and SOCS3-mediated inhibition of 
myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. 
Biochem J, 2014. 458(2): p. 395-405. 
539. Inaba, S., et al., Crystal Structures and Thermodynamic Analysis Reveal Distinct Mechanisms of CD28 
Phosphopeptide Binding to the Src Homology 2 (SH2) Domains of Three Adaptor Proteins. J Biol Chem, 
2017. 292(3): p. 1052-1060. 
540. Higo, K., et al., High Resolution Crystal Structure of the Grb2 SH2 Domain with a Phosphopeptide 
Derived from CD28. PLOS ONE, 2013. 8(9): p. e74482. 
541. Zadjali, F., et al., Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) 
ubiquitin ligase. J Biol Chem, 2011. 286(1): p. 480-90. 
542. Condon, R.G., et al., Development of a Chinese hamster ovary cell line for recombinant adenovirus-
mediated gene expression. Biotechnol Prog, 2003. 19(1): p. 137-43. 
543. Reinhard, L., et al., Optimization of protein buffer cocktails using Thermofluor. Acta Crystallogr Sect 
F Struct Biol Cryst Commun, 2013. 69(Pt 2): p. 209-14. 
544. Kozak, S., et al., Optimization of protein samples for NMR using thermal shift assays. J Biomol NMR, 
2016. 64(4): p. 281-9. 
545. Seabrook, S.A. and J. Newman, High-throughput thermal scanning for protein stability: making a 
good technique more robust. ACS Comb Sci, 2013. 15(8): p. 387-92. 
546. Chen, K.E., et al., Molecular Basis for Membrane Recruitment by the PX and C2 Domains of Class II 
Phosphoinositide 3-Kinase-C2alpha. Structure, 2018. 26(12): p. 1612-1625 e4. 
547. Hunte, C. and H. Michel, Crystallisation of membrane proteins mediated by antibody fragments. Curr 
Opin Struct Biol, 2002. 12(4): p. 503-8. 
548. Prongay, A.J., et al., Preparation and crystallization of a human immunodeficiency virus p24-Fab 
complex. Proc Natl Acad Sci U S A, 1990. 87(24): p. 9980-4. 
549. Jiang, Y., et al., X-ray structure of a voltage-dependent K+ channel. Nature, 2003. 423(6935): p. 33-
41. 
550. McKinstry, W.J., et al., Crystallization of the receptor-binding domain of parathyroid hormone-related 
protein in complex with a neutralizing monoclonal antibody Fab fragment. Acta Crystallogr Sect F 
Struct Biol Cryst Commun, 2009. 65(Pt 4): p. 336-8. 
551. Uysal, S., et al., Crystal structure of full-length KcsA in its closed conformation. Proc Natl Acad Sci U S 
A, 2009. 106(16): p. 6644-9. 
552. Prokop, A. and M.Z. Rosenberg, Bioreactor for mammalian cell culture. Adv Biochem Eng Biotechnol, 
1989. 39: p. 29-71. 
553. McPherson, A. and J.A. Gavira, Introduction to protein crystallization. Acta Crystallogr F Struct Biol 
Commun, 2014. 70(Pt 1): p. 2-20. 
554. Lorber, B., J.B. Bishop, and L.J. DeLucas, Purification of octyl beta-D-glucopyranoside and re-
estimation of its micellar size. Biochim Biophys Acta, 1990. 1023(2): p. 254-65. 
555. Chae, P.S., et al., Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and 
crystallization of membrane proteins. Nat Methods, 2010. 7(12): p. 1003-8. 
556. Slotboom, D.J., et al., Static light scattering to characterize membrane proteins in detergent solution. 
Methods, 2008. 46(2): p. 73-82. 
557. Strop, P. and A.T. Brunger, Refractive index-based determination of detergent concentration and its 
application to the study of membrane proteins. Protein Sci, 2005. 14(8): p. 2207-11. 
558. Sonoda, Y., et al., Tricks of the trade used to accelerate high-resolution structure determination of 
membrane proteins. FEBS Lett, 2010. 584(12): p. 2539-47. 
559. Parker, J.L. and S. Newstead, Current trends in alpha-helical membrane protein crystallization: an 
update. Protein Sci, 2012. 21(9): p. 1358-65. 
249 
 
560. Sonoda, Y., et al., Benchmarking membrane protein detergent stability for improving throughput of 
high-resolution X-ray structures. Structure, 2011. 19(1): p. 17-25. 
561. Thiyagarajan, P. and D.M. Tiede, Detergent micelle structure and micelle-micelle interactions 
determined by small-angle neutron scattering under solution conditions used for membrane protein 
crystallization. The Journal of Physical Chemistry, 1994. 98(40): p. 10343-10351. 
562. Psachoulia, E., P.J. Bond, and M.S. Sansom, MD simulations of Mistic: conformational stability in 
detergent micelles and water. Biochemistry, 2006. 45(30): p. 9053-8. 
563. Durand, G., et al., New Amphiphiles to Handle Membrane Proteins: “Ménage à Trois” Between 
Chemistry, Physical Chemistry, and Biochemistry. 2014. 
564. Rosenbaum, D.M., et al., Structure and function of an irreversible agonist-beta(2) adrenoceptor 
complex. Nature, 2011. 469(7329): p. 236-40. 
565. Cho, K.H., et al., Improved glucose-neopentyl glycol (GNG) amphiphiles for membrane protein 
solubilization and stabilization. Chem Asian J, 2014. 9(2): p. 632-8. 
566. Lee, S.C., et al., Steroid-based facial amphiphiles for stabilization and crystallization of membrane 
proteins. Proc Natl Acad Sci U S A, 2013. 110(13): p. E1203-11. 
567. Matar-Merheb, R., et al., Structuring detergents for extracting and stabilizing functional membrane 
proteins. PLoS One, 2011. 6(3): p. e18036. 
568. Fuxreiter, M. and P. Tompa, Fuzzy complexes: a more stochastic view of protein function. Adv Exp 
Med Biol, 2012. 725: p. 1-14. 
569. Tycko, R., Biomolecular solid state NMR: advances in structural methodology and applications to 
peptide and protein fibrils. Annu Rev Phys Chem, 2001. 52: p. 575-606. 
570. McDermott, A.E., Structural and dynamic studies of proteins by solid-state NMR spectroscopy: rapid 
movement forward. Curr Opin Struct Biol, 2004. 14(5): p. 554-61. 
571. Wuthrich, K., Protein structure determination in solution by NMR spectroscopy. J Biol Chem, 1990. 
265(36): p. 22059-62. 
572. Wagner, G., An account of NMR in structural biology. Nat Struct Biol, 1997. 4 Suppl: p. 841-4. 
573. Fu, R. and T.A. Cross, SOLID-STATE NUCLEAR MAGNETIC RESONANCE INVESTIGATION OF PROTEIN 
AND POLYPEPTIDE STRUCTURE. Annual Review of Biophysics and Biomolecular Structure, 1999. 
28(1): p. 235-268. 
574. Matthews, S.J., NMR of proteins and nucleic acids, in Nuclear Magnetic Resonance: Volume 36. 2007, 
The Royal Society of Chemistry. p. 262-284. 
575. Putnam, C.D., et al., X-ray solution scattering (SAXS) combined with crystallography and computation: 
defining accurate macromolecular structures, conformations and assemblies in solution. Q Rev 
Biophys, 2007. 40(3): p. 191-285. 
576. Rambo, R.P. and J.A. Tainer, Accurate assessment of mass, models and resolution by small-angle 
scattering. Nature, 2013. 496(7446): p. 477-481. 
577. Herzik, M.A., M. Wu, and G.C. Lander, High-resolution structure determination of sub-100 kDa 
complexes using conventional cryo-EM. Nature Communications, 2019. 10(1): p. 1032. 
578. Khoshouei, M., et al., Cryo-EM structure of haemoglobin at 3.2 Å determined with the Volta phase 
plate. Nature communications, 2017. 8: p. 16099-16099. 
579. Fan, X., et al., Single particle cryo-EM reconstruction of 52 kDa streptavidin at 3.2 Angstrom 
resolution. Nature Communications, 2019. 10(1): p. 2386. 
580. Campbell, M.G., et al., 2.8 A resolution reconstruction of the Thermoplasma acidophilum 20S 
proteasome using cryo-electron microscopy. Elife, 2015. 4. 
581. Banerjee, S., et al., 2.3 A resolution cryo-EM structure of human p97 and mechanism of allosteric 
inhibition. Science, 2016. 351(6275): p. 871-5. 
582. Zhang, X., et al., An Atomic Structure of the Human Spliceosome. Cell, 2017. 169(5): p. 918-929 e14. 
583. Greber, B.J., et al., The cryo-electron microscopy structure of human transcription factor IIH. Nature, 
2017. 549: p. 414. 
584. Hirschi, M., et al., Cryo-electron microscopy structure of the lysosomal calcium-permeable channel 
TRPML3. Nature, 2017. 550: p. 411. 
585. Kamat, V. and A. Rafique, Extending the throughput of Biacore 4000 biosensor to accelerate kinetic 
analysis of antibody-antigen interaction. Anal Biochem, 2017. 530: p. 75-86. 
250 
 
586. Rich, R.L. and D.G. Myszka, BIACORE J: a new platform for routine biomolecular interaction analysis. 
J Mol Recognit, 2001. 14(4): p. 223-8. 
587. Todd, M.J. and J. Gomez, Enzyme kinetics determined using calorimetry: a general assay for enzyme 
activity? Anal Biochem, 2001. 296(2): p. 179-87. 
588. Williams, B.A. and E.J. Toone, Calorimetric evaluation of enzyme kinetic parameters. The Journal of 
Organic Chemistry, 1993. 58(13): p. 3507-3510. 
589. Lewis, E.A. and K.P. Murphy, Isothermal titration calorimetry. Methods Mol Biol, 2005. 305: p. 1-16. 
590. Gaborit, N., et al., Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the 
disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using 
monoclonal antibodies. J Biol Chem, 2011. 286(13): p. 11337-45. 
591. Degorce, F., et al., HTRF: A technology tailored for drug discovery - a review of theoretical aspects 
and recent applications. Curr Chem Genomics, 2009. 3: p. 22-32. 
592. Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314. 
593. Tefferi, A., Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am 
J Hematol, 2018. 93(12): p. 1551-1560. 
594. Baxter, E.J., et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative 
disorders. Lancet, 2005. 365(9464): p. 1054-61. 
595. Yoda, A., et al., Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. 
Proc Natl Acad Sci U S A, 2010. 107(1): p. 252-7. 
596. Chapiro, E., et al., Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. 
Leukemia, 2010. 24(3): p. 642-5. 
597. Weijenborg Campos, L., et al., Oncogenic basic amino acid insertions at the extracellular 
juxtamembrane region of IL7RA cause receptor hypersensitivity. Blood, 2019. 133(11): p. 1259-1263. 
598. Ohashi, H., et al., Two rare MPL gene mutations in patients with essential thrombocythemia. 
International journal of hematology, 2009. 90: p. 431-2. 
599. Ma, W., et al., MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative 
disorders. Diagn Mol Pathol, 2011. 20(1): p. 34-9. 
600. Russell, L.J., et al., Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid 
transformation in B-cell precursor acute lymphoblastic leukemia. Blood, 2009. 114(13): p. 2688-98. 
601. Mullighan, C.G., et al., Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated 
acute lymphoblastic leukemia. Nat Genet, 2009. 41(11): p. 1243-6. 
602. Ensor, H.M., et al., Demographic, clinical, and outcome features of children with acute lymphoblastic 
leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood, 2011. 117(7): p. 
2129-36. 
603. Iacobucci, I., et al., Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic 
Leukemia. Cancer Cell, 2016. 29(2): p. 186-200. 
604. Renner, M., D. Choquet, and A. Triller, Control of the postsynaptic membrane viscosity. J Neurosci, 
2009. 29(9): p. 2926-37. 
605. Kuzu, O.F., M.A. Noory, and G.P. Robertson, The Role of Cholesterol in Cancer. Cancer Res, 2016. 
76(8): p. 2063-70. 
606. Zidovetzki, R. and I. Levitan, Use of cyclodextrins to manipulate plasma membrane cholesterol 
content: evidence, misconceptions and control strategies. Biochim Biophys Acta, 2007. 1768(6): p. 
1311-24. 
607. Shrivastava, S., et al., Chronic cholesterol depletion using statin impairs the function and dynamics of 
human serotonin(1A) receptors. Biochemistry, 2010. 49(26): p. 5426-35. 
608. Zhong, S., et al., Statin use and mortality in cancer patients: Systematic review and meta-analysis of 
observational studies. Cancer Treat Rev, 2015. 41(6): p. 554-67. 
609. Murphy, A.J., et al., Cholesterol efflux in megakaryocyte progenitors suppresses platelet production 
and thrombocytosis. Nature medicine, 2013. 19(5): p. 586-594. 
610. Marmor, M.D. and M. Julius, Role for lipid rafts in regulating interleukin-2 receptor signaling. Blood, 
2001. 98(5): p. 1489-97. 
251 
 
611. Tamarit, B., et al., Correction: Membrane microdomains and cytoskeleton organization shape and 
regulate the IL-7 receptor signalosome in human CD4 T-cells. J Biol Chem, 2019. 294(13): p. 5212-
5213. 
612. Jiang, J., et al., 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor 
cells. J Clin Invest, 2012. 122(6): p. 2079-91. 
613. Ferrari, M.L., G.A. Gomez, and H.J. Maccioni, Spatial organization and stoichiometry of N-terminal 
domain-mediated glycosyltransferase complexes in Golgi membranes determined by fret microscopy. 
Neurochem Res, 2012. 37(6): p. 1325-34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
252 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
253 
 
Section A: Hetero-FRET Analysis of TPOR TMD Activating Mutants  
 
Introduction 
 
The initiation of the signal transduction downstream is modulated by conformational changes that 
occur in the receptor upon cytokine binding. The TMD of various receptors has been shown to play 
an important role in mediating these changes. In the archetypal GHR, cytokine binding leads to a left-
handed subunit rotation of the ECD. Consequently, this induces the dimerisation of the TM N-
terminus and separation of the TM C-terminus. This conformational change in the GHR induces the 
separation of the JAK2 JH1 from the JH2 of the corresponding JAK2, both of which are bound to the 
Box1-Box2 motifs. Trans-phosphorylation occurs, resulting in JAK2 activation. This aim seeks to 
perform hetero-FRET to determine the structural requirements of the Box1-Box2 motifs for signal 
transmission in TPOR. In particular, the conformational change (via relative distance changes) that 
occurs between the Box1-Box2 motifs of the receptor monomers after cytokine binding or in clinical 
mutants (W515K, T487A, S505N) was investigated. This may reveal the relationship between the 
conformational changes and the pathogenic signalling.  
FRET is a technique that is used to analyse protein conformational changes and to determine protein 
interactions. Hetero-FRET utilises fluorophore pairs such as the cyan fluorescent protein (CFP) and 
citrine fluorescent protein, which have a high spectral overlap between the emission peak of the donor 
and the excitation peak of the acceptor. In principle, in the case where the acceptor (CFP-tagged) and 
donor molecules (citrine-tagged) are in close proximity (between 1-10nm), energy from the excited 
donor molecule will be transferred to the acceptor, in a process known as FRET (Figure 84). Increased 
proximity between the donor and acceptor molecules produces a stronger FRET signal and vice versa. 
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Figure 84: Hetero-FRET of receptor dimers. 
Upon excitation of both CFP and Citrine, they emit light of different wavelengths, emission peaks 
corresponding to both wavelengths will be observed, resulting in a FRET signal. However, when 
using an excitation wavelength of 480nm, only a CFP emission peak will be observed but if the 
distance between the acceptor and donor is >10nm, it will result in little to no FRET signal. 
 
Materials and methods 
DNA Constructs  
The CFP or Citrine fluorescent gene was added to the C-terminus of the Box2 motif (after residue 
S585 – numberings are based on the original hMPL gene without an N-terminal HA-tag) of HA-
tagged TPOR (WT, W515K, T487A, S505N) via CPEC essentially as described in Chapter 2, with a 
short linker separating the receptor and fluorescent gene to provide flexibility.  
Transfection 
Lenti-X 293T cells were seeded (2 × 105 cells/dish) into 35 mm glass-bottom dishes (Cellvis) and 
cultured overnight in phenol-red free DMEM supplemented with 10% FBS at 37°C in a humidified 
5% CO2 incubator. Cells were transiently transfected with 50-80 ng of the respective receptor 
constructs or together with 20-40 ng JAK2 using 1.5 µl Attractene transfection reagent according to 
manufacturer’s instructions (Qiagen). Control plasmids for FRET were also transfected using 30 ng 
of pmCit-N1 (to calculate acceptor bleed through), pmCFP-N1 (to calculate donor bleed through), or 
pmCFP-mCit N1 (FRET positive control) [131]. After 10 hours incubation at 37°C, cell starvation 
was performed for 4-5 hours prior to imaging. 
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Live Cell Imaging for Hetero-FRET Analysis 
Imaging was performed in three channels: donor (cyan), acceptor (citrine), and FRET (magenta) using 
the spinning disc confocal microscope (SDC) (Nikon) or Inverted LSM 710 BIG confocal microscope 
(Carl Zeiss GmbH). For the SDC, a 60x oil immersion plan Apochromat objective lens was used. For 
the inverted confocal microscope, a 63× water immersion plan LD C-Apochromat objective lens with 
numerical aperture of 1.15 was used. Hetero-FRET was performed essentially as described in [613]. 
Data Analysis  
Description of methods will be based on the images obtained from the inverted confocal microscope 
as SDC images produced high background. FRET efficiencies were calculated using Matlab Software 
applying the script generated by Dr Guillermo Gomez. More detailed description of this analysis can 
be found in [613]. 
 
Results 
 
TPOR FRET constructs are functional  
TPOR FRET constructs were made by tagging the fluorescent gene (CFP or Citrine) after the Box2 
motif. The constructs were truncated directly after the Box2 motif, residue S585, in order to provide 
a marker of receptor movement where the JAK proteins are. Placing FRET reporters at the C-terminus 
of the receptor may not show the movements of the JAK bound regions of the receptors because the 
intracellular domain of cytokine receptors is flexible and intrinsically disordered [231]. As the 
truncation was made after the Box2 motif, little to no interference with JAK2 binding to the receptor 
was expected. Subsequently, the constructs were tested for their functionality. The addition of TPO 
was shown to result in receptor activation of WT and mutant TPOR FRET constructs as demonstrated 
by the increase in pJAK2 and pERK levels upon stimulation (Figure 85) which suggests that these 
constructs were functional. 
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Figure 85: FRET constructs (with Box2 motif) conferred enhanced signalling in the presence of 
TPO. 
HEK293 cells were transiently transfected with JAK2 WT (20 ng) and HA-tagged TPOR WT or 
mutant TPOR FRET constructs (400 ng). Cells were starved overnight and TPO (final concentration 
of 50 ng/ml) was added (+) for 10 minutes. Samples in the absence of TPO (-) were used for 
comparison. Total protein was subjected to SDS-PAGE and immunoblotted with indicated 
antibodies.  
 
The constructs were subjected to FRET using the SDC microscope (Translational Research Institute, 
TRI). However, membrane localisation of the FRET constructs was very low, not allowing clear 
detection using the SDC microscope, in contrast to the observation of strong intra-cytoplasmic 
expression of the constructs, which may have also masked the presence of the receptors at the surface 
(Figure 86).  
 
Figure 86: Sub-optimal surface expression of FRET constructs. 
Lenti-X 293T cells were seeded in glass bottom dishes and cultured overnight at 37°C. Subsequently, 
transient transfection was performed with 100ng of the respective constructs. Cells were imaged 15-
16 hours after transfection using the SDC microscope. Left: expression of CFP-tagged constructs, 
right: expression of Citrine-tagged constructs. 
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Subsequently, expression optimisation was determined empirically by transfecting varying amounts 
of DNA and utilising other cell lines that may allow for enhanced receptor cell surface expression. 
The cell lines tested for FRET included the HEK293, Lenti-X 293T, baby hamster kidney (BHK), 
and COS-7 cells. Co-expression of TPOR with JAK2 was also performed as JAK2 was known to aid 
in TPOR localisation to the cell surface [115]. Optimal fluorescently-tagged TPOR cell surface 
expression will facilitate FRET analysis by reducing expression of the construct in the nuclear 
membrane or the cytoplasm. However, optimal surface expression of the constructs was difficult to 
obtain even after various efforts.  
 
FRET analysis did not yield reproducible results 
 
Cells expressing the constructs were starved for 4-5 hours before visualisation as starvation may aid 
in the surface localisation of the receptors by reducing their production and hence reducing 
aggregation of the protein in the intra-cytoplasmic regions. Upon starving, surface expression of these 
constructs was improved. However, FRET analysis did not yield interpretable results due to the high 
background. An alternative confocal microscope, Inverted LSM 710 BIG, was utilised (QBI, UQ). 
Although cell membrane localisation of the constructs was observed (Figure 87), the analysis of 
FRET did not yield consistent results between experimental days (results not shown). This could be 
due to various parameters that may have caused the experimental variation such as cell condition, 
donor/acceptor expression level, and donor/acceptor fluorescence ratio. Due to the various technical 
difficulties and time limitation, this aim was not pursued further, and instead, the analysis of fusion 
constructs by sptPALM was performed. 
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Figure 87: Successful cell surface expression of FRET-tagged TPOR. 
Lenti-X 293T cells were seeded in glass bottom dishes and cultured overnight at 37 °C. Subsequently, 
transient transfection was performed with the respective constructs. After 10 hours of the transfection, 
cells were starved for 4-5 hours prior to imaging using the Inverted LSM 710 BIG confocal 
microscope. FRET imaging was performed in the acceptor (left image) and donor (middle image) 
channel, and merged (right image).   
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Section B: Replicates and supporting data 
 
 
 
Figure 88: Western data replicates for Figure 18. 
A) Batch 1 transduction, B) Batch 2 transduction, C) Batch 3 transduction. Arrangement of mutants 
is different from Figure 18. 
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Figure 89: Densitometry immunoblot data for quantitation of pSTAT3 and pERK1/2. 
Densitometry data of replicates for Figure 11. Fold change was compared to WT+. 
 
 
A. 
B. 
C. 
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Figure 90: Densitometry immunoblot data for quantitation of JAK2 and TPOR. 
Densitometry data of replicates for Figure 17 IP blot. Fold change was compared to WT lane 1 Figure 
17 IP blot. 
 
A. 
B. 
C. 
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Figure 91: Densitometry immunoblot data for quantitation of JAK2 and TPOR. 
Densitometry data of replicates for Figure 18 IP blot. Fold change was compared to WT lane 2 Figure 
18 IP blot. 
 
Figure 92: Ba/F3 TPOR WT co-transduced with LNK WT was unable to inhibit cell growth. 
A. 
B. 
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Prior to cell seeding, cells were starved for 12-16 hours in RPMI media (no cytokine, 10% FBS). 
Stably transduced Ba/F3 TPOR WT co-transduced with LNK WT (batch 3) in log growth were plated 
at a density of 10 × 103 cells/ml per well in duplicates in 12-well plates in IL-3-free and phenol-red 
free RPMI media (containing 10% FBS). Cells were treated with 10 ng/ml rhTPO or phenol-red free 
RPMI media (no cytokine, 10% FBS). Viable cells were assayed every other day from day 0 to day 
8 using trypan blue exclusion method. Red and green lines represent Ba/F3 TPOR WT, purple and 
orange lines represent Ba/F3 TPOR WT co-transduced with LNK WT. Image representative of n=2 
experiments. 
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Figure 93: Ba/F3 TPOR W515K co-transduced with LNK WT was unable to inhibit cell growth. 
Prior to cell seeding, cells were starved for 12-16 hours in RPMI media (no cytokine, 10% FBS). 
Stably transduced Ba/F3 TPOR WT co-transduced with LNK WT (batch 3) in log growth were plated 
at a density of 10 × 103 cells/ml per well in triplicates in 12-well plates in IL-3-free and phenol-red 
free RPMI media (containing 10% FBS). Cells were treated with 15 ng/ml rhTPO or phenol-red free 
RPMI media (no cytokine, 10% FBS). Viable cells were assayed every other day from day 0 to day 
8 using trypan blue exclusion method. A) Blue and red lines represent Ba/F3 TPOR WT, green and 
purple lines represent Ba/F3 TPOR W515K. b) Green and purple lines represent Ba/F3 TPOR 
W515K, orange and black lines represent Ba/F3 TPOR W515K co-transduced with LNK WT. Image 
representative of n=1 experiment. 
A. 
B. 
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Figure 94: Ba/F3 TPOR S505N co-transduced with LNK WT was unable to inhibit cell 
signalling in the absence of MG132. 
Cells were starved for 12-16 hours in RPMI media containing no FBS and no IL-3. Cells were 
stimulated with 100 ng/ml rhTPO (Peprotech) for 30 minutes. Total protein was subjected to SDS-
PAGE and immunoblotted with indicated antibodies. STAT3 was used as a loading control.  Image 
representative of n=1 experiment. 
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Figure 95: Ba/F3 TPOR WT co-transduced with LNK WT was unable to inhibit cell signalling 
in the absence of MG132. 
Cells were starved for 12-16 hours in RPMI media containing no FBS and no IL-3. Cells were 
stimulated with 50 ng/ml rhTPO (R&D Systems) for 30 minutes. Total protein was subjected to SDS-
PAGE and immunoblotted with indicated antibodies. STAT3 was used as a loading control. Image 
representative of n=1 experiment. 
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Figure 97: Western data replicates for Figure 12. 
A) Batch 1 transduction, B) Batch 2 transduction, C) Batch 3 transduction, D) Batch 4 transduction.  
 
 
Figure 98: TPO dose-response assay replicates for Figure 15. 
A) Batch 1 transduction. B) Batch 3 transduction. 
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Figure 99: Cytokine-independent assay replicates for Figure 16. 
A) Batch 1 transduction. B) Batch 3 transduction. 
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Section C: List of primers to make constructs 
 
To make constructs for sptPALM: 
Primer Sequences (5’ => 3’) 
SP-HA-TPOR Fwd AGATCCGCTAGCATGCCCTCCTGGGCCCTCTTCA 
mEOS2-SP Rvs CCAGGAGGGCATGCTAGCGGATCTGACGGTTCACTAAAC
C  
Vec Linker-mEOS2 
Fwd 
TGGCAGCAGCCTTCGGGCCCGGGATCCGG 
ICD-vec linker-mEOS2 
Rvs 
GGCCCGAAGGCTGCTGCCAATAGCTTAGTGGTAGGT  
SP-FRET Vec Rvs CCGGGCCCGAATCTTGGCTGCTGACTTGGGCCA  
Linker-mEOS Fwd CAGCCAAGATTCGGGCCCGGGATCCGG 
 mEOS2-HA-TPOR Rvs GGAACATCATATGGATATCTGGCATTGTCAGGCAATCCA
GAATG  
mEOS2-HA-TPOR Fwd CCTGACAATGCCAGATATCCATATGATGTTCCAGATTAC
GCAGTCTCCT 
FRET Vec Fwd CAGCAGCCTTAAAGCGGCCGCGACTCTAGATCATAATC 
TPOR Rvs GCGGCCGCTTTAAGGCTGCTGCCAATAGCTTAGTGGT  
Box1 TPOR 
LWASLADLH Fwd 
GGCATGCCCTGTGGGCCGCAGCTGCAGACCTGCACCGGG 
Box1 TPOR 
LWASLADLH Rvs 
CCCGGTGCAGGTCTGCAGCTGCGGCCCACAGGGCATGCC  
 
To make constructs for FRET: 
Primer Sequences (5’ => 3’) 
MPL start fwd (mCFP) GATCCGCTAGCATGCCCTCCTGGGCCCTCTTCA 
pMPL-HA rvs (mCFP) 
CCAGGAGGGCATGCTAGCGGATCTGACGGTTCACTAAAC
C 
p-MPL-HA fwd (mCFP) GTGGAACCCAGCTCGGGCCCGGGATCCGG 
MPL rvs (mCFP) GGGCCCGAGCTGGGTTCCACTTCTTCACAGGTATCTGA 
mCFP/Cit vector Fwd CCCTGTGTTCCTCCTCGGGCCCGGGATCCGG 
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hMPL Box2 Rvs GGCCCGAGGAGGAACACAGGGGCAAAGGAGTC  
FLAG-hMPL ECD linker 
Fwd (homo) 
GATGATTACAAGGATGACGACGATAAGGTCTCCTTGCTGG
CATCAGACTCAGAGC 
Mid-pMX-pGK-
puro/GFP Rvs  
GGAGACCCTCCCAAGGAACAGCGAG  
hMPL ECD linker-FLAG 
Rvs (homo) 
GACCTTATCGTCGTCATCCTTGTAATCATCTTGGCTGCTGA
CTTGGGCCAG  
Mid-pMX-pGK-
puro/GFP Fwd 
CTCGCTGTTCCTTGGGAGGGTCTCC  
 
To make constructs for Ba/F3 hTPOR stable transduction: 
Primer Sequences (5’ => 3’) 
MPL-HA-tag forward 
AAGATTATCCATATGATGTTCCAGATTACGCAGTCTC
CTTGCTGGCATCAGACTCAGAGC 
MPL-HA-tag reverse 
GACTGCGTAATCTGGAACATCATATGGATAATCTTGG
CTGCTGACTTGGGCCAG 
MPL fwd (W515K) TGCTGCTGAGGAAGCAGTTTCCTGC 
MPL rvs (W515K) GCAGGAAACTGCTTCCTCAGCAGCA 
MPL fwd (T487A) GACCGCCGCCGAGACCGCCTG 
MPL rvs (T487A) CAGGCGGTCTCGGCGGCGGTC 
MPL fwd (S505N) TGGGCCTCAACGCCGTCCTGGG 
MPL rvs (S505N) CCCAGGACGGCGTTGAGGCCCA 
MPL-attb1 Fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCCT
CCTGGGCCCTCTTCA 
MPL-attb2 Rvs GGGGACCACTTTGTACAAGAAAGCTGGGTTCAAGGCT
GCTGCCAATAGCTTAGTGG 
HA-tag forward AAGATTATCCATATGATGTTCCAGATTACGCAGTCTC
CTTGCTGGCATCAGACTCAGAGC 
HA-tag reverse GACTGCGTAATCTGGAACATCATATGGATAATCTTGG
CTGCTGACTTGGGCCAG  
Mid-fwd (HA-tag)  CGCTACCAGCGGTGGTTTGTTTGC 
Mid-rvs (HA-tag)  GCAAACAAACCACCGCTGGTAGCG 
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To make hTPOR constructs for co-IP: 
Primer Sequences (5’ => 3’) 
Fwd Y8F GCAGTTTCCTGCACACTTCAGGAGACTGAGGCA 
Rvs Y8F TGCCTCAGTCTCCTGAAGTGTGCAGGAAACTGC 
Fwd Y29F CGGGTCCTAGGCCAGTTCCTTAGGGACACTG 
Rvs Y29F CAGTGTCCCTAAGGAACTGGCCTAGGACCCG 
Fwd Y78F GGCCCAGATGGACTTCCGAAGATTGCAGCC 
Rvs Y78F GGCTGCAATCTTCGGAAGTCCATCTGGGCC 
Fwd Y113F CCCACATTGCCAACCATTCCTTCCTACCACTAAGCTATTG
G 
Rvs Y113F CCAATAGCTTAGTGGTAGGAAGGAATGGTTGGCAATGTG
GG 
Fwd Y118F CCTACCTACCACTAAGCTTTTGGCAGCAGCCTTGA 
Rvs Y118F TCAAGGCTGCTGCCAAAAGCTTAGTGGTAGGTAGG 
Fwd Y113F/Y118F GCCAACCATTCCTTCCTACCACTAAGCTTTTGGCAGCAGC 
Rvs Y113F/Y118F GCTGCTGCCAAAAGCTTAGTGGTAGGAAGGAATGGTTGG
C 
MPLTrunc7-Fwd  GGCAGTTTCCTGCACACTAAAGGAGACTGAGGCAT 
MPLTrunc7-Rvs  ATGCCTCAGTCTCCTTTAGTGTGCAGGAAACTGCC 
MPLTrunc28-Fwd  CGGGTCCTAGGCCAGTAACTTAGGGACACTGC 
MPLTrunc28-Rvs  GCAGTGTCCCTAAGTTACTGGCCTAGGACCCG 
MPLTrunc53-Fwd  GTGAAGAAGTGGAACCCAGCTGACTTGAAATCCTCCCC 
MPLTrunc53-Rvs  GGGGAGGATTTCAAGTCAGCTGGGTTCCACTTCTTCAC 
MPLTrunc69-Fwd  CTCCTTTGCCCCTGTGATCCTCCCAGGC 
MPLTrunc69-Rvs  GCCTGGGAGGATCACAGGGGCAAAGGAG 
MPLTrunc83-Fwd  CGAAGATTGCAGCCTTGATGCCTGGGGACC 
MPLTrunc83-Rvs  GGTCCCCAGGCATCAAGGCTGCAATCTTCG 
MPLTrunc98-Fwd  TGCCCACCCATGGCTTAGTCAGGGTCCT 
MPLTrunc98-Rvs  AGGACCCTGACTAAGCCATGGGTGGGCA 
MPLTrunc111-Fwd  CTGTACCACCCACATTGCCAACCATTAATACCTACCACTA
AGCTATTG 
MPLTrunc111-Rvs  CAATAGCTTAGTGGTAGGTATTAATGGTTGGCAATGTGG
GTGGTACAG 
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MPLTrunc116-Fwd  AACCATTCCTACCTACCACTATGATATTGGCAGCAGCCTT
GA 
MPLTrunc116-Rvs  TCAAGGCTGCTGCCAATATCATAGTGGTAGGTAGGAATG
GTT 
 
To make hLNK constructs for Ba/F3 hLNK stable transduction, co-IP assay, and signalling assay: 
Primer Sequences (5’ => 3’) 
attb1 Fwd-FLAG-hLNK-
WT (corrected) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATTACA
AGGATGACGACGATAAGAACG 
FLAG-hLNK-attb2 rvs-
WT (corrected) 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGAGAGGT
GTGTACTGATTGTCTATGGCCC 
attb1 Fwd-FLAG-hLNK(-
Pro DD) (corrected) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTATGGATTACA
AGGATGACGACGATAAGGAGG 
FLAG-hLNK-attb2 rvs (-
CTD) (corrected 2) 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCACACGTAG
CTGGAGAGCCGGACA 
FLAG-hLNK-attb2 rvs 
(Y572A) 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCAGAGAGGT
GTGGCCTGATTGTCTATGG 
pDONR221 mid vec 
CPEC Fwd 
CGCTACCAGCGGTGGTTTGTTTGC 
pDONR221 mid vec 
CPEC Rvs 
GCAAACAAACCACCGCTGGTAGCG 
PH Start Fwd (-Pro-DD) - 
Corrected GACGACGATAAGGAGGCGCTGAAGGAGGCGGTG 
FLAG start rvs (-Pro-DD) 
- Corrected 
CCTTCAGCGCCTCCTTATCGTCGTCATCCTTGTAATCCATG
GTG 
SH2 Start Fwd (-PH) CGCCACCCCGAGGGCTGGAGAGCACAGAAGCA 
DD start rvs CCAGCCCTCGGGGTGGCGGCTCCCGGG 
Vector Start Fwd (-CTD) - 
Corrected CTCTCCAGCTACGTGTGATAAACCCGCTGATCAGCCTCGA 
LNK start rvs (-CTD) - 
Corrected AGCGGGTTTATCACACGTAGCTGGAGAGCCGGACATCA 
SH2 start fwd (-PH SH2 
linker) corrected 
CGGAGTGCACAGGCTGGTTCCACGGCCCCATCTCC 
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PH start rvs (-PH SH2 
linker) 
GTGGAACCAGCCTGTGCACTCCGAGAGCTCAGC 
C-terminus Fwd (Y572A) 
- Corrected CCATAGACAATCAGGCCACACCTCTCTGA 
C-terminus Rvs (Y572A)  
Corrected TCAGAGAGGTGTGGCCTGATTGTCTATGG 
SH2 Fwd (R392E) GTGTTCCTGGTGGAGCAGAGCGAGACGC 
SH2 Rvs (R392E) GCGTCTCGCTCTGCTCCACCAGGAACAC 
SH2 Fwd (E395K) CGGCAGAGCAAGACGCGGCG 
SH2 Rvs (E395K) CGCCGCGTCTTGCTCTGCCG 
SH2 Fwd R425P GGCCAGTGCCCTGTGCAGCAC 
SH2 Rvs R425P GTGCTGCACAGGGCACTGGCC 
 
To make constructs for protein expression and purification (bacterial system): 
Primer Sequences (5’ => 3’) 
LNK 
fwd 
(pET) TGCACCATCATCATCACCACAACGGGCCTGCCCTGCAGC 
His-tag 
rvs 
(pET) CCGTTGTGGTGATGATGATGGTGCATATGTATATCTCCT 
pET fwd 
(pET) CAGTACACACCTCTCTGAGGATCCGGCTGCTAACAAAGCCC 
LNK rvs 
(pET) AGCCGGATCCTCAGAGAGGTGTGTACTGATTGTCTATGGCCC 
TEV 
start fwd 
(pET11a
) 
CATCATCACCACGAAAACCTGTACTTCCAAAACGGGCCTG 
6His rvs 
(pET11a
) 
TTGGAAGTACAGGTTTTCGTGGTGATGATGATGGTGCATATGTATATCTCC
T  
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TEV 
start fwd 
(del 
N22)  
ACCATCATCATCACCACGAAAACCTGTACTTCCAACGGGGCTGG 
6His rvs 
(del 
N22)  
AAGTACAGGTTTTCGTGGTGATGATGATGGTGCATATGTATATCTCCT  
TEV 
start fwd 
(del 
N37)  
ACCATCATCATCACCACGAAAACCTGTACTTCCAACGGGAGCTGG 
6His rvs 
(del 
N37)  
AAGTACAGGTTTTCGTGGTGATGATGATGGTGCATATGTATATCTCCT  
pET fwd 
(del C2) 
ACAATCAGTACACATGAGGATCCGGCTGCTAACAAAGCC 
LNK rvs 
(del C2) 
CAGCCGGATCCTCATGTGTACTGATTGTCTATGGCCCGCAGG  
LNK 
fwd 
(pHUE) 
CGCGGTGGAAACGGGCCTGCCCTGCAGC 
Ub rvs 
(pHUE) 
CAGGCCCGTTTCCACCGCGGAGGCGCA  
LNK rvs 
(pHUE) 
GAGCTCGAATTCGGATCAGAGAGGTGTGTACTGATTGTCTATGGCCC  
pHUE 
fwd 
(pHUE) 
CACACCTCTCTGATCCGAATTCGAGCTCGGTACCGTC 
LNK 
fwd del 
N22 
(pHUE) 
TCCGCGGTGGACGGGGCTGGAGCGAGTTCTGTG 
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Ub rvs 
del N22 
(pHUE) 
GCCCCGTCCACCGCGGAGGCGCA  
LNK 
fwd del 
N37 
(pHUE) 
CCGCGGTGGACGGGAGCTGGCCCGCCA 
Ub rvs 
del N37 
(pHUE) 
CAGCTCCCGTCCACCGCGGAGGCGCA  
pHUE 
fwd del 
C2 
(pHUE) 
AGACAATCAGTACACATAATCCGAATTCGAGCTCGGTACCGTC 
LNK rvs 
del C2 
(pHUE) 
GAGCTCGAATTCGGATTATGTGTACTGATTGTCTATGGCCCGCAGG  
 
To make constructs for protein expression and purification (bacterial system-codon optimised): 
Primer Sequences (5’ => 3’) 
TEV hLNK WT 
Fwd (TEV-CO) 
CATCATCACCACGAGAATCTGTACTTTCAGAACGGTCCGGC 
6His pET11a Rvs 
(TEV-CO) 
GTTCTGAAAGTACAGATTCTCGTGGTGATGATGATGGTGCATAT
GTATATCTCCT  
pET11a WT Fwd 
(TEV-CO) 
CACCCCGCTGTAAGGATCCGGCTGCTAACAAAGCCCG 
hLNK WT Rvs 
(TEV-CO) 
GCCGGATCCTTACAGCGGGGTGTACTGGTTGTCAATC  
hLNK (-N37) 
Fwd (TEV-CO) 
TGTACTTTCAGCGTGAGCTGGCACGCCAGTATTGG 
TEV hLNK (-
N37) Rvs (TEV-
CO) 
CGTGCCAGCTCACGCTGAAAGTACAGATTCTCGTGGTGATGATG
ATG  
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hLNK (-N22) 
Fwd (TEV-CO) 
TGTACTTTCAGCGTGGTTGGAGCGAGTTTTGCGA 
TEV hLNK (-
N22) Rvs (TEV-
CO) 
CTCGCTCCAACCACGCTGAAAGTACAGATTCTCGTGGTGATGAT
GATG   
pET11a Fwd (-
C2) (TEV-CO) 
CCAGTACACCTAAGGATCCGGCTGCTAACAAAGCCCG 
hLNK WT Rvs (-
C2) (TEV-CO) 
GTTAGCAGCCGGATCCTTAGGTGTACTGGTTGTCAATCGCACGC  
hLNK WT Fwd 
(Ub-CO) 
CCGCGGTGGAAACGGTCCGGCACTGCAACCG 
6His Ub Rvs (Ub-
CO) 
CGGACCGTTTCCACCGCGGAGGCGCA  
pHUE WT Fwd 
(Ub-CO) 
CCCCGCTGTAACTAGCATAACCCCTTGGGGCCTCTAAAC 
hLNK WT Rvs 
(Ub-CO) 
CAAGGGGTTATGCTAGTTACAGCGGGGTGTACTGGTTGTCAATC  
hLNK (-N37) 
Fwd (Ub-CO) 
CCGCGGTGGACGTGAGCTGGCACGCCAGTATTGG 
6His Ub (-N37) 
Rvs (Ub-CO) 
CCAGCTCACGTCCACCGCGGAGGCGCA  
hLNK (-N22) 
Fwd (Ub-CO) 
CCGCGGTGGACGTGGTTGGAGCGAGTTTTGCGA 
6His Ub (-N22) 
Rvs (Ub-CO) 
TCCAACCACGTCCACCGCGGAGGCGCA  
pHUE (-C2) Fwd 
(Ub-CO) 
CCAGTACACCTAACTAGCATAACCCCTTGGGGCCTCTAAAC 
hLNK (-C2) Rvs 
(Ub-CO) 
CCCAAGGGGTTATGCTAGTTAGGTGTACTGGTTGTCAATCGCAC
GC  
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To make hJAK2 JH2-JH1 construct for protein expression and purification (mammalian system): 
Primer Sequences (5’ => 3’) 
TEV-JAK2 Fwd CGAAAATCTGTACTTCCAAGGCCACAAAATCAGAAATGAAGAT
TTGATATTTAATGAAAGCCTTGGCC 
pD454-SR-6xHis-
TEV-JAK2 Rvs 
TTCTGATTTTGTGGCCTTGGAAGTACAGATTTTCGTGGTGATGA
TGATGGTGCAT  
JH1-pD454-SR 
Fwd 
TAACATGGCTGGATGAGGTTGAGGTCTCACCCCCTAGCATAAC
C 
pD454-SR-JH1 
Rvs 
TGAGACCTCAACCTCATCCAGCCATGTTATCCCTTATTTGATCC
ACTC  
6xHis-TEV Fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCACCATCATCA
TCACCACGAAAATCTGTAC 
JH1 Rvs GGGGACCACTTTGTACAAGAAAGCTGGGTTCATCCAGCCATGT
TATCCCTTATTTGATCCACTC 
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Section D: List of sequencing primers  
 
Sequencing primers for hMPL: 
Primer Sequences (5’ => 3’) 
MPL seq fwd 1 CACCTCTGGGTGAAGAATGTGTTCCTA 
MPL seq fwd 2 AACTCCTACTGGCTGCAGCTGCG 
MPL seq fwd 3 CCAAACTTGCACTGGAGGGAGATCT 
MPL seq fwd 4 CGGGTCCTAGGCCAGTACCTTAGG 
MPL seq rvs TGGCCTTGATGATACTGGGGGG 
 
Sequencing primers for hLNK: 
Primer Sequences (5’ => 3’) 
LNK seq 1 fwd ACTACCGGGACACAGGCCGTG 
LNK seq fwd 2 CTCTTCGACCCACCCAAGAGTTCA 
LNK seq fwd 3 CTGCAGGGCCCTGATGCTCAT 
LNK seq fwd 4 AGATCTTCCACCTGGTGCCTTCG 
LNK seq rvs CTCCTCAGAGCTGCGGGCCT 
LNK (-Pro/DD) seq rvs CTCCTGGATGCTGGAGCAAGCT  
LNK seq FLAG CATGGATTACAAGGATGACGACGATAAG 
 
Sequencing primers for hJAK2: 
Primer Sequences (5’ => 3’) 
JAK2 Seq Fwd 
1 
ACCCTTATTCATGGGAATGTATGTGCC 
JAK2 Seq Fwd 
2 
AATTTCTACAGCAACTTGGCAAGGGTAAT 
JAK2 Seq Fwd 
3 
ATCACTGACAGAGAGCAAGTTTTCTGTGG 
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Sequencing primers for pHUE and pET11a vectors: 
Primer Sequences (5’ => 3’) 
pHUE vector seq Fwd primer  GAGCGGATAACAATTCCCCTCTAGAAAT  
pET11a vector seq Fwd primer GAGCGGATAACAATTCCCCTCTAGAAATA 
 
Sequencing primers for codon optimised LNK: 
Primer Sequences (5’ => 3’) 
Seq Fwd 1 hLNK 
(CO) 
GTCCACCGGCGAAAGCCG 
Seq Fwd 2 hLNK 
(CO) 
AGCGCGGTCGTCTGGCG 
Seq Fwd 3 hLNK 
(CO) 
AGGCGCGTCCCCGGGT 
Seq Fwd 4 hLNK 
(CO) 
GTTGTAGTCAGCCAGCCGCCAG 
Seq Fwd Ub (CO) CTGCACCTGGTGTTGCGCCT 
Seq Rvs 1 hLNK 
(CO) 
TAGGCAGGCCCGGTGCG  
Seq Rvs 2 hLNK 
(CO) 
AGCCGAGCTCGGGCTGGA  
 
Sequencing primers for phage display: 
Primer Sequences (5’ => 3’) 
-96 gIII sequencing primer CCCTCATAGTTAGCGTAACG 
-28 gIII sequencing primer GTATGGGATTTTGCTAAACAAC 
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Section E: List of Antibodies for Co-IP Assay and Western Analysis 
 
Antibodies Company Dilution Buffer 
Akt Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
β-actin  Cell Signalling Technology 
(USA) 
1:10 000 5% 
BSA/TBST 
ERK 1/2 Cell Signalling Technology 
(USA) 
1: 1 000 5% 
BSA/TBST 
GAPDH Cell Signalling Technology 
(USA) 
1: 10 000 5% 
BSA/TBST 
Haemagglutinin (HA) BioLegend (USA) 1: 6 000 5% 
BSA/TBST 
JAK2 Cell Signalling Technology 
(USA) 
1: 1 000 5% 
BSA/TBST 
pAkt Cell Signalling Technology 
(USA) 
1: 1 000 5% 
BSA/TBST 
pERK ½ Cell Signalling Technology 
(USA) 
1:2 000 5% 
BSA/TBST 
pJAK2 Cell Signalling Technology 
(USA) 
1:500 5% 
BSA/TBST 
pSrc Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
Src Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
STAT3 Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
pSTAT3 Cell Signalling Technology 
(USA) 
1:2 000 5% 
BSA/TBST 
pSTAT5 Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
STAT5 Cell Signalling Technology 
(USA) 
1:1 000 5% 
BSA/TBST 
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β-tubulin Cell Signalling Technology 
(USA) 
1:10 000 5% 
BSA/TBST 
FLAG  Sigma Aldrich, Merck (USA) 1:8 000 5% 
BSA/TBST 
TPOR/c-Mpl Merck (USA) 1:1 000 5% 
BSA/TBST 
Anti-6x Histidine  Sigma 1:10 000 5% 
BSA/TBST 
Anti-phosphotyrosine (4G10) Merck (USA) 1:2 000 5% 
BSA/TBST 
Goat anti-rabbit IgG, HRP-linked  Cell Signalling Technology 
(USA) 
1:10 000 5% 
BSA/TBST 
Horse anti-mouse IgG, HRP-linked  Cell Signalling Technology 
(USA) 
1:10 000 5% 
BSA/TBST 
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Section F: Human MPL (hTPOR) full-length cDNA and protein sequence 
 
Human MPL (hTPOR) full-length cDNA sequence:  
atgccctcctgggccctcttcatggtcacctcctgcctcctcctggcccctcaaaacctggcccaagtcagcagccaagattatccatatgatgttc
cagattacgcagtctccttgctggcatcagactcagagcccctgaagtgtttctcccgaacatttgaggacctcacttgcttctgggatgaggaag
aggcagcgcccagtgggacataccagctgctgtatgcctacccgcgggagaagccccgtgcttgccccctgagttcccagagcatgccccac
tttggaacccgatacgtgtgccagtttccagaccaggaggaagtgcgtctcttctttccgctgcacctctgggtgaagaatgtgttcctaaaccaga
ctcggactcagcgagtcctctttgtggacagtgtaggcctgccggctccccccagtatcatcaaggccatgggtgggagccagccaggggaac
ttcagatcagctgggaggagccagctccagaaatcagtgatttcctgaggtacgaactccgctatggccccagagatcccaagaactccactgg
tcccacggtcatacagctgattgccacagaaacctgctgccctgctctgcagaggcctcactcagcctctgctctggaccagtctccatgtgctca
gcccacaatgccctggcaagatggaccaaagcagacctccccaagtagagaagcttcagctctgacagcagagggtggaagctgcctcatct
caggactccagcctggcaactcctactggctgcagctgcgcagcgaacctgatgggatctccctcggtggctcctggggatcctggtccctccc
tgtgactgtggacctgcctggagatgcagtggcacttggactgcaatgctttaccttggacctgaagaatgttacctgtcaatggcagcaacagg
accatgctagctcccaaggcttcttctaccacagcagggcacggtgctgccccagagacaggtaccccatctgggagaactgcgaagaggaa
gagaaaacaaatccaggactacagaccccacagttctctcgctgccacttcaagtcacgaaatgacagcattattcacatccttgtggaggtgac
cacagccccgggtactgttcacagctacctgggctcccctttctggatccaccaggctgtgcgcctccccaccccaaacttgcactggagggag
atctccagtgggcatctggaattggagtggcagcacccatcgtcctgggcagcccaagagacctgttatcaactccgatacacaggagaaggc
catcaggactggaaggtgctggagccgcctctcggggcccgaggagggaccctggagctgcgcccgcgatctcgctaccgtttacagctgc
gcgccaggctcaacggccccacctaccaaggtccctggagctcgtggtcggacccaactagggtggagaccgccaccgagaccgcctggat
ctccttggtgaccgctctgcatctagtgctgggcctcagcgccgtcctgggcctgctgctgctgaggtggcagtttcctgcacactacaggagac
tgaggcatgccctgtggccctcacttccagacctgcaccgggtcctaggccagtaccttagggacactgcagccctgagcccgcccaaggcc
acagtctcagatacctgtgaagaagtggaacccagcctccttgaaatcctccccaagtcctcagagaggactcctttgcccctgtgttcctcccag
gcccagatggactaccgaagattgcagccttcttgcctggggaccatgcccctgtctgtgtgcccacccatggctgagtcagggtcctgctgtac
cacccacattgccaaccattcctacctaccactaagctattggcagcagccttga 
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Human thrombopoeitin receptor (hTPOR) amino acid sequence:  
MPSWALFMVTSCLLLAPQNLAQVSSQDYPYDVPDYAVSLLASDSEPLKCFSRTFEDLT
CFWDEEEAAPSGTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPL
HLWVKNVFLNQTRTQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFL
RYELRYGPRDPKNSTGPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPK
QTSPSREASALTAEGGSCLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLP
GDAVALGLQCFTLDLKNVTCQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEE
EKTNPGLQTPQFSRCHFKSRNDSIIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNL
HWREISSGHLELEWQHPSSWAAQETCYQLRYTGEGHQDWKVLEPPLGARGGTLELR
PRSRYRLQLRARLNGPTYQGPWSSWSDPTRVETATETAWISLVTALHLVLGLSAVLGL
LLLRWQFPAHYRRLRHALWPSLPDLHRVLGQYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSS
ERTPLPLCSSQAQMDYRRLQPSCLGTMPLSVCPPMAESGSCCTTHIANHSYLPLSYWQQP* 
 
Extracellular domain = bold  
Signal peptide  
HA-tag 
Transmembrane  
RWQFP 
ICD 
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Section G: Human SH2B3 (LNK) cDNA and protein sequence 
 
Human SH2B3 (LNK) cDNA sequence:  
atggattacaaggatgacgacgataagaacgggcctgccctgcagccctcctcgccctcttccgcgccctcagcctccccggcggcggcccc
gcggggctggagcgagttctgtgagttgcacgccgtagcggcggcccgggagctggcccgccagtactggctgttcgcccgggagcatccg
cagcacgcgccgctgcgcgccgagctggtgtcgctgcagttcaccgacctcttccagcgctacttctgccgcgaggtgcgcgacggacgggc
gccgggccgcgactaccgggacacaggccgtgggcccccagccaaggccgaggcgtccccggagccaggccccggccccgccgcccct
ggcctgcccaaggcccgcagctctgaggagctggccccgccgcggccgcccgggccctgctccttccagcactttcgccgcagcctccgcc
acatcttccgccgccgctcggccggggagctgccagcggcccacaccgctgccgcccccgggacccccggagaggctgctgagaccccc
gcccggcctggcctggccaagaagttcctgccctggagcctggcccgggagccgccacccgaggcgctgaaggaggcggtgctgcgctac
agcctggccgacgaggcctccatggacagcggggcacgctggcagcgcgggaggctggcgctgcgccgggccccgggccccgatggcc
ccgaccgcgtgctggagctcttcgacccacccaagagttcaaggcccaagctacaagcagcttgctccagcatccaggaggtccggtggtgc
acacggcttgagatgcctgacaacctttacacctttgtgctgaaggtgaaggaccggacagacatcatctttgaggtgggagacgagcagcagc
tgaattcatggatggctgagctctcggagtgcacaggccgagggctggagagcacagaagcagagatgcatattccctcagccctagagccta
gcacgtccagctccccaaggggcagcacagattcccttaaccaaggtgcttctcctggggggctgctggacccggcctgccagaagacggac
catttcctgtcctgctacccctggttccacggccccatctccagagtgaaagcagctcagctggttcagctgcagggccctgatgctcatggagt
gttcctggtgcggcagagcgagacgcggcgtggggaatacgtgctcactttcaactttcaggggatagccaagcacctgcgcctgtcgctgac
agagcggggccagtgccgtgtgcagcacctccactttccctcggtcgtggacatgctccaccacttccagcgctcgcccatcccactcgagtgc
ggcgccgcctgtgatgtccggctctccagctacgtggtagtcgtctcccaaccaccaggttcctgcaacacggtcctcttccctttctcccttcctc
actgggattcagagtcccttcctcactggggttcagagttgggccttccccaccttagttcttctggctgtccccgggggctcagcccagagggtc
tcccagggcgatcctcaccccccgagcagatcttccacctggtgccttcgcccgaagaactggccaacagcctgcagcacctggagcatgag
cctgtgaatcgagcccgggactcggactacgaaatggactcatcctcccggagccacctgcgggccatagacaatcagtacacacctctctga 
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Human LNK amino acid sequence:  
MDYKDDDDKNGPALQPSSPSSAPSASPAAAPRGWSEFCELHAVAAARELARQYWLFARE
HPQHAPLRAELVSLQFTDLFQRYFCREVRDGRAPGRDYRDTGRGPPAKAEASPEPGPGPAA
PGLPKARSSEELAPPRPPGPCSFQHFRRSLRHIFRRRSAGELPAAHTAAAPGTPGEAAETPAR
PGLAKKFLPWSLAREPPPEALKEAVLRYSLADEASMDSGARWQRGRLALRRAPGPDGPDR
VLELFDPPKSSRPKLQAACSSIQEVRWCTRLEMPDNLYTFVLKVKDRTDIIFEVGDEQQLNS
WMAELSECTGRGLESTEAEMHIPSALEPSTSSSPRGSTDSLNQGASPGGLLDPACQKTDHFL
SCYPWFHGPISRVKAAQLVQLQGPDAHGVFLVRQSETRRGEYVLTFNFQGIAKHLRLSLTE
RGQCRVQHLHFPSVVDMLHHFQRSPIPLECGAACDVRLSSYVVVVSQPPGSCNTVLFPFSL
PHWDSESLPHWGSELGLPHLSSSGCPRGLSPEGLPGRSSPPEQIFHLVPSPEELANSLQHLEH
EPVNRARDSDYEMDSSSRSHLRAIDNQYTPL* 
 
FLAG-tag 
PH domain  
SH2 
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Section H: Human JAK2 JH2-JH1 cDNA and protein sequence 
 
Human JAK2 JH2-JH1 cDNA sequence:  
ATGCACCATCATCATCACCACGAAAATCTGTACTTCCAAGGCCACAAAATCAGAAATG
AAGATTTGATATTTAATGAAAGCCTTGGCCAAGGCACTTTTACAAAGATTTTTAAAGGC
GTACGGAGAGAAGTAGGAGACTACGGTCAACTGCATGAAACAGAAGTTCTTTTAAAAG
TTCTGGATAAAGCACACAGAAACTATTCAGAGTCTTTCTTTGAAGCAGCAAGTATGAT
GAGCAAGCTTTCTCACAAGCATTTGGTTTTAAATTATGGAGTATGTGTCTGTGGAGACG
AGAATATTCTGGTTCAGGAGTTTGTAAAATTTGGATCACTAGATACATATCTGAAAAA
GAATAAAAATTGTATAAATATATTATGGAAACTTGAAGTTGCTAAACAGTTGGCATGG
GCCATGCATTTTCTAGAAGAAAACACCCTTATTCATGGGAATGTATGTGCCAAAAATAT
TCTGCTTATCAGAGAAGAAGACAGGAAGACAGGAAACCCTCCTTTCATCAAACTTAGT
GATCCTGGCATTAGTATTACAGTTTTGCCAAAGGACATTCTTCAGGAGAGAATACCATG
GGTACCACCTGAATGCATTGAAAATCCTAAAAATTTAAATTTGGCAACAGACAAATGG
AGTTTTGGTACAACTCTGTGGGAAATCTGCAGTGGAGGAGATAAACCTCTAAGTGCTC
TGGATTCTCAAAGAAAGCTACAATTTTATGAAGATAGGCATCAGCTTCCTGCACCAAA
GTGGGCAGAATTAGCAAACCTTATAAATAATTGTATGGATTATGAACCAGATTTCAGG
CCTTCTTTCAGAGCCATCATACGAGATCTTAACAGTTTGTTTACTCCAGATTATGAACT
ATTAACAGAAAATGACATGTTACCAAATATGAGGATAGGTGCCCTAGGGTTTTCTGGT
GCCTTTGAAGACCGGGATCCTACACAGTTTGAAGAGAGACATTTGAAATTTCTACAGC
AACTTGGCAAGGGTAATTTTGGGAGTGTGGAGATGTGCCGGTATGACCCTCTACAGGA
CAACACTGGGGAGGTGGTCGCTGTAAAAAAGCTTCAGCATAGTACTGAAGAGCACCTA
AGAGACTTTGAAAGGGAAATTGAAATCCTGAAATCCCTACAGCATGACAACATTGTAA
AGTACAAGGGAGTGTGCTACAGTGCTGGTCGGCGTAATCTAAAGTTAATTATGGAATA
TTTACCATATGGAAGTTTACGAGATTATCTTCAAAAACATAAAGAACGGATAGATCAC
ATAAAACTTCTGCAGTACACATCTCAGATATGCAAGGGTATGGAGTATCTTGGTACAA
AAAGGTATATCCACAGGGATCTGGCAACGAGAAATATATTGGTGGAGAACGAGAACA
GAGTTAAAATTGGAGATTTTGGGTTAACCAAAGTCTTGCCACAAGACAAAGAATACTA
TAAAGTAAAAGAACCTGGTGAAAGTCCCATATTCTGGTATGCTCCAGAATCACTGACA
GAGAGCAAGTTTTCTGTGGCCTCAGATGTTTGGAGCTTTGGAGTGGTTCTGTATGAACT
TTTCACATACATTGAGAAGAGTAAAAGTCCACCAGCGGAATTTATGCGTATGATTGGC
AATGACAAACAAGGACAGATGATCGTGTTCCATTTGATAGAACTTTTGAAGAATAATG
GAAGATTACCAAGACCAGATGGATGCCCAGATGAGATCTATATGATCATGACAGAATG
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CTGGAACAATAATGTAAATCAACGCCCCTCCTTTAGGGATCTAGCTCTTCGAGTGGATC
AAATAAGGGATAACATGGCTGGATGA 
 
Human JAK2 JH2-JH1 protein sequence:  
MHHHHHHENLYFQGHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVL
DKAHRNYSESFFEAASMMSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNK
NCINILWKLEVAKQLAWAMHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISIT
VLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYE
DRHQLPAPKWAELANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIG
ALGFSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHST
EEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDH
IKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVK
EPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQ
MIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG* 
 
6x Histidine 
Tobacco etch virus (TEV) protease cleavage site 
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